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ABSTRACT 
 
The efficiency, selectivity, and sustainability benefits offered by enzymes are enticing chemists 
to consider biocatalytic transformations to complement or even supplant more traditional synthetic 
routes. Increasing demands for efficient and versatile synthetic methods combined with powerful 
new discovery and engineering tools have prompted innovations in biocatalysis, especially the 
development of new enzymes for precise transformations. The past decade has witnessed 
impressive expansion of the catalytic repertoire of enzymes to include new and useful 
transformations not known (or relevant) in the biological world. The continuing discovery and 
improvement of these new enzyme activities is opening a floodgate that connects the chemistry of 
the biological world to that invented by humans over the last 100 years. 
This thesis describes a new set of enzymes, derived from a cytochrome P450 monooxygenase 
and a cytochrome c electron-transfer protein, which are able to function as carbene transferases to 
construct diverse molecular structures, including strained carbocycles and lactone derivatives. 
Chapter 1 illustrates different approaches researchers have utilized to explore and develop new 
catalytic machineries of diverse enzymes. These efforts have identified new genetically-encoded 
biocatalysts that can be tuned and diversified through directed evolution. Chapter 2 presents the 
discovery of P450 variants that catalyze the formation of highly strained carbocycles, 
bicyclobutanes and cyclopropenes, via carbene addition to carbon‒carbon triple bonds. The 
intrinsic strain energies of these small rigid carbocycles allow them to have broad applications in 
different fields, but also create challenges for their construction. Using a diazo substrate as the 
carbene precursor, the enzyme variants optimized by directed evolution could act on structurally 
diverse alkynes (aromatic or aliphatic, terminal or internal) with high efficiency and selectivity, 
providing an effective route to an array of chiral strained structures. The carbene transferase activity 
is then extended to the assembly of various lactone structures, a fundamental class of organic 
moieties with applications in fields varying from synthetic chemistry, to materials science, to 
medicinal chemistry. Chapter 3 details a strategy using lactone-based carbenes, for the transfer to 
different functionalities, enabling rapid access to a broad range of α-substituted and spiro-lactones 
with unprecedented efficiencies and selectivities. A different approach based on intramolecular 
carbene C–H insertion is outlined in Chapter 4, which allows for the synthesis of lactones in a higher 
order of structural diversity. Directed evolution of a P450 variant identified a lineage of potent 
variants, capable of assembling lactones in different sizes (5- to 7-membered) and also with 
sophisticated three-dimensional structures based on fused, spiro and bridged rings. Computational 
tools were employed to understand the reaction mechanisms and to explain some mutational effect. 
In sum, the thesis work lays out how protein engineering integrated with chemical rationalization 
enables the expansion of the chemical space accessible to native hemeproteins, especially in 
building diverse molecular structures. 
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Chapter 1 
 
ENZYME ENGINEERING FOR NEW CATALYTIC ACTIVITIES: 
AN INTRODUCTION 
 
Material for this chapter appears in: Chen, K.; Arnold, F. H.*, Engineering new catalytic activities 
in enzymes. Nat. Catal. 3, 103–113 (2020). 
 
1.1 Opening remarks 
Nature has evolved an astonishing array of enzymes to catalyze the chemical transformations 
that enable biological systems to eke out a living in diverse environments. Enzymes synthesize 
biological building blocks from available elemental resources, from which more enzymes go on to 
assemble new life, including essential biomolecules, complex natural products and macromolecular 
materials. Enzymes also break down these compounds into reusable fragments. While executing 
their biologically-relevant functions, enzymes can, when needed, exert precise control over reaction 
outcomes. The unique ability of enzymes to do such ‘molecular editing’ has prompted addition of 
some of nature’s catalysts to the organic synthesis toolbox1-3. 
Nature’s repertoire of enzyme functions is striking – from photosynthesis to nitrogen fixation, 
water splitting to aliphatic carbon assembly, there are still no human-made catalysts that can match 
these fundamental processes of life. On the other hand, the biological world has not followed the 
same path as human-invented chemistry, and many valuable transformations invented by synthetic 
chemists have no known enzyme-catalyzed counterparts. Among other reasons, nature does not 
use many of our favorite transformations because the products are not useful to living systems, the 
required reagents do not (stably) exist in nature, or because conditions to effect the reactions are 
not available. 
To bridge nature’s catalytic repertoire and the demands of synthetic chemistry, chemists and 
biologists have started to import human-invented chemistry into enzymes. One approach 
researchers have tried is computational de novo enzyme design based on knowledge of the reaction 
transition-state structure4,5. Given our limited understanding of how enzymes function at an atomic 
level and how sequence encodes catalytic function in macromolecular design, however, an 
alternative avenue of engineering existing proteins has proven more successful, at least for now. 
Researchers are quickly unlocking new catalytic activities of existing enzymes simply by challenging 
and/or engineering them to work with non-natural reagents and in new environments. New 
activities can be released with relatively small modifications, such as introducing a different metal 
center or changing a few amino acids in an active site. (Perhaps this is not surprising, since it is also 
nature’s innovation strategy.) Powerful molecular biology tools like directed evolution can then tune 
and diversify these new functions to provide catalysts that bring the benefits of nature’s 
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biosynthetic machinery to chemical synthesis. This review will cover these latter efforts to engineer 
new enzymes by starting from nature’s designs (Fig. 1.1). 
 
Figure 1.1. Strategies in discovery of new enzyme functions. Discovery of new enzymes, engineering and 
diversification of proteins by directed evolution, exploitation of cofactors for new reactivities, and use of 
synthetic reagents and non-natural conditions have accelerated new enzyme activity development; other 
advances such as machine learning will expand biocatalysts’ capabilities by learning from growing 
gene/function databases. 
A pivotal feature of enzymes, their promiscuity with respect to the substrates they accept and 
even the reactions they catalyze, has played a central role in the discovery and development of new 
biocatalytic functions. Enzymes can often accept various substrates in addition to their native 
one(s); they can even catalyze different transformations when offered the right reagents and 
environments6. These promiscuous activities may be left over from ancestral enzyme functions, or 
they may be activities that were never explored in the natural world and come simply as a result of 
having catalytic machinery that exhibits its hidden capabilities when the environment changes7. 
There is immense potential in nature’s vast repertoire of contemporary enzymes for us to discover 
and use, just as nature has done for more than three billion years. Early examples with hydrolytic 
enzymes showed, for instance, that enzymes whose native functions are amide or ester hydrolysis 
can also utilize their finely tuned networks of active-site residues for hydrolysis of other bonds or 
even formation of new bonds 8 . More recently, chemo-mimetic approaches developed by 
transferring human-invented chemistries to cofactor-dependent enzymes have significantly 
expanded the chemical space accessible to biocatalysis. Protein engineering, using non-
physiological reaction conditions, and combination of chemo- and biocatalysis have further 
unveiled the potential for chemical innovation in existing enzymes. 
Increasing demands for efficient, selective and versatile synthetic methods call for new 
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enzymatic functions that may not be relevant in the biological world9. The challenges are daunting, 
requiring not only that enzymes take on new functions, but also that the newly developed 
biocatalysts exhibit activity and selectivity comparable to or better than current chemo-catalytic 
methods or that they fill gaps in synthetic chemistry. In this chapter, we summarize the current 
status of non-natural biocatalysis and describe how protein engineering integrated with chemical 
rationalization enables innovations that expand the chemical space accessible to enzymes. Creating 
abiological enzymatic functions represents a rising area of research that requires knowledge from 
different fields, including protein engineering, enzymology and synthetic chemistry. We hope this 
introduction will help chemists and biologists recognize, explore and use enzymes for new 
chemistry. 
 
1.2 Utilizing established active sites for new enzymatic functions 
Early studies of enzyme promiscuity illustrated how enzyme active sites can catalyze 
physiologically irrelevant chemical transformations10. Although different in mechanism or path of 
bond formation and breakage, these non-native enzyme functions are typically enabled by the 
superior capacity of enzyme active sites to stabilize similar transition states and precisely control 
key intermediates, as exemplified by a large set of hydrolytic enzymes. Many hydrolases feature an 
oxyanion hole, consisting of backbone amides or positively charged residues that stabilize the 
negative charge on a deprotonated oxygen or alkoxide in the transition state. Such structural 
properties allow the same hydrolases to catalyze diverse chemical reactions proceeding through 
oxyanionic intermediates, including aldol reactions, Michael additions, Mannich reactions, and 
even peroxide-involved oxidative reactions8. For example, in 2003, Berglund and co-workers 
reported that Candida antarctica lipase B (CAL-B) catalyzes aldol reactions between aliphatic 
aldehydes; they used quantum molecular modeling to illustrate the importance of the oxyanion 
hole in stabilizing the enolate intermediate (Fig. 1.2.a)11. Another class of hydrolase, glycosidase, 
was intensively investigated and engineered for promiscuous activities of glycoside synthesis: by 
mutating key residues such as catalytic acid/base pairs, Withers and co-workers converted a 
glycosidase into a glycosynthase12 or a thioglycoligase13 employing different α-glycosyl substrates 
and acceptor sugars. 
The promiscuous functions of enzymes have been used for industrial production of valuable 
compounds. One representative example is halohydrin dehalogenase (HHDH), which in nature 
catalyzes epoxide formation from corresponding substituted chloro- or bromohydrins14. Structural 
studies on various HHDHs revealed several highly conserved catalytic residues in the active sites 
that specifically bind epoxide and halide anion. A key tyrosine residue can act as a catalytic base for 
hydroxyl group deprotonation or a catalytic acid for epoxide protonation, which raised the 
possibility that it could catalyze the reverse reaction, epoxide ring opening. Acceptance of various 
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nucleophiles, including azide, cyanide, nitrite, cyanate, thiocyanate and formate, and high 
enantioselectivity in the epoxide opening process, render HHDHs desirable catalysts for synthetic 
purposes, especially for preparation of enantio-enriched β-substituted alcohol and epoxide 
products. Among the biocatalytic applications of HHDH is the asymmetric synthesis of ethyl (R)-
4-cyano-3-hydroxybutyrate, a precursor of atorvastatin, as reported by scientists at Codexis (Fig. 
1.2.b)15. Directed evolution was used to enhance the activity of Agrobacterium radiobacter HHDH, 
enabling production of the precursor with >99.9% ee based on a substrate loading of 130 g∙L‒1. 
 
Figure 1.2. Promiscuous functions enabled by versatile active sites. a, Aldol reaction with Candida 
antarctica lipase B. b, Epoxide opening with halohydrin dehalogenase. c, Prins reaction with squalene-hopene 
cyclase. 
The promiscuity of terpene cyclases has also attracted attention for abiological chemistry16. 
Terpene cyclases typically use acid/base catalytic residues for cationic cyclization of polyenes. 
Squalene-hopene cyclase (SHC), natively responsible for polycyclization of squalene to pentacyclic 
hopene and hopanol, has been explored as a promiscuous Brønsted-acid biocatalyst to harness a 
plethora of non-natural reactions driven by protonation processes. Hauer and co-workers employed 
SHC to construct abiological carbocyclic skeletons by using different internal nucleophilic 
terminators in the cyclization process17. Reshaping the active-site structure of SHC also allowed 
non-native acidic isomerizations of β-pinene, monocyclization of geraniol and Prins reaction of 
citronellal (Fig. 1.2.c) 18 . For instance, a single amino acid mutation I261A in SHC from A. 
acidocaldarius (AacSHC) improved activity 11-fold for a Prins reaction of (S)-citronellal to an (‒)-
iso-isopulegol isomer product (>99% ee and >99% de). The literature offers more examples of native 
enzymes displaying promiscuous activities. But this scenario for searching new enzymatic activities 
has the obvious limitation that the new reactivity must be quite closely related to the naturally-
established function. 
 
1.3 Exploiting the catalytic potentials of organo-cofactors 
Cofactor-dependent enzymes are of particular interest, as many cofactors possess expansive 
catalytic potential for chemical transformations. This potential has been exploited in natural 
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evolution to create families of enzymes whose functions cover two-electron and single-electron 
redox/non-redox chemistries. The protein scaffold can distinguish and direct the pathway through 
which a given reaction will proceed from among two or more possibilities. In this section, we will 
outline recent advances in realizing new chemistries with enzymes having organo-cofactors, 
including nicotinamide adenine dinucleotide (NADH or NADPH), flavin nucleotides (FMN or 
FAD), thiamine diphosphate (TDP) and pyridoxal phosphate (PLP) (Fig. 1.3). Reaction design and 
protein engineering have both promoted the discovery of new functions for these enzymes. 
Nicotinamide adenine dinucleotides in their reduced form (NADH or NADPH) act as 
biological reducing cofactors/co-substrates of numerous oxidoreductases. For example, keto-
reductases (KREDs) reduce endogenous carbonyl compounds to alcohols. NADPH-dependent 
imine reductases (IREDs)19 are also physiologically capable of reducing carbon‒nitrogen double 
bonds. Recently, Turner and co-workers identified a subclass of IREDs which catalyze imine 
formation from ketones and amines prior to imine reduction and named them reductive aminases 
(RedAms)20. A RedAm from Aspergillus oryzae (AspRedAm), an IRED homologue from a eukaryotic 
source, was discovered to accept a broad range of structurally diverse amines and ketones, which 
provides an attractive biocatalytic route to secondary and tertiary amines21. 
NAD(P)H is generally recognized as a hydride donor in catalysis. But NAD(P)H was recently 
found to be able to implement single-electron-transfer chemistry as well. Hyster and co-workers 
reported an abiological asymmetric radical dehalogenation of α-bromo-α-aryl/alkyl lactones with 
KREDs enabled by a photo-induced electron-transfer strategy22. The NAD(P)H cofactor can be 
excited by blue light to a triplet state, which serves as a potent single-electron reductant. A single 
electron transfer forms a substrate radical anion, which undergoes heterolytic cleavage of a C–Br 
bond to generate an alkyl radical. Then NAD(P)H+• serves as a hydrogen atom donor to afford the 
dehalogenated lactone product. Several KREDs were found to catalyze dehalogenation of α-bromo 
γ/δ-lactones in good yields and enantioselectivities. Another system based on the combination of a 
NADPH-dependent double bond reductase (DBR) and the photocatalyst Rose Bengal (RB) enables 
enantioselective radical deacetoxylation of α-acetoxyl ketones, where the enzyme plays a role in 
activating the substrate for electron transfer followed by deacetoxylation and hydrogen atom 
transfer from NADPH23. 
Flavin cofactor natively appears in the form of flavin mononucleotide (FMN) or flavin adenine 
dinucleotide (FAD) and is exceptionally versatile in enzymes, mediating a plethora of oxidative and 
reductive activities24. Flavin can exist in multiple redox states, including flavin-N5-oxide (FMN or 
FAD oxide), oxidized flavin (quinone, FMN or FAD), flavin semiquinone (FMNH• or FADH•), 
reduced flavin (hydroquinone, FMNH2 or FADH2), as well as flavin-C4-peroxide (FMNOOH or 
FADOOH) when engaging with molecular oxygen. The protein scaffold and reaction conditions 
determine which states of the cofactor are accessible, leading to the diverse redox chemistry of 
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natural flavoenzymes. 
Compared to two-electron processes catalyzed by flavoenzymes, biological reactions with a 
single-electron mechanism involving the semiquinone state are rare. The Hyster lab discovered a 
promiscuous radical dehalogenation of α-bromo esters with flavin-dependent ene-reductases 
(EREDs) by making use of the semiquinone state25. Interestingly, mutation Y177F in ERED from G. 
oxydans abolishes the native ene-reduction function in the absence of a proton donor, but 
significantly improves this non-native function, which further supports the radical mechanism for 
dehalogenation. Coupled with photoredox catalysis, EREDs could also perform ketone reduction 
via a radical-mediated pathway26. Recently, Hyster and his team further expanded the capacity of 
EREDs to perform photo-induced radical cyclization to make various lactams (Fig. 1.3.a)27. They 
reasoned that hydroquinone in the excited state can act as a single-electron reductant strong 
enough to activate α-chloro acetamide and generate the α-acetamide radical, which would cyclize 
to an endo-double bond and then abstract a hydrogen atom from semiquinone to form the desired 
lactam product. Lactam products with ring sizes ranging from 5 to 8 members were accessible via 
endo- or exo-cyclization processes in this system. A naturally-occurring flavin-dependent 
photodecarboxylase from Chlorella variabilis NC64A (CvFAP) was discovered recently by Beisson 
and his team to employ a semiquinone state for a light-induced radical decarboxylation of fatty 
acids to alkanes or alkenes28,29. These newly demonstrated photoenzymatic platforms have revealed 
previously unknown catalytic potentials of the flavin cofactor. 
The thiamine-dependent enzymes offer another good example of how promiscuous catalytic 
functions can be exploited, in nature and by chemists. The TDP cofactor comprises a thiazolium 
core, an aminopyrimidine group and a diphosphate moiety. The aminopyrimidine group acts as a 
key base for deprotonation of the C2 position in the thiazolium ring, which leads to the formation 
of a nucleophilic thiazolium carbene and initiates all types of thiamine catalysis in nature30. The 
thiazolium carbene is a superior nucleophile for addition to carbonyl groups, resulting in an 
enaminol species, known as the Breslow intermediate, for a variety of nucleophilic reactions31. In 
such a way, thiamine enzymes can take electrophilic aldehydes or other carbonyl substrates, turn 
them into a nucleophilic form and further enable desired bond constructions. 
Thiamine-dependent enzymes have been explored for abiological asymmetric C–C bond-
forming reactions that take advantage of the nucleophilic feature of the Breslow intermediate. A 
cross-benzoin condensation between acetaldehyde (after decarboxylation of pyruvate) and 
benzaldehyde was achieved by Müller and co-workers using the cyclohexane-1,2-dione hydrolase 
(CDH) from Azoarcus sp. to produce chiral α-hydroxy ketone products in high enantioselectivity32. 
CDH was also engineered to accept ketones as electrophiles 33 , 34 . The cross-benzoin reaction 
between two aromatic aldehydes is particularly challenging due to the chemo-selectivity problem 
arising from homo-couplings and mixed cross-couplings35. However, benzaldehyde lyase (BAL) 
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from Pseudomonas fluorescens and a variant of benzoylformate decarboxylase (BFD) from 
Pseudomonas putida were found to catalyze this reaction, where the steric control from the ortho-
substituted aldehyde as the electrophile substrate is key to high chemoselectivity36. Instead of 
aldehydes or ketones, α,β-unsaturated carbonyl substrates have also been investigated for this 
nucleophilic addition of the Breslow intermediate in a 1,4-conjugate manner (the Stetter reaction). 
A thiamine enzyme, PigD from Serratia marcescens, catalyzes acetaldehyde addition to α,β-
unsaturated ketones with high enantioselectivity37. 
 
Figure 1.3. New chemistries with cofactor-dependent enzymes. a, Radical dehalogenative cyclization with 
ene-reductase. b, Non-canonical amino acid synthesis with engineered tryptophan synthase. 
Pyridoxal phosphate (PLP) is another highly versatile enzyme cofactor. Taking advantage of 
the aldimine intermediate formed through the condensation between the aldehyde group of PLP 
and amino group from a substrate, PLP-dependent enzymes catalyze transamination, amino acid 
decarboxylation, deamination, racemization, and more. O-Acetylserine sulfhydrylase (OASS) is a 
PLP-dependent enzyme used for cysteine biosynthesis. It forms a key aminoacrylate intermediate 
through the loss of an acetate from the aldimine between O-acetylserine and PLP, and nucleophilic 
addition of H2S to the aminoacrylate gives L-cysteine38. Early work reported that a variety of 
heteroatom-based nucleophiles could also be used by OASS to synthesize non-canonical β-
substituted alanine derivatives39. 
Similar to OASS in mechanism, tryptophan synthase (TrpS) catalyzes the formation of 
tryptophan through addition of indole to the aminoacrylate electrophile formed with serine and 
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PLP in its β-subunit (TrpB). Early work demonstrated that TrpS could accept some indole 
derivatives or other heterocyclic nucleophiles for the synthesis of tryptophan analogues40. Buller 
and co-workers engineered the β-subunit of tryptophan synthase from Pyrococcus furiosus (PfTrpB) 
to serve as a stand-alone enzyme for non-canonical amino acid (ncAA) synthesis with different 
nucleophiles41,42. Further engineering of PfTrpB expanded the scope of the serine electrophile to 
include threonine and other β-alkyl serine derivatives for production of β-substituted tryptophan 
analogues43,44. Recently, Romney and co-workers reported that an evolved PfTrpB can accommodate 
nitroalkane nucleophiles structurally distinct from the indole analogues, amines and thiols that 
were demonstrated previously (Fig. 1.3.b)45. Because the nitro group can serve as a handle for 
further modification, this biocatalytic strategy provides a convenient route to diverse ncAAs with 
aryl and alkyl side-chains. 
Compared to the diversity of small-molecule catalyst scaffolds invented by chemists, nature 
uses a more limited set of organo-cofactors for catalysis. However, the catalytic potential of these 
cofactors is still far from fully discovered or explored. Different protein structures or reaction 
conditions may completely alter the properties of the cofactors, a feature that natural evolution has 
exploited to create functionally diverse enzyme families. This chemical flexibility provides 
opportunities to use the diverse electronic and photo-chemical properties of cofactors to develop 
new reaction pathways that have not been explored by nature. Taking inspiration from the studies 
described here, we imagine that future efforts to the cofactors described here and others such as 
tetrahydrobiopterin (THB) 46 , 4-methylideneimidazole-5-one (MIO) 47  and prenylated flavin 
(prFMN)48, will lead to the discovery of yet more functionally diverse enzymes. 
 
1.4 Taming metalloenzymes for non-native reactions 
Natural enzymes also use metal ions or metal-based cofactors to implement diverse, 
challenging transformations, as exemplified by nitrogenase for nitrogen fixation. The versatility of 
transition metal electronic states and coordination modes lays the foundation for transition metal 
catalysis in chemistry. This versatility also provides opportunities to develop new chemistries 
starting from nature’s vast collection of metalloproteins. 
A given metalloenzyme family can encompass diverse functions, but usually their reactions 
proceed via a specific type of metallo-intermediate. For instance, iron(II)- and α-ketoglutarate-
dependent (Fe/αKG) enzymes employ a high-valent iron-oxo (FeIV) intermediate for C–H 
hydroxylation, desaturation of aliphatic hydrocarbons, epoxidation of olefins, epimerization of sp3-
hybridized carbon centers and others. SyrB2, an Fe/αKG enzyme from the syringomycin 
biosynthetic pathway of Pseudomonas syringae B301D, is responsible for C–H halogenation of the 
side-chain methyl group of a threonine moiety tethered with its carrier protein SyrB1 49 , 50 . 
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Mechanistically, a homolytic coupling between a halogen ligand of iron and a carbon-centered 
radical formed through a hydrogen-atom abstraction process results in the carboN–Halogen bond 
formation. This halogenation activity is thought to originate from the hydroxylation activity of 
Fe/αKG enzyme homologues. Based on further mechanistic study, Bollinger and co-workers 
discovered that incorporation of a non-oxygen ligand at the iron center could lead to new enzymatic 
functions. Azide or nitrite anions can bind to the iron center of SyrB2, thus proceeding through 
radical azidation and nitration with different amino acid-based substrates51. These reactions still 
require carrier protein-appended substrates and can only occur in modest yields under single-
turnover conditions, but such activity provides an unprecedented enzymatic route to C–N bond 
formation with aliphatic C–H bonds. Future work to identify other homologues and enzyme 
engineering may further expand the C–H functionalization chemistries of Fe/αKG enzymes and 
also allow these enzymes to accept diverse substrates for synthetic purposes52. 
Iron-oxo-mediated alkene epoxidation via oxo transfer to C–C double bonds is a well-
established transformation with iron-based oxygenases, such as Fe/αKG or cytochrome P450 
enzymes. Epoxidation typically follows a concerted [2+1] cycloaddition pathway with a low energy 
barrier. With a particular cytochrome P450, however, aldehydes were observed as side-products of 
this epoxidation reaction53. Hammer et al. hypothesized that this promiscuous activity resulted 
from a step-wise pathway of radical addition of iron-oxo to the alkene substrate, single electron 
transfer and a subsequent 1,2-hydride migration to deliver the anti-Markovnikov oxidation 
product54. Hammer then engineered this P450 from the rhodobacterium Labrenzia aggregata 
(P450LA1) to divert the iron-oxo intermediate into this anti-Markovnikov oxidation over the 
kinetically favored epoxidation. Accumulation of mutations in the heme domain of P450LA1 through 
directed evolution led to a variant, aMOx, that catalyzes the anti-Markovnikov oxidation of styrene 
to phenylacetaldehyde with 3800 TTN and 81% selectivity. By providing a chiral environment in the 
enzyme’s active site for this step-wise oxo-transfer pathway, the first example of enantioselective 
anti-Markovnikov oxidation was demonstrated with a prochiral α-methylstyrene substrate, giving 
82% ee. 
The above examples demonstrate the feasibility of hijacking key intermediates in the catalytic 
cycles of metalloenzymes into different reaction pathways in order to access new enzymatic 
activities. Alternatively, one could also enable new chemistries by introducing new reactive 
intermediates that mimic the native intermediates, structurally and functionally 55 . 
Metalloporphyrin complexes have been investigated for more than half a century as structural 
analogues to heme cofactors in proteins. Many metalloporphyrins were developed in an effort to 
mimic the oxo-transfer activities of cytochrome P450s through the formation of high-valent metal-
oxo intermediates56. Meanwhile, intermediates analogous to metal-oxo species, typically metallo-
carbenes and metallo-nitrenes, could also be formed by the metalloporphyrins and used for carbene 
10 
 
 
and nitrene transfer reactions57,58. For instance, a precursor such as a diazo compound can react 
with the transition metal center (e.g., iron, cobalt, rhodium, ruthenium, iridium, osmium, etc.) in 
metalloporphyrin complexes to generate a metal-carbenoid intermediate, which can undergo 
transfer to organic molecules 59 , 60 . Reasoning that translating the non-natural activities of 
metalloporphyrin catalysts to the corresponding heme-dependent enzymes would be a promising 
way to access new enzymatic activities, Coelho and co-workers described the first ‘carbene 
transferase’ enzyme in 2013 (Fig. 1.4)61. 
Cytochrome P450 from Bacillus megaterium (P450BM3) catalyzes alkene cyclopropanation via 
an abiological iron-carbenoid intermediate61. A diazo reagent, ethyl diazoacetate (EDA), reacts with 
the cytochrome P450 in the FeII state and yields an iron-carbenoid intermediate; subsequent 
carbene transfer to styrene substrates led to the corresponding cyclopropane products. A cysteine-
to-serine mutation at the heme-ligating residue furnished a new set of enzymes, designated P411s; 
this mutation increased the reduction potential of the ferric state of the iron center, allowing endo-
cellular reductant NADPH to reduce the ferric state and thus conferred carbene transfer activity in 
vivo (Fig. 1.4.a) 62 , 63 . Histidine ligation was also structurally tolerated by the P450, where it 
accelerated cyclopropanation of acrylamide substrates64. Nature offers a diversity of hemeproteins, 
and our group and the Fasan group have demonstrated that various small hemeproteins, including 
protoglobin, nitric oxide dioxygenase65 and myoglobin66, could also be engineered to catalyze 
cyclopropanation reactions in high efficiency and stereoselectivity, even with electron-deficient and 
electron-neutral alkenes. 
Aziridination via nitrene transfer to alkenes can also be achieved with P411 hemeproteins. Our 
group initially demonstrated aziridination of styrene-type substrates with engineered P411 variants 
using tosyl azide as the reactive nitrene precursor (Fig. 1.4.a)67. After this work, Ohnishi and co-
workers disclosed that BezE, a cytochrome P450 in the biosynthetic pathway of benzastatin from 
Streptomyces sp. RI18, is responsible for an aziridination process via formation of an iron-nitrenoid 
intermediate with an N-acetoxy substrate and a subsequent nitrene transfer to a proximal double 
bond68. This is an excellent example of how non-natural biocatalysis can illuminate underexplored 
paths and lead to new discoveries in biological chemistry. In turn, the Ohnishi study inspired the 
Arnold group to look at hydroxylamine-type nitrene precursors, which can be more accessible and 
have fewer stability issues compared to the azide compounds. Recently, cytochrome c, an electron-
transfer protein, was shown to be capable of styrene aziridination, using O-pivaloyl 
hydroxylammonia triflate as the reagent to generate a putative unprotected nitrene species69. Under 
aqueous conditions, these aziridines are labile and undergo hydrolysis to afford unprotected chiral 
1,2-amino alcohols. 
In carbene- and nitrene-transfer chemistries, alkene cyclopropanation and aziridination are 
analogous to P450s’ native epoxidation activities; the abiological counterparts to C–H hydroxylation 
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are C–H alkylation and C–H amination. Early in the 1980s, Dawson and co-workers reported that a 
rabbit-liver cytochrome P450 catalyzed a nitrene C–H insertion reaction using an abiological 
iminoiodinane substrate as nitrene precursor with very limited turnovers70. Inspired by this work, 
McIntosh et al. achieved intramolecular nitrene insertion into a proximal C(sp3)‒H bond using a 
P411 as a whole-cell catalyst, affording sultam products in decent yield and good enantioselectivity71. 
Fasan also showed that P450BM372 or myoglobin73 variants are capable of such intramolecular C–H 
amination reactions. In addition, the evolved P450 variants can also function with azidoformates 
for intramolecular C–N bond formation, providing oxazolidinones as the amination products74. 
 
Figure 1.4. Chemo-mimetic carbene- and nitrene-transfer chemistries with engineered hemeproteins. 
a, Nitrene and carbene transfer to alkenes for aziridine and cyclopropane formation. b, Intermolecular nitrene 
and carbene insertion into C(sp3)‒H bonds. c, Enzyme evolution trajectory. 
Engineering site-selective C–H amination is of great interest, since regioselectivity with small-
molecule catalysis is usually dominated by the inherent properties of the C–H bonds. Hyster and 
co-workers demonstrated that the active site of P450 can be reshaped to facilitate C–H amination 
in a regio-divergent manner 75 . With a sulfonylazide bearing two types of C(sp3)‒H bonds 
geometrically accessible to amination, different P411 variants were evolved to direct intramolecular 
nitrene insertion to benzylic and homo-benzylic C(sp3)‒H bonds, forming 5- and 6-membered 
sultam products selectively. Given the differences in bond dissociation energies of the C–H bonds, 
the distinct product outcomes show that properly engineering the active-site environment for 
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catalysis can override the inherent reactivity of the C–H bonds and guide product formation along 
desired reaction pathways. P411s were also engineered to catalyze intermolecular nitrene C–H 
insertion enantioselectively76 , a problem with only limited examples of solutions with small-
molecule catalysts. Accumulation of active-site mutations in a P411 enzyme helped to precisely 
orient the substrate in the distal pocket and accelerate the desired C–H insertion. Using tosyl azide 
as the nitrene precursor, evolved P411CHA enantioselectively aminated benzylic C–H bonds of alkyl 
benzene substrates (Fig. 1.4.b and 1.4.c). 
Carbene C–H insertion to install alkyl groups onto organic molecules is also feasible with 
cytochrome P411 variants77,78. A variant obtained in the evolutionary lineage of P411CHA displayed 
promiscuous activity for carbene insertion into C–H bonds and thus served as a parent for evolution 
of a powerful alkyl-transferase, P411CHF, which can target benzylic, allylic, propargylic and α-amino 
C–H bonds for carbene insertion (Fig. 1.4.b and 1.4.c). Interestingly, P411CHF alkylates a benzylic C–
H bond in a substrate bearing a terminal alkene moiety, while an early P411 variant, P-I263F only 
cyclopropanates the double bond in the same molecule. This demonstration of catalyst-controlled 
chemoselectivity once again speaks to the high tunability of enzyme catalysis, which provides a 
promising solution to long-standing selectivity challenges. 
Analogous to heteroatom oxidation by cytochrome P450s, electrophilic nitrene or carbene 
intermediates formed with hemeproteins, such as P411 or myoglobin variants, can be intercepted by 
sulfides to furnish sulfimides79 and sulfonium ylides. Moreover, with prochiral allylic sulfides, the 
corresponding allylic sulfimide or sulfonium ylide products can further undergo [2,3]-sigmatropic 
rearrangement to yield chiral allylic amines80 or chiral sulfides81. 
Another useful class of carbene-transfer reactions is X‒H (X = heteroatom, including N, S, Si, 
B, P and others) bond insertion. Our group showed that P450BM3 variants can catalyze N-alkylation 
of aniline substrates via a formal carbene N–H insertion process82; the Fasan lab also described N–
H insertion83 and S–H insertion84 reactions with engineered myoglobins. Carbene Si‒H or B–H 
insertion reactions provide efficient routes for building C–Si and C–B bonds, which are not found 
in biological systems but are useful and important in human-made products. Hemeproteins are 
capable of forming these bonds with much higher activities than reported for transition metal 
catalysts. Wild-type cytochrome c from Rhodothermus marinus (Rma cyt c) was discovered to 
catalyze carbene Si‒H insertion using ethyl 2-diazopropanoate (Me-EDA) and 
phenyldimethylsilane as substrates with a modest turnover (44 TTN) but good enantioselectivity 
(97% ee)85. Introduction of three active-site mutations improved catalytic efficiency by over 30-fold. 
Evaluation of silane scope established that the evolved Rma cyt c is particularly selective for the 
desired silylation even with substrates bearing other functionalities that can participate in carbene-
transfer chemistry. Rma cyt c was also engineered for enantioselective carbene B–H insertion 
reactions using N-heterocyclic carbene-stabilized boranes 86 , 87 . By modifying the active-site 
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structure of Rma cyt c, a variety of structurally different carbenes can be accommodated for this B–
H insertion reaction. 
With the established carbene chemistries of hemeproteins, Lewis was able to capture a carbene 
intermediate bound to the iron center of an Rma cyt c mutant in a crystal structure88. The physical 
chemistry study of this iron-carbenoid species together with computational investigation provided 
insight into how protein structure enables the desired chemistries. The Hilvert lab also 
characterized a different type of carbene adduct with an Nδ-methylhistidine-ligated myoglobin 
variant, a bridged Fe(III)‒C–N(pyrrole) carbenoid, which could equilibrate with an end-on 
carbenoid isomer and thus participate in carbene-transfer reactions89. 
These newly-discovered carbene- and nitrene-transfer activities of hemeproteins expand 
nature’s catalytic repertoire to include many transformations which are not biologically relevant but 
are highly useful for chemical synthesis. For most of the reactions described here, the free heme 
cofactor catalyzes the reaction not at all or only with very poor efficiency, highlighting the 
contribution of the protein to enabling and facilitating these transformations. Although small-
molecule catalysts have been developed for many of these chemistries, hemeproteins stand out as 
competent catalysts with high catalytic efficiency and readily tunable stereo-/regio-
/chemoselectivities. With the help of strategies to discover and improve new carbene and nitrene 
transferases, we foresee that hemeprotein biocatalysts will address more challenging problems in 
synthetic chemistry and will move to wider use at scale. 
 
1.5 Developing new enzymes with artificial cofactors 
The above examples show how small-molecule catalysis can inspire discovery of new enzyme 
functions. However, there are still many synthetically important reactions carried out with human-
invented catalysts for which enzyme candidates have not yet been identified. Chemists have been 
trying to fill some of this large gap between classical catalysis and biocatalysis by incorporating 
catalytically competent artificial cofactors into proteins. Artificial metalloenzymes (ArMs), for 
example, can be traced back to the late 1970s when Wilson and Whitesides assembled an artificial 
metallo-hydrogenase for hydrogenation of α-acetamidoacrylic acid by introducing a biotin-tethered 
diphosphine-rhodium(I) complex to avidin90. Most early studies focused on proving that new 
enzymes with human-invented metallocatalysts could be made, and many functions performed by 
these ArMs, such as ester/amide hydrolysis, alcohol/olefin oxidation and ketone/imine/acrylate 
reduction, were already well-known for enzymes, despite mechanistic differences. More recently, 
the development of ArMs has been greatly accelerated by advances in organometallic chemistry and 
protein engineering. A broad range of ArMs have been created for important transformations in 
synthetic chemistry. A recent review from the Ward and Lewis groups comprehensively summarizes 
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work in the field of ArMs91. Here we will focus only on representative ArMs with abiological 
functions. 
Non-covalent binding of metallo-cofactors using specific protein ligands is a strategy used 
widely to construct ArMs. The biotin-(strept)avidin system is a typical example, as avidin and 
streptavidin (Sav) feature deep binding pockets for biotin and provide a chiral environment for the 
catalytic center. Ward and co-workers applied this to the creation of palladium-ArMs for Suzuki-
cross coupling 92  and allylic alkylation 93  and rhodium-ArMs for C–H activation/annulation 
reactions 94 . Based on their early work on ruthenium-ArMs for olefin metathesis 95 , the team 
developed a system for selective assembly of artificial ‘metathases’ within the periplasm of E. coli 
cells through the fusion of Sav with the signal peptide OmpA96. This in vivo construction strategy 
substantially expedited application of directed evolution, leading to an evolved metathase with 
higher activity than the free 2nd-generation Grubbs catalyst towards a ring-closing metathesis 
reaction. Recently, the Rovis lab also reported a monomeric streptavidin (mSav) Rh(III)-ArM for 
enantioselective C–H activation/annulation with acrylamide hydroxamate esters and styrenes for 
the synthesis of a variety of substituted δ-lactams (Fig. 1.5.a) 97. Artificial transfer hydrogenases 
(ATHases) based on iridium cofactors have been constructed with the biotin-Sav framework, and 
engineering the protein has enabled enantioselective reduction of ketone, imine and quinoline 
substrates with high efficiency98,99. A similar non-covalent anchoring strategy based on the high 
binding affinity of an iron(III)-containing azotochelin complex with protein CeuE was also 
employed by Duhme-Klair for the assembly of an Ir-based ATHase; interestingly, the 
(dis)association of the cofactor could be tuned through the different oxidation states of the iron 
center100. A recent study of an ArM created with an albumin binding protein demonstrated prodrug 
activation of an anticancer agent through ring-closing metathesis101. 
ArMs can also be assembled through covalent linkages of metallo-cofactors to the protein. The 
thiol group on cysteine is typically used as a handle for covalent assembly via nucleophilic 
substitution or conjugate addition, as demonstrated for the Ru-based olefin metathases reported 
by Hilvert102 and Rh(I)-based olefin hydroformylase reported by Jarvis and Kamer103. However, 
selective ArM assembly with this thiol-linkage strategy is difficult when the protein has multiple 
accessible cysteine residues. Lewis and co-workers thus used a genetically-encoded 
azidophenylalanine (pN3Phe) for specific coupling with strained alkyne-modified metallocofactors 
through click chemistry104. They selected a prolyl oligopeptidase (POP) featuring a large internal 
cavity as the protein scaffold and constructed diRh(II)-ArMs through the cycloaddition between a 
strained alkyne pre-installed on a dirhodium catalyst and a pN3Phe residue in the active site of 
POP105. This rapid and selective assembly system allowed them to develop a practical platform to 
evolve diRh(II)-ArMs for stereo-selective cyclopropanation of styrenes with donor-acceptor diazos 
using random mutagenesis and screening (Fig. 1.5.b)106. 
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Figure 1.5. Different strategies for artificial enzyme assembly. a, Artificial Rh(III)-enzyme-catalyzed C–H 
activation/annulation. b, Artificial diRh(II)-enzyme-catalyzed olefin cyclopropanation. 
Binding of metals or metal complexes with coordinating residues represents an alternative 
strategy for constructing ArMs. Ueno, Watanabe and co-workers reported a ‘Suzukiase’ enabled by 
ligation of a [Pd(allyl)Cl]2 complex in apo-ferritin107. Metalation of native carbonic anhydrase (hCA) 
with a [Rh(acac)(CO)2] complex generated a hydroformylase, and further protein engineering 
helped to improve the overall enzyme activity and selectivity for the linear aldehyde product over 
the branched one108. The Roelfes group also utilized coordinating ncAAs to bind metal ions for new 
catalytic functions, as exemplified by the Cu(II)-ArMs for Friedel‒Crafts alkylation of indoles109 and 
hydration with α,β-unsaturated ketones110. A cofactor switch strategy has also been realized to 
generate ArMs. Hartwig, Clark and co-workers explored a set of iridium-substituted ArMs 
generated from myoglobin 111  and cytochrome P450 112  for carbene C–H insertion reactions. 
Engineered Ir-ArMs are also able to carry out cyclopropanation of unactivated or internal alkenes113 
and intramolecular nitrene C–H insertion114. It is interesting to note that most of these functions 
have been demonstrated with engineered iron-hemeproteins that are fully genetically encoded. 
Artificial enzymes with non-natural catalytic centers can be constituted in a fully genetically-
encoded scenario using non-canonical amino acid (ncAA) incorporation. A wide range of ncAAs 
can now be genetically encoded and incorporated into protein scaffolds, which allows introduction 
of unnatural cofactors for new catalytic functions. A recent review by Budisa summarizes the 
development of biocatalysts using this genetic strategy115. Most examples only employ ncAAs to tune 
the properties of enzyme active sites or natural cofactors and to enhance the native catalytic 
functions. Until now, there are only a few examples of using catalytically functional ncAAs for new 
enzymatic activity, among which is the use of p-aminophenylalanine (pAF) for catalytic 
condensation of carbonyls with hydrazines and hydroxylamines by the Roelfes’ group116,117. And, 
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recently, the Green lab designed and evolved an artificial hydrolytic enzyme using an 
unconventional mechanism based on a non-canonical Nδ-methylhistidine (Me-His) as the 
catalytically functional residue118. 
Reaction design based on the selection of suitable catalytic scaffolds together with protein 
engineering has produced artificial enzymes for synthetically important chemical transformations. 
However, compared to natural enzymes, most artificial enzymes still exhibit low catalytic efficiency 
with limited turnovers and are usually not as versatile as the best small-molecule catalysts for the 
same type of reactions. Preparation of most ArMs still requires tedious processes, including 
chemical synthesis of specific metal cofactors, purification of the apo-proteins followed by 
assembly steps, and sometimes removal of excess cofactor from the system, which render tuning by 
directed evolution difficult. Developing versatile, amenable, readily evolvable systems is an 
important challenge for future research. 
 
1.6 Conclusion and outlook 
The third wave of biocatalysis, starting in the early 1990s and empowered by directed evolution 
and other methods, saw solutions to many practical problems in enzyme catalysis, including 
enzyme stability issues, limitations in substrate breadth, efficiency, selectivity, and others119. These 
developments laid a solid foundation for widespread adoption of biocatalysis in pharmaceuticals, 
fine chemicals, agriculture, materials and more120. In a recent perspective, Bornscheuer describes a 
fourth wave of biocatalysis121 with discovery of new enzyme classes and development of non-
natural activities as major new directions. These efforts lead not only to a broader appreciation of 
enzymes’ capabilities but also fulfill the demand for new, sustainable methods in organic 
synthesis122. 
We predict that enzymes invented in the laboratory will become powerful complements and 
alternatives to synthetic catalysts. For example, engineered hemeprotein carbene and nitrene 
transferases, unknown less than ten years ago, are capable of catalyzing diverse transformations 
which are also accessible with synthetic catalysts based on rhodium, iridium and other transition 
metals. However, directed evolution has enabled the enzymes to display orders of magnitude higher 
turnovers, using an earth-abundant iron center; the enzymes also have selectivities that none of the 
small-molecule catalysts can offer. Perhaps most exciting, the enzymes can make molecules that are 
inaccessible to small-molecule catalysts. It is thrilling to realize that the ability of enzymes to control 
reaction intermediates and specifically accelerate a desired reaction can now be used to control 
chemistry invented by us! 
On the other hand, many of the new enzymes described here still exhibit low catalytic 
efficiencies, limited substrate ranges and moderate selectivities. It is reasonable to think that a 
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natural enzyme co-opted for new chemistry or an artificial enzyme assembled from a protein 
scaffold and a synthetic cofactor does not have an active site that is optimal for the entire 
mechanistic pathway of a new reaction. Directed evolution can step in to reorganize enzyme 
structures for non-natural catalysis, but this requires systems for mutagenesis and screening to 
identify beneficial changes in the protein sequence. We can anticipate that improved rational 
protein design as well as new protein engineering methods based on machine learning will help 
navigate the landscape of enzyme activities and protein sequence to guide further engineering with 
reduced experimental effort123. 
The field still has to grapple with the fact that the catalytic repertoire of enzymes is still quite 
restricted compared to synthetic methods. For example, organofluorine moieties are particularly 
important in medicinal chemistry, but until now only one class of enzyme, fluorinase, is known to 
catalyze a C‒F bond-forming reaction with high substrate specificity124. Bimolecular cycloadditions, 
developed by synthetic chemists to build various ring structures in a modular way, are barely 
utilized by natural enzymes125. Furthermore, most newly identified enzymes are not robust enough 
for synthetic or industrial application. Compared to transaminases, for example, which natively 
catalyze C–N bond formation and are also used widely in the pharmaceutical industry126, the recent 
enzymatic C–H amination strategy using nitrene transfer to a C–H bond provides a straightforward 
way to get to the same targets without needing a pre-installed carbonyl functionality. However, 
utility for synthetic purposes necessitates further improvements in the enzyme and reaction 
engineering; the enzymes also have to be made broadly available to users. In principle, genetically 
encoded catalysts are available to anyone with access to the sequence. In practice, however, few 
synthetic laboratories have the expertise and equipment to exploit them. 
Overall, we see a bright future for enzymes in a world that needs clean, efficient catalysts. New 
activities will be discovered at an ever faster pace as chemists look at enzymes with their goals in 
mind. The current challenges are feasible and worthy targets for creative problem solvers. 
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Chapter 2 
 
ENZYMATIC CONSTRUCTION OF HIGHLY STRAINED CARBOCYLES, 
BICYCLOBUTANES AND CYCLOPROPENES 
 
Material for this chapter appears in: (1) Chen, K.; Huang, X.; Kan, S. B. J.; Zhang, R. K.; Arnold, F. 
H.*, Enzymatic construction of highly strained carbocycles. Science 360, 71–75 (2018). (2) Chen, K.; 
Arnold, F. H.*, Engineering cytochrome P450s for enantioselective cyclopropenation of internal 
alkynes. J. Am. Chem. Soc. 142, 6891–6895 (2020). 
 
2.1 Abstract 
Small carbocycles are structurally rigid and possess high intrinsic energy due to their 
significant ring strain. These unique features lead to broad applications of these structures in 
different fields, but also create challenges for their construction. We report the discovery and 
engineering of hemeproteins that catalyze the formation of chiral bicyclobutanes, one of the most 
strained four-membered carbocycles, via successive carbene addition to unsaturated carbon‒
carbon bonds. Enzymes that produce cyclopropenes, putative intermediates to the bicyclobutanes, 
were also identified. These genetically-encoded proteins are readily optimized by directed evolution, 
function in Escherichia coli, and act on structurally diverse substrates with high efficiency and 
selectivity (up to 5760 TTN and >99.9% ee), providing an effective route to an array of chiral 
strained structures. This biotransformation is easily performed on preparative scale and the 
resulting strained carbocycles can be derivatized, opening myriad potential applications. 
 
2.2 Introduction 
 In cyclic organic molecules, ring strain arises from distortions of bond angle and bond length, 
steric clashes of non-bonded substituents, and other effects 127 . The simplest carbocycles, 
cyclopropanes and cyclobutanes, possess ring strains of 26‒28 kcal/mol128. Introducing carbon‒
carbon multiple bonds or bridges to these small ring systems induces additional strain as well as 
structural rigidity. For example, cyclopropenes with an endo-cyclic double bond bear a strain of 54 
kcal/mol, whereas bicyclo[1.1.0]butanes, folded into puckered structures, distinguish themselves as 
one of the most strained four-membered carbocycles with around 66 kcal/mol strain (Fig. 2.1.a). 
These carbocycles are particularly attractive intermediates in chemical and materials synthesis, 
since they can undergo strain-release transformations to furnish a myriad of useful scaffolds129-132. 
The structural rigidity imparted by strained rings in supramolecular materials can lead to 
interesting physical properties, such as mechanical stability 133  and high glass-transition 
temperature134. The intrinsic energy of these strained structures can also be relieved in response to 
exogenous force, which leads to radical changes in physical properties (e.g. conductivity), a feature 
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highly desirable for stimulus-responsive materials135,136. 
High ring strain, however, greatly increases the difficulty of synthesis. A commonly used 
method for preparing bicyclobutanes starts from dibromo-2-(bromomethyl)cyclopropane 
substructures and utilizes organolithium reagents for lithium-halogen exchange followed by 
nucleophilic substitution under rigorously anhydrous and cryogenic conditions. An alternative 
route relies on the double transfer of a carbene to alkynes, but the few examples in the literature are 
mostly limited to methylene carbene137-139. Asymmetric bicyclobutane construction is particularly 
challenging, with multiple chiral centers generated at the same time140,141 (Fig. 2.1.b). Cyclopropene 
synthesis through enantioselective single carbene addition to alkynes also requires chiral transition 
metal catalysts based on rhodium142,143, iridium144 and cobalt145. Development of a sustainable 
catalytic system that performs with high efficiency and selectivity under ambient conditions would 
be a significant advance for construction of these useful, highly strained carbocycles. 
 
Figure 2.1. Strained carbocycles. a, Ring strain in small carbocycle systems. b, Two major synthetic methods 
for bicyclobutane formation. *Calculated strain energy values for hypothetical bicyclo[1.1.0]but-1(3)-ene and 
tricyclo[1.1.0.02,4]butane (tetrahedrane) structures. 
Enzymes, the catalytic workhorses of biology, are capable of accelerating chemical 
transformations by orders of magnitude while exhibiting exquisite control over selectivity 146 . 
Although nature synthesizes various cyclopropane-containing products 147 , cyclopropene or 
bicyclobutane fragments are extremely rare (Fig. 2.2)148,149. This may be attributed to the lack of 
biological machinery for synthesizing these motifs and/or the instability of these structures under 
biological or natural product isolation/purification conditions. Nevertheless, we envisioned that 
existing enzymes could be repurposed to forge strained carbocycles by taking advantage of their 
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catalytic promiscuity6,7,10,150, 151 in the presence of non-natural substrates and by using directed 
evolution to increase the newly-discovered activity and selectivity152. 
 
Figure 2.2. Cyclopropenes and bicyclobutanes in natural products. The proposed biosynthesis of the 
bicyclobutane fragment in a linolenic acid is outlined. 
In the past several years, we and others have engineered natural hemeproteins to catalyze 
reactions not known in nature61,62,67,71,75,76,85,86. We hypothesized that carbene transfer to triple bonds 
with a heme-dependent enzyme might afford highly strained cyclopropene and bicyclobutane 
structures and do so enantioselectively. We anticipated several challenges at the outset, especially 
in bicyclobutane formation, as it involves two sequential carbene additions to the alkyne substrate: 
(1) the enzyme would need to bind the alkyne in a specific conformation in order to transfer the 
carbene enantioselectively; (2) the high-energy cyclopropene intermediate generated by the first 
carbene addition would need to be accepted and stabilized by the protein; (3) compared to 
methylene carbene used previously, a substituted carbene (e.g. with an ester group) might hinder 
access of the cyclopropene to the iron-carbenoid; and (4) the protein would also be expected to 
possess precise stereocontrol over the second carbene transfer step regardless of structural 
differences between the initial alkyne and the cyclopropene intermediate. Despite these challenges, 
we decided to investigate whether a starting enzyme with this unusual and non-natural activity 
could be identified, and whether its active site could be engineered to create a suitable environment 
for substrate binding, intermediate stabilization, and selective product formation. 
 
2.3 Bicyclobutane formation from terminal aromatic alkynes 
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2.3.1 Identification of P411 enzymes capable of carbene transfer to alkynes 
We first tested whether free heme (± bovine serum albumin), which is known to catalyze 
styrene cyclopropanation, could transfer carbene to an alkyne substrate. Reactions using ethyl 
diazoacetate (EDA) and phenylacetylene (1a) as substrates in neutral buffer (M9-N minimal 
medium, pH 7.4) at room temperature, however, gave no cyclopropene or bicyclobutane product. 
Next, a panel of hemeproteins including variants of cytochromes P450 and P411, cytochrome c and 
globins in the form of E. coli whole-cell catalysts were tested for the desired transformation under 
anaerobic conditions. Most of the hemeproteins tested were ineffective, except for several highly 
engineered P411 variants (Table 1). Interestingly, these P411 variants are closely related, with only a 
few mutations away from each other, but gave very different product outcomes (Fig. 2.3). Variant 
P411-P I263W, synthesized an unexpected furan product (3b) with a total turnover of 210. However, 
a related variant, P411-P I263F with only one mutation away, provided a product mixture of 3b and 
the desired bicyclobutane product 2a. However, several further variants, P411-P4 and P411-E10, 
which were initially evolved for different nitrene-transfer reactions, sulfimidation80 and C–H 
amination reactions76, afforded the bicyclobutane products almost exclusively. 
 
Figure 2.3. Enzymatic carbene transfer to alkynes for bicyclobutane synthesis. a, Overall reaction of 
carbene transfer to an alkyne catalyzed by an engineered hemeprotein. b, Proposed catalytic cycle of carbene 
transfer to phenylacetylene to form cyclopropene and bicyclobutane structures. *Simplified heme cofactor is 
presented here. 
Since other furan analogs have been identified as adducts of carbenes and alkynes153, we were 
curious as to how furan 3b was generated and how different enzyme variants exerted different 
chemo-selectivity. Preliminary kinetic study of the enzymatic reaction with variant P411-P I263W 
revealed that a cyclopropene product was formed at the beginning of the reaction and then 
gradually disappeared as the furan adduct was slowly formed (Fig. A-2 in Appendix A). This 
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observation suggests that the formation of the furan adduct might result from the rearrangement 
of the unstable cyclopropene intermediate (3a). Alternatively, another possible route to the furan 
3b could be via a formal [3+2] cycloaddition154 between the carbene intermediate and the alkyne 
substrate, as elucidated in other metallo-carbene systems. 
Table 2.1. Screening of different hemeproteins for bicyclobutane formation. *n.d. = not detected. 
 
To gain more insight into the reaction details, we applied DFT calculations to study the 
reaction mechanism first with a truncated heme model. The computational study revealed a step-
wise radical-addition pathway for carbene transfer to alkyne, where the resulting intermediate can 
easily rotate around the newly formed C–C bond, giving two conformations at similar energy levels, 
one eclipsed and another staggered (Fig. A-4 in Appendix A). The two conformations undergo 
different cyclization processes, forming the cyclopropene and the furan products, respectively. 
Further molecular dynamic simulation in the active sites of different enzyme variants suggested 
that the active-site mutations, especially the residue at position 263, play a significant role in 
controlling the intermediate conformation, thus leading to different product outcomes (Fig. A-5 in 
Appendix A). Further mechanistic study is still ongoing to obtain more information on reaction 
mechanism and selectivity. 
 
2.3.2 Directed evolution of P411-E10 for bicyclobutane synthesis 
According to the screening results, variant P411-E10 (= P4 A78V A82L F263L), which was 
engineered from P4 for nitrene-transfer reactions, catalyzed the desired transformation with 530 
TTN. NMR analysis revealed an exo, endo-configuration of the enzymatically-produced 
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bicyclobutane 2a, which is distinct from the only reported achiral endo, endo-isomer, made using 
an osmium-porphyrin complex155,156. To further improve the catalytic efficiency for bicyclobutane 
formation, we then chose this P411-E10 variant as the starting template for directed evolution of a 
more efficient bicyclobutane-constructing enzyme. 
 
Figure 2.4. Directed evolution of P411-E10 for bicyclobutane synthesis. Active-site structure of P411-E10 
(PDB ID: 5UCW) is shown here, and amino acid residues V78, L263, S438 and S400 (heme axial ligand) are 
highlighted. Reactions in quadruplicate were performed on analytical scale using suspensions of E. coli 
expressing P411-E10 variants (OD600 = 10–30), 10 mM phenylacetylene (1a), 10 mM EDA, 5 vol% EtOH, M9-N 
buffer (pH 7.4) at room temperature under anaerobic conditions for 6 h. TTN refers to the total desired product, 
as quantified by GC, divided by total hemeprotein. 
As the active-site residues have been found to be important to enzyme activity and selectivity, 
we then performed site-saturation mutagenesis (SSM) of variant E10 at various active-site positions 
and screened whole E. coli cells expressing the mutated proteins for improved production of 
bicyclobutane 2a (Fig. 2.4). Specifically, as the side chain of residue 263, located right above the 
heme cofactor, has been found to influence the formation of the bicyclobutane product, site 263 
was investigated first. However, the parent enzyme having leucine at this position (263L) turned 
out the most active, and other amino acid residues either lowered the reactivity towards 
bicyclobutane formation or delivered the furan product. In parallel, two additional residues in E10, 
V78 and S438, were also targeted by SSM. Aromatic residues were found to be activating at 78, with 
a phenylalanine (F) or tyrosine (Y) mutation giving 1.5 to 2-fold improvement over E10. This 
beneficial mutational effect may stem from some π-π stacking interaction between the side chain 
and the alkyne substrate or the cyclopropene intermediate. A single S438A mutation on a loop 
residing above the heme also significantly improves the catalytic efficiency, giving >2.5-fold increase 
in total turnover, presumably by releasing space for substrate accommodation. Finally, 
recombination of V78F/Y and S438A mutations led to the discovery of even more powerful 
biocatalysts for bicyclobutane formation; and variant E10 V78F S438A was the most active with 1880 
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TTN to bicyclobutane product 2a. 
 
2.3.3 Evaluation of bicyclobutane scope with the evolved P411 enzyme 
With the evolved E10 V78F S438A variant in hand, we next assayed the bacterial catalyst (E. 
coli harboring E10 double mutant) against a panel of aromatic alkyne coupling partners. 
Biotransformations with 10 different substrates were performed on 0.1 to 0.2 mmol scale. These 
preparative-scale reactions proceeded smoothly to furnish the corresponding bicyclobutanes with 
up to 1760 TTN and 80% yield (Fig. 2.5.a). Additionally, three alkynes, 1k, 1l and 1m, were 
transformed in mmol scale, and bicyclobutanes were isolated in hundred-milligram quantities, 
demonstrating that the biocatalytic transformation is readily scalable. Among the 13 different 
substrates, the engineered P411 hemeprotein did not exhibit strong preference toward specific 
electronic or steric features by the substitutions on the aromatic groups. Electron-deficient halides 
(2b‒2d), which can be used as pre-functionalities for further transformations as well as electron-
rich alkyl or alkoxyl groups (2e‒2h and 2k) at meta- or para-position of the phenyl group were also 
accepted by this enzymatic platform. Even heterocyclic substrates such as thiophene (2j) served as 
suitable alkyne partners, albeit with lower reactivity. 
Free functionalities, including alcohols (2i and 2m) and a second terminal alkyne (2l), are well-
preserved, providing an additional opportunity for derivatization of these products (Fig. 2.5.b). A 
terminal alkyne allows copper-catalyzed click chemistry, through which bicyclobutane 2l can be 
modified with a simple sulfonyl azide (4a) or even decorated with biologically relevant fragments, 
such as a phenylalanine derivative (4b). An unprotected hydroxyl group could also offer the 
possibility of linkage to useful structures. In order to probe the enantiopurity of bicyclobutane 
products, we derivatized 2l and 2m with chiral molecules, L-azido-phenylalanine derivative and 
(R)-Mosher’s acid, respectively, as the diastereomeric excess of these derivatized products would 
inform us the enantiomeric ratio of the bicyclobutanes. In fact, we observed only one diastereomer 
of derivatized bicyclobutanes 4b and 4c by NMR, based on further comparison to the bicyclobutane 
products derivatized with D-azido-phenylalanine derivative and (S)-Mosher’s acid to guarantee the 
diastereomers can be resolved by NMR. These results suggest the specific stereocontrol by the 
enzyme scaffold in the two carbene-transfer steps, leading to only one stereoisomer out of four 
potential ones. In addition, the dicarboxylic esters on the bicyclobutane structure can be reduced 
easily with a mild reducing reagent, LiBH4, to give a diol product 4d with the strained ring preserved, 
while stronger reductants, such as LiAlH4 or DIBAL, destroyed bicyclobutane structure and resulted 
in a cyclobutene product. The diol product 4d allowed for the unequivocal confirmation of the 
bicyclobutane structure and determination of the absolute configuration through X-ray 
crystallography. 
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Figure 2.5. Scope of bicyclobutane formation and further derivatization of bicyclobutanes. a, Scope of 
P411-E10 V78F S438A-catalyzed bicyclobutane formation. Standard conditions of preparative-scale reactions 
(0.1–0.2 mmol scale, unless otherwise indicated): suspension of E. coli (OD600=15–20) expressing P411 E10-V78F 
S438A, 1.0 equiv. aromatic alkyne, 2.0–4.0 equiv. EDA, 10–15 mM D-glucose, 1–5 vol% EtOH, M9-N buffer (pH 
7.4) at room temperature under anaerobic conditions for 12 hours. Isolated yields. TTN determined based on 
isolated yields. b, Derivatization of bicyclobutane products. a) and b) copper-catalyzed click cyclization of 2l 
with azide substrates; c) esterification of 2m with Mosher’s acid; d) ester reduction of 2k to diol with LiBH4. 
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2.4 Cyclopropene formation from terminal aliphatic alkynes 
2.4.1 Identification and evolution of P411 enzymes for cyclopropenation 
Having established a biocatalytic platform for bicyclobutane construction, we next asked 
whether the enzyme could stop at the cyclopropene product if less reactive aliphatic alkynes are 
used. To this end, we examined enzyme variants from the P411-P lineage for cyclopropene formation, 
using 4-phenylbutyne (5a) and EDA as starting reagents. Encouragingly, P4 catalyzed the desired 
cyclopropenation with 260 TTN and 91% ee. We then performed further evolution using P4 as the 
engineering parent to improve its catalytic efficiency for cyclopropene synthesis. 
We first targeted position 87 for site-saturation mutagenesis, as this site is known for its 
importance to substrate recognition in P450-catalyzed oxidation chemistries157. Interestingly, three 
mutations were observed with similar activity but very different enantioselectivities during library 
screening (Fig. 2.6). Tryptophan mutation (A87W) improved enantioselectivity to 94% ee. However, 
a phenylalanine mutation (A87F) completely flipped the stereo-selectivity, giving ‒94% ee, while 
only a small enantioselectivity (‒24% ee) was obtained with an isoleucine mutation (A87I). It is 
pretty striking to us that tryptophan and phenylalanine mutations gave the opposite 
enantioselectivities, as they are both aromatic residues featuring similar structural and electronic 
properties. One possibility is that the two residues may have different orientations in the active site, 
therefore blocking one side for substrate approaching. However, the branched isoleucine residue 
does not give a clear preference on which side the substrate can approach from. Alternatively, 
mutations at site 87 may lead to a major effect on the orientation of the carbene intermediate, thus 
exerting distinct stereo-preference for cyclopropenation. No matter which scenario it is, this result 
has suggested that residue 87 can also exert precise stereocontrol for non-native carbene chemistry. 
 
Figure 2.6. Mutational effect at site 87 on enantioselectivity of cyclopropenation. One possible scenario 
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is shown here to elucidate the origin of stereocontrol by residue 87. 
Using P4-A87F and P4-A87W as parents, single- and double-site-saturation mutagenesis and 
screening were conducted sequentially to improve both reactivity and selectivity (Fig. 2.7). The final 
K10 and C6 variants performed with >10-fold higher reactivity compared to the initial P4 variant 
and with excellent stereocontrol (99.1% ee and 99.9% ee, respectively). During the evolution, we 
also noticed that distinct mutations were obtained at the same sites for cyclopropenation with the 
opposite enantioselectivities, such as glycine (G) and phenylalanine (F) at site 437, valine (V) and 
proline (P) at site 327, and methionine (M) and glycine (G) at site 261. These results indicate that 
different orientations of substrate binding were imposed by the original mutation at site 87, and 
evolution helped to further reorganize the active site to improve the specificity of substrate binding 
and also facilitate the desired cyclopropene formation. 
 
Figure 2.7. Directed evolution of P411-P4 for enantio-divergent synthesis of cyclopropenes. Active-site 
structure of P411-E10 (PDB ID: 5UCW) was used to guide directed evolution, and amino acid residues targeted 
for mutagenesis are highlighted. Reactions in quadruplicate were performed on analytical scale using 
suspensions of E. coli expressing P411-P4 variants (OD600 = 10–30), 10 mM 4-phenylbutyne (5a), 10 mM EDA, 5 
vol% EtOH, M9-N buffer (pH 7.4) at room temperature under anaerobic conditions for 12 h. TTN refers to the 
total desired product, as quantified by GC, divided by total hemeprotein. 
 
2.4.2 Scope evaluation of enzymatic cyclopropenation 
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With the evolved P411 enzymes for cyclopropene synthesis, we next set to evaluate the substrate 
range of this enzymatic platform. We focused on P411-C6 and examined structurally diverse 
aliphatic alkynes. Enzymatic reactions with 12 alkynes in preparative scale (up to 5.0 mmol scale) 
afforded the desired cyclopropenes with TTNs ranging from hundreds to thousands and good to 
excellent stereoselectivities (Fig. 2.8.a). Alkynes with a linear carbon chain (5b) or cyclic fragments 
(5g, 5h and 5j) all served as good substrates. Different functional groups, including ether (5f, 5h, 5i 
and 5l), ester (5d), acetal (5e), and chloride (5k), were well-tolerated. In fact, other functionalities, 
which can oftentimes inhibit general transition metal catalysts, such as free alcohols (5m), tertiary 
amines and heterocycles, were found to be compatible with our enzymatic system (Fig. 2.8.a and 
Table A-7 in Appendix A). Further optimization of reaction conditions with slow addition of EDA, 
for example, would likely improve the isolated yields, as demonstrated for cyclopropene 6h (from 
66% yield to 94% yield). 
 
Figure 2.8. Scope of cyclopropene formation and further derivatization of cyclopropenes. a, Scope of 
P411-C6-catalyzed cyclopropene formation. Standard conditions of preparative-scale reactions (0.08–0.4 mmol 
scale): suspension of E. coli expressing P411-C6 (OD600 = 10–32), 10–150 mM alkyne, 1.0–4.0 equiv EDA (6.0 
equiv for 5m), 10–15 mM D-glucose, 1–5 vol% EtOH, M9-N buffer (pH 7.4) at room temperature under 
anaerobic conditions for 12 hours. Isolated yields. TTN determined based on isolated yields and enantiomeric 
excess (ee) determined by chiral HPLC. b, Enzymatic cyclopropenation at mmol scale and derivatization of 
corresponding products. a) copper-catalyzed addition to cyclopropene 6a for synthesizing a multi-substituted 
cyclopropane; b) Diels-Alder reaction of cyclopropene 6h with 2,3-diMe-butadiene to form a fused ring system. 
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Cyclopropenes are used as synthetic building blocks158, bio-orthogonal imaging precursors159, 
and monomers in polymer synthesis160. Our ability to construct these motifs using bacteria at scale 
allows us to further explore their potential utility in diverse fields. Here we also present two simple 
transformations of cyclopropenes to build a multi-substituted cyclopropane 7a and a fused ring 
system, bicyclo[4.1.0]heptene 7b (Fig. 2.8.b), both of which are substructures common in 
pharmaceutical candidates and bioactive natural products. 
 
2.5 Cyclopropene formation from internal alkynes 
2.5.1 Background on cyclopropenation of internal alkynes 
Until now, our P411 enzymes as well as small-molecule transition metal catalysts based on 
rhodium141,142,161-165, iridium144 and cobalt145 have been shown to catalyze carbene transfer to terminal 
alkynes to yield enantio-enriched cyclopropenes. However, enantioselective carbene transfer to 
internal alkynes still remains largely unexplored. Only two systems with chiral gold/silver166 or 
rhodium167 (co-)catalysts have been reported to take internal aromatic alkynes for asymmetric 
cyclopropene synthesis with good stereoselectivities (Fig. 2.9.a). These systems require precious 
metal catalysts in relatively high loading together with complicated ligands and have not been 
shown to work with internal aliphatic alkynes. We wanted to develop an efficient biocatalytic 
platform that uses earth-abundant iron to access internal cyclopropenes. 
 
Figure 2.9. Catalytic cyclopropenation of internal alkynes. a, The only examples in literature on 
enantioselective cyclopropenation of internal alkynes. b, Rationalization of steric effect in different 
mechanisms of cyclopropenation with hemeprotein system. 
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With more and more challenging non-native reactions (based on carbene and nitrene transfers) 
achieved with our P450-based enzymatic platform, we hypothesized that P450 enzymes may have 
the potential to accomplish the difficult task, carbene transfer to internal alkynes for cyclopropene 
construction. The major difficulty for internal alkyne cyclopropenation lies in the severe steric clash 
between the linear π-system and the planar heme cofactor, especially if the reaction involves a 
concerted carbene-transfer mechanism168 (Fig. 2.9.b). However, our previous computational study 
has revealed a step-wise carbene-transfer process for hemeprotein-catalyzed cyclopropenation with 
terminal alkynes. We thus reasoned that proper engineering of the enzyme active site may help to 
accommodate internal alkyne substrates and meanwhile facilitate the desired carbene transfer 
through a step-wise pathway to afford cyclopropene products. 
 
2.5.2 Identification and evolution of P411 enzymes for internal cyclopropenation 
We initiated investigation of internal aromatic alkyne cyclopropenation using ethyl 
diazoacetate (EDA) as the carbene precursor and 1-phenylbutyne (8a) as the model alkyne substrate. 
Screening various hemeprotein variants based on cytochromes P450 and P411, cytochromes c and 
globins in the form of whole E. coli cell catalysts identified a P411 variant, P411-C10, that formed the 
desired internal cyclopropene. P411-C10 belongs to the family of P411CHF (five amino acid 
substitutions away), which was evolved for a carbene C–H insertion reaction77. Surprisingly, the 
cyclopropene product 9a synthesized by P411-C10 was determined to be a single enantiomer, which 
suggests the enzyme scaffold binds the alkyne and directs carbene transfer in a well-defined 
orientation. 
Having identified a promising enzyme, P411-C10, capable of cyclopropenation of an internal 
alkyne 8a with modest activity (55 TTN) but excellent enantioselectivity (>99% ee), we next 
performed directed evolution targeting active-site residues for site-saturation mutagenesis to 
enhance the overall catalytic efficiency (Fig. 2.10). Residue 263, located right above the heme 
cofactor (in the heme domain), was previously found to play an important role in controlling 
carbene transfer to phenylacetylene using other P411 variants. To our delight, screening the enzyme 
library made by site-saturation mutagenesis at residue 263 yielded a tryptophan mutation at this 
site that improved TTN over 11 fold. Sequential mutagenesis targeting sites in the loop regions led 
to beneficial mutations Q437I, S72F and L436R and afforded the highly efficient variant WIRF, with 
2680 TTN towards the desired cyclopropene formation. 
With the evolved P411 variant, C10-WIRF, we evaluated the scope of internal alkynes bearing 
different aromatic rings or carbon chains. Unfortunately, a lot of internal alkynes with substitutions 
on the aromatic ring showed poor to moderate reactivities compared to the model substrate 8a. 
Thinking that the evolved WIRF variant may have acquired some specificity for the non-substituted 
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aromatic ring or for electron-neutral/rich alkynes, we decided to use a less reactive alkyne substrate 
(compared to 8a), 8b, with an electron-deficient para-chloro substitution, to further evolve the 
enzyme (Fig. 2.10). A site-saturation library targeting residue 332 afforded mutation S332G, which 
boosted the total turnover by almost 5 fold. We reasoned that the glycine substitution might help 
make space in the active site to accommodate substrates with substitutions on the aromatic ring. 
Mutagenesis of residues spatially close to 332 was investigated, and two additional beneficial 
mutations, G74A and E70K, yielded the final WIRF_GAK variant with 2320 TTN for substrate 8b. 
 
Figure 2.10. Directed evolution of P411-C10 for internal cyclopropene synthesis. Reaction conditions: 10 
mM alkyne, 10 mM EDA, E. coli harboring P411-C10 variants (OD600 = 15 to 60), D-glucose (25 mM), M9-N 
buffer/EtOH (19:1), anaerobic, 6 h. Product formation was quantified by GC and TTNs were determined based 
on protein concentration. The heme-domain structure of P411-E10 variant (pdb: 5UCW) was used to guide site-
saturation mutagenesis; mutation sites are highlighted. 
To interrogate how evolution improved enzyme activity, we performed whole-cell kinetic 
studies using the two alkyne substrates, 8a and 8b, with respect to different enzyme variants (Fig. 
A-3 in Appendix A). Comparison of the initial reaction rates established that evolution enhanced 
the reaction rate. Relative to parent P411-C10, the evolved variant WIRF catalyzed the 
cyclopropenation reaction of alkyne 8a seventeen times faster; and WIRF_GAK exhibited 4.5-fold 
32 
 
 
improvement in initial rate of cyclopropenation with substrate 8b, compared to WIRF. Evolution 
might have also improved the lifetime of the enzyme variants: WIRF_GAK remained fully active 
towards cyclopropenation of 8b after 2 h, while the formation of product 9b with variant WIRF 
slowed down after 100 min. 
 
2.5.3 Scope study of enzymatic cyclopropenation of internal alkynes 
We then revisited the substrate scope of this biocatalytic platform using the whole lineage of 
cyclopropene-forming enzyme variants (from C10 to WIRF and then to WIRF_GAK) (Fig. 2.11.a). 
The WIRF variant turned out to be efficient for non-substituted or ortho-substituted aromatic 
alkynes (8a, 8c and 8d), catalyzing the desired cyclopropene synthesis with 1200 to 2670 total 
turnovers, while variants from later in the evolution showed impaired activity with these substrates. 
Although we did not specifically evolve the enzyme for activity on meta-substituted aromatic 
alkynes, variant WIRF_G exhibited improved efficiency for a meta-methoxyl alkyne substrate (8f), 
compared to WIRF. For aromatic alkynes bearing para-substitutions or di-substitutions (8b and 8g 
to 8l), the final variant WIRF_GAK catalyzes the desired transformations with unprecedentedly 
high efficiency compared to all previously reported systems for cyclopropene formation. For 
instance, an electronically-withdrawing trifluoromethyl-substituted alkyne (8g) was well-accepted 
by the enzymatic system. It is worth noting that all of the internal cyclopropenes produced 
enzymatically were determined to be single enantiomers (>99.9% ee for all), which further supports 
our hypothesis that the engineered enzymes impose a specific binding orientation of the alkyne 
substrate in the protein active site, allowing for efficient carbene addition to triple bonds with 
perfect stereocontrol. 
To further demonstrate the utility of this highly stereoselective enzymatic platform, we carried 
out large-scale preparation of internal cyclopropenes at mmol scale (Fig. 2.11.b). With a simple 
modification of the reaction conditions using the diazo reagent in excess (2.4 equivalents added in 
three portions), we obtained high isolated yields of the desired cyclopropene products (90% for 9d 
with variant WIRF, and 87% for 9g with variant WIRF_GAK). Interestingly, the enzyme turnovers 
of the large-scale reactions are typically higher than those obtained with analytical-scale ones, 
indicating that the evolved enzymes in whole cells might still retain (partial) activity after the 
reactions and the turnovers were limited by consumption of the diazo substrate. Based on this, we 
also further derivatized the enzymatically-synthesized cyclopropene 9d by sequential 
hydrogenation and ester reduction reactions to afford an all-cis cyclopropane product, which is 
otherwise difficult to prepare due to the cis-stereochemistry of the three substituents on the 
cyclopropane ring. As cyclopropenes are versatile building blocking, allowing for numerous 
transformations to furnish diverse molecular structures via strain-release processes, we anticipate 
that these enantio-pure cyclopropenes readily available through carbene transfer to internal alkynes 
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with our evolved enzymes will find applications in different fields, such as pharmaceutical 
development. 
 
Figure 2.11. Scope of internal cyclopropene formation and further derivatization. a, Scope of P411-C10 
variants-catalyzed internal cyclopropene formation. Reactions were performed in quadruplicate under the 
following conditions: 10 mM alkyne, 10 mM EDA, E. coli harboring P411-C10 variants (OD600 = 10–20), D-
glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 16 h. Product formation was quantified by GC and TTNs 
were determined based on protein concentration. b, Preparative-scale synthesis of internal cyclopropenes and 
further derivatization. 
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2.5.4 Enzymatic cyclopropenation of internal aliphatic alkynes 
Compared to internal aromatic alkynes described above, internal aliphatic alkynes are typically 
more challenging substrates for enantioselective cyclopropene formation in terms of reactivity and 
selectivity. As the aryl groups on aromatic alkynes can provide a stabilizing effect through the 
conjugated system in the carbene transfer process, purely aliphatic alkynes without additional 
intramolecular effects may suffer from a higher energy barrier for carbene transfer. Additionally, 
alkyl groups at the two ends of the triple bond are less easy to distinguish than the alkyl and aryl 
groups on aromatic alkynes. Until now, no catalytic systems have been reported for enantioselective 
cyclopropene synthesis with internal aliphatic alkynes. However, we believed that enzymes can 
accomplish this, as their active sites can provide a unique chiral environment that can recognize 
minor steric differences for chiral induction169. 
Testing the evolved enzymes for a cyclopropenation reaction with internal aliphatic alkyne 8m 
was not fruitful, as only trace activity was detected. With the parent enzyme P411-C10 we observed 
the desired cyclopropene product 9m (Fig. 2.12) with only modest activity (43 TTN). This might be 
because the whole enzyme lineage was evolved for a set of structurally different aromatic alkynes. 
Further screening of variants in the C10 family identified a triple mutant of C10, C10_VLC, which 
catalyzed the formation of internal cyclopropene 9m with improved activity (64 TTN) and perfect 
stereocontrol (>99% ee). We anticipate that further evolution will lead to more efficient enzymes 
for internal aliphatic cyclopropene construction, as we have demonstrated for aromatic alkynes. 
As the parent P411-C10 enzyme was initially engineered for a carbene C–H insertion reaction, 
we took a deeper look at the chemoselectivity between cyclopropenation and C–H insertion77 (Fig. 
2.12). Internal alkyne substrate 8n, bearing a propargylic ether group, was found to mainly undergo 
a carbene insertion reaction into the propargylic C–H bond with high enantioselectivity with 
catalyst P411CHF, while a cyclopropene compound 9n was also detected as a minor product. However, 
P411-C10 reversed the chemoselectivity to favor the cyclopropene 9n as the major product. And a 
third product observed in low proportion in this latter reaction was confirmed to be a furan 
derivative, 9n-2, which may be generated through a [3+2]-cycloaddition154. After intensive screening 
of variants in the families of P411CHF and P411-C10, we discovered two related variants, P411-C11 and 
P411-L8, which could catalyze the C–H insertion reaction and the cyclopropenation reaction with 
even higher activity and selectivity (compared to P411CHF and P411-C10, respectively). A C10 triple 
mutant, C10_PVV, was found to flip the chemoselectivity to favor formation of the furan product. 
These variants are closely related, differing by only a few amino acid substitutions, but gave very 
different chemoselectivities without any specific enzyme evolution. We believe that further 
evolution can improve both catalytic efficiency and selectivity. These results, together with our 
previous demonstration of enzyme-controlled reaction selectivity between C–H insertion and 
cyclopropanation77, highlight how enzyme catalysis can solve chemoselectivity problems in 
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synthetic methodology. 
 
Figure 2.12. Cyclopropenation of internal aliphatic alkynes and chemoselectivity study. Reactions were 
performed in quadruplicate under the following conditions: 10 mM alkyne, 10 mM EDA, E. coli harboring P411 
variants (OD600 = 15 to 20), D-glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 16 h. Product formation 
was quantified by GC and TTNs were determined based on protein concentration. 
 
2.6 Conclusion 
From terminal alkynes to internal alkynes, we have witnessed and explored the potential of 
cytochrome P450 enzymes in carbene-transfer chemistries. Engineering a set of serine-ligated P450 
(P411) enzymes allowed these hemeproteins to be quickly adapted (in 2–6 mutational steps) to 
produce these highly strained structures, including cyclopropenes and bicyclobutanes, highlighting 
the superior evolvability of the P411 scaffolds and their potential to direct the construction of 
complex molecular architectures. Directed evolution helped to reorganize the protein structures 
and thus enabled these desired biotransformations through activation of iron-carbenoid for 
carbene addition to alkynes, stabilization of the reactive cyclopropene intermediate (in 
bicyclobutane formation), and precise stereocontrol of the carbene transfer processes. 
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With terminal alkynes, the engineered enzymatic platform carried out the transformations 
with a surprisingly broad substrate scope with high activity and selectivity, providing a rapid route 
to more than 25 strained carbocycles in preparative scale. The enzymes were also engineered to 
perform the desired cyclopropenation in an enantio-divergent manner through specific 
stereocontrol by key active-site residues. With internal alkynes, the versatile biocatalytic system 
also offers rapid access to an array of structurally diverse internal cyclopropenes with 
unprecedentedly high stereoselectivities (>99.9% ee for all) and efficiencies (up to 5670 TTN). This 
enzymatic platform is also readily scalable for the production of the internal cyclopropenes in 
preparative quantities, with even higher efficiencies compared to the analytical-scale reactions. In 
addition, enantioselective cyclopropenation of internal aliphatic alkynes was shown to be possible. 
The versatility and tunability of these hemeprotein biocatalysts was demonstrated once again with 
chemoselectivity that can be switched among cyclopropenation, carbene C–H insertion and [3+2] 
cycloaddition. 
Not only has the biocatalytic platform developed here expanded the catalytic repertoire of 
these hemeproteins to access highly strained carbocycles, through directed evolution, but also has 
provided synthetic chemists a new, efficient, selective and amenable biocatalytic strategy to 
construct these synthetically challenging structures. We anticipate that further engineering of this 
enzymatic platform would likely allow us to access even broader ranges of strained carbocycles for 
applications in different fields, not limited to synthetic purposes but also including chemical 
biology, material science and others. 
 
2.7 Experimental methods 
See Appendix A for supporting tables and figures, synthesis and characterization of 
compounds, assignment of absolute stereochemistry, and determination of enantioselectivity. 
NMR spectra and calibration curves are in the Supporting Information of the published paper, but 
not included here. 
 
2.7.1 General information 
Unless otherwise noted, all chemicals and reagents were obtained from commercial suppliers 
(Sigma-Aldrich, VWR, Alfa Aesar, Acros, Combi-Blocks, TCI and Ark Pharm) and used without 
further purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were taken using a Bruker Prodigy 400 MHz instrument and are 
internally referenced to the residual solvent peak (chloroform). Data for 1H NMR are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet 
37 
 
 
of doublets), coupling constant (Hz), integration. Sonication was performed using a Qsonica Q500 
sonicator. High-resolution mass spectra were obtained at the California Institute of Technology 
Mass Spectral Facility. Synthetic reactions were monitored using thin layer chromatography (Merck 
60 gel plates) using a UV-lamp for visualization. 
 
2.7.2 Chromatography 
Analytical reversed-phase high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and a Kromasil 100 C18 column (4.6 × 50 mm, 5 µm) with 
water and acetonitrile as the mobile phase and visualization at 210 nm for library screening. 
Analytical normal-phase HPLC was carried out using an Agilent 1200 series instrument and chiral 
columns Chiralpak IC (4.6 mm × 25 cm), IA (4.6 mm × 25 cm), AS-H (4.6 mm × 25 cm) and OJ-H 
(4.6 mm × 25 cm) with n-hexane and isopropanol as the mobile phase and visualization at 210 nm 
for chiral separation. Gas chromatography (GC) analyses were carried out using an Agilent 7820A 
or Shimadzu GC-17A gas chromatograph, FID detector, a J&W HP-5 column (30 m × 0.32 mm, 0.25 
μm film) and CycloSil-B column (30 m × 0.25 mm, 0.25 μm film). Gas chromatography-mass 
spectrometry (GC-MS) analyses were carried out using a Shimadzu GCMS-QP2010SE system and 
J&W HP-5m column. Semi-preparative HPLC was performed using an Agilent XDB-C18 column 
(9.4 × 250 mm, 5 µm) with water and acetonitrile as the mobile phase. 
 
2.7.3 Cloning and site-saturation mutagenesis 
pET22b(+) containing a C-terminal 6x-His tag was used as a cloning and expression vector for 
all enzymes described in this study. Site-saturation mutagenesis was performed using a modified 
QuikChangeTM mutagenesis protocol170. Primer sequences are available upon request. The PCR 
products were digested with DpnI, gel purified, and fragments were assembled using Gibson Mix171. 
The ligation mixture was used to directly transform E. coli strain BL21 E. cloni® (Lucigen). Cells were 
grown using Luria-Bertani medium (LB) or Hyperbroth (AthenaES) (HB) with 0.1 mg/mL ampicillin 
(LBamp or HBamp). Electrocompetent E. coli cells were prepared following the protocol of Sambrook 
et al172. T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New England 
Biolabs (NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N buffer; pH 7.4) was 
used as a buffering system for whole cells, lysates, and purified proteins, unless otherwise specified. 
M9-N buffer was used without a carbon source; it contains 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 
8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2. 
 
2.7.4 Determination of hemeprotein concentration 
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 1. Preparation of cell lysate: Aliquots of ~3 mL OD600 = 60 cells were prepared in 15 mL 
conical tubes, which were then placed on wet ice. Cells were lysed by sonication following the 
program below: sonication for 4 min, 1 second on - 1 second off, 35% amplitude. The sonicated 
samples were then transferred to two Eppendorf tubes, and then centrifuged down (14,000 rpm, 15 
min, 4 °C). The supernatants (~2.5 mL) were then collected to a 5-mL glass vial for analysis. 
2. Hemechrome assay for protein concentration measurement:  
Method 1 (used for 2.3 and 2.4): A solution of sodium dithionite (10 mg/mL) was prepared in 
M9-N buffer. Separately, a solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed 
by centrifugation (10,000 × g, 30 s) to separate the excess aqueous layer to give a pyridine-NaOH 
solution. To a cuvette containing 700 μL protein solution (purified protein or lysate) in M9-N buffer, 
50 μL of dithionite solution (0.1 M in M9-N) and 250 μL pyridine-NaOH solution were added. The 
cuvette was sealed with Parafilm, and the UV-Vis spectrum of the reduced FeII state was recorded 
immediately. To another cuvette containing 700 μL protein solution (purified protein or lysate) in 
M9-N buffer, 50 μL of potassium ferricyanide (0.1 M in M9-N) and 250 μL pyridine-NaOH solution 
were added. The cuvette was sealed with Parafilm, and the UV-Vis spectrum of the oxidized FeIII 
state was recorded immediately. The protein concentration was determined using ε_[557reduced ‒ 
540oxidized] = 23.98 mM‒1cm‒1 (ref 173). 
Method 2 (used for 2.5): A solution of NaOH/pyridine was prepared by mixing 1 mL of NaOH 
aqueous solution (1 M), 2 mL of water and 2 mL of pyridine. To 4.5 mL of NaOH/pyridine solution, 
22.5 μL of K3Fe(CN)6 aqueous solution (0.1 M) was added to make solution 1. A background 
solution was prepared by mixing 500 μL M9-N and 500 μL of the NaOH/pyridine solution, which 
was used for UV background subtraction. When measuring samples with a UV spectrometer, a 
spectrum of a mixed solution (oxidized spectrum) with 500 μL cell lysate + 500 μL solution 1 was 
taken at the wavelength range 380 nm to 650 nm. Subsequently, 5 μL of dithionite solution (0.5 M 
in 0.1 M NaOH solution) was added to the same sample and mixed by pipetting; a spectrum of this 
solution (reduced spectrum) was taken at 380 nm to 650 nm. The protein concentration was 
calculated using the extinction coefficient and dilution factor (2× dilution in volume): ε_[557reduced 
‒ 540oxidized] = 23.98 mM‒1cm‒1. 
 
2.7.5 Expression of P450 and P411 proteins 
E. coli BL21 E. cloni® cells carrying a plasmid encoding a P450 or P411 variant were grown 
overnight in 5 mL LBamp (37 °C, 250 rpm). The pre-culture was used to inoculate 45 mL of HBamp in 
a 125 mL Erlenmeyer flask; this culture was incubated at 37 °C, 220 rpm for 2 h and 15 min. Cultures 
were then cooled on ice (20‒40 min), and expression was induced with isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 5-aminolevulinic acid (ALA) with final concentrations of 0.5 mM 
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and 1.0 mM, respectively. Expression was conducted: (1) at 23 °C, at 130 rpm, for 18–22 h (for 2.3 and 
2.4); (2) at 24 °C, at 140 rpm, for 20 h (± 20 min) (for 2.5). Cultures were then centrifuged (4,500 × 
g, 5 min, 4 °C), and the pellets were resuspended to an OD600 of 60 or 30 in M9-N minimal medium 
(no nitrogen). Aliquots of the cell suspension (3–4 mL) were used to determine the P450 and P411 
expression level after lysis by sonication. The expression level in OD600 = 60 lysates is typically in 
the range of 4‒14 μM for P411-P4 or E10 variants and 6‒13 μM for P411-C10 variants. 
 
2.7.6 Biotransformations 
The cell suspension in M9-N (with a certain OD600) was degassed by sparging with argon in 
sealed vials or flasks for 30 min (no degassing process for 2.5). Separately, a glucose solution (250 
mM in M9-N) was degassed by sparging with argon for 30 minutes. All solutions were uncapped 
and transferred into an anaerobic chamber (oxygen level: < 40 ppm). Resuspended cells (340 µL) 
were added to 2 mL vials, followed by D-glucose (40 µL, 250 mM in M9-N), alkyne (10 µL of an 
EtOH stock), and EDA (10 µL of an EtOH stock). Final concentrations were typically 10.0–20.0 mM 
alkyne, 10.0–20.0 mM EDA (alkyne:EDA = 1:1), and 25 mM glucose; final reaction volume was 400 
µL. The vials were sealed, removed from the anaerobic chamber, and shaken at room temperature 
and 560 or 600 rpm for a set time. After the reaction was completed and the vials removed from the 
anaerobic chamber, internal standard 1,3,5-trimethoxybenzene, 1,2,3-trimethoxybenzene or ethyl 2-
phenylacetate (20 μL of 20 mM stock solution in toluene) was added followed by mixed solvent 
(hexane/ethyl acetate = 1:1, 1.0 mL). The mixture was transferred to a 1.7 mL Eppendorf tube, and 
then subjected to vortexing (15 s × 3) and centrifugation (14,000 rpm, 5 min) to completely separate 
the organic and aqueous layers. A sample of the organic layer (0.8 mL) was transferred to a vial for 
GC analysis. The procedures for preparative-scale enzymatic reactions are outlined in detail (See 
Appendix A). 
 
2.7.7 Reaction screening in 96-well plate format 
Libraries (single/double-site-saturation libraries generated employing the “22c-trick” method 
or collections of heme protein variants) were screened in 96-well plates. E. coli libraries for P411 
variants were cultured in LBamp (300 µL/well) at 37 °C, 250 rpm and 80% relative humidity overnight. 
HBamp (950 µL/well) was inoculated with the pre-culture (50 µL/well) and incubated at 37 °C, 230 
rpm, 80% humidity for 2 h and 45 min. The plates were cooled on ice for 30 minutes, and expression 
was induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was conducted: 
(1) at 20 °C and 200 rpm for 18–22 h (for 2.3 and 2.4); (2) at 22 °C and 220 rpm for 20 h (for 2.5). The 
cells were pelleted (4,500 × g, 5 min, 4 °C) and resuspended with M9-N buffer (340 µL/well) and D-
glucose solution (40 µL/well, in M9-N). The 96-well plate was then transferred to an anaerobic 
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chamber. In the anaerobic chamber, alkyne (10 µL/well, 400 mM in EtOH) and EDA (10 µL/well, 
400 mM in EtOH) were added to the plate. The plate was sealed with an aluminum foil and shaken 
inside the anaerobic chamber at 560 or 600 rpm. 
Bicyclobutane formation screening with terminal alkynes. After 16 h, the plate was taken out of 
the anaerobic chamber. The seal was removed and mixed solvent (cyclohexane/ethyl acetate = 1:1, 
600 µL/well) and internal standard 1,3,5-trimethoxybenzene (20 µL/well of a toluene stock) were 
added. The plate was tightly sealed with a reusable silicone mat, vortexed (15 s × 3) and centrifuged 
(4,500 × g, 5 min) to completely separate the organic and aqueous layers. The organic layers (200 
µL/well) were transferred to 300 µL vial inserts, which were then placed in 2 mL vials labeled with 
corresponding wells in the plate for GC or GC-MS analysis (HP-5 column, gradient from 130 °C to 
280 °C, 60 °C/min, 2.5 min). 
Cyclopropene formation screening with terminal alkynes. After 16 h, the plate was taken out of 
the anaerobic chamber. The seal was removed and acetonitrile (580 µL/well) and internal standard 
ethyl phenylacetate (PhEA, 20 mM in acetonitrile, 20 µL/well) were added. The plate was tightly 
sealed with a reusable silicone mat, vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min). The 
supernatant (200 µL/well) was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a 
shallow-well plate for reversed-phase HPLC analysis (Poroshell C18 column, MeCN:H2O = 70:30, 1.2 
mL/min flow, 1.7 min, 210 nm). 
Cyclopropene formation screening with internal alkynes. After 6 h, the plate was taken out of 
the anaerobic chamber. The seal was removed and acetonitrile (580 µL/well) and internal standard 
p-methylanisole (20 mM in acetonitrile, 20 µL/well) were added. The plate was tightly sealed with 
a reusable silicone mat, vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min). The supernatant (200 
µL/well) was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well plate for 
reversed-phase HPLC analysis (Kromasil C18 column, MeCN:H2O = 60:40 or 70:30, 1.2 mL/min flow, 
3.2 min, 210 nm). 
 
2.7.8 Protein purification 
E. coli BL21 E. cloni® cells carrying a plasmid encoding a P411 variant were grown overnight in 
105 mL LBamp (37 °C, 250 rpm). HBamp (1 L) in a 2.8 L flask was inoculated with 100 mL of the pre-
culture and incubated at 37 °C and 240 rpm for 2 h and 15 min. Cultures were then cooled on ice (30 
min) and induced with 0.5 mM IPTG and 1.0 mM ALA (final concentrations). Expression was 
conducted at 20 °C, 130 rpm, for 20 h. Cultures were then centrifuged (4,500 × g, 8 min, 4 °C) and 
the cell pellets frozen at –20 °C. For purification, frozen cells from two such cultures were 
resuspended in buffer A (25 mM Tris-HCl buffer, 20 mM imidazole, 100 mM NaCl, pH 7.5, 4 mL/g 
of cell wet weight), loaded with hemin (1 mg/gram wet cell weight) and powdered DNaseI, and lysed 
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by sonication. To pellet cell debris, lysates were centrifuged (20,000 × g, 20 min, 4 °C). Proteins were 
expressed in a construct containing a 6x-His tag and purified using a nickel NTA column (1 mL 
HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTA or AKTAxpress purifier FPLC system 
(GE healthcare). P411 enzymes were eluted with a linear gradient from 100% buffer A to 100% buffer 
B (25 mM tris, 300 mM imidazole, 100 mM NaCl, pH 7.5) over 10 column volumes. Proteins were 
then pooled, concentrated, and subjected to three exchanges of phosphate buffer (0.1 M KPi, pH 
8.0) using centrifugal filters (10 kDa molecular weight cut-off, Amicon Ultra, Merck Millipore) to 
remove excess salt and imidazole. Concentrated proteins were aliquoted, flash frozen on powdered 
dry ice, and stored at –80 or –20 °C. 
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Appendix A 
 
SUPPLEMENTARY INFORMATION FOR CHAPTER 2 
 
Material for this chapter appears in: (1) Chen, K.; Huang, X.; Kan, S. B. J.; Zhang, R. K.; Arnold, F. 
H.*, Enzymatic construction of highly strained carbocycles. Science 360, 71–75 (2018). (2) Chen, K.; 
Arnold, F. H.*, Engineering cytochrome P450s for enantioselective cyclopropenation of internal 
alkynes. J. Am. Chem. Soc. 142, 6891–6895 (2020). 
 
A.1 Supporting Tables A-1 to A-7 
Table A-1. Detailed information of P450 variants in 2.3.1. 
variant mutations 
P450-WT (CYP102A1)174 - 
P450-CIS61 
V78A F87V P142S T175I A184V S226R H236Q E252G T268A A290V L353V 
I366V E442K (relative to P450-WT) 
P411-CIS62 C400S (relative to P450-CIS) 
P411-“H2-5-F10” L75A I263A L437A (relative to P411-CIS) 
P411-“H2A10” L75A L181A (relative to P411-CIS) 
P411-“H2A10” I263F A328V L75A L181A I263F A328V (relative to P411-CIS) 
P450-Hstar H100N H92N175 V78M H92N H100N L181V T268A C400H L437W (relative to P450-WT) 
P411-CIS T438S (P)67 T438S (relative to P411-CIS) 
P411-CIS T438S I263W I263W T438S (relative to P411-CIS) 
P411-P175 I263F T438S (relative to P411-CIS) 
P411-P280 I263F A328V T438S (relative to P411-CIS) 
P411-P3 V87A I263F A328V T438S (relative to P411-CIS) 
P411-P4 V87A I263F A268G A328V T438S (relative to P411-CIS) 
P411-“A82L” A82L V87A I263F A268G A328V T438S (relative to P411-CIS) 
P411-E1076 A78V A82L V87A I263L A268G A328V T438S (relative to P411-CIS) 
 
Table A-2. P411 variants with activities of carbene transfer to alkyne in 2.3.1. 
 
variant activities 
P411-P - 
P411-P I263W 210 ± 20 TTN, 3b only 
P411-P1 low activity (<20 TTN), 3b:2a ~ 2:1 
P411-P2 23 ± 8 TTN, 2a:3b ~ 10:1 
P411-P3 60 ± 10 TTN, 2a:3b > 20:1 
P411-P4 80 ± 10 TTN, 2a:3b > 50:1 
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P411-“A82L” 280 ± 30 TTN, 2a:3b > 50:1 
P411-E10 530 ± 20 TTN, 2a:3b > 50:1 
Note: TTNs reported are the average of biological replicates from enzymatic reactions using whole-cell 
catalysts (at OD600=30). The errors in all tables are standard deviations. 
 
Table A-3. Directed evolution of P411-E10 in 2.3.2.  
 
P411 variants TTN 
P411-P4 80 ± 10 
P411-“A82L” 280 ± 20 
E10 530 ± 20 
E10-V78Y 800 ± 30 
E10-V78F 1030 ± 60 
E10-S438A 1400 ± 50 
E10-V78Y S438A 1560 ± 70 
E10-V78F S438A 1880 ± 80 
Note: The TTNs were obtained for OD600=30 for P411-P4, P411-“A82L” and P411-E10 variants, OD600=15 for E10-
V78Y and E10-V78F variants, and OD600=10 for E10-S438A, E10-V78Y S438A and E10-V78F S438A variants. 
TTNs reported are the average of biological duplicates. Each biological set contains four experiments. The 
errors in all tables are standard deviations. 
 
Table A-4. Directed evolution of P411-P4 in 2.4.1.  
 
P411-P4 variants TTN ee 
P4 260 ± 30 +91.0% 
P4-A87F (K1) 290 ± 20 ‒94.0% 
K1-F261G T327P (K3) 660 ± 40 ‒94.8% 
K3-S72W L437F (K5) 1100 ± 120 ‒95.8% 
K5-T269L (K6) 1280 ± 80 ‒96.2% 
K6-A78S A330V (K8) 1900 ± 200 ‒98.9% 
K8-L188C T436M (K10) 3300 ± 180 ‒99.1% 
P4-A87W (C1) 240 ± 40 +94.2% 
C1-L437G (C2) 1400 ± 100 +98.7% 
C2-V328Y (C3) 1600 ± 120 +99.6% 
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C3-T327V (C4) 1700 ± 100 +99.8% 
C4-F261M T436H (C6) 2500 ± 140 +99.9% 
Note: The TTNs were obtained for OD600=60 for P411-P4, C1 and K1 variants, OD600=30 for K3, K5, K6, C2, C3 
and C4 variants, and OD600=15 for K8, K10 and C6 variants. TTNs reported are the average of biological 
duplicates. Each biological set contains four experiments. The errors in all tables are standard deviations. 
 
Table A-5. Directed evolution of P411-C10 in 2.5.2.  
 
P411-C10 variant (with substrate 8a) TTN ee 
C10 55 ± 2 >99% 
C10-Y263W (W) 620 ± 15 >99.9% 
C10-A87V 110 ± 10 >99.9% 
C10-Y263W Q437I (WI) 1280 ± 40 >99.9% 
C10-Y263W Q437I S72F (WIF) 2450 ± 60 >99.9% 
C10-Y263W Q437I L436R S72F (WIRF) 2680 ± 100 >99.9% 
Note: The TTNs were obtained for OD600=60 for P411-C10, OD600=30 for C10-W, and OD600=15 for the rest. 
TTNs reported are the average of four experiments. The errors in all tables are standard deviations. 
 
P411-C10 variant (with substrate 8b) TTN ee 
C10 110 ± 10 >99% 
WIRF 300 ± 10 >99% 
WIRF-S332G (WIRF_G) 1440 ± 40 >99.9% 
WIRF-S332G G74A (WIRF_GA) 1610 ± 50 >99.9% 
WIRF-S332G G74A E70K (WIRF_GAK) 2140 ± 40 >99.9% 
Note: The TTNs were obtained for OD600=30 for P411-C10 and WIRF, OD600=20 for the rest. TTNs reported are 
the average of four experiments. The errors in all tables are standard deviations. 
 
Table A-6. List of mutations in P411 variants involved in Chapter 2. 
P411 variant Mutations relative to wild-type P450BM3 
P4 
V78A F87A P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328V L353V 
I366V C400S T438S E442K 
“A82L” 
V78A A82L F87A P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328V 
L353V I366V C400S T438S E442K 
E10 
A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V L353V 
I366V C400S T438S E442K 
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E10-V78Y 
V78Y A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V 
L353V I366V C400S T438S E442K 
E10-V78F 
V78F A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V 
L353V I366V C400S T438S E442K 
E10-S438A 
A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V L353V 
I366V C400S T438A E442K 
E10-V78Y S438A 
V78Y A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V 
L353V I366V C400S T438A E442K 
E10-V78F S438A 
V78F A82L F87A P142S T175I A184V S226R H236Q E252G I263L T268G A290V A328V 
L353V I366V C400S T438A E442K 
K1 
V78A P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328V L353V I366V 
C400S T438S E442K 
K3 
V78A P142S T175I A184V S226R H236Q E252G F261G I263F T268G A290V T327P A328V 
L353V I366V C400S T438S E442K 
K5 
S72W V78A P142S T175I A184V S226R H236Q E252G F261G I263F T268G A290V T327P 
A328V L353V I366V C400S L437F T438S E442K 
K6 
S72W V78A P142S T175I A184V S226R H236Q E252G F261G I263F T268G T269L A290V 
T327P A328V L353V I366V C400S L437F T438S E442K 
K8 
S72W V78S P142S T175I A184V S226R H236Q E252G F261G I263F T268G T269L A290V 
T327P A328V A330V L353V I366V C400S L437F T438S E442K 
K10 
S72W V78S P142S T175I A184V L188C S226R H236Q E252G F261G I263F T268G T269L 
A290V T327P A328V A330V L353V I366V C400S T436M L437F T438S E442K 
C1 
V78A F87W P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328V L353V 
I366V C400S T438S E442K 
C2 
V78A F87W P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328V L353V 
I366V C400S L437G T438S E442K 
C3 
V78A F87W P142S T175I A184V S226R H236Q E252G I263F T268G A290V A328Y L353V 
I366V C400S L437G T438S E442K 
C4 
V78A F87W P142S T175I A184V S226R H236Q E252G I263F T268G A290V T327V A328Y 
L353V I366V C400S L437G T438S E442K 
C6 
V78A F87W P142S T175I A184V S226R H236Q E252G F261M I263F T268G A290V T327V 
A328Y L353V I366V C400S T436H L437G T438S E442K 
P411-C10 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263Y H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L L437Q E442K 
ΔFAD 
P411CHF 
N70E A74P V78L A82L F87A P142S T175I M177L A184V S226R H236Q E252G I263Y H266V 
T268G A290V A328V A330Y L353V I366V C400S T436L E442K ΔFAD 
C10-W 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L L437Q E442K 
ΔFAD 
C10-WI 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L L437I E442K 
ΔFAD 
C10-WIF N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
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E252G I263W H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L L437I 
E442K ΔFAD 
C10-WIRF 
N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263W H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436R L437I 
E442K ΔFAD 
C10-WIRF_G 
N70E S72F A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263W H266V T268G A290V A328V A330Y S332G L353V I366V C400S I401L T436R 
L437I E442K ΔFAD 
C10-WIRF_GA 
N70E S72F V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V A328V A330Y S332G L353V I366V C400S I401L T436R L437I 
E442K ΔFAD 
C10-WIRF_GAK 
N70K S72F V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V A328V A330Y S332G L353V I366V C400S I401L T436R L437I 
E442K ΔFAD 
C10-VLC 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263Y H266V T268G A290V T327V A328V A330Y S332C L353V I366V C400S I401L T436L 
E442K ΔFAD 
P411-C11 
N70E A74T V78L A82L F87A P142S T175I M177L A184V S226R H236Q E252G I263Y H266V 
T268G A290V A328V A330Y L353V I366V C400S T436L E442K ΔFAD 
P411-L8 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263Y A264S H266V E267D T268G A290V T327P A328V A330Y S332A L353V I366V C400S 
I401L T436L E442K ΔFAD 
C10-II 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401L T436L L437I E442K 
ΔFAD 
C10-PVV 
N70E A74G V78L A82L F87V M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263Y H266V T268G A290V T327V A328V A330Y L353V I366V C400S I401L T436L L437P 
E442K ΔFAD 
Note: ΔFAD means FAD domain truncation. See the publications for the nucleotide and amino acid sequences 
of the P411 variants. 
 
Table A-7. Additional alkyne substrates tested with promising reactivity in 2.3.3 and 2.4.2. 
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A.2 Supporting Figures A-1 to A-5 
 
 
 
 
 
 
 
Figure A-1. GC-MS traces of cyclopropene 3a, furan 3b and bicyclobutane 2a. *High temperature (> 250 °C) of 
the GC might degrade the bicyclobutane to some extent, resulting in a broad peak and another small peak (the 
H
CO2EtH
Ph
m/z 188
Ph
H
CO2Et
EtO2C H
H
m/z 274
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whole signal is from pure bicyclobutane 2a). The signal is nonetheless suitable for quantitative analysis. 
 
 
 
Figure A-2. Time courses of furan formation with P411-P I263W variant (top) and bicyclobutane formation 
with P411-E10 variant (bottom). *Reactions were set up in parallel according to the standard procedure using 
whole-cell catalyst (OD600 = 30). The reactions were quenched at certain time points and analyzed by GC-MS. 
Every data point (average of two reaction) is the peak area of cyclopropene 3a, furan 3b or bicyclobutane 2a 
divided by that of internal standard on GC-MS. Cyene = cyclopropene; bicyane = bicyclobutane. 
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Figure A-3. Time courses of whole-cell cyclopropenation with different substrates (top: 1-phenylbutyne, 
bottom: 1-(4-chlorophenyl)butyne) and enzyme variants. *Reactions were set up in parallel according to the 
standard procedure using whole-cell catalyst (OD600 = 15 for C10, WIRF and WIRF_GAK). The reactions were 
quenched at certain time points and analyzed by GC-MS. Every data point (average of two reactions) is the 
peak area of cyclopropenes 9a or 9b divided by that of internal standard on GC. Relative activity was 
normalized by protein concentration. 
 
 
Figure A-4. Mechanism of carbene transfer to alkyne by computational calculation using a simplified iron-
porphyrin model system with an oxygen axial ligand. Gibbs free energy was obtained at the (U)B3LYP-
D3(BJ)/Def2TZVP/PCM(ε = 4)//(U)B3LYP/6-31G(d)+SDD(Fe)/PCM(ε = 4) level. 
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Figure A-5. Molecular dynamic (MD) simulation of reaction intermediates in the active sites of different P411 
variants. Residue 263 may lead to a major influence on the conformation of the intermediate, leading to 
cyclopropene or furan formation. 
 
A.3 Preparation of alkyne substrates 
Oct-7-yn-1-yl cyclobutanecarboxylate (5d) 
 
In a 100 mL round-bottom flask, oct-7-yn-1-ol (0.631 g, 5.0 mmol), 
triethylamine (0.9 mL, 1.3 equiv.) and N,N-dimethylpyridin-4-
amine (DMAP, 61 mg, 10 mol%) in dry DCM (20 mL) was cooled 
to 0 °C. A solution of cyclobutanecarbonyl chloride (0.711 g, 6.0 mmol) in dry DCM (5 mL) was 
added dropwise slowly over 5 min. The reaction was allowed to warm to room temperature and 
stirred for 8 hours. The reaction mixture was diluted with DCM (20 mL) and washed with water (20 
mL) and brine (20 mL), dried over MgSO4, and then concentrated under reduced pressure. The 
crude product was purified by silica column chromatography with hexane/ethyl acetate (20:1) to 
afford 5d (1.02 g, 98%). 1H NMR (400 MHz, CDCl3) δ 4.06 (t, J = 6.7 Hz, 2H), 3.12 (pd, J = 8.5, 1.0 Hz, 
1H), 2.34–2.13 (m, 6H), 2.04–1.83 (m, 3H), 1.69–1.59 (m, 2H), 1.57–1.48 (m, 2H), 1.47–1.32 (m, 4H). 13C 
NMR (101 MHz, CDCl3) δ 175.62, 84.51, 68.25, 64.28, 38.17, 28.54, 28.34, 28.32, 25.45, 25.28, 18.43, 
18.33. HRMS (FAB) m/z: 209.1548 (M+H+); calc. for C13H21O2: 209.1542. 
 
2-(Hept-6-yn-1-yl)-1,3-dioxolane (5e) 
 
In a 250 mL round-bottom flask, DMSO (1.95 g, 25.0 mmol) was 
dissolved in dry DCM (40 mL) and then cooled to ‒78 °C under argon. 
A solution of oxalyl dichloride (2.6 mL, 30.0 mmol) in dry DCM (10 mL) was added dropwise slowly 
over 10 min. After the mixture was stirred at ‒78 °C for 1 h, a solution of oct-7-yn-1-ol (0.631 g, 5.0 
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mmol) in dry DCM (10 mL) was added dropwise slowly over 10 min. The resulting mixture was 
maintained at ‒78 °C for another 2 h before the dropwise addition of triethylamine (7.0 mL, 50.0 
mmol) in dry DCM (10 mL). The reaction was then allowed to warm to room temperature over 1 h 
and stirred for another 2 h. The reaction mixture was diluted with DCM (30 mL) and washed with 
HCl (10%, 50 mL), NaHCO3 (50 mL, sat. aq.), and brine (50 mL), dried over MgSO4, and then 
concentrated under reduced pressure (100 torr). The crude product mixture was used for the next 
step without further purification. The crude product was dissolved in benzene (50 mL) in a 100 mL 
round-bottom flask. Ethylene glycol (0.465 g, 7.5 mmol) and TsOH (130 mg, 0.075 mmol) were 
added. The solution was heated up to a refluxing temperature, 90 °C, and maintained for 2 h. After 
removal of benzene under reduced pressure, the crude product was purified by silica column 
chromatography with hexane/ether (20:1 to 15:1) to afford 5e (0.675 g, 80%). 1H NMR (400 MHz, 
CDCl3) δ 4.85 (t, J = 4.8 Hz, 1H), 4.01–3.91 (m, 2H), 3.90–3.79 (m, 2H), 2.19 (td, J = 7.0, 2.6 Hz, 2H), 
1.93 (t, J = 2.7 Hz, 1H), 1.70–1.61 (m, 2H), 1.59–1.51 (m, 2H), 1.49–1.39 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 104.66, 84.73, 68.32, 64.99, 33.89, 28.78, 28.53, 23.69, 18.45. HRMS (FAB) m/z: 167.1067 
((M+H+)‒H2); calc. for C10H15O2: 167.1072. 
 
5-Isopropoxypent-1-yne (5f) 
 
In a 100 mL round-bottom flask, pent-4-yn-1-ol (0.841 g, 10.0 mmol), 
triethylamine (1.8 mL, 1.3 equiv.) and DMAP (122 mg, 10 mol%) in dry DCM 
(50 mL) was cooled to 0 °C. 4-Methylbenzenesulfonyl chloride (TsCl, 2.10 g, 11.0 mmol) was added 
portion-wise. The reaction was allowed to warm to room temperature and stirred for 6 hours. The 
reaction mixture was diluted with DCM (30 mL) and washed with water (20 mL) and brine (20 mL), 
dried over MgSO4, and then concentrated under reduced pressure. The crude product was purified 
by silica column chromatography with hexane/ethyl acetate (4:1) to afford pent-4-yn-1-yl 4-
methylbenzenesulfonate (2.35 g, 99%).  
 Isopropanol (0.361 g, 6.0 mmol) and tetrabutylammonium bromide (161 mg, 0.5 mmol) were 
dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) was 
added portion-wise to the solution. The resulting mixture was stirred at 0 °C for 1 h before the 
dropwise addition of pent-4-yn-1-yl 4-methylbenzenesulfonate (1.19 g, 5.0 mmol) in anhydrous 
DMF (10 mL). The reaction was allowed to warm to room temperature and stirred for 4 hours. The 
reaction mixture was quenched with NH4Cl (20 mL, sat. aq.) and the product was extracted with 
Et2O (30 mL × 3). The combined organic layer was washed with water (20 mL), brine (20 mL), dried 
over MgSO4, and then concentrated under reduced pressure (200 torr). The crude product was 
purified by silica column chromatography with pentane/ether (10:1) to afford 5f (0.597 g, 95%).  
 
4-((Oct-7-yn-1-yloxy)methyl)tetrahydro-2H-pyran (5h) 
 
In a 500 mL round-bottom flask, oct-7-yn-1-ol (6.31 g, 50.0 
mmol), triethylamine (9.1 mL, 1.3 equiv.) and DMAP (609 mg, 
10 mol%) in dry DCM (200 mL) was cooled to 0 °C. TsCl (10.50 g, 55.0 mmol) was added portion-
wise. The reaction was allowed to warm to room temperature and stirred for 6 hours. The reaction 
mixture was diluted with DCM (100 mL) and washed with water (200 mL) and brine (200 mL), dried 
over MgSO4, and then concentrated under reduced pressure. The crude product was purified by 
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silica column chromatography with hexane/ethyl acetate (10:1) to afford oct-7-yn-1-yl 4-
methylbenzenesulfonate (13.29 g, 95%). 
 In a 100 mL round-bottom flask, (tetrahydro-2H-pyran-4-yl)methanol (0.697 g, 6.0 mmol) and 
tetrabutylammonium bromide (161 mg, 0.5 mmol) were dissolved in anhydrous DMF (50 mL) and 
then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) was added portion-wise to the solution. The 
resulting mixture was stirred at 0 °C for 1 h before the dropwise addition of oct-7-yn-1-yl 4-
methylbenzenesulfonate (1.40 g, 5.0 mmol) in anhydrous DMF (10 mL). Then reaction was allowed 
to warm to room temperature and stirred for 4 hours. The reaction mixture was quenched with 
NH4Cl (20 mL, sat. aq.) and the product was extracted with Et2O (50 mL × 3). The combined organic 
layer was washed with water (20 mL), brine (20 mL), dried over MgSO4, and then concentrated 
under reduced pressure. The crude product was purified by silica column chromatography with 
hexane/ethyl acetate (10: 1) to afford 5h (1.10 g, 98%). 1H NMR (400 MHz, CDCl3) δ 3.96 (ddt, J = 11.5, 
4.6, 1.1 Hz, 2H), 3.43–3.34 (m, 4H), 3.24 (d, J = 6.6 Hz, 2H), 2.18 (td, J = 7.0, 2.7 Hz, 2H), 1.93 (t, J = 
2.7 Hz, 1H), 1.89–1.77 (m, 1H), 1.68–1.61 (m, 2H), 1.60–1.49 (m, 4H), 1.46–1.34 (m, 4H), 1.33–1.25 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ 84.80, 76.11, 71.24, 68.28, 67.90, 35.60, 30.19, 29.70, 28.70, 28.56, 
25.83, 18.49. HRMS (FAB) m/z: 225.1855 (M+H+); calc. for C14H25O2: 225.1855. 
 
((Oct-7-yn-1-yloxy)methyl)cyclopropane (5i) 
 
In a 100 mL round-bottom flask, cyclopropylmethanol (0.433 g, 
6.0 mmol) and tetrabutylammonium bromide (161 mg, 0.5 mmol) 
were dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) 
was added portion-wise to the solution. The resulting mixture was stirred at 0 °C for 1 h before the 
dropwise addition of oct-7-yn-1-yl 4-methylbenzenesulfonate (1.40 g, 5.0 mmol) in anhydrous DMF 
(10 mL). The reaction was allowed to warm to room temperature and stirred for 4 hours. The 
reaction mixture was quenched with NH4Cl (20 mL, sat. aq.) and the product was extracted with 
Et2O (50 mL × 3). The combined organic layer was washed with water (20 mL), brine (20 mL), dried 
over MgSO4, and then concentrated under reduced pressure. The crude product was purified by 
silica column chromatography with hexane/ether (50: 1) to afford 5i (840 mg, 93%). 1H NMR (400 
MHz, CDCl3) δ 3.42 (t, J = 6.7 Hz, 2H), 3.24 (d, J = 6.9 Hz, 2H), 2.18 (td, J = 7.0, 2.6 Hz, 2H), 1.93 (t, 
J = 2.6 Hz, 1H), 1.64–1.57 (m, 2H), 1.56–1.49 (m, 2H), 1.47–1.30 (m, 4H), 1.12–0.97 (m, 1H), 0.58–0.45 
(m, 2H), 0.19 (dt, J = 6.0, 4.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 84.82, 75.73, 70.77, 68.26, 29.78, 
28.72, 28.57, 25.85, 18.49, 10.82, 3.13. HRMS (FAB) m/z: 181.1590 (M+H+); calc. for C12H21O: 181.1592. 
 
Trans-1-(methoxymethyl)-4-((oct-7-yn-1-yloxy)methyl)cyclohexane (5l) 
 
In a 100 mL round-bottom flask, (tran-cyclohexane-
1,4-diyl) dimethanol (2.88 g, 20.0 mmol) and 
tetrabutylammonium bromide (32 mg, 0.1 mmol) 
were dissolved in anhydrous DMF (50 mL) and then cooled to 0 °C. NaH (60%, 960 mg, 24.0 mmol) 
was added portion-wise to the solution. The resulting mixture was stirred at 0 °C for 1 h before the 
dropwise addition of methyl iodide (MeI, 1.5 mL, 24.0 mmol) in anhydrous DMF (10 mL). The 
reaction was allowed to warm to room temperature and stirred for 4 hours. The reaction mixture 
was quenched with NH4Cl (20 mL, sat. aq.) and the product was extracted with Et2O (50 mL × 4). 
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The combined organic layer was washed with water (50 mL), brine (50 mL), dried over MgSO4, and 
then concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane/ethyl acetate (1:1) to afford (trans-4-
(methoxymethyl)cyclohexyl)methanol (2.02 g, 64%). 
In a 100 mL round-bottom flask, (trans-4-(methoxymethyl)cyclohexyl)methanol (0.949 g, 6.0 
mmol) and tetrabutylammonium bromide (161 mg, 0.5 mmol) were dissolved in anhydrous DMF 
(50 mL) and then cooled to 0 °C. NaH (60%, 240 mg, 6.0 mmol) was added portion-wise to the 
solution. The resulting mixture was stirred at 0 °C for 1 h before the dropwise addition of oct-7-yn-
1-yl 4-methylbenzenesulfonate (1.40 g, 5.0 mmol) in anhydrous DMF (10 mL). Then reaction was 
allowed to warm to room temperature and stirred for 4 hours. The reaction mixture was quenched 
with NH4Cl (20 mL, sat. aq.) and the product was extracted with Et2O (50 mL × 3). The combined 
organic layer was washed with water (20 mL), brine (20 mL), dried over MgSO4, and then 
concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane/ethyl acetate (10:1) to afford 5l (743 mg, 56%). 1H NMR (400 MHz, 
CDCl3) δ 3.38 (t, J = 6.6 Hz, 2H), 3.32 (s, 3H), 3.20 (d, J = 6.5 Hz, 2H), 3.18 (d, J = 6.4 Hz, 2H), 2.18 
(td, J = 7.0, 2.7 Hz, 2H), 1.93 (t, J = 2.7 Hz, 1H), 1.86–1.74 (m, 4H), 1.58–1.49 (m, 6H), 1.46–1.30 (m, 
4H), 1.01–0.86 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 84.84, 78.93, 76.90, 71.17, 68.26, 58.98, 38.37 (2 
carbons), 29.73, 29.65, 29.55, 28.73, 28.58, 25.85, 18.50. HRMS (FAB) m/z: 267.2325 (M+H+); calc. for 
C17H31O2: 267.2324. 
 
General procedure for internal aromatic alkyne synthesis (8b and 8d to 8l): 
 
To a 100-mL flask were added aryl bromide or iodide (10.0 mmol, 1.0 equiv.), 2-pentynoic acid 
(1.18 g, 12.0 mmol, 1.2 equiv.), PdCl2(Ph3P)2 (70 mg, 0.1 mol, 1 mol%), 1,4-bis(diphenylphosphino) 
butane (dppb, 86 mg, 0.2 mmol, 2 mol%) and anhydrous DMSO (30 mL). The mixture was stirred 
at room temperature for 3 minutes, and then the flask was capped, degassed and charged with N2. 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 4.4 mL, 30 mmol, 3.0 equiv.) was added to the reaction 
under N2. The reaction was stirred at 110 °C for 12 hours before being cooled to room temperature, 
quenched by NH4Cl (sat. aq., 20 mL) and diluted with water (30 mL). The product was extracted by 
ether (25 mL × 3). The combined organic layer was then washed with water (30 mL) and brine (30 
mL), and dried over magnesium sulfate. The organic layer was filtered and concentrated under 
reduced pressure. Distillation of the crude mixture under high vacuum (<100 Pa, 80-125 °C) gave the 
desired product in 60% to 90% yield and with NMR purity of 98% to >99%. 
 
1-(But-1-yn-1-yl)-4-chlorobenzene (8b) 
 
Compound 8b was prepared following the general procedure using the 
corresponding aryl bromide. The reaction was set up in 80-mmol scale 
and distillation afforded the alkyne 8b as a colorless liquid (11.4 g, 86%). 
1H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.7 Hz, 2H), 7.25 (d, J = 8.7 Hz, 2H), 2.41 (q, J = 7.5 Hz, 2H), 
1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 133.53, 132.88, 128.61, 122.64, 92.86, 78.97, 13.95, 
Me
Cl
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13.24. 
 
1-(But-1-yn-1-yl)-2-fluorobenzene (8d) 
 
Compound 8d was prepared following the general procedure using the 
corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 7.39 (td, J = 7.6, 1.8 
Hz, 1H), 7.24 (dddd, J = 8.2, 7.2, 5.2, 1.8 Hz, 1H), 7.10–7.00 (m, 2H), 2.47 (q, J = 
7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 164.14, 161.66 (d, J = 250.9 Hz), 
133.70, 133.69 (d, J = 1.6 Hz), 129.28, 129.20 (d, J = 8.0 Hz), 123.93, 123.90 (d, J = 3.7 Hz), 115.57, 115.36 
(d, J = 21.3 Hz), 112.65, 112.49 (d, J = 15.8 Hz), 97.28, 97.24 (d, J = 3.3 Hz), 73.31, 13.92, 13.45. 
 
1-(But-1-yn-1-yl)-4-fluorobenzene (8e) 
 
Compound 8e was prepared following the general procedure using the 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 8.8, 
5.4 Hz, 2H), 6.97 (t, J = 8.8 Hz, 2H), 2.40 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 163.39, 160.93 (d, J = 249.2 Hz), 133.46, 133.38 (d, J = 8.2 Hz), 
120.20, 120.17 (d, J = 3.6 Hz), 115.62, 115.40 (d, J = 22.0 Hz), 91.41, 91.40 (d, J = 1.6 Hz), 78.94, 14.03, 
13.18. 
 
1-(But-1-yn-1-yl)-3-methoxybenzene (8f) 
 
Compound 8f was prepared following the general procedure using 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.21 (dd, J = 8.3, 
7.6 Hz, 1H), 7.02 (dt, J = 7.6, 1.2 Hz, 1H), 6.96 (dd, J = 2.6, 1.4 Hz, 1H), 
6.85 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 3.82 (s, 3H), 2.44 (q, J = 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 159.38, 129.36, 125.13, 124.22, 116.46, 114.30, 91.69, 79.92, 55.36, 14.04, 13.24. 
 
1-(But-1-yn-1-yl)-4-trifluoromethylbenzene (8g) 
 
Compound 8g was prepared following the general procedure using 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.2 
Hz, 2H), 7.48 (d, J = 8.2 Hz, 2H), 2.44 (q, J = 7.5 Hz, 2H), 1.25 (t, J = 7.5 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 131.89, 129.38 (q, J = 32.7 Hz), 128.04 (q, J = 3.8 Hz), 125.24 (q, 
J = 38.7 Hz), 124.17 (q, J = 273.0 Hz), 94.62, 78.97, 13.84, 13.28. 
 
1-(But-1-yn-1-yl)-4-difluoromethoxybenzene (8h) 
 
Compound 8h was prepared following the general procedure using 
corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 
8.7 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 6.52 (t, J = 73.7 Hz, 1H), 2.43 (q, J 
= 7.5 Hz, 2H), 1.26 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 150.48, 133.17, 121.47, 119.41, 118.48, 
115.90, 113.31 (t, J = 260.8 Hz), 92.15, 78.90, 13.99, 13.21. 
 
Me
F
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1-(But-1-yn-1-yl)-4-toluene (8i) 
 
Compound 8i was prepared following the general procedure using 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.2 
Hz, 2H), 7.09 (d, J = 7.7 Hz, 2H), 2.41 (q, J = 7.5 Hz, 2H), 2.33 (s, 3H), 1.24 
(t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 137.57, 131.52, 129.07, 121.02, 90.97, 80.00, 21.54, 14.13, 
13.26. 
 
1-(But-1-yn-1-yl)-4-anisole (8j) 
 
Compound 8j was prepared following the general procedure using 
corresponding aryl iodide. 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.9 
Hz, 2H), 6.81 (d, J = 8.9 Hz, 2H), 3.80 (s, 3H), 2.40 (q, J = 7.5 Hz, 2H), 
1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 159.11, 132.97, 116.28, 113.92, 90.17, 79.68, 55.38, 
14.19, 13.24. 
 
4-(But-1-yn-1-yl)-2-methyl-1-chlorobenzene (8k) 
 
Compound 8k was prepared following the general procedure using 
corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 1.9 
Hz, 1H), 7.24 (d, J = 8.2 Hz, 1H), 7.14 (dd, J = 8.2, 1.9 Hz, 1H), 2.40 (q, J = 
7.5 Hz, 2H), 2.33 (s, 3H), 1.23 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 136.09, 134.02, 133.82, 
130.24, 129.04, 122.57, 92.35, 79.13, 20.01, 14.00, 13.24. 
 
4-(But-1-yn-1-yl)-2-methyl-1-methoxybenzene (8l) 
 
Compound 1l was prepared following the general procedure using 
corresponding aryl bromide. 1H NMR (400 MHz, CDCl3) δ 7.24 (dd, J = 
8.3, 2.0 Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 6.75 (d, J = 8.3 Hz, 1H), 3.84 (s, 
3H), 2.42 (q, J = 7.5 Hz, 2H), 2.20 (s, 3H), 1.25 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 157.43, 
133.90, 130.37, 126.69, 115.69, 109.78, 89.78, 79.90, 55.43, 16.16, 14.23, 13.25. 
 
1-Ethoxyhex-3-yne (8m) 
 
Hex-3-yn-1-ol (2.94 g, 30 mmol, 1.0 equiv.) was dissolved in anhydrous DMF 
(60 mL) in a 250-mL flask. NaH (1.44 g, 60% in mineral oil, 36 mmol, 1.2 
equiv.) was slowly added to the solution in portions over 20 min at 0 °C. The resulting mixture was 
stirred at 0 °C for 1.5 h before slow addition of ethyl iodide (3.6 mL, 45 mmol, 1.5 equiv.). The reaction 
was slowly warmed to room temperature over 30 min and then stirred for additional 2 h before 
being quenched by NH4Cl (sat. aq., 20 mL) and diluted with water (30 mL). The product was 
extracted by ether (40 mL × 3). The combined organic layer was then washed with water (50 mL × 
2) and brine (50 mL), and dried over sodium sulfate. The organic layer was filtered and concentrated 
under reduced pressure. The crude product was purified through a silica column using hexane/ethyl 
acetate (100:0 to 20:1) as eluents to afford the alkyne 8m as a clear liquid (3.72 g, 98% yield). 1H NMR 
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(400 MHz, CDCl3) δ 3.51 (td, J = 7.1, 5.3 Hz, 4H), 2.42 (tt, J = 7.2, 2.4 Hz, 2H), 2.16 (qt, J = 7.5, 2.4 Hz, 
2H), 1.20 (t, J = 7.0 Hz, 3H), 1.11 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 82.88, 76.15, 69.42, 
66.36, 20.28, 15.29, 14.33, 12.58. 
 
1-Methoxyoct-2-yne (8n) 
 
Oct-2-yn-1-ol (3.79 g, 30 mmol, 1.0 equiv.) was dissolved in anhydrous 
DMF (60 mL) in a 250-mL flask. NaH (1.44 g, 60% in mineral oil, 36 
mmol, 1.2 equiv.) was slowly added to the solution in portions over 20 min at 0 °C. The resulting 
mixture was stirred at 0 °C for 1.5 h before slow addition of iodomethane (2.8 mL, 45 mmol, 1.5 
equiv.). The reaction was slowly warmed to room temperature over 30 min and then stirred for 
additional 2 h before being quenched by NH4Cl (sat. aq., 20 mL) and diluted with water (30 mL). 
The product was extracted by ether (40 mL × 3). The combined organic layer was then washed with 
water (50 mL × 2) and brine (50 mL), and dried over sodium sulfate. The organic layer was filtered 
and concentrated under reduced pressure. The crude product was purified through a silica column 
using hexane/ethyl acetate (100:0 to 20:1) as eluents to afford the alkyne 8n as a clear liquid (4.04 g, 
96% yield). 1H NMR (400 MHz, CDCl3) δ 4.07 (t, J = 2.2 Hz, 2H), 3.36 (s, 3H), 2.21 (tt, J = 7.2, 2.2 Hz, 
2H), 1.56–1.48 (m, 2H), 1.41–1.26 (m, 4H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 87.39, 
75.80, 60.38, 57.53, 31.19, 28.47, 22.34, 18.85, 14.11. 
 
A.4 Preparation of racemic standard products 
General procedure for rhodium-catalyzed cyclopropenation of terminal alkynes: 
To a 20 mL vial was added alkyne (1.0 mmol, 1.0 equiv.), Rh2(OAc)4 (4.4 mg, 1 mol%) and DCM 
(10 mL). The mixture was cooled to –78 °C, after which EDA (2.0 mmol, 2.0 equiv.) was added 
dropwise to the solution. The reaction was allowed to slowly warm up to room temperature over 8 
hours and stirred at room temperature for another 8 hours. Evaporation of the organic solvent and 
purification by silica column chromatography using hexane and ethyl acetate as eluents afforded 
racemic cyclopropene products 5a‒5i, 5k and 5l in 10‒30% yields. (Note: this protocol did not work 
for cyclopropyl-substituted alkyne 5j.) 
 
Ethyl 2-phenethylcycloprop-2-ene-1-carboxylate (6a) 
 
1H NMR (400 MHz, CDCl3) δ 7.33–7.27 (m, 2H), 7.24–7.18 (m, 3H), 6.36 (dt, J 
= 1.4 Hz, 1H), 4.21–4.05 (m, 2H), 2.96–2.79 (m, 4H), 2.14 (d, J = 1.5 Hz, 1H), 
1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.61, 140.81, 128.58, 128.45, 126.36, 115.01, 95.03, 
60.39, 33.00, 26.90, 20.00, 14.52. HRMS (FAB) m/z: 217.1221 (M+H+); calc. for C14H17O2: 217.1229. 
 
 
Ethyl 2-octylcycloprop-2-ene-1-carboxylate (6b) 
 
1H NMR (400 MHz, CDCl3) δ 6.31 (dt, J = 1.4 Hz, 1H), 4.12 (qd, J = 7.1, 5.0 Hz, 
2H), 2.48 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 1H), 1.61–1.52 (m, 2H), 1.35–
1.22 (m, 13H), 0.91–0.83 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 176.80, 115.77, 
H
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94.01, 60.28, 31.97, 29.39, 29.32, 29.27, 26.80, 25.10, 22.79, 19.86, 14.52, 14.24. HRMS (FAB) m/z: 
225.1862 (M+H+); calc. for C14H25O2: 225.1855. 
 
Ethyl 2-(hex-5-yn-1-yl)cycloprop-2-ene-1-carboxylate (6c) 
 
1H NMR (400 MHz, CDCl3) δ 6.35 (dt, J = 1.5 Hz, 1H), 4.20–4.04 (m, 2H), 2.52 
(td, J = 7.2, 1.4 Hz, 2H), 2.21 (td, J = 6.9, 2.6 Hz, 2H), 2.13 (d, J = 1.6 Hz, 1H), 1.94 
(t, J = 2.6 Hz, 1H), 1.71 (dtd, J = 8.7, 7.1, 5.4 Hz, 2H), 1.60 (dtd, J = 9.1, 6.9, 4.9 
Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.63, 115.25, 94.60, 84.14, 68.69, 60.33, 
27.89, 25.84, 24.63, 19.85, 18.23, 14.51. HRMS (FAB) m/z: 193.1220 (M+H+); calc. for C12H17O2: 193.1229. 
 
6-(3-(Ethoxycarbonyl)cycloprop-1-en-1-yl)hexyl cyclobutanecarboxylate (6d) 
 
1H NMR (400 MHz, CDCl3) δ 6.33 (dt, J = 1.5 Hz, 1H), 4.17–4.08 (m, 2H), 
4.05 (t, J = 6.7 Hz, 2H), 3.12 (p, J = 8.5 Hz, 1H), 2.49 (td, J = 7.3, 1.1 Hz, 
2H), 2.33–2.13 (m, 4H), 2.12 (d, J = 1.6 Hz, 1H), 2.05–1.82 (m, 2H), 1.66–
1.55 (m, 4H), 1.43–1.32 (m, 4H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.74, 175.74, 
115.55, 94.26, 64.38, 60.33, 38.29, 28.87, 28.68, 26.68, 25.74, 25.42, 25.03, 19.85, 18.56, 14.54. HRMS 
(FAB) m/z: 295.1910 (M+H+); calc. for C17H27O4: 295.1909. 
 
Ethyl 2-(5-(1,3-dioxolan-2-yl)pentyl)cycloprop-2-ene-1-carboxylate (6e) 
 
1H NMR (400 MHz, Acetone-d6) δ 6.61 (dt, J = 1.5 Hz, 1H), 4.81 (t, J = 4.8 
Hz, 1H), 4.09 (qd, J = 7.1, 2.3 Hz, 2H), 3.98–3.88 (m, 2H), 3.87–3.76 (m, 2H), 
2.54 (tdd, J = 7.1, 2.2, 1.4 Hz, 2H), 2.07 (d, J = 1.6 Hz, 1H), 1.67–1.57 (m, 4H), 
1.52–1.41 (m, 4H), 1.23 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Acetone-d6) δ 175.78, 115.81, 104.67, 94.74, 
65.05, 59.93, 34.29, 27.09, 25.03, 24.19, 19.69, 14.44 (one carbon peak may be overlapping with the 
solvent peaks). HRMS (FAB) m/z: 255.1593 (M+H+); calc. for C14H23O4: 255.1596. 
 
Ethyl 2-(3-isopropoxypropyl)cycloprop-2-ene-1-carboxylate (6f) 
 
1H NMR (400 MHz, CDCl3) δ 6.34 (dt, J = 1.4 Hz, 1H), 4.12 (qd, J = 7.1, 4.2 Hz, 
2H), 3.53 (hept, J = 6.2 Hz, 1H), 3.45 (td, J = 6.3, 1.9 Hz, 2H), 2.58 (td, J = 7.3, 1.4 
Hz, 2H), 2.13 (d, J = 1.5 Hz, 1H), 1.88–1.78 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.13 
(d, J = 6.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 176.69, 115.36, 94.47, 71.61, 66.92, 60.31, 27.43, 22.24, 
22.02, 19.89, 14.51. HRMS (FAB) m/z: 213.1485 (M+H+); calc. for C12H21O3: 213.1491. 
 
Ethyl 2-(cyclohexylmethyl)cycloprop-2-ene-1-carboxylate (6g) 
 
1H NMR (400 MHz, CDCl3) δ 6.33 (d, J = 1.4 Hz, 1H), 4.12 (qd, J = 7.1, 3.3 
Hz, 2H), 2.38 (d, J = 7.2 Hz, 2H), 2.10 (d, J = 1.6 Hz, 1H), 1.82–1.52 (m, 6H), 
1.27–1.07 (m, 6H), 0.98 (qt, J = 13.6, 3.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 176.76, 114.74, 94.58, 
60.28, 36.22, 33.18, 33.17, 32.68, 26.41, 26.27, 26.25, 19.93, 14.53. HRMS (FAB) m/z: 209.1537 (M+H+); 
calc. for C13H21O2: 209.1542. 
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Ethyl 2-(6-((tetrahydro-2H-pyran-4-yl)methoxy)hexyl)cycloprop-2-ene-1-carboxylate (6h) 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.4 Hz, 1H), 4.13 (qd, J = 
7.1, 5.5 Hz, 2H), 4.00–3.91 (m, 2H), 3.44–3.34 (m, 4H), 3.24 (d, J = 
6.6 Hz, 2H), 2.49 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.5 Hz, 1H), 1.83 
(ttt, J = 10.5, 6.7, 3.8 Hz, 1H), 1.67–1.62 (m, 2H), 1.60–1.52 (m, 4H), 1.43–1.34 (m, 4H), 1.34–1.28 (m, 
2H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.78, 115.66, 94.15, 76.12, 71.25, 67.90, 60.32, 
35.61, 30.19, 29.73, 29.11, 26.77, 26.02, 25.06, 19.86, 14.54. HRMS (FAB) m/z: 311.2210 (M+H+); calc. for 
C18H31O4: 311.2222. 
 
Ethyl 2-(6-(cyclopropylmethoxy)hexyl)cycloprop-2-ene-1-carboxylate (6i) 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.5 Hz, 1H), 4.12 (qd, J = 7.1, 5.2 
Hz, 2H), 3.42 (t, J = 6.7 Hz, 2H), 3.24 (d, J = 6.9 Hz, 2H), 2.49 (td, J = 7.3, 
1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 1H), 1.62–1.54 (m, 4H), 1.41–1.34 (m, 4H), 
1.25 (t, J = 7.2 Hz, 3H), 1.12–0.97 (m, 1H), 0.59–0.42 (m, 2H), 0.28–0.09 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 176.78, 115.68, 94.13, 75.74, 70.78, 60.31, 29.79, 29.11, 26.76, 26.04, 25.05, 19.86, 14.54, 10.82, 
3.13. HRMS (FAB) m/z: 267.1955 (M+H+); calc. for C16H27O3: 267.1960. 
 
Ethyl 2-(4-chlorobutyl)cycloprop-2-ene-1-carboxylate (6k) 
 
1H NMR (400 MHz, CDCl3) δ 6.37 (s, 1H), 4.12 (dd, J = 7.1, 4.2 Hz, 2H), 3.54 (t, 
J = 6.5 Hz, 2H), 2.54 (t, J = 7.0 Hz, 2H), 2.13 (s, 1H), 1.91–1.80 (m, 2H), 1.80–
1.70 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.54, 114.98, 
94.94, 60.37, 44.67, 31.89, 24.39, 24.12, 19.83, 14.49. HRMS (FAB) m/z: 203.0846 (M+H+); calc. for 
C10H16ClO2: 203.0839. 
 
Ethyl 2-(6-((trans-4-(methoxymethyl)cyclohexyl)methoxy)hexyl)cycloprop-2-ene-1-carbo- 
xylate (6l) 
 
1H NMR (400 MHz, CDCl3) δ 6.32 (dt, J = 1.4 Hz, 1H), 4.12 (qd, 
J = 7.1, 5.4 Hz, 2H), 3.37 (t, J = 6.6 Hz, 2H), 3.32 (s, 3H), 3.21–
3.17 (m, 4H), 2.49 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (d, J = 1.6 Hz, 1H), 1.87–1.74 (m, 4H), 1.63–1.52 (m, 6H), 
1.37 (tt, J = 6.3, 3.3 Hz, 4H), 1.25 (t, J = 7.1 Hz, 3H), 0.99–0.86 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
176.79, 115.69, 94.12, 78.93, 76.90, 71.17, 60.31, 58.98, 38.37 (two carbons), 29.74, 29.65, 29.55, 29.11, 
26.77, 26.03, 25.06, 19.86, 14.54. HRMS (FAB) m/z: 353.2699 (M+H+); calc. for C21H37O4: 353.2692. 
 
Ethyl 2-(6-hydroxyhexyl)cycloprop-2-ene-1-carboxylate (6m) 
 
To a 100 mL flask, hept-6-yn-1-ol (1.12 g, 10.0 mmol) and imidazole (885 mg, 
13.0 mmol) were dissolved in anhydrous DMF (50 mL). Tert-
butylchlorodiphenylsilane (TBDPS‒Cl, 3.30 g, 12.0 mmol) was added to the solution. The resulting 
mixture was stirred for 6 hours. The reaction mixture was quenched with water (40 mL) and the 
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product was extracted with Et2O (50 mL × 3). The combined organic layer was washed with water 
(20 mL), brine (20 mL), dried over MgSO4, and then concentrated under reduced pressure. The 
crude product was purified by silica column chromatography with hexane/ether (50:1) to afford tert-
butyl(hept-6-yn-1-yloxy)diphenylsilane (3.44 g, 98%). 
To a 20 mL vial was added tert-butyl(hept-6-yn-1-yloxy)diphenylsilane (1.0 mmol, 1.0 equiv.), 
Rh2(OAc)4 (4.4 mg, 1 mol%) and DCM (10 mL). The mixture was cooled to –78 °C, after which EDA 
(2.0 mmol in 2 mL DCM, 2.0 equiv.) was added dropwise to the solution. The reaction was allowed 
to slowly warm up to room temperature in 8 hours and stirred at room temperature for another 8 
hours. Evaporation of the organic solvent and purification by silica column chromatography with 
hexane/ethyl acetate (20:1) as eluent afforded the crude cyclopropene product in ~30% yield. 
To a 10 mL flask, the protected cyclopropene product was dissolved in THF (8 mL). 
Tetrabutylammonium fluoride (TBAF, 1M in THF, 0.9 mL) was added to the solution. The resulting 
mixture was stirred at room temperature for 5 h. Evaporation of the organic solvent and purification 
by silica column chromatography with hexane/ethyl acetate (1.5:1) as eluent afforded the racemic 
cyclopropene 6m (48 mg, ~80% yield). 1H NMR (400 MHz, Acetone-d6) δ 6.56 (dt, J = 1.5 Hz, 1H), 
4.05 (qd, J = 7.1, 2.5 Hz, 2H), 3.52 (t, J = 6.2 Hz, 2H), 2.50 (tt, J = 7.1, 1.6 Hz, 2H), 2.03 (d, J = 1.6 Hz, 
1H), 1.63–1.56 (m, 2H), 1.55–1.49 (m, 2H), 1.48–1.40 (m, 2H), 1.19 (t, J = 7.1 Hz, 3H) (O‒H proton is 
not resolved). 13C NMR (101 MHz, Acetone-d6) δ 176.12, 116.11, 94.99, 62.12, 60.23, 33.34, 27.33, 26.16, 
25.47, 19.98, 14.72. HRMS (FAB) m/z: 199.1342 (M+H+); calc. for C11H19O3: 199.1334. 
 
General procedure for rhodium-catalyzed cyclopropenation of internal alkynes: 
To a 20 mL vial was added alkyne (1.5 mmol, 1.0 equiv.), Rh2(OAc)4 (6.6 mg, 2 mol%) and DCM 
(3 mL). A solution of EDA (3.0 mmol, 2.0 equiv.) in DCM (3 mL) was added dropwise to the reaction 
mixture over 10 hours through a syringe pump. The reaction was stirred at room temperature for 
another 6 hours. Evaporation of the organic solvent and purification by silica column 
chromatography using hexane and ethyl acetate as eluents afforded cyclopropene products (or 
products in mixture form with carbene dimers, diethyl maleate and diethyl fumarate). For most 
cyclopropene products, further purification by C18 column reverse-phase chromatography using 
acetonitrile and water as eluents was required to separate the cyclopropene products from the 
carbene dimers. The cyclopropene products were obtained mostly in 1% to 10% yields. 
 
Ethyl 2-ethyl-3-phenylcycloprop-2-ene-1-carboxylate (9a) 
 
1H NMR (400 MHz, CDCl3) δ 7.44–7.37 (m, 2H), 7.35–7.29 (m, 2H), 7.27–7.22 (m, 
1H), 4.15–4.02 (m, 2H), 2.62 (q, J = 7.5 Hz, 2H), 2.38 (s, 1H), 1.26 (t, J = 7.5 Hz, 
3H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.05, 129.48, 128.75, 
128.70, 127.19, 111.64, 104.65, 60.25, 22.34, 19.30, 14.57, 12.21. HRMS (TOF) m/z: 217.1194 (M+H+); calc. 
for [C14H16O2+H+]: 217.1223. 
 
Ethyl 2-ethyl-3-(4-chorophenyl)cycloprop-2-ene-1-carboxylate (9b) 
 
1H NMR (400 MHz, CDCl3) δ 7.45–7.31 (m, 4H), 4.22–4.07 (m, 2H), 2.69 (q, 
J = 7.5 Hz, 2H), 2.44 (s, 1H), 1.32 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.71, 134.62, 130.63, 129.08, 125.79, 112.55, 
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103.78, 60.36, 22.34, 19.30, 14.55, 12.16. HRMS (TOF) m/z: 251.0847 (M+H+); calc. for [C14H15ClO2+H+]: 
251.0833. 
 
Ethyl 2-methyl-3-phenylcycloprop-2-ene-1-carboxylate (9c) 
 
1H NMR (400 MHz, CDCl3) δ 7.49–7.44 (m, 2H), 7.42–7.36 (m, 2H), 7.35–7.28 
(m, 1H), 4.16 (qd, J = 7.1, 3.7 Hz, 2H), 2.43 (s, 1H), 2.33 (s, 3H), 1.25 (t, J = 7.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 175.92, 129.42, 128.76, 128.71, 127.29, 106.51, 
105.40, 60.30, 22.72, 14.59, 10.89. HRMS (TOF) m/z: 203.1054 (M+H+); calc. for [C13H14O2+H+]: 
203.1067. 
 
Ethyl 2-ethyl-3-(2-fluorophenyl)cycloprop-2-ene-1-carboxylate (9d) 
 
1H NMR (400 MHz, CDCl3) δ 7.38–7.27 (m, 2H), 7.16 (td, J = 7.5, 1.1 Hz, 1H), 7.10 
(ddd, J = 9.3, 8.2, 1.0 Hz, 1H), 4.23–4.09 (m, 2H), 2.74 (qdd, J = 7.5, 2.4, 0.8 Hz, 
2H), 2.43 (s, 1H), 1.30–1.22 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 175.84, 161.02 
(d, J = 253.5 Hz), 130.71 (d, J = 2.8 Hz), 130.49 (d, J = 8.0 Hz), 124.35 (d, J = 3.7 Hz), 115.80 (d, J = 15.4 
Hz), 115.57 (d, J = 20.5 Hz), 114.08 (d, J = 3.8 Hz), 98.73 (d, J = 1.8 Hz), 60.34, 21.23, 19.26, 14.54, 11.45 
(d, J = 2.0 Hz). HRMS (TOF) m/z: 235.1145 (M+H+); calc. for [C14H15FO2+H+]: 235.1129. 
 
Ethyl 2-ethyl-3-(4-fluorophenyl)cycloprop-2-ene-1-carboxylate (9e) 
 
1H NMR (400 MHz, CDCl3) δ 7.51–7.38 (m, 2H), 7.13–7.04 (m, 2H), 4.23–4.07 
(m, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.43 (s, 1H), 1.32 (t, J = 7.5 Hz, 3H), 1.25 (t, J 
= 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.89, 162.92 (d, J = 250.2 Hz), 
131.25 (d, J = 8.5 Hz), 123.53 (d, J = 3.4 Hz), 115.97 (d, J = 22.1 Hz), 111.17, 103.71, 
60.32, 22.37, 19.19, 14.56, 12.20. HRMS (TOF) m/z: 235.1134 (M+H+); calc. for [C14H15FO2+H+]: 235.1129. 
 
Ethyl 2-ethyl-3-(3-methoxyphenyl)cycloprop-2-ene-1-carboxylate (9f) 
 
1H NMR (400 MHz, CDCl3) δ 7.34–7.27 (m, 1H), 7.08 (dt, J = 7.6, 1.2 Hz, 
1H), 6.99 (dd, J = 2.7, 1.5 Hz, 1H), 6.87 (ddd, J = 8.3, 2.6, 1.0 Hz, 1H), 4.22–
4.08 (m, 2H), 3.83 (s, 3H), 2.69 (q, J = 7.5 Hz, 2H), 2.44 (s, 1H), 1.33 (t, J = 
7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.96, 159.84, 129.81, 128.46, 122.06, 
114.69, 114.52, 112.03, 104.69, 60.26, 55.47, 22.48, 19.30, 14.57, 12.18. HRMS (TOF) m/z: 247.1331 (M+H+); 
calc. for [C15H18O3+H+]: 247.1329. 
 
Ethyl 2-ethyl-3-(4-trifluoromethylphenyl)cycloprop-2-ene-1-carboxylate (9g) 
 
1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.1 Hz, 2H), 7.57 (d, J = 8.1 Hz, 
2H), 4.16 (qd, J = 7.1, 5.3 Hz, 2H), 2.73 (q, J = 7.5 Hz, 2H), 2.49 (s, 1H), 1.34 
(t, J = 7.5 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 175.40, 
130.72 (q, J = 2.2 Hz), 130.07 (q, J = 32.8 Hz), 129.57, 125.76 (q, J = 3.9 Hz), 
124.11 (q, J = 272.0 Hz), 115.19, 103.88, 60.47, 22.41, 19.44, 14.53, 12.10. HRMS (TOF) m/z: 285.1118 
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(M+H+); calc. for [C15H15F3O2+H+]: 285.1097. 
 
Ethyl 2-ethyl-3-(4-(difluoromethoxy)phenyl)cycloprop-2-ene-1-carboxylate (9h) 
 
1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 8.8 Hz, 
2H), 6.52 (t, J = 73.6 Hz, 1H), 4.21–4.09 (m, 2H), 2.69 (q, J = 7.5 Hz, 2H), 
2.44 (s, 1H), 1.32 (t, J = 7.5 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 175.80, 151.30 (t, J = 2.7 Hz), 130.95, 124.64, 119.87, 115.85 
(t, J = 261.4 Hz), 111.95, 103.70, 60.35, 22.36, 19.25, 14.56, 12.20. HRMS (TOF) m/z: 283.1139 (M+H+); 
calc. for [C15H16F2O3+H+]: 283.1140. 
 
Ethyl 2-ethyl-3-(p-tolyl)cycloprop-2-ene-1-carboxylate (9i) 
 
1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.1 Hz, 2H), 7.19 (d, J = 7.8 Hz, 2H), 
4.21–4.06 (m, 2H), 2.67 (q, J = 7.5 Hz, 2H), 2.42 (s, 1H), 2.37 (s, 3H), 1.32 (t, 
J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.20, 
138.79, 129.49, 129.42, 124.38, 110.28, 104.50, 60.19, 22.30, 21.60, 19.25, 14.57, 
12.24. HRMS (TOF) m/z: 231.1378 (M+H+); calc. for [C15H18O2+H+]: 231.1380. 
 
Ethyl 2-ethyl-3-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylate (9j) 
 
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.8 Hz, 2H), 6.92 (d, J = 8.9 Hz, 
2H), 4.20–4.09 (m, 2H), 3.83 (s, 3H), 2.66 (q, J = 7.4 Hz, 2H), 2.40 (s, 1H), 
1.31 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
176.31, 160.04, 130.93, 128.47, 119.91, 114.32, 108.80, 104.05, 60.18, 55.50, 22.33, 
19.17, 14.58, 12.29. HRMS (TOF) m/z: 247.1338 (M+H+); calc. for [C15H18O3+H+]: 247.1329. 
 
Ethyl 2-ethyl-3-(4-chloro-3-methylphenyl)cycloprop-2-ene-1-carboxylate (9k) 
 
1H NMR (400 MHz, CDCl3) δ 7.35 (d, J = 8.2 Hz, 1H), 7.31 (d, J = 1.4 Hz, 1H), 
7.24 (dd, J = 8.2, 1.9 Hz, 1H), 4.21–4.08 (m, 2H), 2.68 (q, J = 7.5 Hz, 2H), 2.42 
(s, 1H), 2.38 (s, 3H), 1.32 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 175.84, 136.59, 134.87, 131.70, 129.51, 128.06, 125.74, 112.13, 
103.86, 60.32, 22.34, 20.15, 19.28, 14.55, 12.16. HRMS (TOF) m/z: 265.1002 (M+H+); calc. for 
[C15H17ClO2+H+]: 265.0990. 
 
Ethyl 2-ethyl-3-(4-methoxy-3-methylphenyl)cycloprop-2-ene-1-carboxylate (9l) 
 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.24 (m, 2H), 6.83 (d, J = 8.2 Hz, 1H), 
4.14 (dddd, J = 17.9, 10.8, 7.1, 3.7 Hz, 2H), 3.84 (s, 3H), 2.66 (q, J = 7.5 Hz, 
2H), 2.39 (s, 1H), 2.22 (s, 3H), 1.31 (t, J = 7.5 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 176.43, 158.32, 131.76, 128.42, 127.19, 119.32, 
110.08, 108.38, 104.17, 60.14, 55.55, 22.32, 19.15, 16.30, 14.59, 12.29. HRMS (TOF) m/z: 261.1463 (M+H+); 
calc. for [C16H20O2+H+]: 261.1485. 
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Ethyl 2-(2-ethoxyethyl)-3-ethylcycloprop-2-ene-1-carboxylate (9m) 
 
1H NMR (400 MHz, CDCl3) δ 4.11 (q, J = 7.1 Hz, 2H), 3.66 – 3.55 (m, 2H), 
3.49 (qd, J = 7.0, 0.7 Hz, 2H), 2.69 (tq, J = 6.9, 1.5 Hz, 2H), 2.43 (qt, J = 
7.5, 1.5 Hz, 2H), 2.07 (s, 1H), 1.24 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H), 
1.14 (t, J = 7.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.01, 108.55, 102.81, 67.90, 66.38, 59.98, 25.58, 
22.19, 18.35, 15.32, 14.56, 11.64. HRMS (TOF) m/z: 213.1481 (M+H+); calc. for [C12H20O3+H+]: 213.1485. 
 
Ethyl 2-(methoxymethyl)-3-pentylcycloprop-2-ene-1-carboxylate (9n) 
 
1H NMR (400 MHz, CDCl3) δ 4.37 (t, J = 1.5 Hz, 2H), 4.12 (q, J = 7.1 Hz, 
2H), 3.39 (s, 3H), 2.47 (tt, J = 7.5, 1.5 Hz, 2H), 2.20 (s, 1H), 1.63–1.52 (m, 
2H), 1.32 (tt, J = 6.7, 3.5 Hz, 4H), 1.24 (t, J = 7.1 Hz, 3H), 0.93–0.85 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 176.17, 110.25, 102.48, 65.78, 60.19, 58.58, 31.54, 26.65, 24.68, 22.71, 
22.48, 14.53, 14.13. HRMS (TOF) m/z: 227.1626 (M+H+); calc. for [C13H22O3+H+]: 227.1642. 
 
Ethyl 3-methoxydec-4-ynoate (9n-1) 
 
In a dry 100-mL round bottom flask, under argon, a solution of 
diisopropylamine (6 mmol, 1.2 equiv.) in THF (30 mL) was cooled to 
–78 °C. n-Butyllithium (6 mmol, 1.2 equiv., 1.6 M in hexanes) was 
added dropwise and the resulting mixture was stirred at the appropriate temperature for 30 min. 
The mixture was cooled to –78 °C before ethyl acetate (5 mmol, 1.0 equiv.) was added dropwise and 
the mixture was stirred for an additional 30 min. Then, a solution of oct-2-ynal (5.5 mmol, 1.1 equiv.) 
in THF (15 mL) was added slowly and the solution was stirred for a further 2 h. The reaction was 
allowed to room temperature and then quenched by NH4Cl (sat. aq., 30 mL). Phases were separated 
and the aqueous phase was extracted with diethyl ether (30 mL × 3). The combined organics were 
washed with NH4Cl (sat. aq., 2 × 10–15 mL), brine (10 mL), dried over Na2SO4, and concentrated 
under reduced pressure. Purification by silica column chromatography with hexanes/ethyl acetate 
afforded ethyl 3-hydroxydec-4-ynoate (1.02 g, 95% yield). 
In a 50-mL round bottom flask, ethyl 3-hydroxydec-4-ynoate (3 mmol, 1.0 equiv.), Ag2O (9 
mmol, 3.0 equiv.), and dry ether (20 mL) were combined, followed by iodomethane (9 mmol, 3.0 
equiv.). The reaction in aluminum foil to protect its contents from light was then stirred at the room 
temperature for 24 h. The crude mixture was filtered through a pad of Celite and concentrated 
under reduced pressure. Purification by silica column chromatography with hexanes/ethyl acetate 
afforded compound 9n-1 (302.6 mg, 45% yield). 1H NMR (400 MHz, CDCl3) δ 4.39 (ddt, J = 8.2, 5.4, 
2.0 Hz, 1H), 4.16 (qd, J = 7.2, 1.0 Hz, 2H), 3.39 (s, 3H), 2.73 (dd, J = 15.5, 8.4 Hz, 1H), 2.63 (dd, J = 15.5, 
5.4 Hz, 1H), 2.20 (td, J = 7.1, 2.0 Hz, 2H), 1.50 (p, J = 7.4 Hz, 2H), 1.40–1.28 (m, 4H), 1.26 (t, J = 7.1 Hz, 
3H), 0.89 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.35, 87.30, 77.48, 67.75, 60.79, 56.57, 
41.70, 31.11, 28.39, 22.30, 18.75, 14.32, 14.12. HRMS (TOF) m/z: 227.1634 (M+H+); calc. for 
[C13H22O3+H+]: 227.1642. 
 
A.5 Analysis of biotransformations for strained carbocycle construction 
A.5.1 Enzymatic synthesis of bicyclobutanes 
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All enzymatic reactions for bicyclobutane formation in preparative scale were conducted 
following the general procedure described below and the corresponding bicyclobutane products 
were isolated. Detailed conditions for the preparative-scale reactions of different substrates are 
indicated separately. 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing P411 E10-
V78F S438A variant (OD600 = 10‒20), alkyne (0.1‒0.2 mmol, larger scales for 1k‒1m), EDA (2.0‒4.0 
equiv.), D-glucose (10–15 mM, 250 mM stock in M9-N), 1–5 vol% EtOH, M9-N buffer (pH 7.4) under 
anaerobic conditions. The vial or flask was capped and shaken (420 rpm for vials and 220 rpm for 
flasks) at room temperature for 12 h. 
After the reaction was completed, every 30 mL portion of preparative-scale reaction mixture 
was transferred to a 50 mL Falcon centrifuge tube. The reaction container was washed with water (2 
mL × 2) followed by mixed organic solvent (cyclohexane/ethyl acetate = 1:1, 2 mL × 3). The washing 
solution was combined with the reaction mixture in the centrifuge tubes. Additional 12 mL of 
cyclohexane/ethyl acetate solvent was added to every tube. After the tube (with ~45 mL mixture in 
total) was capped, it was vortexed (1 min × 3), shaken vigorously, and centrifuged (14,000 × g, 5 min). 
The organic layer was separated and the aqueous layer was subjected to three more rounds of 
extraction. Then organic layers were combined, dried over Na2SO4, and concentrated under reduced 
pressure. Purification by silica column chromatography with hexane/ethyl acetate as eluent 
afforded the desired bicyclobutanes. TTNs were calculated based on measured protein 
concentration and the isolated yield of the product. 
 
Diethyl (2R,4R)-1-phenylbicyclo[1.1.0]butane-2,4-dicarboxylate (2a) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 24.0 4.17 0.100 1.0 ~10 
alkyne (1a) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.00 180 0.18 2.00 180 0.36 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
31.3 0.114 63% 1140 
Note: [PC] = protein concentration in original cell suspension, n_pro = amount of protein in the reaction, [Glu] 
= D-glucose concentration in reaction mixture, n_1 = amount of alkyne in the reaction, n_2 = amount of EDA 
in the reaction, m[Pdt] = mass of product isolated, n[Pdt] = amount of product. The same for the following 
tables. 
1H NMR (400 MHz, CDCl3) δ 7.34–7.22 (m, 5H), 4.14 (qd, J = 7.2, 2.4 Hz, 2H), 
4.07 (qd, J = 7.2, 3.7 Hz, 2H), 3.26 (s, 1H), 3.13 (d, J = 3.0 Hz, 1H), 3.10 (d, J = 3.0 
Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
δ 170.36, 167.91, 132.68, 128.50, 128.45, 127.56, 60.99, 60.91, 44.64, 42.55, 28.18, 
20.47, 14.37, 14.16. HRMS (FAB) m/z: 275.1271 (M+H+); calc. for C16H19O4: 
275.1283. [α]23D = ‒124.8 ± 1.1° (c 0.1, ethyl acetate). 
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Diethyl (2R,4R)-1-(4-fluorophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2b) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 24.0 4.17 0.100 1.0 ~10 
alkyne (1b) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 180 0.18 2.0 180 0.36 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
36.6 0.125 70% 1250 
1H NMR (400 MHz, CDCl3) δ 7.32–7.26 (m, 2H), 7.05–6.94 (m, 2H), 4.21–4.11 
(m, 2H), 4.11–4.00 (m, 2H), 3.23 (d, J = 0.5 Hz, 1H), 3.09 (d, J = 3.0 Hz, 1H), 3.04 
(dd, J = 3.0, 0.6 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.20, 167.80, 163.59 (d, JC-F = 246.4 Hz), 130.55 (d, JC-F = 
8.2 Hz), 128.31, (d, JC-F = 3.3 Hz), 115.63, (d, JC-F = 21.8 Hz), 61.06, 60.98, 44.83, 
42.70, 27.50, 19.89, 14.37, 14.20. HRMS (FAB) m/z: 293.1179 (M+H+); calc. for 
C16H18FO4: 293.1189. [α]23D = ‒110.1 ± 2.0° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-chlorophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2c) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 36.0 4.17 0.150 1.5 ~10 
alkyne (1c) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 200 0.20 2.0 400 0.80 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
45.2 0.146 73% 980 
1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.9 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 
4.14 (qd, J = 7.1, 2.4 Hz, 2H), 4.08 (qd, J = 7.1, 2.2 Hz, 2H), 3.24 (d, J = 0.6 Hz, 
1H), 3.10 (d, J = 3.0 Hz, 1H), 3.08 (dd, J = 3.0, 0.5 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 
1.16 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.06, 167.75, 133.48, 131.27, 
129.93, 128.71, 61.10, 61.06, 44.77, 42.65, 27.47, 20.61, 14.36, 14.21. HRMS (FAB) 
m/z: 309.0902 (M+H+); calc. for C16H18ClO4: 309.0894. [α]23D = ‒141.5 ± 2.6° (c 
0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-bromophenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2d) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 36.0 4.17 0.150 1.5 ~10 
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alkyne (1d) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 300 0.60 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
42.5 0.120 80% 800 
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.7 Hz, 2H), 7.17 (d, J = 8.7 Hz, 2H), 
4.14 (qd, J = 7.1, 2.4 Hz, 2H), 4.08 (qd, J = 7.1, 1.8 Hz, 2H), 3.24 (d, J = 0.6 Hz, 
1H), 3.10 (d, J = 3.1 Hz, 1H), 3.09 (dd, J = 3.1, 0.5 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 
1.16 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.02, 167.73, 131.84, 131.64, 
130.22, 121.56, 61.11, 61.07, 44.74, 42.62, 27.53, 20.71, 14.36, 14.21. HRMS (FAB) 
m/z: 353.0399 (M+H+); calc. for C16H18BrO4: 353.0388 (79Br). [α]23D = ‒128.4 ± 
0.8° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(p-tolyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2e) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 20.0 2.92 0.0584 1.0 ~13 
alkyne (1e) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
29.6 0.103 64% 1760 
1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 8.2 Hz, 2H), 7.11 (d, J = 7.9 Hz, 2H), 
4.18–4.03 (m, 4H), 3.23 (d, J = 0.6 Hz, 1H), 3.08 (dd, J = 3.0, 0.6 Hz, 1H), 3.06 
(d, J = 3.0 Hz, 1H), 2.32 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.48, 168.01, 137.37, 129.42, 129.22, 128.41, 60.94, 
60.87, 44.62, 42.50, 28.09, 21.34, 20.07, 14.37, 14.20. HRMS (FAB) m/z: 289.1450 
(M+H+); calc. for C17H21O4: 289.1440. [α]23D = ‒143.6 ± 1.0° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-ethylphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2f) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 32.0 2.92 0.0934 1.5 ~11 
alkyne (1f) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 100 0.10 2.0 100 0.20 
purification eluent Product 
Ethyl acetate in hexanes m[Pdt]/mg n[Pdt]/mmol yield TTN 
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(0% to 8% gradient) 16.8 0.0556 56% 600 
1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 
4.20–4.01 (m, 4H), 3.23 (d, J = 0.6 Hz, 1H), 3.09 (dd, J = 3.0, 0.6 Hz, 1H), 3.07 
(d, J = 3.0 Hz, 1H), 2.62 (q, J = 7.6 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H), 1.21 (t, J = 7.6 
Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.49, 168.02, 
143.73, 129.69, 128.46, 128.04, 60.93, 60.87, 44.57, 42.50, 28.72, 28.13, 20.14, 
15.67, 14.38, 14.19. HRMS (FAB) m/z: 303.1588 (M+H+); calc. for C18H23O4: 
303.1596. [α]23D = ‒133.7 ± 1.8° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(3-methoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2g) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
18 20.0 2.92 0.0584 1.0 ~13 
alkyne (1g) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
27.2 0.0894 56% 1530 
1H NMR (400 MHz, CDCl3) δ 7.24–7.19 (m, 1H), 6.88 (ddd, J = 7.6, 1.6, 1.0 Hz, 
1H), 6.85–6.82 (m, 1H), 6.80 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 4.20–4.01 (m, 4H), 
3.78 (s, 3H), 3.25 (d, J = 0.6 Hz, 1H), 3.13 (dd, J = 3.0, 0.6 Hz, 1H), 3.09 (d, J = 
3.0 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.31, 167.90, 159.67, 134.22, 129.54, 120.75, 114.01, 113.20, 61.01, 60.95, 
55.35, 44.69, 42.58, 28.18, 20.69, 14.37, 14.20. HRMS (FAB) m/z: 305.1383 (M+H+); calc. for C17H21O5: 
305.1389. [α]23D = ‒122.6 ± 1.5° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(3,5-dimethoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2h) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 45.0 2.54 0.114 3.0 ~16 
alkyne (1h) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 225 0.45 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
19.8 0.0592 40% 520 
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1H NMR (400 MHz, CDCl3) δ 6.44 (d, J = 2.2 Hz, 2H), 6.36 (t, J = 2.3 Hz, 1H), 
4.15 (qd, J = 7.1, 2.5 Hz, 2H), 4.09 (qd, J = 7.1, 3.9 Hz, 2H),3.76 (s, 6H), 3.24 (s, 
1H), 3.12 (d, J = 3.0 Hz, 1H), 3.09 (d, J = 3.0 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.17 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.14, 167.76, 160.71, 134.80, 
106.29, 99.71, 60.88, 60.84, 55.33, 44.56, 42.45, 28.23, 20.67, 14.23, 14.11. HRMS 
(FAB) m/z: 335.1480 (M+H+); calc. for C18H23O6: 335.1495. [α]23D = ‒144.6 ± 3.5° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(3-hydroxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2i) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 45.0 2.14 0.0963 3.0 ~16 
alkyne (1i) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 120 0.12 2.0 180 0.36 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 20% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
10.4 0.0358 30% 370 
1H NMR (400 MHz, CDCl3) δ 7.15 (td, J = 8.1, 1.7 Hz, 1H), 6.87–6.83 (m, 1H), 
6.78–6.74 (m, 1H), 6.73–6.68 (m, 1H), 5.06 (s, 1H), 4.21–4.02 (m, 4H), 3.23 (d, J 
= 0.6 Hz, 1H), 3.11 (dd, J = 3.1, 0.6 Hz, 1H), 3.09 (d, J = 3.0 Hz, 1H), 1.27 (t, J = 7.1 
Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.22, 167.87, 
155.59, 134.27, 129.62, 120.76, 115.15, 114.58, 60.94, 60.92, 44.54, 42.43, 27.86, 
20.58, 14.23, 14.04. HRMS (FAB) m/z: 291.1237 (M+H+); calc. for C16H19O5: 291.1232. 
 
Diethyl (2R,4R)-1-(thiophen-2-yl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2j) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 54.0 4.30 0.232 3.2 ~14 
alkyne (1j) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 100 0.10 2.0 200 0.40 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
11.4 0.0407 41% 160 
1H NMR (400 MHz, CDCl3) δ 7.20 (dd, J = 5.2, 1.2 Hz, 1H), 7.05 (dd, J = 3.5, 1.3 
Hz, 1H), 6.94 (dd, J = 5.2, 3.5 Hz, 1H), 4.19–4.10 (m, 4H), 3.27 (s, 1H), 3.10 (d, J 
= 3.1 Hz, 1H), 3.06 (dd, J = 3.1, 0.6 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H), 1.20 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.92, 167.46, 135.29, 128.55, 126.97, 
125.42, 61.14, 61.12, 45.87, 44.10, 23.88, 21.23, 14.37, 14.22. HRMS (FAB) m/z: 
281.0839 (M+H+); calc. for C14H17O4S: 281.0848. 
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Diethyl (2R,4R)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2k) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
15 24.0 2.43 0.0583 1.0 ~10 
alkyne (1k) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 160 0.16 2.0 160 0.32 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
32.4 0.107 67% 1830 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 600 2.96 1.77 30 ~12 
alkyne (1k) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/mM volume/mL n_2/mmol 
2.0 2.40 4.80 2.0 7.20 14.40 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
680.4 2.34 47% 1260 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 
4.20–3.99 (m, 4H), 3.79 (s, 3H), 3.21 (s, 1H), 3.04 (d, J = 2.9 Hz, 1H), 3.01 (d, J = 
2.9 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 170.53, 168.01, 159.21, 130.03, 124.27, 113.99, 60.93, 60.85, 55.43, 44.68, 
42.63, 27.90, 19.35, 14.38, 14.22. HRMS (FAB) m/z: 305.1375 (M+H+); calc. for 
C17H21O5: 305.1389. [α]23D = ‒138.2 ± 1.6° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-ethynylxyphenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2l) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 36.0 3.44 0.124 2.0 ~13 
alkyne (1l) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 150 0.15 2.0 225 0.45 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
28.7 0.0962 64% 780 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
69 
 
 
18 600 3.03 1.82 30 ~12 
alkyne (1l) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 1.40 2.80 2.0 4.20 8.40 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
393.7 1.32 47% 730 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.5 Hz, 2H), 7.26 (d, J = 8.6 Hz, 2H), 
4.17 (qd, J = 7.2, 2.9 Hz, 2H), 4.11 (qd, J = 7.1, 0.6 Hz, 2H), 3.29 (d, J = 0.6 Hz, 
1H), 3.18 (dd, J = 3.1, 0.6 Hz, 1H), 3.15 (d, J = 3.1 Hz, 1H), 3.11 (s, 1H), 1.29 (t, J = 
7.1 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.04, 167.73, 
133.79, 132.24, 128.28, 121.22, 83.47, 77.86, 61.12, 61.07, 44.73, 42.67, 27.88, 21.40, 
14.36, 14.19. HRMS (FAB) m/z: 299.1282 (M+H+); calc. for C18H19O4: 299.1283. 
[α]23D = ‒152.6 ± 3.1° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-(hydroxymethyl)phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (2m) 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 75.0 3.72 0.279 4.0 ~13 
alkyne (1m) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 2.0 540 1.08 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
52.8 0.174 48% 630 
 
E. coli suspension in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
16 160 2.68 0.428 10 ~15 
alkyne (1m) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 1.00 1.00 2.0 2.00 4.00 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
152.1 0.500 50% 580 
1H NMR (400 MHz, CDCl3) δ 7.30 (d, J = 2.5 Hz, 4H), 4.68 (d, J = 5.0 Hz, 2H), 
4.14 (qd, J = 7.1, 2.3 Hz, 2H), 4.08 (qd, J = 7.1, 0.9 Hz, 2H), 3.26 (d, J = 0.5 Hz, 
1H), 3.13 (dd, J = 3.1, 0.6 Hz, 1H), 3.10 (d, J = 3.0 Hz, 1H), 1.62 (t, J = 5.7 Hz, 1H), 
1.27 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.30, 
167.93, 140.24, 132.11, 128.68, 127.15, 65.20, 61.02, 60.96, 44.72, 42.54, 27.96, 
20.58, 14.37, 14.22. HRMS (FAB) m/z: 303.1230 ((M+H+)‒H2); calc. for C17H19O5: 
H
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303.1232. [α]23D = ‒130.8 ± 1.2° (c 0.1, ethyl acetate). 
 
A.5.2 Enzymatic synthesis of terminal cyclopropenes 
All enzymatic reactions for cyclopropene formation in analytical scale were conducted 
following the general procedure described below and analyzed with gas chromatography (GC). All 
TTNs for the different products were determined using the GC standard curve of the corresponding 
racemic standard product made with Rh2(OAc)4. 
All enzymatic reactions for cyclopropene formation in preparative scale were conducted 
following the general procedure described below and the corresponding cyclopropene products 
were isolated. Detailed conditions for preparative-scale reactions of different substrates are 
indicated separately. 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing P411-C6 
or K10 variant (OD600 = 10‒60), alkyne (0.08‒0.4 mmol, larger scales for 5a and 5h), EDA (1.0‒4.0 
equiv.), D-glucose (10–15 mM, 250 mM stock in M9-N), 1–5 vol% EtOH, M9-N buffer (pH 7.4) under 
anaerobic conditions. The vial or flask was capped and shaken (420 rpm for vials and 220 rpm for 
flasks) at room temperature for 12 h. 
After the reaction was completed, every 30 mL portion of preparative-scale reaction mixture 
was transferred to a 50 mL Falcon centrifuge tube. The reaction container was washed with water (2 
mL × 2) followed by mixed organic solvent (cyclohexane/ethyl acetate = 1:1, 2 mL × 3). The washing 
solution was combined to reaction mixture in centrifuge tubes. An additional 12 mL of 
cyclohexane/ethyl acetate solvent was added to every tube. After the tube (with ~45 mL mixture in 
total) was capped, it was vortexed (1 min × 3) and shaken vigorously, and centrifuged (14,000 × g, 5 
min). The organic layer was separated and the aqueous layer was subjected to three more rounds of 
extraction. The organic layers were combined, dried over Na2SO4 and concentrated under reduced 
pressure. Purification by silica column chromatography with hexane/ethyl acetate as eluent 
afforded the desired cyclopropenes. Enantioselectivity was measured by chiral HPLC. TTNs were 
calculated based on measured protein concentration and isolated product yield. 
 
Ethyl (S)-2-phenethylcycloprop-2-ene-1-carboxylate (S-6a) 
Analysis Data (10 mM 5a, P411-K10): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6a-(1) 4637.1 590.6 7.852 6.24 1.93 3242   
6a-(2) 4639.5 592.1 7.836 6.23 1.93 3236   
6a-(3) 4797.4 582.9 8.230 6.54 1.93 3399   
6a-(4) 4674.5 588.0 7.950 6.32 1.93 3283 3290 63.3% 
Preparative-scale reaction: 
E. coli suspension expressing P411-K10 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 28.0 3.12 0.0874 1.5 ~13 
alkyne (5a) stock in EtOH EDA stock in EtOH 
71 
 
 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
37.8 0.175 44% 2000 
 
Ethyl (R)-2-phenethylcycloprop-2-ene-1-carboxylate (R-6a) 
Analysis Data (10 mM 5a, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6a-(1) 4577.9 511.2 8.955 7.12 2.83 2518   
6a-(2) 4659.1 515.1 9.045 7.19 2.83 2543   
6a-(3) 4647.7 518.4 8.965 7.13 2.83 2521   
6a-(4) 4608.7 518.6 8.887 7.07 2.83 2499 2520 71.3% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 28.0 4.04 0.113 1.5 ~13 
alkyne (5a) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
46.8 0.216 54% 1910 
 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
24 800 5.35 4.28 50 ~15 
alkyne (5a) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 2.50 5.0 2.0 2.50 × 3 15.0 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
824.1 3.81 76% 1780 
 
(S)-6a: [α]23D = ‒ 64.7 ± 3.6° (c 0.1, cyclohexane); (R)-6a: [α]23D = + 62.2 ± 2.5° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
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rac-6a R-6a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
8.820 5105.03 50.19 9.057 7330.2 99.95 
9.144 5066.41 49.81 9.416 4.4 0.05 
Total 10171.44 100.00 Total 7334.6 100.00 
S-6a 
Retention Time 
(min) 
Area (mAU*s) Area % 
8.893 48.5 0.45 
9.200 10437.1 99.55 
Total 10485.6 100.00 
 
Ethyl (R)-2-octylcycloprop-2-ene-1-carboxylate (6b) 
Analysis Data (10 mM 5b, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6b-(1) 1195.2 523.7 2.282 1.49 1.82 815   
6b-(2) 1128.3 528.7 2.134 1.39 1.82 763   
6b-(3) 1023.1 521.4 1.962 1.28 1.82 701 760 13.9% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 20.0 × 3 3.83 0.230 1.5 ~12 
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alkyne (5b) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 250 0.20 0.80 250 0.20 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
27.2 0.121 61% 530 
 
(R)-6b: [α]23D = + 32.6 ± 1.8° (c 0.1, cyclohexane) [Note: (S)-6b (87% ee) was reported with [α]23D = ‒ 
30° (c 1.55, CHCl3)142]. 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm. 
 
rac-6b R-6b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
6.475 4707.7 49.89 6.594 5043.93 98.02 
6.927 4729.1 50.11 7.099 102.06 1.98 
Total 9436.8 100.00 Total 5145.99 100.00 
 
Ethyl (R)-2-(hex-5-yn-1-yl)cycloprop-2-ene-1-carboxylate (6c) 
Analysis Data (20 mM 5c, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6c-(1) 1084.2 344.6 3.146 2.39 1.67 1434   
6c-(2) 1164.4 407.1 2.860 2.17 1.67 1304   
6c-(3) 1079.9 385.7 2.800 2.13 1.67 1276   
6c-(4) 985.5 350.1 2.815 2.14 1.67 1283 1324 11.1% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 30.0 6.33 0.190 1.5 ~12 
alkyne (5c) stock in EtOH EDA stock in EtOH 
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stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 500 0.40 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 6% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
46.2 0.240 60% 1260 
 
(R)-6c: [α]23D = + 52.2 ± 1.8° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
rac-6c R-6c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.347 6143.95 49.77 10.367 8079.11 98.00 
11.454 6201.66 50.23 11.547 165.21 2.00 
Total 12345.61 100.00 Total 8244.32 100.00 
 
(R)-6-(3-(Ethoxycarbonyl)cycloprop-1-en-1-yl)hexyl cyclobutanecarboxylate (6d) 
Analysis Data (10 mM 5d, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6d-(1) 24642 4192 5.878 3.88 2.01 1930   
6d-(2) 22575 4190 5.388 3.56 2.01 1769   
6d-(3) 22572 4242 5.321 3.51 2.01 1747   
6d-(4) 24260 4249 5.710 3.77 2.01 1875 1831 36.8% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
32 25.0 6.48 0.162 1.5 ~11 
alkyne (5d) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 1.0 900 0.90 
H
CO2Et
H
4
(R)-6c
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purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
56.7 0.193 54% 1190 
 
(R)-6d: [α]23D = + 31.7 ± 1.7° (c 0.1, cyclohexane). 
Chiralpak IC, 9% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
rac-6d R-6d 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.027 6378.13 49.91 17.055 7518.01 95.28 
18.715 6401.27 50.09 19.063 372.37 4.72 
Total 12779.4 100.00 Total 7890.38 100.00 
 
Ethyl (R)-2-(5-(1,3-dioxolan-2-yl)pentyl)cycloprop-2-ene-1-carboxylate (6e) 
Analysis Data (10 mM 5e, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6e-(1) 7788 4377 1.779 1.48 1.77 838   
6e-(2) 7579 4283 1.770 1.47 1.77 834   
6e-(3) 7654 4377 1.749 1.46 1.77 824   
6e-(4) 7263 4296 1.691 1.41 1.77 797 823 14.6% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
24 25.0 × 2 5.32 0.266 2.0 ~10 
alkyne (5e) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 240 0.24 1.0 720 0.72 
(R)-6d
H
CO2Et
H
O
6
O
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purification eluent product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
42.8 0.168 70% 630 
 
(R)-6e: [α]23D = + 29.8 ± 1.3° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
rac-6e R-6e 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
15.335 4382.18 50.47 15.031 17990.7 96.81 
16.815 4300.19 49.53 16.922 592.4 3.19 
Total 8682.37 100.00 Total 18583.1 100.00 
 
Ethyl (R)-2-(3-isopropoxypropyl)cycloprop-2-ene-1-carboxylate (6f) 
Analysis Data (10 mM 5f, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6f-(1) 212.9 504.7 0.422 0.38 1.82 207   
6f-(2) 289.9 514.0 0.564 0.50 1.82 276   
6f-(3) 252.4 511.2 0.494 0.44 1.82 242 242 4.4% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.27 0.251 2.0 ~12 
alkyne (5f) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
800 100 0.08 800 300 0.24 
purification eluent product 
(R)-6e
H
CO2Et
H
O
O
5
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Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
13.6 0.0641 80% 260 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
rac-6f R-6f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.414 4415.92 50.11 9.419 4104.93 97.27 
10.871 4396.46 49.89 10.917 115.14 2.73 
Total 8812.38 100.00 Total 4220.07 100.00 
 
Ethyl (R)-2-(cyclohexylmethyl)cycloprop-2-ene-1-carboxylate (6g) 
Analysis Data (20 mM 5g, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6g-(1) 1044.5 704.1 1.483 0.97 1.67 585   
6g-(2) 903.7 654.8 1.380 0.91 1.67 544   
6g-(3) 1102.7 701.6 1.572 1.03 1.67 620   
6g-(4) 1105.0 726.7 1.521 1.00 1.67 600 587 4.9% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 20.0 × 3 3.83 0.230 1.5 ~12 
alkyne (5g) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
0.80 250 0.20 0.80 500 0.40 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 5% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
23.1 0.111 55% 480 
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(R)-6g: [α]23D = + 53.4 ± 1.5° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
rac-6g R-6g 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
7.550 5484.74 49.83 7.127 7090.46 93.05 
8.102 5522.14 50.17 7.563 529.64 6.95 
Total 11006.88 100.00 Total 7620.10 100.00 
 
Ethyl (R)-2-(6-((tetrahydro-2H-pyran-4-yl)methoxy)hexyl)cycloprop-2-ene-1-carboxylate 
(6h) 
Analysis Data (10 mM 5h, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6h-(1) 40106 4085 9.818 7.31 1.77 4137   
6h-(2) 40775 4175 9.766 7.28 1.77 4115   
6h-(3) 39655 4125 9.613 7.16 1.77 4051   
6h-(4) 38780 4188 9.260 6.90 1.77 3902 4051 71.6% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
10 70.0 1.27 0.0886 3.0 ~10 
alkyne (5h) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/mL n_2/mmol 
1.0 400 0.40 1.0 1.20 1.20 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
81.3 0.262 66% 2960 
 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
(R)-6g
H
CO2Et
H
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OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 200 4.84 0.968 12.0 ~11 
alkyne (5h) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
2.0 1.50 3.0 2.0 1.50 × 3 9.0 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 12% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
872.4 2.81 94% 2900 
 
(R)-6h: [α]23D = + 74.9 ± 1.8° (c 0.1, cyclohexane). 
Chiralpak IC, 12% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
 
rac-6h R-6h 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.527 2944.10 50.03 17.272 1166.58 98.95 
20.370 2940.07 49.97 20.548 12.34 1.05 
Total 5884.17 100.00 Total 1178.92 100.00 
 
Ethyl (R)-2-(6-(cyclopropylmethoxy)hexyl)cycloprop-2-ene-1-carboxylate (6i) 
Analysis Data (10 mM 5i, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6i-(1) 26575 4144 6.413 4.44 2.01 2207   
6i-(2) 26599 4150 6.409 4.43 2.01 2206   
6i-(3) 26021 4086 6.368 4.40 2.01 2191   
6i-(4) 26300 4154 6.331 4.38 2.01 2179 2196 44.1% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
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OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
32 25.0 6.48 0.162 1.5 ~11 
alkyne (5i) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 360 0.36 1.0 900 0.90 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 10% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
61.8 0.232 64% 1430 
 
(R)-6i: [α]23D = + 43.1 ± 1.5° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
rac-6i R-6i 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.107 7660.01 49.18 14.192 8396.37 95.83 
14.954 7914.53 50.82 15.257 365.59 4.17 
Total 15574.54 100.00 Total 8761.96 100.00 
 
Ethyl (R or S)-2-([1,1'-bi(cyclopropan)])-2-ene-1-carboxylate (R or S-6j) 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 25.0 4.47 0.112 1.2 ~11 
alkyne (5j) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 250 0.10 400 375 0.15 
purification eluent product 
Ether in pentane m[Pdt]/mg n[Pdt]/mmol yield TTN 
81 
 
 
(0% to 20% gradient) 10.7 0.0703 70% 630 
 
E. coli suspension expressing P411-K10 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 25.0 3.07 0.0767 1.2 ~11 
alkyne (5j) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 250 0.10 400 375 0.15 
purification eluent product 
Ether in pentane 
(0% to 20% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
11.2 0.0736 74% 960 
1H NMR (600 MHz, Acetone-d6) δ 6.47 (d, J = 1.6 Hz, 1H), 4.13 – 4.03 (m, 2H), 
1.99 (d, J = 1.5 Hz, 1H), 1.91 (tt, J = 7.9, 4.6 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H), 1.01 – 
0.94 (m, 2H), 0.84 – 0.80 (m, 1H), 0.61 – 0.58 (m, 1H). 13C NMR (151 MHz, acetone) 
δ 175.54, 117.94, 92.45, 59.99, 18.65, 14.46, 6.79, 6.05, 5.78. HRMS (EI) m/z: 
152.0865 (M+∙); calc. for C9H12O2: 152.0837. 
 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
 
  
S-6j R-6j 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
11.327 10039.7 33.26 11.325 11590.7 93.43 
11.739 20144.1 66.73 11.791 814.5 6.57 
Total 30183.8 100.00 Total 12405.2 100.00 
 
Ethyl (R)-2-(4-chlorobutyl)cycloprop-2-ene-1-carboxylate (6k) 
Analysis Data (10 mM 5k, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6k-(1) 322.4 517.1 0.623 0.56 1.82 308   
(R)-6j
H
CO2Et
H
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6k-(2) 363.5 517.4 0.703 0.63 1.82 347   
6k-(3) 342.8 523.4 0.655 0.59 1.82 324 326 6.0% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.27 0.251 2.0 ~12 
alkyne (5k) stock in EtOH EDA stock in EtOH 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
800 125 0.10 800 375 0.30 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 8% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
17.6 0.0868 87% 340 
 
(R)-6k: [α]23D = + 25.7 ± 1.6° (c 0.1, cyclohexane). 
Chiralpak IC, 5% i-PrOH in hexane, 1.0 mL/min, 210 nm 
  
rac-6k R-6k 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.944 6736.15 49.72 10.970 9049.69 94.15 
12.452 6811.65 50.28 12.610 562.69 5.85 
Total 13547.8 100.00 Total 9612.38 100.00 
 
Ethyl (R)-2-(6-((trans-4-(methoxymethyl)cyclohexyl)methoxy)hexyl)cycloprop-2-ene-1- 
carboxylate (6l) 
Analysis Data (10 mM 5l, P411-C6): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
6l-(1) 14861 4259 3.489 2.41 1.93 1252   
6l-(2) 13735 4274 3.214 2.22 1.93 1153   
6l-(3) 16271 4222 3.854 2.66 1.93 1383   
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6l-(4) 13204 4323 3.054 2.11 1.93 1096 1221 23.5% 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
10 35.0 × 2 1.27 0.0886 3.0 ~10 
alkyne (5l) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 180 0.18 1.0 540 0.54 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 15% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
22.1 0.0627 35% 710 
 
(R)-6l: [α]23D = + 62.6 ± 2.7° (c 0.1, cyclohexane). 
Chiralpak IC, 7% i-PrOH in hexane, 1.0 mL/min, 210 nm 
   
rac-6l R-6l 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.132 11165.0 49.76 10.065 16783.3 96.39 
11.214 11274.8 50.24 11.435 628.6 3.61 
Total 22439.8 100.00 Total 17411.9 100.00 
 
Ethyl (R)-2-(6-hydroxyhexyl)cycloprop-2-ene-1-carboxylate (6m) 
Preparative-scale reaction: 
E. coli suspension expressing P411-C6 in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
30 40.0 6.80 0.272 1.5 ~12 
alkyne (5m) stock in EtOH EDA stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
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1.0 250 0.25 2.0 750 1.50 
purification eluent product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
38.2 0.193 80% 710 
 
(R)-6m: [α]23D = + 80.1 ± 3.4° (c 0.1, ethyl acetate). 
Chiralpak IC, 12% i-PrOH in hexane, 1.0 mL/min, 210 nm 
  
rac-6m R-6m 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
15.695 8828.78 49.97 15.760 8045.71 96.00 
16.614 8838.24 50.03 16.860 335.20 4.00 
Total 17667.02 100.00 Total 8380.91 100.00 
 
A.5.3 Enzymatic synthesis of internal cyclopropenes 
All enzymatic reactions for internal cyclopropene formation in analytical scale were conducted 
following the general procedure described below and analyzed with gas chromatography (GC). All 
TTNs for the different products were determined using the GC standard curves of the 
corresponding racemic standard products made with Rh2(OAc)4. 
General procedure for preparative-scale reactions:  
To a 500 mL flask were added a suspension of E. coli expressing P411-C10 variant (OD600 = 15), 
alkyne (1.0 mmol), EDA (0.8 mmol, 0.8 equiv.), D-glucose (20 mM), M9-N buffer/EtOH (20:1 v/v) 
under anaerobic conditions. The flask was capped and shaken (300 rpm) inside the anaerobic 
chamber at room temperature for 2 h. The second portion of EDA (0.8 mmol, 0.8 equiv.) was added 
to the reaction before the reaction was shaken for another 2 h and a third portion of EDA (0.8 mmol, 
0.8 equiv.) was then added. The reaction was shaken for another 20 h. 
After the reaction was completed, the reaction mixture were transferred to 500 mL centrifuge 
bottle. The reaction flask was washed with water (3 mL × 3) followed by mixed organic solvent 
(hexane/ethyl acetate = 1:1, 5 mL × 3). The washing solution was combined with the reaction mixture 
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in the centrifuge bottle. An additional 100 mL of hexane/ethyl acetate solvent was added to the 
centrifuge bottle. After the bottle was capped, it was shaken vigorously and centrifuged (6,000 × g, 
6 min). The organic layer was separated and the aqueous layer was subjected to three more rounds 
of extraction. The organic layers were combined, dried over Na2SO4 and concentrated under 
reduced pressure. Purification by silica column chromatography with hexane/ethyl acetate as 
eluents followed by C18 column reverse-phase chromatography using acetonitrile/water as eluents 
afforded the desired cyclopropenes. TTNs were calculated based on measured protein 
concentration and isolated product yield. 
 
Ethyl 2-ethyl-3-phenylcycloprop-2-ene-1-carboxylate (9a) 
Analysis Data (WIRF, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9a-(1) 6839.6 806.9 8.476 6.03 2.26 2671  
9a-(2) 6587.7 776.4 8.485 6.03 2.26 2673  
9a-(3) 6650.3 779.8 8.528 6.06 2.26 2686  
9a-(4) 6678.4 789.6 8.458 6.01 2.26 2665 2674 
 
Chiralpak IC, 4% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
 
  
Racemic 9a Enzymatically produced 9a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.45 3903.5 51.03 - - - 
13.04 3745.9 48.97 12.97 13104.9 100.00 
Total 7649.4 100.00 Total 13104.9 100.00 
 
Ethyl 2-ethyl-3-(4-chorophenyl)cycloprop-2-ene-1-carboxylate (9b) 
Analysis Data (WIRF_GAK, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. 
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TTN 
9b-(1) 6612.8 780.1 8.477 4.62 2.18 2124  
9b-(2) 6951.3 789.3 8.807 4.81 2.18 2210  
9b-(3) 6318.4 783.2 8.067 4.39 2.18 2018  
9b-(4) 6829.4 789.4 8.651 4.72 2.18 2169 2130 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
  
Racemic 9b Enzymatically produced 9b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
6.20 10374.7 49.98 - - - 
7.84 10382.2 50.02 7.95 14886.3 100.00 
Total 20756.9 100.00 Total 14886.3 100.00 
 
Ethyl 2-methyl-3-phenylcycloprop-2-ene-1-carboxylate (9c) 
Analysis Data (WIRF, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9c-(1) 6449.8 776.8 8.303 5.47 2.26 2426  
9c-(2) 6363.9 784.1 8.116 5.35 2.26 2370  
9c-(3) 5895.1 779.2 7.566 4.98 2.26 2207  
9c-(4) 6059.4 756.8 8.007 5.27 2.26 2338 2335 
 
Chiralpak IC, 2.8% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9c Enzymatically produced 9c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
8.81 7897.2 49.93 - - - 
11.50 7918.6 50.07 11.88 28691.3 100.00 
Total 15815.8 100.00 Total 28691.3 100.00 
 
Ethyl 2-ethyl-3-(2-fluorophenyl)cycloprop-2-ene-1-carboxylate (9d) 
Analysis Data (WIRF, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9d-(1) 6031.1 769.7 7.836 3.83 3.01 1273  
9d-(2) 5341.5 767.4 6.961 3.40 3.01 1129  
9d-(3) 5778.2 778.0 7.427 3.63 3.01 1206  
9d-(4) 5862.0 793.9 7.384 3.61 3.01 1198 1201 
Preparative-scale reaction: 
E. coli suspension expressing WIRF in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol Mass/g [Glu]/mM 
15 200 3.11 0.621 0.75 ~20 
alkyne (8d) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
0.50 2.00 1.00 0.8 1.00 × 3 2.4 
purification eluent Product 
Silica column: EtOAc in 
hexanes (0% to 10% gradient) 
C18 column: MeCN in H2O 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
210.3 0.898 90% 1445 
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(0% to 100% gradient) 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
 
  
Racemic 9d Enzymatically produced 9d 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
7.04 9178.0 50.14 - - - 
8.80 9127.6 49.86 8.74 13107.2 100.00 
Total 18305.6 100.00 Total 13107.2 100.00 
 
Ethyl 2-ethyl-3-(4-fluorophenyl)cycloprop-2-ene-1-carboxylate (9e) 
Analysis Data (WIRF_G, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9e-(1) 6531.9 788.0 8.289 4.27 2.69 1589  
9e-(2) 6825.3 801.1 8.520 4.39 2.69 1634  
9e-(3) 6455.4 793.5 8.135 4.19 2.69 1560  
9e-(4) 6645.0 772.6 8.601 4.43 2.69 1649 1608 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9e Enzymatically produced 9e 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
6.00 11344.7 49.84 - - - 
6.88 11418.2 50.16 6.87 16055.4 100.00 
Total 22762.9 100.00 Total 16055.4 100.00 
 
Ethyl 2-ethyl-3-(3-methoxyphenyl)cycloprop-2-ene-1-carboxylate (9f) 
Analysis Data (WIRF_G, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9f-(1) 2136.3 808.3 2.643 1.27 2.69 472  
9f-(2) 2365.8 793.6 2.981 1.43 2.69 533  
9f-(3) 2582.1 791.1 3.264 1.57 2.69 584  
9f-(4) 2161.4 798.1 2.708 1.30 2.69 484 519 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9f Enzymatically produced 9f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.28 9133.9 50.03 - - - 
16.34 9122 49.97 16.41 6722.22 100.00 
Total 18255.9 100.00 Total 6722.22 100.00 
 
Ethyl 2-ethyl-3-(4-trifluoromethylphenyl)cycloprop-2-ene-1-carboxylate (9g) 
Analysis Data (WIRF_GAK, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9g-(1) 4817.3 781.3 6.166 3.13 2.18 1440  
9g-(2) 5442.6 810.4 6.716 3.41 2.18 1568  
9g-(3) 5254.5 795.8 6.603 3.36 2.18 1542  
9g-(4) 5083.1 790.7 6.429 3.27 2.18 1501 1513 
Preparative-scale reaction: 
E. coli suspension expressing WIRF_GAK in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol Mass/g [Glu]/mM 
15 200 1.75 0.351 0.75 ~20 
alkyne (8g) stock in EtOH EDA stock in EtOH 
stock/M volume/mL n_1/mmol stock/M volume/mL n_2/mmol 
0.50 2.00 1.00 0.8 1.00 × 3 2.4 
purification eluent Product 
Silica column: EtOAc in 
hexanes (0% to 10% gradient) 
C18 column: MeCN in H2O 
(0% to 100% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
245.8 0.865 87% 2465 
 
Chiralpak IC, 2.2% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9g Enzymatically produced 9g 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
5.71 4652.4 51.70 - - - 
5.93 4346.5 48.30 5.91 9992.6 100.00 
Total 8998.9 100.00 Total 9992.6 100.00 
 
Ethyl 2-ethyl-3-(4-(difluoromethoxy)phenyl)cycloprop-2-ene-1-carboxylate (9h) 
Analysis Data (WIRF_GAK, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9h-(1) 6396.0 798.8 8.007 3.76 2.18 1728  
9h-(2) 5479.1 797.3 6.872 3.22 2.18 1481  
9h-(3) 5087.7 773.4 6.578 3.08 2.18 1417  
9h-(4) 5472.5 792.5 6.905 3.24 2.18 1488 1529 
Chiralpak IC, 4% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9h Enzymatically produced 9h 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
6.91 7905.5 50.00 - - - 
8.15 7905.8 50.00 8.12 9799.3 100.00 
Total 15811.3 100.00 Total 9799.3 100.00 
 
Ethyl 2-ethyl-3-(p-tolyl)cycloprop-2-ene-1-carboxylate (9i) 
Analysis Data (WIRF_GAK, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9i-(1) 11891.3 785.0 15.148 9.44 1.63 5782  
9i-(2) 11667.8 788.5 14.797 9.20 1.63 5639  
9i-(3) 12089.5 792.8 15.249 9.50 1.63 5823  
9i-(4) 11862.7 781.8 15.174 9.45 1.63 5792 5759 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
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Racemic 9i Enzymatically produced 9i 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
8.83 13306.4 49.97 - - - 
17.84 13320.3 50.03 17.49 29535.2 100.00 
Total 26626.7 100.00 Total 29535.2 100.00 
 
Ethyl 2-ethyl-3-(4-methoxyphenyl)cycloprop-2-ene-1-carboxylate (9j) 
Analysis Data (WIRF_GAK, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9j-(1) 10209.8 807.4 12.645 7.30 1.63 4470  
9j-(2) 10484.6 800.1 13.104 7.57 1.63 4639  
9j-(3) 10350.3 811.8 12.750 7.36 1.63 4509  
9j-(4) 9927.8 803.9 12.350 7.12 1.63 4361 4495 
 
Chiralpak IC, 5% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
 
  
Racemic 9j Enzymatically produced 9j 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.33 7394.3 49.92 - - - 
18.38 7417.0 50.08 18.51 25171.5 100.00 
Total 14811.3 100.00 Total 25171.5 100.00 
 
Ethyl 2-ethyl-3-(4-chloro-3-methylphenyl)cycloprop-2-ene-1-carboxylate (9k) 
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Analysis Data (WIRF_GAK, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9k-(1) 4779.0 788.6 6.060 2.46 2.18 1131  
9k-(2) 4771.1 786.6 6.065 2.46 2.18 1132  
9k-(3) 4815.2 763.1 6.310 2.56 2.18 1178  
9k-(4) 4556.0 787.0 5.789 2.35 2.18 1080 1130 
 
Chiralpak IC, 3% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
  
Racemic 9k Enzymatically produced 9k 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
6.31 21041.9 49.45 - - - 
6.96 21508.1 50.55 6.90 10024.1 100.00 
Total 42550.0 100.00 Total 10024.1 100.00 
 
Ethyl 2-ethyl-3-(4-methoxy-3-methylphenyl)cycloprop-2-ene-1-carboxylate (9l) 
Analysis Data (WIRF_GAK, OD600=20): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9l-(1) 7021.1 797.6 8.803 3.73 2.18 1714  
9l-(2) 7502.1 809.4 9.269 3.94 2.18 1809  
9l-(3) 6806.2 807.3 8.431 3.56 2.18 1638  
9l-(4) 7147.9 807.5 8.852 3.75 2.18 1724 1721 
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Chiralpak IC, 5% isopropanol in hexane, 1.2 ml/min, 32 °C, 254nm 
 
  
Racemic 9l Enzymatically produced 9l 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.30 8567.5 49.90 - - - 
12.53 8601.3 50.10 12.49 13311.0 100.00 
Total 17168.8 100.00 Total 13311.0 100.00 
 
Ethyl 2-(2-ethoxyethyl)-3-ethylcycloprop-2-ene-1-carboxylate (9m) 
Analysis Data (C10, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9m-(1) 125.9 1066.5 0.118 0.11 2.34 46  
9m-(2) 123.4 1041.9 0.118 0.11 2.34 46  
9m-(3) 125.5 1032.3 0.122 0.11 2.34 47  
9m-(4) 118.2 1047.3 0.113 0.10 2.34 44 46 
Analysis Data (C10-T327V Q437L S332C, OD600=15): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
9m-(1) 211.5 1039.4 0.203 0.17 2.57 64  
9m-(2) 217.2 1056.9 0.206 0.17 2.57 65  
9m-(3) 212.3 1055.3 0.201 0.16 2.57 64  
9m-(4) 208.6 1024.0 0.204 0.17 2.57 64 64 
 
CycloSil-B, 88 °C isothermal for 92 min -> 2°C/min gradient -> 110°C isothermal for 3 min -> 
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60 °C/min gradient -> 240 °C isothermal for 5 min, flow rate 2.0 ml/min 
 
 
 
Racemic 9m 9m produced by C10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
85.56 400.29 49.63 85.64 2.47 0.49 
86.67 406.21 50.37 86.69 500.01 99.51 
Total 806.50 100.00 Total 500.48 100.00 
9m produced by C10_VLC 
Retention Time 
(min) 
Area (mAU*s) Area % 
85.60 3.48 0.46 
86.61 759.84 99.54 
Total 763.32 100.00 
 
Chemoselectivity in carbene transfer to internal alkyne 8n with different P411 variants: 
 
 
With C10 
With C10-T327V Q437L S332C 
(C10_VLC) 
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GC trace: HP5 column, 80 °C isothermal for 2 min -> 6°C/min gradient -> 180°C -> 60 °C/min 
gradient -> 250 °C isothermal for 2 min 
 
 
 
 
 
 
With C10 
With C10-Q437I V328I 
(C10_II) 
With C10-A87P 
A264S E267D T327P 
S332A Q437L (L8) 
With P411-CHF 
With C10-G74T S118M L162F 
L401I Q437L (C11) 
With C10-T327P Q437V 
A87V (C10_PVV) 
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Product assignment: 
Retention 
time 
14.24 min 14.33 min 14.42 min 
Compound # 9n 9n-1 9n-2 
Compound 
structure 
  
 
 
TTN for all products based on carbene transfer (OD600=20 for L8, OD600=15 for the rest): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: C10 
n-(1) 309.4 1026 0.302 0.24 2.72 90  
9n-1:9n:9n-2 
30:60:10 
n-(2) 272.1 989.2 0.275 0.22 2.72 82  
n-(3) 283.4 1021.1 0.278 0.23 2.72 83  
n-(4) 303.7 1005.6 0.302 0.25 2.72 90 86 
 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: 
C10_II 
n-(1) 272.7 1064.9 0.256 0.21 2.90 72  
9n-1:9n:9n-2 
5:80:15 
n-(2) 259.5 988.2 0.263 0.21 2.90 74  
n-(3) 257.1 987.8 0.260 0.21 2.90 73  
n-(4) 248.2 973.9 0.255 0.21 2.90 71 72 
 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: L8 
n-(1) 394.9 1028.2 0.384 0.31 2.34 133  
9n-1:9n:9n-2 
22:70:8 
n-(2) 395.2 1015.3 0.389 0.32 2.34 135  
n-(3) 402.1 1010.6 0.398 0.32 2.34 138  
n-(4) 382.2 994.3 0.384 0.31 2.34 133 135 
 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: CHF 
n-(1) 759 1002.5 0.757 0.61 2.20 278  
9n-1:9n:9n-2 
67:30:3 
n-(2) 747.3 1006.1 0.743 0.60 2.20 272  
n-(3) 720.9 1008.8 0.715 0.58 2.20 262  
n-(4) 745.4 1017.1 0.733 0.59 2.20 269 270 
 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: C11 
n-(1) 1221.8 1003.8 1.217 0.98 2.44 399  9n-1:9n: 
9n-2 
82:16:2 
n-(2) 1176.6 992.0 1.186 0.95 2.44 389  
n-(3) 1170.9 992.9 1.179 0.95 2.44 387  
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n-(4) 1182.0 991.1 1.193 0.96 2.44 391 392 
 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Enzyme: 
C10_PVV 
n-(1) 227.5 1014.7 0.224 0.18 3.03 60  
9n-1:9n: 
9n-2 
18:22:60 
n-(2) 229.3 1004.4 0.228 0.19 3.03 61  
n-(3) 224.9 991.0 0.227 0.18 3.03 61  
n-(4) 233.1 1016.0 0.229 0.19 3.03 62 61 
 
Chiral GC trace: CycloSil-B, 100 °C isothermal for 20 min -> 0.2°C/min gradient -> 120°C isothermal 
for 20 min -> 60 °C/min gradient -> 240 °C isothermal for 5 min, flow rate 2.0 ml/min 
  
  
  
Racemic 9n Racemic 9n-1 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
118.18 58.08 50.06 128.19 2479.29 49.90 
118.88 57.94 49.94 130.63 2489.35 50.10 
Total 116.02 100.00 Total 4968.64 100.00 
9n-2 
Retention Time 
(min) 
Area (mAU*s) Area % 
124.92 978.08 100.00 
 
CO2Et
Me
OMe
H
racemic 9n
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9n produced by C10 9n-1 produced by C10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
117.89 1.77 0.10 129.85 21.91 2.47 
118.47 1836.33 99.90 131.49 864.68 97.53 
Total 1838.10 100.00 Total 886.59 100.00 
 
 
9n produced by C10_II 9n-1 produced by C10_II 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
117.85 0.84 0.08 129.98 2.15 3.41 
118.44 1116.91 99.92 132.12 59.87 96.59 
Total 1117.75 100.00 Total 63.02 100.00 
 
 
9n produced by L8 9n-1 produced by L8 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
117.84 4.49 0.32 129.70 26.91 6.35 
118.37 1398.48 99.68 131.68 396.70 93.65 
Total 1402.97 100.00 Total 423.61 100.00 
 
With C10 
With C10-Q437I V328I 
(C10_II) 
With C10-A87P A264S E267D 
T327P S332A Q437L (L8) 
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9n produced by CHF 9n-1 produced by CHF 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
118.00 1.24 0.13 129.56 24.90 1.22 
118.61 968.48 99.87 130.83 2021.91 98.78 
Total 969.72 100.00 Total 2046.81 100.00 
 
 
9n produced by C11 9n-1 produced by C11 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
- - - 129.51 23.65 1.50 
118.65 312.97 100.00 130.88 1549.75 98.50 
Total 969.72 100.00 Total 1573.40 100.00 
 
 
9n produced by C10_PVV 9n-1 produced by C10_PVV 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
118.32 48.08 10.64 129.85 30.70 8.39 
118.78 403.71 89.36 131.95 335.11 91.61 
Total 451.79 100.00 Total 365.81 100.00 
 
 
 
 
With P411-CHF 
With C10-G74T S118M L162F 
L401I Q437L (C11) 
With C10-PVV 
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5-Ethoxy-3-(methoxymethyl)-2-pentylfuran (9n-2) 
 
Compound 9n-2 was isolated from a large-scale enzymatic reaction 
using alkyne 8n and EDA as substrates and C10-PVV as the enzyme 
variant. 1H NMR (400 MHz, CDCl3) δ 5.08 (s, 1H), 4.17 (s, 2H), 4.03 (q, J = 7.1 Hz, 2H), 3.32 (s, 3H), 
2.50 (t, J = 7.5 Hz, 2H), 1.62–1.54 (m, 2H), 1.39 (t, J = 7.1 Hz, 3H), 1.35–1.22 (m, 4H), 0.88 (t, J = 7.0 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 159.24, 143.80, 116.69, 81.16, 66.73, 66.20, 57.73, 31.41, 28.57, 25.76, 
22.54, 14.76, 14.16. HRMS (TOF) m/z: 227.1641 (M+H+); calc. for [C13H22O3+H+]: 227.1642. The 
isolated furan adduct was identified to be the regio-isomer shown here, according to NOE signals. 
 
 
 
A.6 Derivatization of enzymatically produced strained carbocycles 
Diethyl (2R,4R)-1-(4-(1-((4-acetamidophenyl)sulfonyl)-1H-1,2,3-triazol-4-yl)phenyl) bicyclo 
[1.1.0]butane-2,4-dicarboxylate (4a) 
 
Bicyclobutane 2l (41.6 mg, 0.139 mmol) was dissolved in toluene (3 mL) in 
a 20 mL vial. Copper(I) thiophene-2-carboxylate (CuTc, 3.2 mg, 12 mol%) 
was added. The mixture was kept stirring at 0 °C. A suspension of 4-
acetamidobenzenesulfonyl azide (40.2 mg, 0.167 mmol) in toluene (5 mL) 
was added dropwise over 1 h. The resulting mixture was then allowed to 
warm to room temperature and stirred for 15 h. The reaction was diluted 
with ethyl acetate (15 mL), washed with NH4Cl/NH3 (2:1, 20 mL, aq.), and 
brine (50 mL), dried over MgSO4, and then concentrated under reduced pressure. The crude 
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product was purified by silica column chromatography with hexane/ethyl acetate (4:1 to 1:3 gradient) 
to afford 4a (69.2 mg, 0.129 mmol, 93%). 1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 8.10 (s, 1H), 8.00 
(d, J = 9.0 Hz, 2H), 7.74 (dd, J = 12.8, 8.7 Hz, 4H), 7.34 (d, J = 8.6 Hz, 2H), 4.15 (dq, J = 7.1, 3.5 Hz, 
2H), 4.08 (q, J = 7.1 Hz, 2H), 3.28 (d, J = 0.6 Hz, 1H), 3.19 (dd, J = 3.1, 0.6 Hz, 1H), 3.14 (d, J = 3.1 Hz, 
1H), 2.20 (s, 3H), 1.27 (t, J = 7.2 Hz, 3H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.14, 
169.15, 167.88, 147.11, 145.13, 134.03, 130.40, 129.53, 128.96, 127.92, 126.19, 119.62, 119.22, 61.17, 61.13, 44.75, 
42.63, 27.84, 24.93, 21.39, 14.35, 14.21. HRMS (FAB) m/z: 539.1605 (M+H+); calc. for C26H27O7SN4: 
539.1600. [α]23D = ‒81.5 ± 2.1° (c 0.1, ethyl acetate). 
 
Diethyl (2R,4R)-1-(4-(1-((S)-1-methoxy-1-oxo-3-phenylpropan-2-yl)-1H-1,2,3-triazol-4-yl) 
phenyl)bicyclo[1.1.0]butane-2,4-dicarboxylate (4b) 
 
Sodium azide (7.02 g, 108 mmol) was dissolved in a mixture of water (30 mL) 
and DCM (15 mL) at 0 °C. Triflic anhydride (Tf2O, 3 mL, 18 mmol) was added 
dropwise over 10 min. The reaction was then stirred for 2 h. The reaction was 
diluted with DCM (15 mL), washed by NaHCO3 (50 mL, sat. aq.), and brine 
(50 mL), and dried over Na2SO4. A solution of triflic azide (TfN3, ~15 mmol) 
in DCM was used for the next step. 
Methyl L-phenylalaninate hydrochloride (1.73 g, 8.0 mmol), was 
dissolved in MeOH (16 mL). A aqueous solution of CuSO4 (1.28 mL, 10 g/L, 1 mol%) and N,N-
diisopropylethylamine (DIPEA, 2.09 mL, 12.0 mmol) were added. The resulting solution was stirred 
for 30 min before the dropwise addition of triflic azide (TfN3, ~15 mmol in DCM) over 20 min. The 
reaction was stirred for 15 h. The reaction mixture was diluted with DCM (40 mL), washed by water 
(50 mL), HCl (50 mL, 5%, aq.), NaHCO3 (50 mL, sat. aq.), and brine (50 mL), and dried over Na2SO4. 
After evaporation of solvent under reduced pressure, the product mixture was purified by silica 
column chromatography with hexane/ethyl acetate (1:0 to 12:1 gradient) to afford methyl (S)-2-
azido-3-phenylpropanoate (1.65 g, 8.0 mmol, quantitative). 
Bicyclobutane 2l (49.5 mg, 0.166 mmol) was dissolved in THF/H2O (1:1, 1.6 mL) in a 20 mL vial. 
An aqueous solution of CuSO4 (17 μL, 1N, 10 mol%) and Cu powder (10.6 mg, 0.166 mmol) were 
added. The mixture was kept stirring at 0 °C. A solution of methyl (S)-2-azido- 3-phenylpropanoate 
(50.1 mg, 0.249 mmol) in THF (0.5 mL) was added dropwise over 5 min. The resulting mixture was 
then allowed to warm to room temperature and stirred for 24 h. The reaction was diluted with DCM 
(15 mL), washed with NH4Cl (10 mL, aq. sat.), and brine (30 mL), dried over MgSO4, and then 
concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane/ethyl acetate (8:1 to 2:1 gradient) to afford 4b (82.5 mg, 0.164 mmol, 
99%) as one major diastereomer determined by 1H NMR. 1H NMR (400 MHz, CDCl3) δ 7.80 (s, 1H), 
7.78–7.69 (m, 2H), 7.37–7.30 (m, 2H), 7.28–7.20 (m, 3H), 7.08–7.03 (m, 2H), 5.63 (dd, J = 8.1, 6.7 Hz, 
1H), 4.15 (qd, J = 7.1, 2.6 Hz, 2H), 4.08 (q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 3.52 (dd, J = 7.4, 3.2 Hz, 2H), 
3.28 (d, J = 0.5 Hz, 1H), 3.17 (dd, J = 3.1, 0.6 Hz, 1H), 3.13 (d, J = 3.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.15 
(t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.24, 168.84, 167.87, 147.40, 134.77, 132.77, 129.67, 
129.08, 128.98, 128.84, 127.77, 125.80, 119.75, 64.17, 61.05, 61.01, 53.26, 44.71, 42.64, 39.12, 27.99, 20.89, 
14.36, 14.22. HRMS (FAB) m/z: 504.2148 (M+H+); calc. for C28H30O6N3: 504.2135. [α]23D = ‒278.7 ± 4.0° 
(c 0.0625, ethyl acetate). 
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Note: A diastereomer of 4b was prepared through the same procedure using D-azido-phenylalanine. 
It was confirmed that the pair of diastereomers can be resolved on 1H NMR at the α-C–H position 
of phenylalanine (splitting peaks: D-phenylalanine: 5.6410, 5.6242, 5.6208, 5.6041; L-phenylalanine: 
5.6462, 5.6296, 5.6261, 5.6093; FWHM (full width at half maxima) = 0.0030 ppm; Δf1 = 0.0053 ppm, 
close to baseline separation). 
 
Diethyl (2R,4R)-1-(4-((((R)-3,3,3-Trifluoro-2-methoxy-2-phenylpropanoyl)oxy)methyl) 
phenyl) bicyclo[1.1.0]butane-2,4-dicarboxylate (4c) 
 
Bicyclobutane 2m (16.1 mg, 0.053 mmol) and (R)-3,3,3-trifluoro-2- methoxy-
2-phenylpropanoic acid (R-Mosher’s acid, 30.4 mg, 0.13 mmol) were dissolved 
in dry DCM (2 mL) in a 10 mL vial. 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDCI, 24.9 mg, 0.13 
mmol), triethylamine (TEA, 18 μL, 0.13 mmol) and 4-dimethylaminopyridine 
(DMAP, 2.0 mg, 0.015 mmol) were added to the solution. The reaction mixture 
was then stirred at room temperature for 16 h. The reaction was diluted with 
DCM (5 mL), washed with water (10 mL), and brine (10 mL), dried over MgSO4, and then 
concentrated under reduced pressure. The crude product was purified by silica column 
chromatography with hexane / ethyl acetate (1:0 to 4:1 gradient) to afford 4c (25.2 mg, 0.048 mmol, 
91%) as one major diastereomer determined by 1H NMR. 1H NMR (400 MHz, CDCl3) δ 7.48–7.41 (m, 
2H), 7.41–7.32 (m, 3H), 7.27 (s, 4H), 5.33 (d, J = 12.3 Hz, 1H), 5.29 (d, J = 12.2 Hz, 1H), 4.15 (qd, J = 7.2, 
2.6 Hz, 2H), 4.07 (qd, J = 7.2, 2.0 Hz, 2H), 3.51 (q, JH-F = 1.2 Hz, 3H), 3.26 (d, J = 0.6 Hz, 1H), 3.14 (dd, 
J = 3.1, 0.6 Hz, 1H), 3.11 (d, J = 3.1 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.1 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 170.01, 167.67, 166.43, 133.67, 133.32, 132.11, 129.64, 128.54, 128.53, 128.42, 127.54, 127.28, 
127.27, 124.68, 121.81, 118.94, 84.75, 67.60, 60.96, 60.88, 55.54, 44.61, 42.44, 27.66, 20.85, 14.23, 14.03 
(CF3, 127.54, 124.68, 121.81, 118.94, JC-F = 288.8 Hz; ). HRMS (FAB) m/z: 519.1651 ((M+H+)‒H2); calc. 
for C27H26O7F3: 519.1631. [α]23D = ‒43.2 ± 2.4° (c 0.1, ethyl acetate).  
 
Note: A diastereomer of 4c was prepared through the same procedure using S-Mosher’s acid. It was 
confirmed that the pair of diastereomers can be resolved on 1H NMR at one benzylic C–H position 
and 19F NMR, albeit not perfectly (splitting peaks on 1H NMR: R-Mosher’s acid: 5.3027, 5.2721; S-
Mosher’s acid: 5.3044, 5.2737; FWHM = 0.0024‒0.0029 ppm  ppm; Δf1 = 0.0017 ppm; chemical shift 
on 19F NMR: R-Mosher’s acid: ‒71.665; S-Mosher’s acid: ‒71.654; FWHM = 0.015 ppm  ppm; Δf1 = 
0.011 ppm). 
 
((1R,2R)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2,4-diyl)dimethanol (4d) 
 
Bicyclobutane 2k (101.3 mg, 0.33 mmol) was dissolved in anhydrous ether (10 
mL) in a 50 mL flask. Dry methanol (67 μL, 1.67 mmol) was added to the 
solution, followed by the addition of lithium borohydride (LiBH4, 2M in THF, 
0.84 mL, 1.67 mmol). The reaction mixture was then heated up to a refluxing 
temperature, 45 °C, for 1 h, before ethyl acetate (0.5 mL) was added and the 
mixture was stirred at room temperature for 30 min. Then the reaction was 
quenched with NH4Cl (10 mL, sat. aq.) and diluted with water (10 mL). The product was extracted 
O
Ph
OMe
O
F3C
H
CO2Et
EtO2C H
H
H
OMe
HO
OH
H
H
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with ethyl acetate (20 mL × 6). The combined organic layer was dried over MgSO4, and then 
concentrated under reduced pressure. White solid product crashed out during the removal of 
solvent. Collecting the solid product and recrystallization with acetone/hexane system afforded the 
diol 4d (52.2 mg, 0.237 mmol, 71%). 1H NMR (400 MHz, Acetone-d6) δ 7.31 (d, J = 8.9 Hz, 2H), 6.85 
(d, J = 8.8 Hz, 2H), 3.78 (s, 3H), 3.71–3.65 (m, 1H), 3.65 – 3.61 (m, 1H), 3.57–3.51 (m, 1H), 3.49–3.43 
(m, 2H), 2.28 (t, J = 5.8 Hz, 1H), 1.92 (dd, J = 3.6, 1.0 Hz, 1H) (O‒H protons are not resolved). 13C 
NMR (101 MHz, Acetone) δ 158.07, 129.14, 129.08, 113.58, 60.27, 60.14 (splitting), 55.88, 55.75 
(splitting), 54.56, 49.65, 49.61 (splitting), 46.08, 46.04 (splitting), 21.53, 16.55. (Note: the diol 
product might have two rotating conformations, resulting in splitting of 4 carbon peaks.) HRMS 
(FAB) m/z: 221.1168 (M+H+); calc. for C13H17O3: 221.1178. [α]23D = ‒50.8 ± 1.2° (c 0.1, acetone). 
 
Crystal structure information of 4d: 
 
 
Identification code      p17505 
Empirical formula      C13H16O3 
Formula weight       220.26 
Temperature        175 K 
Wavelength        1.54178 Å 
Crystal system       Monoclinic 
Space group        P 1 21 1 
Unit cell dimensions     a = 5.3738(7) Å a= 90° 
         b = 7.6719(8) Å b= 98.413(9)° 
         c = 13.7357(19) Å g = 90° 
Volume        560.19(12) Å3 
Z         2 
Density (calculated)     1.306 Mg/m3 
Absorption coefficient     0.747 mm-1 
F(000)        236 
Crystal size       0.22 x 0.18 x 0.06 mm3 
Theta range for data collection   3.252 to 79.483°. 
Index ranges       -6<=h<=6, -9<=k<=9, -16<=l<=17 
Reflections collected     17841 
Independent reflections     2338 [R(int) = 0.0437] 
Completeness to theta = 67.679°   99.9 %  
Absorption correction     Semi-empirical from equivalents 
Max. and min. transmission    1.0000 and 0.8812 
Refinement method     Full-matrix least-squares on F2 
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Data / restraints / parameters   2338 / 1 / 148 
Goodness-of-fit on F2     1.111 
Final R indices [I>2sigma(I)]    R1 = 0.0471, wR2 = 0.1225 
R indices (all data)      R1 = 0.0482, wR2 = 0.1232 
Absolute structure parameter   0.15(7) 
Extinction coefficient     n/a 
Largest diff. peak and hole    0.337 and -0.270 e.Å‒3 
 
Ethyl (1R,2R)-4-(hydroxymethyl)-1-(4-methoxyphenyl)bicyclo[1.1.0]butane-2-carboxylate 
(4e) 
 
Mono-alcohol 4e was obtained from the reduction of bicyclobutane 2k. 
Collecting the mother liquor after recrystallization, evaporation of organic 
solvent followed by purification by silica column chromatography with 
hexane/ethyl acetate (5:1 to 3:1 gradient) afforded 4e (14.6 mg, 0.056 mmol, 17%) 
with ~7:1 r.r. determined by 1H NMR. 1H NMR (400 MHz, Acetonitrile-d3) δ 
7.20 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.05 (qd, J = 7.1, 0.5 Hz, 2H), 
3.78 (s, 3H), 3.43 (t, J = 6.3 Hz, 2H), 2.75 (tdd, J = 7.0, 3.3, 0.7 Hz, 1H), 2.70 (t, J = 5.9 Hz, 1H), 2.68 (s, 
1H), 2.64 (d, J = 3.3 Hz, 1H), 1.14 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CD3CN) δ 168.54, 159.04, 
129.70, 127.38, 114.20, 60.92, 56.42, 55.44, 47.23, 42.52, 24.86, 18.43, 13.99. MS (EI) m/z: 262 (M+∙); 
calc. for C15H18O4: 262. 
 
(2-(4-Methoxyphenyl)cyclobut-1-ene-1,3-diyl)dimethanol (4f) 
 
Bicyclobutane 2k (54.7 mg, 0.18 mmol) was dissolved in anhydrous ether 
(5 mL) in a 20 mL vial and then cooled down to ‒78 °C. Lithium 
aluminium hydride (LAH, 13.7 mg, 0.36 mmol) was slowly added to the 
solution in portions. The reaction mixture was slowly warmed up to ‒
20 °C over 2 h, before ethyl acetate (0.5 mL) was added and the mixture was stirred at ‒20 °C for 
another 30 min. Then the reaction was quenched with NH4Cl (10 mL, sat. aq.) and diluted with 
water (10 mL). The product was extracted with ethyl acetate (20 mL × 3). The combined organic 
layer was dried over MgSO4, and then concentrated under reduced pressure. The crude product was 
purified by silica column chromatography with hexane/ethyl acetate (2:1 to 1:2 gradient) to afford 4f 
(18.1 mg, 0.082 mmol, 46%). 1H NMR (400 MHz, Acetonitrile-d3) δ 7.34 (d, J = 8.8 Hz, 2H), 6.92 (d, 
J = 8.9 Hz, 2H), 4.30 (d, J = 3.1 Hz, 2H), 3.80 (s, 5H), 3.57 (ddd, J = 11.2, 7.2, 4.3 Hz, 1H), 3.21–3.12 (m, 
1H), 2.95 (t, J = 5.7 Hz, 1H), 2.70 (t, J = 5.5 Hz, 1H), 2.59 (dd, J = 13.7, 4.6 Hz, 1H). 13C NMR (101 MHz, 
CD3CN) δ 159.59, 140.27, 140.19, 128.91, 128.55, 114.63, 65.02, 59.23, 55.79, 42.11, 31.40. MS (EI) m/z: 
220 (M+∙); calc. for C13H16O3: 220. 
 
Ethyl (1R,2R,3S)-3-allyl-2-methyl-2-phenethylcyclopropane-1-carboxylate (7a) 
 
Cyclopropene (R)-6a (54.0 mg, 0.25 mmol) and CuI (5.0 mg, 0.026 mmol, 
10 mol%) were dissolved in anhydrous ether (3 mL) to form a suspension 
in a 25 mL flask. Then the flask was charged with argon and cooled to ‒
MeO
OH
HO
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78 °C. Methylmagnesium bromide (0.75 mL, 1M in ether, diluted from 3M solution in ether) was 
added dropwise to the reaction mixture over 10 min. The reaction was slowly warmed to ‒40 °C over 
30 min and held at this temperature for another 1 h. A solution of allyl bromide (43 μL, 0.50 mmol) 
in ether (1 mL) was then added to the reaction dropwise over 5 min. The reaction was stirred at ‒
40 °C for 1 h, before it was quenched with NH4Cl/NH3 (2:1, aq., 5 mL) at ‒20 °C. The aqueous layer 
was extracted twice with ether. The combined organic layers were washed with water (10 mL), and 
brine (10 mL), dried over MgSO4, and then concentrated under reduced pressure. The crude product 
was purified by silica column chromatography with hexane/ethyl acetate (1:0 to 50:1 gradient) to 
afford 7a (48.0 mg, 0.176 mmol, 71%) as a single diastereomer. 1H NMR (400 MHz, CDCl3) δ 7.23–
7.17 (m, 2H), 7.13–7.07 (m, 3H), 5.73 (ddt, J = 17.3, 10.2, 6.2 Hz, 1H), 4.97 (dq, J = 17.2, 1.7 Hz, 1H), 4.89 
(ddt, J = 10.2, 2.0, 1.4 Hz, 1H), 4.07–3.96 (m, 2H), 2.68–2.60 (m, 2H), 2.33 (ddt, J = 7.6, 6.2, 1.5 Hz, 
2H), 1.57–1.51 (m, 2H), 1.40 (d, J = 8.9 Hz, 1H), 1.23 (s, 3H), 1.18 (t, J = 7.1 Hz, 3H), 1.09 (dt, J = 8.8, 7.4 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 171.68, 142.04, 137.72, 128.38, 128.33, 125.81, 114.58, 59.80, 45.06, 
32.87, 31.77, 29.13, 27.89, 27.34, 14.39, 11.53. HRMS (FAB) m/z: 273.1849 (M+H+); calc. for C18H25O2: 
273.1855. [α]23D = ‒61.3 ± 1.7° (c 0.1, ethyl acetate). 
 
Ethyl (1R,6R,7R)-3,4-dimethyl-1-(6-((tetrahydro-2H-pyran-4-yl)methoxy)hexyl) bicyclo 
[4.1.0]hept-3-ene-7-carboxylate (7b) 
 
Cyclopropene (R)-6g (65.6 mg, 0.211 mmol) was dissolved 2,3-
dimethylbutadiene (0.5 mL). Then the reaction was heated and 
stirred at 80 °C in a sealed tube for 23 h. After cooling to room 
temperature, the resulting mixture was concentrated under reduced pressure. The crude product 
was purified by silica column chromatography with hexane / ethyl acetate (1:0 to 6:1 gradient) to 
afford 7b (81.1 mg, 0.207 mmol, 98%) as a single diastereomer. 1H NMR (400 MHz, CDCl3) δ 4.09 
(qd, J = 7.1, 0.4 Hz, 2H), 4.01–3.90 (m, 2H), 3.45–3.32 (m, 4H), 3.24 (d, J = 6.6 Hz, 2H), 2.43–2.29 (m, 
1H), 2.30–2.09 (m, 3H), 1.90–1.75 (m, 1H), 1.67–1.60 (m, 4H), 1.58–1.50 (m, 10H), 1.46–1.38 (m, 1H), 
1.36–1.26 (m, 5H), 1.26–1.15 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 173.76, 122.00, 121.77, 76.09, 71.37, 
67.91, 60.21, 35.85, 35.60, 32.93, 32.16, 30.85, 30.20, 29.80, 29.69, 27.92, 26.89, 26.86, 26.33, 19.30, 
19.09, 14.55. HRMS (FAB) m/z: 393.2992 (M+H+); calc. for C24H41O4: 393.3005. [α]23D = ‒48.2 ± 1.1° (c 
0.1, ethyl acetate). 
 
All-cis ethyl 2-ethyl-3-(2-fluorophenyl)cyclopropane-1-carboxylate (10a) 
 
Product 9d (46.9 mg, 0.2 mmol) from enzymatic reaction was dissolved in 
toluene (2 mL) in a vial and then Pd/C (10.6 mg, 10% palladium on carbon, 5 
mol% Pd) was added to the solution. The vial was then capped, and the 
solution was degassed with H2 using a H2 balloon. The reaction was then stirred under H2 
atmosphere at room temperature for 12 h. After the reaction is completed, the organic solvent was 
removed under reduced pressure. Purification by silica column chromatography with hexane/ethyl 
acetate as eluents afforded the desired all-cis cyclopropane product 10a (47.1 mg, >99% yield). 1H 
NMR (400 MHz, CDCl3) δ 7.25–7.15 (m, 2H), 7.05 (td, J = 7.5, 1.3 Hz, 1H), 6.99 (ddd, J = 9.9, 8.6, 1.3 
Hz, 1H), 4.06 (qd, J = 7.2, 2.2 Hz, 2H), 2.48 (td, J = 8.8, 1.1 Hz, 1H), 2.13 (t, J = 8.6 Hz, 1H), 1.91 – 1.76 
(m, 1H), 1.72 – 1.57 (m, 2H), 1.18 (t, J = 7.1 Hz, 3H), 0.95 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, CDCl3) 
CO2EtH
H
O5
O
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δ 171.01, 162.63 (d, J = 246.9 Hz), 132.10 (d, J = 4.1 Hz), 128.40 (d, J = 8.4 Hz), 123.48 (d, J = 3.6 Hz), 
122.86 (d, J = 15.1 Hz), 115.12 (d, J = 22.1 Hz), 60.09, 27.24, 23.39 (d, J = 1.8 Hz), 21.70 (d, J = 1.4 Hz), 
17.47, 14.33, 14.04. HRMS (TOF) m/z: 237.1277 (M+H+); calc. for [C14H17FO2+H+]: 237.1285. 
 
All-cis (2-ethyl-3-(2-fluorophenyl)cyclopropyl)methanol (10b) 
 
Cyclopropane 10a (47.1 mg, 0.2 mmol) was dissolved in anhydrous THF (2 mL) 
in a 50 mL flask, which was then placed in an ice-water bath. LiAlH4 (15.2 mg, 
0.4 mmol, 2.0 equiv.) was slowly added to the solution. The reaction was 
allowed to slowly warm to room temperature over 1 h and then stirred for another 1h. NaOH (2 mL, 
1M aq.) was added to quench the reaction. The crude product was extracted with ether (10 mL × 4). 
The combined organic layer was dried over Na2SO4 and concentrated under reduced pressure. 
Purification by silica column chromatography with hexane/ethyl acetate as eluents afforded the 
desired all-cis cyclopropane product 10b (36.4 mg, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.34 
(tdd, J = 7.6, 1.9, 1.1 Hz, 1H), 7.23–7.16 (m, 1H), 7.09–6.97 (m, 2H), 3.68 (d, J = 7.4 Hz, 2H), 2.13 (td, J 
= 8.8, 1.1 Hz, 1H), 1.65–1.51 (m, 3H), 1.34–1.25 (m, 1H), 1.17–1.02 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
163.05 (d, J = 245.5 Hz), 132.44 (d, J = 4.2 Hz), 128.13 (d, J = 8.4 Hz), 124.47 (d, J = 15.5 Hz), 123.93 (d, 
J = 3.5 Hz), 115.43 (d, J = 22.7 Hz), 60.18 (d, J = 1.5 Hz), 21.93, 21.66, 18.60 (d, J = 2.8 Hz), 18.51, 14.70. 
HRMS (TOF) m/z: 177.1071 (M+H+‒H2O); calc. for [C12H15FO+H+‒H2O]: 177.1074. 
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Chapter 3 
 
ENZYMATIC SYNTHESIS OF DIVERSE LACTONE DERIVATIVES: 
A LACTONE-CARBENE STRATEGY 
 
Material for this chapter appears in: (1) Chen, K.†; Zhang, S.-Q.†; Brandenberg, O. F.; Hong, X.*; 
Arnold, F. H.*, Alternate heme ligation steers activity and selectivity in engineered cytochrome 
P450-catalyzed carbene transfer reactions. J. Am. Chem. Soc. 140, 16402–16407 (2018). (2) Chen, K.; 
Huang, X.; Zhang, S.-Q.; Kan, S. B. J.; Zhou, A. Z.; Hong, X.*; Arnold, F. H.*, Engineered cytochrome 
c-catalyzed lactone-carbene B–H insertion. Synlett 30, 378–382 (2019). (3) Zhou, A. Z.; Chen, K.*; 
Arnold, F. H.*, Enzymatic lactone-carbene C–H insertion to build contiguous chiral centers. ACS 
Catal. 10, 5393–5398 (2020). 
 
3.1 Abstract 
Lactones are a fundamental class of organic moieties that possess wide applications in fields 
varying from synthetic chemistry, to materials science, to medicinal chemistry. Nature employs 
different machineries to assemble these cyclic esters, however, with limitations in synthesizing 
structurally diverse lactone products. We therefore desired to expand nature’s capacity for lactone 
formation using our enzymatic carbene-transfer strategy. Compared to de novo construction of 
cyclic esters, direct incorporation of lactone substructures to target molecules is an attractive 
approach, which can efficiently build lactone-based complex molecules and lead to broader 
structural diversity through a convergent biosynthetic scenario. Directed evolution significantly 
expanded the capacity of our enzymatic systems, enabling rapid and selective transfer of lactone-
based carbenes to substrates with different functionalities. This newly demonstrated enzymatic 
platform allowed us to access a broad range of α-(heteroatom)substituted lactone and spiro-lactone 
derivatives with unprecedented efficiencies and selectivities. 
 
3.2 Introduction 
 Lactones, as cyclic esters, belong to an important class of structural motifs that frequently 
appear in bioactive natural products 176 - 178 , pharmaceuticals 179 , 180 , agrochemicals 181  and aroma 
chemicals,182 and are also intensively employed as building blocks for the production of other fine 
chemicals183 as well as monomers for polyester synthesis184. For instance, 5-membered γ-lactones 
are widely distributed in the natural world, present in around 10% of natural products discovered 
to date185. Many of them have been found to display diverse biological profiles including antibiotic, 
antiviral, antifungal, anticancer, anti-inflammatory and cytostatic properties 186 . These unique 
biologically relevant activities have captured the great attention of biochemists to take them as 
promising lead structures for pharmaceutical development187, as exemplified by the drug molecules 
shown in Fig 3.1. 
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Figure 3.1. Representative examples of pharmaceutical compounds containing lactone structures. 
Some of these drugs are basically natural products, such as erythromycin, pilocarpine and artemisinin, or 
derivatives of natural products, such as etoposide and spironolactone. 
Given the importance of lactones in different fields, chemists have devoted a great deal of effort 
to the development of synthetic methods for these cyclic ester structures185,188. Meanwhile, the 
widespread occurrence of lactone-based compounds in nature has also prompted chemists to visit 
nature’s strategies for lactone formation. In fact, nature employs an array of machineries to 
assemble cyclic esters189, among which three major approaches are intramolecular esterification of 
hydroxyl carboxylic acids by acyltransferases, oxidative lactonization of diols by alcohol 
dehydrogenases (ADHs)190, and Baeyer-Villiger oxidation of cyclic ketones by monooxygenases 
(BVMOs)191 (Fig. 3.2.a). In the recent decade, enzyme engineering, especially on ADHs and BVMOs, 
has expanded the scope of lactone products accessible to these native enzymatic systems189. Besides, 
fermentation processes employ fatty acids as substrates to synthesize lactones through 
hydroxylation by hydroxylases (e.g., P450 or other metallo-oxidases) or hydratases and then 
intramolecular lactonization192-194. These native approaches, optimized by different engineering 
processes, have offered the synthetic community an alternative toolkit based on biocatalysis that 
can more selectively and efficiently produce desired lactone products compared to the existing 
chemical methods. 
While seeing the promise of using biocatalysis for lactone synthesis, we also realized that there 
are still limitations in these native strategies. From the standpoint of retro-synthetic analysis, these 
natural enzymatic approaches are all based on C‒O bond disconnection, which typically limits the 
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structural diversity of lactone products and renders the native strategies less versatile for broad 
synthetic purposes. Therefore, we desired to develop new enzymatic strategies using different 
disconnection modes for the synthesis of diverse lactone derivatives while taking advantage of 
enzymes’ benefits with respect to efficiency and selectivity. 
 
Figure 3.2. Enzymatic strategies for lactone assembly. a, Native strategies using acytransferase, alcohol 
dehydrogenase and flavin monooxygenase for lactone synthesis. b, Access to diverse lactone derivatives with a 
lactone-carbene strategy. Lactone-carbene X‒H insertion (X = B, S, N and C) and cyclopropanation are 
presented here. 
Our continuing effort on engineering hemeproteins for carbene chemistries thus inspired us 
to look at a new set of carbenes based on lactone structures for the transfer to different 
functionalities to assemble lactone derivatives (Fig 3.2.b). In fact, a few studies have demonstrated 
that α-diazo lactones can be utilized by rhodium complexes for carbene-transfer reactions195,196. 
However, these rhodium‒carbenes are prone to β-hydride migration197, which gives rise to undesired 
unsaturated lactones; optimization of the rhodium catalysts and cryogenic reaction conditions are 
thus required to attenuate these side reactions. Additionally, no enantioselective versions of these 
transformations have been reported. Our previous work on engineering hemeproteins for transfer 
of acyclic carbenes highlighted the power of directed evolution to shape protein active sites and 
greatly improve both reactivity and selectivity. We therefore speculated that aptly engineered 
hemeproteins would be capable of generating and stabilizing lactone-carbene intermediates, 
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circumventing unwanted β-hydride migration, and facilitating subsequent carbene-transfer 
reactions with exquisite stereocontrol. This proposed enzymatic approach would provide a concise 
route to a broad array of lactone-containing products. 
 
3.3 Enzymatic cyclopropanation for spiro[2.4]lactone synthesis 
We initially focused on constructing cyclopropane-containing spiro-lactones using α-diazo-γ-
lactone (LAD) and styrene (11a) as substrates. Transferring a cyclic carbene to an olefin double bond 
is expected to form a spiro-carbon center. Quaternary stereogenic centers frequently occur in 
biologically relevant molecules and medicinal compounds198, but are challenging to make due to 
the highly congested nature of these centers199,200. The anticipated reaction produces a strained, 
three-membered ring and furnishes two chiral centers in a stereoselective manner, which 
necessitates precise control of the three-dimensional orientation of two coupling partners. We 
believe this is a good challenge for an enzyme catalyst. 
We began by testing a panel of cytochrome P411 variants expressed in E. coli and used as whole-
cell catalysts, with LAD and 11a as substrates (Fig. 3.3). Variant P411-CIS61, previously engineered to 
react with EDA and transfer the corresponding α-mono-substituted carbene to styrene to forge a 
cis-cyclopropane, showed modest reactivity towards spiro-lactone formation, with 120 ± 10 total 
turnovers (TTN) and 90% de. Several P411 variants with various active site mutations (e.g., T268A 
or T438S) were tested, but did not exhibit substantial improvements in reactivity. However, to our 
delight, P411-CIS double mutant L437F T438Q (referred to as P411-G8), previously evolved for 
carbene transfer to heteroatom-substituted olefins63, was found to have 10-fold higher reactivity, 
providing 1320 ± 190 TTN while also showing improved stereoselectivity (97% de). A variant with 
two additional mutations, L75Y and L181I (referred to as P411-G8S), was an even better biocatalyst, 
furnishing the desired spiro-lactone product 12a in 3090 ± 120 TTN, 99% de and >98% ee. Control 
experiments showed that free heme does not catalyze this reaction. 
 
Figure 3.3. Comparison of P411 variants for forming spiro[2.4]-lactone 12a. Reactions were performed in 
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quadruplicate: suspensions of E. coli expressing P411 variants (OD600 = 30), 10 mM 11a, 10 mM LAD, 25 mM D-
glucose and 5 vol% EtOH in M9-N buffer at room temperature under anaerobic conditions for 12 h. Product 
formation was quantified by GC and TTNs were determined based on protein concentration. 
To examine whether the serine axial ligand of this P411 variant played a significant role in 
promoting in vivo cyclopropanation activity, we mutated serine back to the canonical P450 axial 
ligand cysteine and found that the resulting P450-G8S variant synthesized 12a with much lower 
activity (380 ± 20 TTN) but the same stereoselectivity (Fig. 3.5). 
 
Figure 3.4. Scope of spiro[2.4]lactones with variant P411-G8S. Reactions were performed in quadruplicate: 
suspensions of E. coli expressing P411-G8S (OD600 = 15 or 30), 10 mM alkene, 10 mM LAD, 25 mM D-glucose 
and 5 vol% EtOH in M9-N buffer at room temperature under anaerobic conditions for 12 h. Product formation 
was quantified by GC and TTNs were determined based on protein concentration. a5 mM olefin, 5 mM LAD. 
bAbsolute configuration not determined. 
With the highly active and selective P411-G8S variant, we next explored the scope of olefin 
substrates for spiro-lactone construction (Fig. 3.4). Electron-rich styrenyl olefins (11b and 11c) are 
particularly good substrates, with over 10,000 TTNs. Halides (11e, 11f and 11h) are also well-tolerated, 
offering opportunities for further derivatization through coupling methods. Fluorine-containing 
substrates, despite the strong electrondeficiency, are also accepted (e.g., 11g). Additionally, steric 
bulk (e.g., 2-vinyl naphthalene 11i) did not have a significant influence on reactivity. All tested 
styrenyl substrates gave (E)-spiro[2.4]lactone products with high-to-perfect stereoselectivity (98.6 
to >99.9% de, and 98.3 to 99.8% ee). Unactivated aliphatic olefins such as 4-phenyl butene are also 
accepted by this biocatalytic system with 1740 TTN. Interestingly, NMR analysis revealed a (Z)-
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configuration of product 12j, which indicates potentially different binding modes for aromatic vs. 
aliphatic olefins in the enzyme’s active site. The enzymatic reactions are also readily scalable and 
maintain stereoselectivity and high reactivity. Products 12b and 12c were prepared in hundred-
milligram quantities with good isolated yields (71% yield, 6500 TTN and 95% yield, 6970 TTN). The 
absolute configurations of products 12b and 12f were unambiguously assigned as (1S, 2S) by X-ray 
crystallography. 
 
3.4 Enzymatic S–H insertion for α-thio-γ-lactone synthesis 
3.4.1 Enzymatic synthesis of α-thio-γ-lactones  
Having established this biocatalytic platform for the efficient synthesis of spiro-lactones, we 
speculated that the active-site environment of P411-G8S may be especially suited to stabilize the 
iron-lactone-carbene intermediate. We were eager to examine whether this P411 variant can catalyze 
the transfer of this lactone-carbene to other functionalities, such as thiols. Carbene S–H insertion 
is poorly developed among carbene-transfer reactions; one challenge is that thiols can poison 
transition-metal catalysts through coordination. To date, only a few catalytic systems were 
developed for asymmetric carbene S–H insertion, and these exhibit limited catalytic efficiency201 
and/or low stereoselectivity104,202-204. Fasan and coworkers reported carbene S–H insertion with up 
to 49% ee by an engineered myoglobin84. Whereas carbene Si–H and N–H insertions with iron-
porphyrin (bio)catalysts have been revealed to undergo concerted Si‒H insertion88 and nucleophilic 
attack by amine at the carbene center 205 , the mechanism of carbene S–H insertion remains 
obscure206. We thus decided to take a closer look at lactone-carbene S–H insertion with the current 
enzymatic system. 
 
Figure 3.5. Comparison of P411-G8S and P450-G8S for lactone-carbene cyclopropanation and S–H 
insertion. Reactions were performed in quadruplicate: suspensions of E. coli expressing P411 or P450-G8S 
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(OD600 = 15 or 30), 10 mM 11a or 13a, 10 mM LAD, 25 mM D-glucose and 5 vol% EtOH in M9-N buffer at room 
temperature under anaerobic conditions for 12 h (for cyclopropanation) and 40 min (for S–H insertion). 
Product formation was quantified by GC and TTNs were determined based on protein concentration. The 
overlay of P450-CIS (PDB: 4h24, in green) and P411-CIS (PDB: 4h23, in pink) active-site structures is shown as 
analogy to P450/P411-G8S. 
Using P411-G8S as a whole-cell catalyst, thiophenol 13a reacted with LAD to give the desired 
α-thio-γ-lactone product 14a in 300 ± 30 TTN, but with poor enantioselectivity (15 ± 2% ee). In an 
effort to improve reactivity and selectivity, we wanted to explore how the identity of the heme axial 
ligand62,64,111,207,208 affected the S–H insertion process. We thus tested this reaction with a library of 
mutant enzymes made by site-saturation mutagenesis of the axial-ligand residue S400 in P411-G8S. 
To our delight, simply replacing the axial serine with cysteine (the native ligating residue in P450s) 
substantially improved reactivity and selectivity, to 1610 ± 60 TTN and 84 ± 1% ee (Fig. 3.5). 
We next evaluated the substrate range of this cysteine-ligated P450-G8S variant for lactone-
carbene S–H insertion (Fig. 3.6). Thiophenols with meta-OMe and para-halide substituents were 
successfully converted into the corresponding α-thio-γ-lactone products (14b to 14e) with good 
TTNs and enantioselectivities. However, para-(fluorinated)alkyl groups (13f to 13h) or a bulkier 
aromatic ring (13j) gave lower reactivity and selectivity, suggesting that steric hindrance may affect 
substrate orientation. Products 14d and 14e were also synthesized in hundred-milligram scale under 
modified conditions; good isolated yields were obtained with slightly improved enantioselectivity. 
 
Figure 3.6. Scope of α-thio-γ-lactones with variant P450-G8S. Reactions were performed in quadruplicate: 
suspensions of E. coli expressing P450-G8S (OD600 = 15 or 30), 10 mM thiol, 10 mM LAD, 25 mM D-glucose and 
5 vol% EtOH in M9-N buffer at room temperature under anaerobic conditions for 40 min. Product formation 
was quantified by GC and TTNs were determined based on protein concentration. *For preparative-scale 
reaction: 2.0 equiv. thiol, 2 h. 
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3.4.2 Mechanistic study of enzymatic S–H insertion   
It struck us as interesting that the P411/P450-G8S variants behaved so differently in the S–H 
insertion and cyclopropanation reactions (Fig 3.5; Table B-2 and B-4 in Appendix B). According 
to a previous structural study of P411-CIS and P450-CIS variants that also differed solely at the axial-
ligand residue, the cysteine-to-serine mutation maintains almost identical active-site geometries. 
As also demonstrated in previous work on in vivo reactions using P411 variants, the endogenous 
reductant NADPH can act as an electron donor to reduce FeIII to FeII, which is required for the iron 
center to activate diazo compounds to form iron-carbenoid intermediates62. Cysteine-ligated heme, 
on the other hand, has a lower reduction potential of the ferric state and thus results in poor 
reduction efficiency of the iron center by NADPH. Consequently, P411-G8S exhibits significantly 
higher cyclopropanation activity compared to P450-G8S, though both show similar selectivities. 
However, for carbene S–H insertion, thiol substrates can also serve as a strong reductant and enable 
P450 variants to form iron-carbenes. But this did not explain the significant disparity between P411-
G8S and P450-G8S in both reactivity and selectivity, causing us to speculate that the axial ligand 
was exerting a heretofore unobserved effect on the reaction mechanism. 
To explore the effects of axial coordination on the S–H insertion reaction in more detail, we 
used DFT calculations. The generation of iron-carbenoid species is reasonably facile, according to 
previous experimental and computational studies88,209,210. Our computational investigations thus 
focused on the insertion steps. Simplified iron-porphyrin models (cat1 and cat2) were used, where 
SMe and OMe were chosen to mimic deprotonated Cys and Ser ligands. 
The free energy diagram of the most favorable pathway for S–H insertion is shown in Fig. 3.7. 
The insertion occurs in a stepwise fashion, involving one hydrogen-atom-transfer (HAT) step and 
subsequent C–S bond formation with a thiyl radical. Both cat1 and cat2 showed similar reactivities 
for S–H bond insertion, with free energy barriers of 19.4 kcal/mol and 18.5 kcal/mol, respectively. 
However, we found that the iron-alkyl intermediates (int2SMe and int2OMe) can undergo a reversible 
C–Fe bond homolytic cleavage (via TS3SMe and TS3OMe), which erodes the enantioenriched alkyl-
substituted stereocenter. The two pathways, radical rebound and C–Fe bond cleavage, are 
differentiated by the axial coordination. With SMe ligation, C–S bond formation is more favorable 
than C–Fe bond homolytic cleavage (TS2SMe, ΔG≠ = 6.7 kcal/mol vs. TS3SMe, ΔG≠ = 10.4 kcal/mol), 
while the opposite is true for the OMe-ligated intermediate int2OMe (TS2OMe, ΔG≠ = 7.3 kcal/mol vs. 
TS2SMe, ΔG≠ = 6.2 kcal/mol). These results indicate that Cys-ligated P450 enzymes should achieve 
much higher enantioselectivities than Ser-ligated P411 enzymes, which matches the experimental 
observations. The axial coordination has a limited effect on C–S rebound, but strongly controls the 
feasibility of C–Fe bond dissociation211-213. Since oxygen has a much higher electronegativity than 
sulfur, the anionic cat2 is more stable than the sulfur-coordinated cat1. Therefore, C–Fe homolytic 
cleavage with OMe ligation, which releases cat2, has a lower activation barrier and is more 
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exothermic than that with sulfur coordination. The difference in exothermicity drives the change in 
reaction barrier, which eventually leads to the difference in enantioselectivities of the two catalysts. 
 
Figure 3.7. Free energy diagrams for the most favorable reaction pathways of S–H insertion with 
model catalysts. Gibbs free energy obtained at the B3LYP/def2-TZVP//B3LYP/6-31G(d)-LANL2DZ level. The 
most stable spin states are shown in parentheses. OSS is open-shell singlet; CSS is closed-shell singlet. 
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3.5 Enzymatic C–H insertion for β-amino lactone synthesis 
3.5.1 Identification and evolution of P411 enzymes for lactone-carbene C–H insertion 
Enantioselective C(sp3)‒H alkylation via carbene insertion into C–H bonds provides a powerful 
strategy for C(sp3)‒C(sp3) bond formation to build diverse molecular skeletons and for late-stage 
modification of complex molecules 214 - 216 . Transition-metal catalysts based on rhodium 217 - 221 , 
iridium222-225, cobalt226,227, copper228,229, and other metals230-235 have been shown to catalyze carbene 
insertion into C–H bonds. In most reported methods, carbenes bearing one electron-donating 
aryl/alkenyl group and one electron-withdrawing group (‘donor-acceptor carbenes’)236 , 237  have 
been demonstrated to be superior for intermolecular C–H insertions, with control over reactivity 
and selectivity in these catalytic systems238-242. Other carbenes, however, such as acceptor-only 
carbenes, are less explored for C–H insertion reactions223; acceptor-only carbenes with an additional 
alkyl substituent at the α-position are even more challenging to use in these systems due to 
competitive β-hydride migration upon the formation of the metallo-carbene species195. 
Recently, we reported the engineering of cytochromes P411 for the transfer of carbene moieties 
to C–H bonds using diazo compounds bearing a single electron-withdrawing substituent and the 
establishment of this enzymatic platform for stereoselective C–C bond assembly with a chiral center 
formed at the β-position77,78. We thus anticipated that the P411 enzymes could be evolved further to 
adopt branched carbenes for C–H insertion, which would enable them to build a chiral center at α-
position or even contiguous chiral centers at both α and β-positions. With our previous success on 
using lactone-based carbenes for cyclopropanation and S–H insertion, we would like to further 
explore these cyclic carbenes for C–H functionalization rather than the well-studied donor-acceptor 
carbenes. 
We initiated this investigation of carbene C–H insertion with α-diazo-γ-lactone (LAD) and 
4,N,N-trimethylaniline (15a) as substrates (Fig. 3.8). The expected carbene transfer reaction leads 
to the formation of a β-amino lactone product, 16a, through carbene insertion into an α-amino C–
H bond with a chiral center generated at the α-position. Such β-amino lactone products are analogs 
of sesquiterpene-lactone amino derivatives, which possess desirable pharmaceutical properties243. 
Screening various hemeproteins, including P450 variants, P411s, and cytochromes c in the form of 
whole E. coli cell catalysts identified a P411 variant, P411-C10, capable of the desired C–H insertion 
transformation. P411-C10, previously found with activity for internal cyclopropene formation, 
catalyzed the C–H insertion reaction using a cyclic carbene with modest efficiency (105 TTN) and 
stereoselectivity (47% ee). 
To enhance enzyme activity and selectivity by directed evolution, we targeted active-site 
residues for site-saturation mutagenesis and screening (Fig. 3.8). Loop residues in the enzyme’s 
active site were tested first, and beneficial mutations T327V and Q437L together increased total 
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turnovers 9-fold. However, enantioselectivity decreased to 40% ee after three rounds of evolution. 
As substrate 15a is symmetric, we hypothesized that it might bind with different orientations 
relative to the carbene intermediate, which would lead to the diminished stereoselectivity. To 
address this, we next targeted amino acids previously shown to dramatically affect stereoselectivity 
in either native or non-native functions of this P450, such as sites 87, 264, 268, and 32861,63,75,244-247. 
Screening a site-saturation library at site 87 for increased enantioselectivity resulted in discovery of 
a proline mutation giving 56% ee, albeit with decreased TTN. Residue 264 is the closest residue to 
the iron center, which may also influence binding of substrate or the orientation of the carbene 
intermediate. The A264S mutation improved both activity and enantioselectivity. Revisiting site 327 
identified another proline mutation, which boosted the ee to 75%. The three mutations A87P, A264S, 
and V327P may have improved enantioselectivity by providing a more restricted binding mode for 
substrate 1a in the enzyme. 
 
Figure 3.8. Directed evolution of P411-C10 for lactone-carbene insertion into α-amino C–H bonds. 
Reactions were performed in quadruplicate under the following conditions: 10 mM 4,N,N-trimethyl aniline 
(15a), 10 mM LAD, E. coli harboring P411-C10 variants (OD600 = 15 to 60), D-glucose (25 mM), M9-N 
buffer/EtOH (19:1), anaerobic, 24 h. Product formation was quantified by HPLC, TTNs were determined based 
on protein concentration, and enantioselectivity was measured using chiral HPLC. The active-site structure of 
P411-E10 variant (pdb: 5UCW) was used to guide site-saturation mutagenesis. 
Further rounds of evolution accumulated two more mutations, E264D and V328L, to give final 
variant L9 that produces 16a with 90% ee. Although the TTN of L9 dropped to approximately 600 
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under screening conditions, optimization of enzyme expression and reaction conditions improved 
TTN 1.5- to 2.5-fold (Fig. 3.9, entry 16a; and Table B-6 in Appendix B). Another variant, L10, with 
a V328R mutation obtained from the 328X site-saturation library, showed the opposite stereo-
preference (‒68% ee) for this C–H insertion reaction, suggesting that this biocatalytic platform may 
be tunable for enantio-divergent synthesis63,169,248. 
 
3.5.2 Scope evaluation of enzymatic lactone-carbene C–H insertion 
As different variants in the enzyme lineage (L1 to L10) showed different levels of activity or 
selectivity for the C–H insertion reaction, we selected representative variants (L6 to L10) with which 
to evaluate the transformation of various N,N-dialkyl aniline derivatives, as shown in Fig. 3.9.a. 
Substituents on the phenyl ring, including methyl, methoxyl or halide, are all compatible with the 
biocatalytic system, giving TTNs ranging from 410 to 2920. Variants L9 and L10 showed consistently 
opposite stereo-preference for diverse substrates (e.g., for 16d and 16e, 84% ee and 75% ee with L9, 
‒55% and ‒86.5% ee with L10), whereas activity had different trends in some cases (e.g., for 16d and 
16e, 1410 TTN and 410 TTN with L9, 720 TTN and 1800 TTN with L10). Interestingly, with N-methyl, 
N-ethyl aniline (15g), L9 only synthesized the primary C–H insertion product 16g with high 
efficiency (1710 TTN) and high enantioselectivity (95% ee); L10, in contrast, gave a mixture of the 
primary and secondary C–H insertion products, 16g and 16g’, with a ratio of 71:29, where product 
16g’ was found to be mainly a single diastereomer and enantiomer (>95:5 d.r. and 97.5% ee). Based 
on this result, we anticipated that this enzyme lineage may have the potential to functionalize 
secondary C–H bonds to build contiguous chiral centers. 
To explore the enzymes’ ability to insert the lactone-carbene into secondary C–H bonds, we 
selected dialkyl-aniline, pyrrolidine, azetidine, and other N-aryl amine derivatives as substrates. We 
first screened the entire enzyme lineage with more than 10 substrates in 96-well plates (Table B-6 
and B-7 in Appendix B). We were pleasantly surprised to see that many of the reactions formed the 
corresponding C–H insertion products. We picked the most promising combinations of enzyme 
variants and substrates for validation and further confirmation of the products. As shown in Fig. 
3.9.b, the enzymes are particularly efficient toward carbene insertion into secondary C–H bonds, 
giving up to 4000 TTN. The final two variants, L9 and L10, gave good to high diastereoselectivities 
and enantioselectivities. For instance, L9 and L10 formed the same diastereomer with diethyl 
aniline (15h), giving 94:6 d.r. and 99:1 d.r., respectively; however, the diastereomers were obtained 
with opposite enantioselectivity (81% ee and ‒94.5% ee, respectively). The same trend was observed 
with N-phenyl pyrrolidine (15i). With 2,3-dimethyl phenylpyrrolidine (15k), only moderate 
diastereoselectivity was achieved with the selected variants, but the diastereomers can be separated 
easily by chromatography, and high enantioselectivity was observed for both diastereomers (up to 
96% ee and 99% ee, respectively). Finally, N-phenyl azetidine (15m), which has a higher C–H bond 
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dissociation energy on a strained ring,  was also active for C–H insertion, but only poor 
enantioselectivity was achieved (>95:5 d.r. and 13% ee for product 16m), presumably reflecting its 
distinct structure from that of substrate 15a used for evolution. 
 
Figure 3.9. Scope of lactone-carbene insertion into α-amino C–H bonds. a, Primary C–H bond insertion. 
b, Secondary C–H bond insertion. Reactions were performed in triplicate or quadruplicate under the following 
conditions: 12 mM aniline derivatives, 12 mM LAD, E. coli harboring P411-C10 variants (OD600 = 30 or 60), D-
glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 24 h. Product formation was quantified by HPLC and 
TTNs were determined based on protein concentration. Enantioselectivity was measured using chiral HPLC; 
diastereoselectivity and regioselectivity were determined by HPLC and NMR. 
It is worth revisiting the cases where L9 and L10 formed the same major diastereomer but the 
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opposite enantiomer in carbene insertion into secondary C–H bonds. This suggests that the single 
mutation going from L9 to L10, L328R, inverted two chiral centers simultaneously. As leucine and 
arginine possess very distinct features, we reasoned that the two residues might drive opposite 
orientations of the carbene intermediates with the hydrophobic side facing L328 and the 
hydrophilic side facing R328 (Fig. 3.10). Then C–H insertion might take place with the substrate 
approaching from different sides to give the opposite enantiomers. The detailed mechanism of C–
H insertion, however, is still elusive--the reaction can undergo a radical pathway of hydrogen atom 
abstraction followed by radical rebound225-227,230 or a concerted insertion pathway249-251, which may 
further affect the stereochemistry of the α-chiral center252. Mechanistic studies are ongoing to gain 
further insights into the C–H insertion reactions. 
 
Figure 3.10. Possible explanation for stereocontrol in lactone-carbene insertion into secondary C–H 
bonds. 
 
3.6 Enzymatic N–H insertion for α-amino lactone synthesis 
Carbene insertion into N–H bonds represents one powerful method to forge C–N bonds253,254. 
For instance, rhodium-catalyzed carbene N–H insertion is employed in the synthesis of 
thienamycin, one of the most potent naturally produced antibiotics till now255,256. In the recent two 
decades, a variety of chiral catalytic scaffolds based on different transition metals have been 
developed for the enantioselective version of carbene N–H insertion using anilines 257 - 261 , 
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amides262,263, imines264 and even aliphatic amines265 as the nitrogen sources. Recent advances with 
metalloenzymes have also revealed that hemeproteins, such as P450s82 or myoglobins83,266, are also 
capable of transferring carbenes to amine functionalities. Computational studies have disclosed a 
formal N–H insertion mechanism205 with hemeproteins via nucleophilic attack, ylide 
rearrangement followed by enol tautomerization, where the final proton shift step leads to the 
formation of α-chiral centers (Fig. 3.11.a). Unlike a lot of synthetic methods using chiral H-bonding 
catalysts to promote enantioselective proton transfer263-265, the enol intermediate released from the 
heme cofactor inside enzymes’ active sites is surrounded by numerous proton sources, including 
backbone amides, protic side chains and free water molecules. Therefore, the major challenge in 
this category of transformations lies on how to leverage the enzyme scaffolds to induce desired 
stereo-control on the proton transfer process. 
 
Figure 3.11. Carbene N–H insertion catalyzed by hemeproteins. a, Mechanism of iron-porphyrin- 
catalyzed carbene N–H insertion. b, N–H insertion as a side reaction in lactone-carbene C–H insertion. 
 Lactone-carbene N–H insertion is expected to produce α-amino lactones, a class of structural 
motifs found in numerous biologically active natural products as well as pharmaceuticals and also 
used as versatile precursors for α-amino acid derivative preparation 267 - 269 . Although rhodium 
catalysts have been reported for N–H insertion with lactone-carbenes197, enantioselective versions 
have yet to be documented. As our P411 enzymes have shown the potential to accommodate lactone-
carbenes for the transfer to different functionalities, we surmised that these specifically engineered 
P411 variants may have reorganized their active sites to impose unique binding modes for the lactone 
moieties. This would be a desirable feature to effect chiral induction in the proton transfer process 
for enantioselective N–H insertion. 
 In fact, we observed small amount of N–H insertion products in our lactone-carbene C–H 
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insertion reactions when using aniline derivatives as substrates (Fig. 3.11.b). We rationalized that 
elimination of α-methylene-γ-butyrolactone from the C–H insertion product 16g led to a 
demethylated amine, which could further couple with another lactone-carbene and then release 
the amine insertion product 16g’’ in the presence of P411 lactone-carbene transferase. And 
surprisingly, the ‘side’ product 16g’’ by N–H insertion was determined with moderate to high 
enantioselectivities (98% ee with L9 and 70% ee with L10), which provides a strong evidence for our 
hypothesis that the engineered P411 enzymes could also exert requisite stereo-control on N–H 
insertion reactions. 
 Based on this result, we would like to examine whether the enzyme lineage evolved from P411-
C10 (L1 to L10, initially for lactone-carbene C–H insertion) could also provide a generalized platform 
for enantioselective N–H insertion reactions. We screened the entire enzyme lineage against various 
amine substrates, including anilines, N-alkyl anilines, indoline, tetrahydroquinoline and even 
aliphatic amines, in 96-well plates, and used chiral HPLC to determine reaction conversion (enzyme 
activity) and enantioselectivity. The screening result established that the desired N–H insertion 
reactions could proceed smoothly with all the tested amines, giving decent to excellent reactivities 
with different P411 variants in this enzyme lineage, as summarized in Fig. 3.12. Anilines (17a to 17c) 
were found to be highly reactive, affording 100% conversion to the N–H insertion products in a 
stereodivergent way, where variants L4 and L5 displayed the opposite stereo-preference compared 
to L6 to L9. Electronically-deficient aniline 17d showed relatively low reactivity but maintained 
good enantioselectivity with variants L6 and L7. N-alkyl anilines (17e to 17h) also served as superior 
amine substrates in terms of both reactivity and enantioselectivity; by selecting suitable enzyme 
variants for each substrate, products 18e to 18h could be synthesized in high enantiopurity (95% to 
98% ee). Cyclic amines (17i and 17j) were also successfully coupled with the lactone carbene in an 
enantioselective manner when using variants L6 and L7; on the other side, L8 and L9 displayed 
nonetheless higher activities for these substrates, but only delivered low to modest selectivities. 
Again, it would be important to choose the right enzyme variant for each substrate featuring 
different steric or electronic properties. 
In addition to aniline derivatives, aliphatic amines, such as benzylamine (17k) or 
phenethylamine (see Table B-9 in Appendix B), were also compatible with this biocatalytic system 
for lactone-carbene N–H insertion, giving >98% ee for 18k using variants L6 to L8, albeit with 
limited activity. Interestingly, a reaction using a non-lactone-type carbene (Me-EDA, with 
substitutions of a methyl group and an ester group at α-position) also produced the desired N–H 
insertion product 18l in 53% ee using variant L10, which further demonstrated the possibility of 
extending this enzymatic N–H insertion platform to more different types of carbene partners. 
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Figure 3.12. Lactone-carbene N–H insertion with P411-C10 lineage. Results were obtained from plate 
screening under the following conditions: 10 mM amine, 10 mM LAD, E. coli harboring P411-C10 variants, D-
glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 24 h. Enantioselectivity and substrate conversion were 
determined by chiral HPLC; TTNs were estimated based on substrate conversion and expression level of C10 
variants. 
 
3.7 Enzymatic B–H insertion for α-boryl lactone synthesis 
The broad applications of organoboron compounds270-273 have prompted chemists to develop 
efficient, selective and modular synthetic platforms for installing boron motifs onto carbon 
backbones274-276. One major class of methods for forming carbon‒boron (C–B) bonds relies on 
transition metal-catalyzed B–H bond insertion of carbenes277-283, as first introduced by Curran and 
co-workers. Recently, our lab developed the first biocatalytic system for this transformation using 
engineered variants of cytochrome c from the Gram-negative, thermohalophilic bacterium 
Rhodothermus marinus (Rma cyt c)86. The laboratory-evolved enzymes exhibited very high 
efficiency (up to 15,300 turnovers and 6,100 h‒1 turnover frequency) and enantioselectivity (up to 
98% ee) with different carbenes and boranes. To expand the catalytic range of this enzymatic C–B 
bond-forming platform, we engineered Rma cyt c to accept structurally different carbenes. In 
previous work, we typically used α-ester-substituted diazo compounds as carbene precursors; 
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recently, we also demonstrated that Rma cyt c mutants can be evolved to use a spectrum of α-
trifluoromethyl-α-alkyl carbenes to furnish a wide array of chiral α-trifluoromethylated 
organoborons87. We were curious whether cyclic carbenes can also be used by Rma cyt c, despite 
significant structural differences compared to the acyclic carbenes used in previous work. 
We therefore started to explore the borylation reaction using the lactone diazo LAD and an N-
heterocyclic carbene (NHC)-stabilized borane as substrates in the presence of whole E. coli bacteria 
expressing Rma cyt c variants (Fig. 3.13). We first tested the variants obtained during directed 
evolution for borylation with acyclic carbene precursors (e.g., Me-EDA) (Table B-10 in Appendix 
B). We were pleasantly surprised to see that wild-type Rma cyt c exhibited high efficiency for lactone 
carbene B–H insertion, with 960 total turnovers (TTN) and 70% GC yield. The enantioselectivity, 
however, was poor, with only 36% ee. A distal axial-ligand M100D mutation, previously discovered 
to facilitate both carbene Si‒H and B–H insertion, improved the yield, but did not improve the 
enantio-control of this reaction. Residue V75 in an α-helix region was previously shown to affect 
carbene orientation. Screening of M100D variants containing mutations at V75 identified M100D 
V75R as the most selective, with 87% ee, whereas V75T/C/K/P/G mutations resulted in poor to 
moderate enantioselectivities. An additional M103V mutation led to more precise stereo-control, 
giving 90% ee. 
To further increase the enantioselectivity of lactone-carbene B–H insertion, we subjected the 
Rma cyt c V75R M100D M103V (RDV) variant to site-saturation mutagenesis, targeting active-site 
amino acid residues which are close to the iron center in wild-type Rma cyt c (within 10 Å) (Fig. 
3.13). It is known that the residues residing on the flexible front loop are important for controlling 
the structure of the heme pocket88, which is presumably the active site for this novel function. 
Consequently, introducing suitable mutations on this loop may help to orient the iron-carbene 
intermediate or tune the approach of the borane substrate and thus lead to desired 
enantioselectivity. A double-site-saturation mutagenesis library at residues M99 and T101 was 
cloned and screened as whole-cell catalysts in four 96-well plates for improved borylation 
enantioselectivity. Double mutant M99Q T101Y (BORLAC) was finally identified to exhibit higher 
selectivity 92.5% ee and good catalytic efficiency (970 TTN, 80% GC yield). 
With an efficient and selective borylating variant BORLAC in hand, we then assessed the scope 
of boranes that this platform can use (Fig. 3.14.a). Boranes without stabilizing groups are highly 
reactive and unstable in aqueous conditions. Lewis bases, such as ethers, amines, phosphines and 
NHCs, are generally used as good stabilizing groups for free boranes 284 . Considering the 
biocompatibility and cell permeability of the borane reagents, NHC-stabilized boranes turned out 
to be suitable candidates for this borylation platform285. Indeed, borane complexes stabilized by 
NHCs featuring different electronic properties, steric hindrance and/or lipophilicity all served as 
good substrates for the target borylation reaction, furnishing the desired products with up to 1160 
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TTN and enantioselectivities up to 94% ee. For instance, fluorine-containing alkyl groups (e.g., 20c), 
which are electron-withdrawing and usually exhibit very different lipophilicity and hydrophilicity 
relative to general aliphatic alkyl groups, were found to be compatible with the whole-cell reaction 
conditions. 
 
Figure 3.13. Directed evolution of Rma cyt c for lactone-carbene B–H insertion. a, Whole protein 
structure and active-site structure of wild-type Rma cyt c (PDB: 3CP5). b, Yields and ee’s of selected Rma cyt c 
variants for B–H insertion. Reactions were conducted in quadruplicate: suspensions of E. coli expressing Rma 
cyt c variants (OD600 = 20), 10 mM borane 19a, 10 mM LAD, and 5 vol% acetonitrile in M9-N buffer (pH 7.4) at 
room temperature under anaerobic conditions for 18 hours. TTN refers to the molar ratio of total desired 
product, as quantified by gas GC-MS, to total heme protein. Enantioselectivity was determined by chiral HPLC. 
To explore the longevity of the biocatalyst, we tried portion-wise addition of the two substrates 
(Fig. 3.14.c). Every 1.5 hours, we added an additional aliquot corresponding to 12.5 mM of each 
substrate to the reaction. Over 20 additions, we observed continuous and steadily increasing 
product formation, which indicates that the catalyst maintained function over 30 hours. However, 
we did notice that enantioselectivities decreased. Covalent modification of the protein backbone by 
carbene species and non-covalent binding of borane substrate or product to the protein may cause 
structural changes that compromise stereo-control175. Further reaction engineering and 
optimization, such as using a flow system to maintain consistent concentrations of reagents, may 
be able to address this selectivity drop. 
Given that the 5-membered cyclic lactone-carbene worked so well for this biocatalytic B–H 
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insertion, we wondered whether other cyclic carbenes, particularly lactone-carbenes with different 
ring sizes, would also be accepted (Fig. 3.14.a). 6- and 7-membered lactone diazos (LAD-2 and 
LAD-3) were readily prepared from corresponding lactones and used as cyclic carbene precursors 
for testing B–H insertion using variant BORLAC. The 6-membered lactone-carbene showed high 
reactivities (up to 1190 TTN and 92% ee) for the desired borylation with three different borane 
substrates. Additionally, enzymatic borylation with both 5- and 6-membered lactone carbenes was 
readily scalable to millimole level, affording the desired products in high isolated yields (Fig. 3.14.b). 
However, with one additional carbon in the ring, the 7-membered lactone-carbene behaved in a 
completely different manner: BORLAC exhibited only low activity with this carbene precursor (< 50 
TTN). 
 
Figure 3.14. BORLAC–catalyzed for lactone-carbene B–H insertion. a, Scope of lactone-carbene B–H 
insertion with BORLAC. Reactions were conducted in quadruplicate: suspensions of E. coli expressing Rma cyt 
c variants (OD600 = 20), 10 mM borane 2, 10 mM lactone diazo 1, 4 or 6, and 5 vol% acetonitrile in M9-N buffer 
(pH 7.4) at room temperature under anaerobic conditions for 18 hours. b, Preparative-scale synthesis of 
organoborons. Reaction conditions: suspensions of E. coli expressing Rma cyt c variants (OD600 = 20), 12 mM 
borane 19a, 12 mM lactone diazo LAD or LAD-2, and 5 vol% acetonitrile in M9-N buffer (pH 7.4) at room 
temperature under anaerobic conditions for 18 hours. c, Enzymatic synthesis of organoborons with portion-
wise addition of substrates. Reactions were conducted in duplicate using the standard reaction conditions 
except for using 2.5 M solution stocks of borane 19b and LAD (one portion = 2 μL of each substrate stock). 
To understand the origins of this dramatic impact of ring size on Rma cyt c-catalyzed lactone-
carbene B–H insertion chemistry, we employed DFT calculations to compare the structures and the 
electronic properties of three lactone-type IPCs. Unlike 5-membered lactone-based IPC2, which 
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takes on a rigid planar structure, 6-membered lactone-carbene IPC3 showed a slightly flexible 
structure with a dihedral angle d(Fe-C-C-O) of 46° in the ground OSS state, while its triplet state 
still possesses a near-planar geometry (Fig. B-2 in Appendix B). However, 7-membered lactone 
IPC4 takes on highly twisted conformations with d(Fe-C-C-O) from 47° to 73° in all electronic 
states197. It is apparent that none of the electronic states in IPC4 shares a similar structure with IPC2. 
This may explain why BORLAC, which was evolved for the 5-membered lactone carbene, did not 
exhibit high reactivity towards borylation with the 7-membered lactone carbene. But this does not 
necessarily mean that Rma cyt c cannot be engineered to accommodate the 7-membered lactone 
carbene for B–H insertion; further engineering using BORLAC as a starting template could well lead 
to variants with improved reactivity on this 7-membered lactone carbene. 
 
3.8 Conclusion 
By establishing five biocatalytic methods, we now have expanded our enzymatic platform 
based on hemeprotein carbene transferases to assemble a broad array of structurally diverse lactone 
derivatives, including α-thio/amino/alkyl/boryl lactones and spiro[2.4]lactones. These 
demonstrations have provided a convergent biosynthetic scheme, offering a succinct method to 
construct complex lactone-based structures, as an alternative to nature’s strategy of de novo 
assembly of lactone moieties. Enzyme engineering starting from the same original cytochrome 
P450BM3, quickly diverted its catalytic capability to new functions, including lactone-carbene C–
H/N–H/S–H insertions and cyclopropanation, which once again speaks to the superior plasticity of 
the P450 (or P411) scaffolds and the immense potential to direct the construction of complex 
molecular structures. 
In the development of the first two methods, it is interesting to note that simply altering the 
heme ligation (serine or cysteine) in the cytochrome P450 variants was able to rapidly optimize the 
two carbene-transfer reactions, cyclopropanation and S–H insertion, with unprecedented levels of 
efficiency and stereo-control (up to 11150 TTN and >99.9% ee). To understand how axial ligation 
affects both selectivity and reactivity in carbene S–H insertion, we conducted a DFT study and 
described two mechanistic pathways involving a radical coupling process between a thiyl radical 
and a heme-bound alkyl species or a free alkyl radical. The different electronic properties of serine 
and cysteine ligands lead to opposite preferences in the reaction pathways and distinct product 
profiles. The development of novel reactions combined with thorough mechanistic analyses does 
not only expand the biocatalytic repertoire of hemeproteins but also provides valuable insights into 
how these enzymes can be tuned for further exploration of new chemistries. 
The engineered platform for lactone-carbene C–H insertion allowed us to functionalize 
primary or secondary C–H bonds at α-amino positions. The biocatalytic system was rapidly evolved 
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to take N,N-dialkylaniline derivatives as substrates to furnish chiral β-amino lactone products with 
high catalytic efficiency (up to 4000 TTN) and in a stereo-divergent manner. A single mutation can 
control the stereoselectivity of carbene insertion into secondary C–H bonds, inverting the two 
contiguous chiral centers and leading to the opposite enantiomers of the same major diastereomers. 
And interestingly, the enzyme lineage obtained in the C–H insertion study was also able to carry out 
highly efficient and selective lactone-carbene N–H insertion reactions with a broad range of amines, 
setting up a powerful system to build diverse α-amino lactones. These results have again highlighted 
the promiscuity of our enzymes especially when engineered to accommodate the same or similar 
types of substrates or intermediates. We could anticipate that these newly evolved P411 variants 
would probably serve as potential engineering templates for the further development of more 
challenging carbene- or nitrene-transfer reactions. 
Not limited to P450 enzymes, the biocatalytic platform based on Rma cyt c hemeproteins has 
also been demonstrated with extended capacity on using cyclic lactone carbenes for B–H insertion 
reactions. A range of organoborons were accessed at preparative scales and with unprecedented 
catalytic efficiencies (up to 24,500 TTN) and high enantioselectivities (up to 94% ee). 
The new chemistries in the chapter have presented a good example of how to systematically 
explore the new functions that natural enzymes can potentially take on. We believe that exploiting 
the catalytic promiscuity of native enzymes coupled with evolutionary strategies will further open 
the chemical space of genetically encoded biocatalysts to fulfill increasing demands in the synthetic 
world. 
 
3.9 Experimental methods 
See Appendix B for supporting tables and figures, synthesis and characterization of 
compounds, assignment of absolute stereochemistry, and determination of enantioselectivity. 
NMR spectra and calibration curves are in the Supporting Information of the published paper, but 
not included here. 
 
3.9.1 General information 
Unless otherwise noted, all chemicals and reagents were obtained from commercial suppliers 
(Sigma-Aldrich, VWR, Alfa Aesar, Acros, Combi-Blocks, TCI and Ark Pharm) and used without 
further purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were taken using a Bruker Prodigy 400 MHz instrument and are 
internally referenced to the residual solvent peak (chloroform). Data for 1H NMR are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = 
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pentet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet 
of doublets), coupling constant (Hz), integration. Sonication was performed using a Qsonica Q500 
sonicator. High-resolution mass spectra were obtained at the California Institute of Technology 
Mass Spectral Facility. Synthetic reactions were monitored using thin layer chromatography (Merck 
60 gel plates) using a UV-lamp for visualization. 
 
3.9.2 Chromatography 
Analytical reversed-phase high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and a Kromasil 100 C18 column (4.6 × 50 mm, 5 µm) with 
water and acetonitrile as the mobile phase and visualization at 210 nm for library screening. 
Analytical normal-phase HPLC was carried out using an Agilent 1200 series instrument and chiral 
columns Chiralpak IC (4.6 mm × 25 cm), IA (4.6 mm × 25 cm), AS-H (4.6 mm × 25 cm) and OJ-H 
(4.6 mm × 25 cm) with n-hexane and isopropanol as the mobile phase and visualization at 210 nm 
for chiral separation. Gas chromatography (GC) analyses were carried out using an Agilent 7820A 
or Shimadzu GC-17A gas chromatograph, FID detector, a J&W HP-5 column (30 m × 0.32 mm, 0.25 
μm film) and CycloSil-B column (30 m × 0.25 mm, 0.25 μm film). Gas chromatography-mass 
spectrometry (GC-MS) analyses were carried out using a Shimadzu GCMS-QP2010SE system and 
J&W HP-5m column. 
 
3.9.3 Cloning and site-saturation mutagenesis 
pET22b(+) containing a C-terminal 6x-His tag was used as a cloning and expression vector for 
all enzymes described in this study. Site-saturation mutagenesis was performed using a modified 
QuikChangeTM mutagenesis protocol170. Primer sequences are available upon request. The PCR 
products were digested with DpnI, gel purified, and fragments were assembled using Gibson Mix171. 
The ligation mixture was used to directly transform E. coli strain BL21 E. cloni® (Lucigen). Cells were 
grown using Luria-Bertani medium (LB) or Hyperbroth (AthenaES) (HB) with 0.1 mg/mL ampicillin 
(LBamp or HBamp) for P411 or P450; cells expressing cyt c requires an additional antibiotic 20 μg/mL 
chloramphenicol (LBamp/chlor). Electrocompetent E. coli cells were prepared following the protocol 
of Sambrook et al172. T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New 
England Biolabs (NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N buffer; pH 7.4) 
was used as a buffering system for whole cells, lysates, and purified proteins, unless otherwise 
specified. M9-N buffer was used without a carbon source; it contains 47.7 mM Na2HPO4, 22.0 mM 
KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2. 
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3.9.4 Determination of hemeprotein concentration 
 1. Preparation of cell lysate: Aliquots of ~3 mL OD600 = 60 cells were prepared in 15 mL 
conical tubes, which were then placed on wet ice. Cells were lysed by sonication following the 
program below: sonication for 4 min, 1 second on - 1 second off, 35% amplitude. The sonicated 
samples were then transferred to two Eppendorf tubes, and then centrifuged down (14,000 rpm, 15 
min, 4 °C). The supernatants (~2.5 mL) were then collected to a 5-mL glass vial for analysis. 
2. Hemechrome assay for protein concentration measurement:  
Method 1 (used for 3.3 and 3.4): A solution of sodium dithionite (10 mg/mL) was prepared in 
M9-N buffer. Separately, a solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed 
by centrifugation (10,000 × g, 30 s) to separate the excess aqueous layer to give a pyridine-NaOH 
solution. To a cuvette containing 700 μL protein solution (purified protein or lysate) in M9-N buffer, 
50 μL of dithionite solution (0.1 M in M9-N) and 250 μL pyridine-NaOH solution were added. The 
cuvette was sealed with Parafilm, and the UV-Vis spectrum of the reduced FeII state was recorded 
immediately. To another cuvette containing 700 μL protein solution (purified protein or lysate) in 
M9-N buffer, 50 μL of potassium ferricyanide (0.1 M in M9-N) and 250 μL pyridine-NaOH solution 
were added. The cuvette was sealed with Parafilm, and the UV-Vis spectrum of the oxidized FeIII 
state was recorded immediately. The protein concentration was determined using ε_[557reduced ‒ 
540oxidized] = 23.98 mM‒1cm‒1 (ref 173). 
Method 2 (used for 3.5): A solution of NaOH/pyridine was prepared by mixing 1 mL of NaOH 
aqueous solution (1 M), 2 mL of water and 2 mL of pyridine. To 4.5 mL of NaOH/pyridine solution, 
22.5 μL of K3Fe(CN)6 aqueous solution (0.1 M) was added to make solution 1. A background 
solution was prepared by mixing 500 μL M9-N and 500 μL of the NaOH/pyridine solution, which 
was used for UV background subtraction. When measuring samples with a UV spectrometer, a 
spectrum of a mixed solution (oxidized spectrum) with 500 μL cell lysate + 500 μL solution 1 was 
taken at the wavelength range 380 nm to 650 nm. Subsequently, 5 μL of dithionite solution (0.5 M 
in 0.1 M NaOH solution) was added to the same sample and mixed by pipetting; a spectrum of this 
solution (reduced spectrum) was taken at 380 nm to 650 nm. The protein concentration was 
calculated using the extinction coefficient and dilution factor (2× dilution in volume): ε_[557reduced 
‒ 540oxidized] = 23.98 mM‒1cm‒1. 
Method 3 (used for 3.7): A solution of 0.5 M sodium dithionite in 0.5 M NaOH was first 
prepared. Separately, a solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed by 
centrifugation (10,000 × g, 30 seconds) to separate the excess aqueous layer and give a pyridine-
NaOH solution. To a cuvette containing 400 μL protein solution (purified protein or heat-treated 
lysate) in M9-N buffer, 400 μL pyridine-NaOH solution was added and mixed thoroughly. 2 µL of 
sodium dithionite solution was added to the solution and the cuvette was sealed with Parafilm, and 
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the UV-Vis spectrum was recorded immediately. Cytochrome c concentration was determined 
using ε550 = 30.27 mM‒1cm‒1 (ref 173). 
 
3.9.5 Expression of P450, P411 and cyt c proteins 
(1) P450 and P411 enzymes: E. coli BL21 E. cloni® cells carrying a plasmid encoding a P450 or 
P411 variant were grown overnight in 5 mL LBamp (37 °C, 250 rpm). The pre-culture was used to 
inoculate 45 mL of HBamp in a 125 mL Erlenmeyer flask; this culture was incubated at 37 °C, 220 rpm 
for 2 h and 15 min. Cultures were then cooled on ice (20‒40 min), and expression was induced with 
IPTG and ALA with final concentrations of 0.5 mM and 1.0 mM, respectively. Expression was 
conducted at 24 °C, at 140 rpm, for 20 h (± 20 min). Cultures were then centrifuged (4,500 × g, 5 
min, 4 °C), and the pellets were resuspended to an OD600 of 60 or 30 in M9-N minimal medium (no 
nitrogen). Aliquots of the cell suspension (3–4 mL) were used to determine the P450 and P411 
expression level after lysis by sonication. The expression level in OD600 = 60 lysates is typically in 
the range of 16‒24 μM for P450-G8S, 2.4‒6 μM for P411-G8S and 3‒13 μM for P411-C10 variants. 
(2) Cyt c proteins: (a) Plasmid construction. All variants described in this paper were cloned 
and expressed using the pET22b(+) vector (Novagen). The gene encoding Rma cyt c (UNIPROT ID 
B3FQS5) was obtained as a single gBlock (IDT), codon-optimized for E. coli, and cloned using 
Gibson assembly into pET22b(+) (Novagen) between restriction sites NdeI and XhoI in frame with 
an N-terminal pelB leader sequence (to ensure periplasmic localization and proper maturation; 
MKYLLPTAAAGLLLLAAQPAMA) and a C-terminal 6xHis-tag. This plasmid was co-transformed 
with the cytochrome c maturation plasmid pEC86 into E. cloni® EXPRESS BL21(DE3) cells (Lucigen). 
(b) Expression of cytochrome c variants. 25 mL HBamp/chlor in a 125 mL flask was inoculated with 
an overnight culture (0.5 mL, LBamp/chlor) of recombinant E. cloni® EXPRESS BL21(DE3) cells 
containing a pET22b(+) plasmid encoding the cytochrome c variant, and the pEC86 plasmid. The 
culture was shaken at 37 °C and 230 rpm (no humidity control) until the OD600 was 0.7 
(approximately 3 hours). The culture was placed on ice for 30 minutes, and IPTG and ALA were 
added to final concentrations of 20 μM and 200 μM, respectively. The incubator temperature was 
reduced to 20 °C, and the culture was allowed to shake for 22 hours at 160 rpm. Cells were harvested 
by centrifugation (4 °C, 5 min, 4,000 × g). The cell pellet was resuspended in M9-N buffer to an 
OD600 of 60 or 30 in M9-N minimal medium (no nitrogen). Aliquots of the cell suspension (3–4 mL) 
were used to determine the cyt c expression level after lysis by sonication. The expression level in 
OD600 = 30 lysates is typically in the range of 12‒20 μM. 
 
3.9.6 Biotransformations 
The cell suspension in M9-N (with a certain OD600) was degassed by sparging with argon in 
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sealed vials or flasks for 30 min (no degassing process for 3.5 to 3.7). Separately, a glucose solution 
(250 mM in M9-N) was degassed by sparging with argon for 30 minutes. All solutions were 
uncapped and transferred into an anaerobic chamber (oxygen level: < 40 ppm). Resuspended cells 
(340 µL) were added to 2 mL vials, followed by D-glucose (40 µL, 250 mM in M9-N), substrate (10 
µL of an EtOH stock), and LAD (10 µL of an EtOH stock). Final concentrations were typically 10.0 
mM substrate, 10.0 mM LAD (substrate:LAD = 1:1), and 25 mM glucose; final reaction volume was 
400 µL. The vials were sealed and shaken inside the anaerobic chamber at room temperature and 
560 or 600 rpm for a set time.  
(1) For 3.3, 3.4 and 3.7: After the reaction was completed and the vials removed from the 
anaerobic chamber, internal standard 1,3,5-trimethoxybenzene, 1,2,3-trimethoxybenzene or ethyl 2-
phenylacetate (20 μL of 20 mM stock solution in toluene) was added followed by mixed solvent 
(hexane/ethyl acetate = 1:1, 1.0 mL). The mixture was transferred to a 1.7 mL Eppendorf tube, and 
then subjected to vortexing (15 s × 3) and centrifugation (14,000 rpm, 5 min) to completely separate 
the organic and aqueous layers. A sample of the organic layer (0.8 mL) was transferred to a vial for 
GC analysis. 
(2) For 3.5: After the reaction was completed and the vials removed from the anaerobic 
chamber, internal standard 1,3,5-trimethoxybenzene (1,3,5-TMOB), p-methyl anisole (pMe-anisole), 
ethyl 2-phenylacetate (PhEA), or allyl phenyl ether (AllylOPh) (20 μL of 20 mM stock solution in 
acetonitrile) was added followed by acetonitrile (0.58 mL). The mixture was transferred to a 1.7-mL 
Eppendorf tube, and then subjected to vortexing (15 s × 3) and centrifugation (14,000 rpm, 5 min, 
4 °C). A sample of the supernatant (0.8 mL) was transferred to a vial for reverse-phase HPLC analysis. 
The procedures for preparative-scale enzymatic reactions are outlined in detail (See Appendix 
B). 
 
3.9.7 Reaction screening in 96-well plate format 
Enzyme libraries (single/double-site-saturation libraries generated employing the “22c-trick” 
method or collections of heme protein variants) were screened in 96-well plates. 
E. coli libraries for P411 variants were cultured in LBamp (300 µL/well) at 37 °C, 250 rpm and 80% 
relative humidity overnight. HBamp (950 µL/well) was inoculated with the pre-culture (50 µL/well) 
and incubated at 37 °C, 230 rpm, 80% humidity for 2 h and 45 min. The plates were cooled on ice 
for 30 minutes, and expression was induced with 0.5 mM IPTG and 1.0 mM ALA (final 
concentrations). Expression was conducted: (1) at 24 °C and 200 rpm for 20–24 h (for 3.3 and 3.4); 
(2) at 22 °C and 220 rpm for 20 h (for 3.5 and 3.6). 
E. coli libraries for Rma cytochrome c variants were cultured in LBamp/chlor (400 µL/well) at 37 °C, 
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250 rpm and 80% relative humidity overnight. HBamp/chlor (950 µL/well) was inoculated with the pre-
culture (30 µL/well) and incubated at 37 °C, 250 rpm, 80% humidity for 2 h and 45 min. The plates 
were cooled on ice for 30 minutes, and expression was induced with 20 µM IPTG and 0.2 mM 5-
aminolevulinic acid (final concentrations). Expression was conducted at 24 °C and 200 rpm for 20–
24 h. 
The cells were pelleted (4,500 × g, 5 min, 4 °C) and resuspended with M9-N buffer (340 µL/well) 
and D-glucose solution (40 µL/well, in M9-N). The 96-well plate was then transferred to an 
anaerobic chamber. In the anaerobic chamber, substrate (10 µL/well, 400 mM in EtOH) and LAD 
(10 µL/well, 400 mM in EtOH) were added to the plate. The plate was sealed with an aluminum foil, 
removed from the anaerobic chamber, and shaken at 600 rpm. 
Cyclopropanation screening. After 12 h, the seal was removed and acetonitrile (580 µL/well) 
and internal standard ethyl phenylacetate (PhEA, 20 mM in acetonitrile, 20 µL/well) were added. 
The plate was tightly sealed with a reusable silicone mat, vortexed (15 s × 3) and centrifuged (4,500 
× g, 5 min). The supernatant (200 µL/well) was filtered through an AcroPrep 96-well filter plate (0.2 
µm) into a shallow-well plate for reversed-phase HPLC analysis (C18 poroshell column, MeCN:H2O 
= 50:50, 1.2 mL/min flow, 2.95 min, 210 nm). 
S–H insertion screening. After 8 h, the seal was removed and mixed solvent (hexane/ethyl 
acetate = 1:1, 600 µL/well) was added. The plate was tightly sealed with a reusable silicone mat, 
vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min) to completely separate the organic and aqueous 
layers. The organic layers (200 µL/well) were transferred to 300 µL vial inserts, which were then 
placed in 2 mL vials for normal-phase chiral HPLC analysis (OJ-H chiral column, hexane:iPrOH = 
60:40, 1.35 mL/min flow, 12.5 min, 220 nm). 
C–H insertion screening. After 24 h, the seal was removed and acetonitrile (580 µL/well) and 
internal standard (1,3,5-trimethoxybenzene, p-methyl anisole, ethyl 2-phenylacetate or allyl phenyl 
ether; 20 mM in acetonitrile; 20 µL/well) were added. The plate was tightly sealed with a reusable 
silicone mat, vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min). The supernatant (200 µL/well) 
was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well plate for reversed-
phase HPLC analysis (C18 Kromasil column, MeCN:H2O gradient from 40:60 to 100:0, 1.2 mL/min 
flow, 230 or 254 nm). 
N–H insertion screening. After 24 h, the seal was removed and mixed solvent (hexane/ethyl 
acetate = 1:1, 600 µL/well) was added. The plate was tightly sealed with a reusable silicone mat, 
vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min) to completely separate the organic and aqueous 
layers. The organic layers (200 µL/well) were transferred to 300 µL vial inserts, which were then 
placed in 2 mL vials for normal-phase chiral HPLC analysis (IC chiral column, hexane:iPrOH = 85:15, 
1.2 mL/min flow, 15 min, 254 nm). 
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B–H insertion screening. After 12 h, the seal was removed and mixed solvent 
(hexanes/ethylacetate = 4:6, 600 µL/well) was added followed by the addition of internal standard 
(20 μL of 20 mM 1,3,5-trimethoxybenzene in toluene). The plates were tightly sealed with reusable 
silicone mats and shaken vigorously to thoroughly mix the organic and aqueous layers. The plates 
were centrifuged (4,000 × g, 5 min) and the organic layer (300 μL) was transferred to autosampler 
vials with inserts for chiral HPLC analysis (IC chiral column, hexane:iPrOH = 60:40, 1.5 mL/min 
flow, 15 min, 235 nm). 
 
3.9.8 Protein purification 
To obtain purified protein of P411 and P450 variants, single colonies of E. coli BL21(DE3) freshly 
transformed with plasmid encoding either of the two variants were used to inoculate 30 mL LBamp 
broth and cultures were grown at 37 °C, 250 rpm for 14h. Subsequently, 950 mL of HBamp broth in a 
2.8 L flask were inoculated with 15 mL of the precultures and incubated at 37 °C, 180 rpm for 2.5 h 
(to OD600~1.5). Cultures were then cooled in an ice-water bath for 20 min and induced with 0.5 mM 
IPTG and 1.0 mM ALA (final concentrations). Expression was conducted at 24 °C, 150 rpm, for 18 h. 
Cultures were then centrifuged (5,000 × g, 5 min, 4 °C), the supernatant was discarded, and the cell 
pellets were frozen on dry ice and stored at –20 °C. For protein purification, frozen cells were thawed 
on ice and resuspended in buffer A (25 mM tris, 20 mM imidazole, 100 mM NaCl, pH 7.5; 4 mL 
buffer per g of wet cell weight). The cell suspension was supplemented with 1 mg/mL lysozyme, 0.1 
mg/mL DNAse I, and one protease inhibitor tablet (Pierce Protease Inhibitor Tablets, Thermo 
Scientific). The cell suspension was lysed by sonication (QSonica sonicator, 1 min total time, 1 s on 
/ off cycles, 40% output). To pellet insoluble material, lysates were centrifuged (20,000 × g, 20 min, 
4 °C), and the cleared lysate was filtered through a 0.45 µm filter unit. His-tagged P411 or P450 
proteins were purified from the lysate using a nickel NTA column (1 mL HisTrap HP, GE Healthcare) 
using an AKTAxpress purifier FPLC system (GE healthcare). Proteins were eluted on a stepwise 
gradient from 100% buffer A to 100% buffer B (25 mM tris, 300 mM imidazole, 100 mM NaCl, pH 
7.5): 0 to 35 % buffer B over 5 column volumes (CV), held at 35% buffer B for 5 CV, and 35 to 100 % 
buffer B over 3 CV. P411 or P450 variants were eluted at 30–35 % buffer B. Fractions containing eluted 
protein were pooled and subjected to three rounds of buffer exchange to storage buffer (25 mM Tris-
HCl, 100 mM NaCl, pH 7.5) using centrifugal spin filters (30 kDa molecular weight cut-off, Amicon 
Ultra, Merck Millipore). Subsequently, the concentrated protein was aliquoted, flash-frozen on 
powdered dry ice, and stored at –20 °C. Protein concentrations were determined via the 
pyridine/hemochrome assay specified above prior to setting up biocatalytic reactions. 
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Appendix B 
 
SUPPLEMENTARY INFORMATION FOR CHAPTER 3 
 
Material for this chapter appears in: (1) Chen, K.†; Zhang, S.-Q.†; Brandenberg, O. F.; Hong, X.*; 
Arnold, F. H.*, Alternate heme ligation steers activity and selectivity in engineered cytochrome 
P450-catalyzed carbene transfer reactions. J. Am. Chem. Soc. 140, 16402–16407 (2018). (2) Chen, K.; 
Huang, X.; Zhang, S.-Q.; Kan, S. B. J.; Zhou, A. Z.; Hong, X.*; Arnold, F. H.*, Engineered cytochrome 
c-catalyzed lactone-carbene B–H insertion. Synlett 30, 378–382 (2019). (3) Zhou, A. Z.; Chen, K.*; 
Arnold, F. H.*, Enzymatic lactone-carbene C–H insertion to build contiguous chiral centers. ACS 
Catal. 10, 5393–5398 (2020). 
 
B.1 Supporting Tables B-1 to B-11 
Table B-1. Summary of different heme proteins tested for spiro[2.4]-lactone formation. 
 
 
location name Mutations 
A1 P450BM3-wild type (WT, CYP102A1) - 
A2 P450-C400S C400S (relative to P450-WT) 
A3 P411-CIS 
V78A F87V P142S T175I A184V S226R H236Q 
E252G T268A A290V L353V I366V C400S E442K 
(relative to P450-WT) 
A4 P450-CIS S400C (relative to P411-CIS) 
A5 P450-CIS C400H C400H (relative to P450-CIS) 
A6 P411-A10 T438S I263F A328V L437V (relative to P411-CIS) 
A7 P450-A10 S400C (relative to P411-A10) 
A8 P450-A10 C400H C400H (relative to P450-A10) 
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A9 P450-A10 C400A C400A (relative to P450-A10) 
A10 P411-CIS T438S (P) T438S (relative to P411-CIS) 
B1 P411-CIS T268A T268A (relative to P411-CIS) 
B2 P411-CIS T268A F87V T268A F87V (relative to P411-CIS) 
B3 P411-CIS T268A F87A T268A F87A (relative to P411-CIS) 
B4 P411- CIS I263F T438S (P1) I263F T438S (relative to P411-CIS) 
B5 P411- CIS I263Y T438S I263Y T438S (relative to P411-CIS) 
B6 P411- CIS I263M T438S I263M T438S (relative to P411-CIS) 
B7 P411-CIS L75A L181A L75A L181A (relative to P411-CIS) 
B8 P411-CIS L75A I263A L437A L75A I263A L437A (relative to P411-CIS) 
B9 P411-P2 A328V (relative to P411-“I263F”) 
B10 P411-P3 A328V V87A (relative to P411-“I263F”) 
C1 P411-P4 V87A A268G A328V (relative to P411-“I263F”) 
C2 P11-“A82L” V87A A268G A328V A82L (relative to P411-“I263F”) 
C3 P11-P5 V87A A268G A328V A82I (relative to P411-“I263F”) 
C4 P411-E10 A78V F263L (relative to P411-“A82L”) 
C5 P411-E10 E267D E267D (relative to P411-E10) 
C6 P411-E10 S438A S438A (relative to P411-E10) 
C7 P411-E10 V78F V78F (relative to P411-E10) 
C8 P411-E10 V78Y V78Y (relative to P411-E10) 
C9 P411-E10 V78F S438A V78F S438A (relative to P411-E10) 
C10 P411-E10 V78Y S438A V78Y S438A (relative to P411-E10) 
D1 P411-K1 A87F (relative to P411-P4) 
D2 P411-C1 A87W (relative to P411-P4) 
D3 P411-P4 A87I A87I (relative to P411-P4) 
D4 P411-C2 L437G (relative to P411-C1) 
D5 P411-C3 V328Y (relative to P411-C2) 
D6 P411-C4 T328V (relative to P411-C3) 
D7 P411-C6 F261M T436H (relative to P411-C4) 
D8 P411-K3 F261G T327P (relative to P411-K1) 
D9 P411-K5 S72W L437F (relative to P411-K3) 
D10 P411-K6 T269L (relative to P411-K5) 
E1 P411-K8 A78S A330V (relative to P411-K6) 
E2 P411-K10 L188C T436M  (relative to P411-K8) 
E3 P411-P4 F261M F261M (relative to P411-P4) 
E4 P411-P4 F261M T269L F261M T269L (relative to P411-P4) 
E5 P411-P4 A87F F261C A87F F261C (relative to P411-P4) 
E6 P411-P4 F81V F81V (relative to P411-P4) 
E7 P411-“A82L” F263Y A78L T327L F263Y A78L T327L (relative to P411-“A82L”) 
E8 
P411-“M177L” H266V N70E A330Y 
ΔFAD 
N70E A74G A78L A82L M177L F263Y H266V T327I 
A330Y T436L L437Q S438T (relative to P411-P4) 
with FAD domain truncated 
E9 P411-“L437Q” S438T T436L V178E A74G A78L A82L V178E F263Y T327I T436L L437Q 
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ΔFAD S438T (relative to P411-P4) with FAD domain 
truncated 
E10 P411-“A82L” F263Y A78L T327I F263Y A78L T327I (relative to P411-A82L) 
F1 P411-G8 L437F T438Q (relative to P411-CIS) 
F2 P411-G8 L75Y L75Y (relative to P411-G8) 
F3 P411-G8S (or P411-VACcis) L75Y L181I (relative to P411-G8) 
F4 P411-G8 L181V L181V (relative to P411-G8) 
F5 P411-E12 I263G L437F (relative to P411-CIS) 
F6 P411-E12 V87L V87L (relative to P411-E12) 
F7 P411-E12 V87L L181R V87L L181R (relative to P411-E12) 
F8 P411-F3 V87T T438C (relative to P411-CIS) 
F9 P411-H9 I263G L437F (relative to P411-F3) 
F10 P411-6C9 
V87T L181G I263M V281L T438C (relative to P411-
CIS) with FAD domain truncated 
G1 Rma cyt c-wild type (WT) - 
G2 Rma cyt c-M100D M100D (relative to Rma cyt c-WT) 
G3 Rma cyt c-V75K M100D V75K M100D (relative to Rma cyt c-WT) 
G4 Rma cyt c-V75P M100D V75P M100D (relative to Rma cyt c-WT) 
G5 Rma cyt c-V75G M100D V75G M100D (relative to Rma cyt c-WT) 
G6 Rma cyt c-V75C M100D V75C M100D (relative to Rma cyt c-WT) 
G7 Rma cyt c-V75T M100D M103E V75T M100D M103E (relative to Rma cyt c-WT) 
G8 Rma cyt c-V75T M100D M103D V75T M100D M103D (relative to Rma cyt c-WT) 
G9 Rma cyt c-V75T M100D M103N V75T M100D M103N (relative to Rma cyt c-WT) 
G10 Rma cyt c-V75T M100D M103A V75T M100D M103A (relative to Rma cyt c-WT) 
H1 Rma cyt c-R66Y V75G M100D R66Y V75G M100D (relative to Rma cyt c-WT) 
H2 Rma cyt c-V75G M89H M100D V75G M89H M100D (relative to Rma cyt c-WT) 
H3 Rma cyt c-V75K M100D M103V V75K M100D M103V (relative to Rma cyt c-WT) 
H4 
Rma cyt c-V75K M100D T101C 
M103A 
V75K M100D T101C M103A (relative to Rma cyt c-
WT) 
H5 
Rma cyt c-V75R M99C M100D 
M103D 
V75R M99C M100D M103D (relative to Rma cyt c-
WT) 
H6 
Rma cyt c-V75R M100D T101Q 
M103D 
V75R M100D T101Q M103D (relative to Rma cyt c-
WT) 
H7 Rma cyt c-V75P M99Y M100D V75P M99Y M100D (relative to Rma cyt c-WT) 
H8 
Rma cyt c-V75P M99Y M100D 
T101W 
V75P M99Y M100D T101W (relative to Rma cyt c-
WT) 
H9 Rma cyt c-R67W V75G M100D R67W V75G M100D (relative to Rma cyt c-WT) 
H10 Rma cyt c-R67P V75G M100D R67P V75G M100D (relative to Rma cyt c-WT) 
Note: P/I value refers to the peak area ratio of cyclopropane products to internal standard based on the 
absorbance at wavelength of 210 nm by HPLC screening. 
 
Table B-2. Comparison of P450-G8S and P411-G8S for cyclopropanation and S–H insertion. 
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G8S variant TTN de ee 
P411-G8S 3090 ± 120 >99% >98.5% 
P450-G8S 380 ± 20 >99% 99% 
 
G8S variant TTN ee 
P411-G8S 1610 ± 120 84 ± 1% 
P450-G8S 300 ± 30 15 ± 2% 
Note: Analytical reactions using whole-cell catalysts were set up in quadruplicate and were analyzed by GC. 
The TTNs for spiro[2.4]-lactone formation were obtained using cell suspensions at OD600 = 30 for both variants; 
the TTNs for S–H insertion were obtained using cell suspensions at OD600 = 30 for P411-G8S variant and OD600 
= 15 for P450-G8S. The errors in all tables are standard deviations. Diastereoselectivity and enantioselectivity 
were determined by chiral HPLC.  
 
Table B-3. Comparison of G8S variants for cyclopropanation and S–H insertion in different forms. 
 
G8S variant relative activity de ee 
P411-G8S whole cell 1.000 ± 0.013 >99% 98.6% 
P411-G8S lysate 0.0063 ± 0.0003 n.d. n.d. 
P411-G8S purified protein 0.0077 ± 0.0007 n.d. n.d. 
P450-G8S whole cell 0.183 ± 0.010 >99.5% >99% 
P450-G8S lysate 0.028 ± 0.001 >99.5% 99% 
P450-G8S purified protein 0.037 ± 0.001 >99.5% 99% 
 
G8S variant relative activity ee 
P450-G8S whole cell 1.000 ± 0.019 85% 
P450-G8S lysate 0.481 ± 0.019 78% 
P450-G8S purified protein 0.571 ± 0.010 80% 
P411-G8S whole cell 0.167 ± 0.006 13% 
P411-G8S lysate 0.022 ± 0.001 n.d. 
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P411-G8S purified protein 0.035 ± 0.001 n.d. 
Note: Analytical reactions were set up in triplicate using protein catalysts in forms of whole cell, lysate and 
purified protein, and were analyzed by GC. Protein concentration of P450-G8S catalyst was adjusted to 4.25 
μM, and that of P411-G8S catalyst was adjusted to 1.70 μM in the analytical reactions. Relative activity was 
normalized by protein concentration. The errors in all tables are standard deviations. Diastereoselectivity and 
enantioselectivity were determined by chiral HPLC. n.d. = not determined. 
 
Table B-4. Competition reactions (cyclopropanation vs S–H insertion) with G8S variants. 
 
 
G8S variant 
TTN for S–H 
insertion 
TTN for 
cyclopropanation 
S–H insertion: 
cyclopropanation 
P450-G8S 1330 ± 10 84 ± 16 16 : 1 
P411-G8S 1100 ± 80 2200 ± 40 1 : 2 
Note: Analytical reactions were set up in triplicate using whole-cell catalyst (P411-G8S at OD600 = 30 and P450-
G8S at OD600 = 15) and were analyzed by GC. The errors in the table are standard deviations. 
 
Table B-5. Directed evolution of P411-C10 for lactone-carbene C–H insertion. 
 
P411-C10 variant TTN ee 
C10 (L1) 105 ± 10 47% 
C10-T327V (L2) 350 ± 20 44% 
C10-T327V Q437L (L3) 930 ± 140 40% 
C10-T327V Q437L S332A (L4) 1220 ± 60 39% 
C10-T327V Q437L S332A A87P (L5) 770 ± 30 56% 
C10-T327V Q437L S332A A87P A264S (L6) 1980 ± 90 64.5% 
Me
N
O
O
N2
LAD, 10 mM
Me
N
O
O
M9-N buffer, room temp.
anaerobic, 24 h
E. coli harboring
C10 variants
+
16a15a, 10 mM
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C10-T327P Q437L S332A A87P A264S (L7) 2010 ± 50 75% 
C10-T327P Q437L S332A A87P A264S E267D (L8) 1060 ± 110 80.5% 
C10-T327P Q437L S332A A87P A264S E267D V328L (L9) 590 ± 30 90% 
C10-T327P Q437L S332A A87P A264S E267D V328R (L10) 180 ± 15 ‒66% 
Note: Analytical reactions were set up in quadruplicate using whole E. coli cells harboring P411-C10 variants 
(OD600 = 60 for L1, L5 and L10, OD600 = 30 for the rest). Product formation was quantified by HPLC and TTNs 
were determined based on protein concentration. Enantioselectivity was determined by chiral HPLC. 
 
Table B-6. Optimization of expression and reaction conditions for lactone-carbene C–H insertion. 
Variant 
Enzyme expression conditions (1) 
+ Reaction conditions (1) 
Enzyme expression conditions (2) 
+ Reaction conditions (2) 
L6 
OD600 = 30 
2070 TTN, 72% yield, 64.5% ee 
OD600 = 60 
2760 TTN, 82% yield, 63% ee 
L7 
OD600 = 30 
1960 TTN, 86% yield, 75% ee 
OD600 = 30 
2920 TTN, >99% yield, 74.5% ee 
L9 
OD600 = 30 
610 TTN, 16% yield, 90% ee 
OD600 = 60 
1380 TTN, 61% yield, 90.5% ee 
L10 
OD600 = 60 
180 TTN, 6% yield, ‒66% ee 
OD600 = 60 
360 TTN, 8% yield, ‒68% ee 
Enzyme expression conditions (1) for Table S1: 22 °C, at 150 rpm, for 20 h (± 20 min). 
Enzyme expression conditions (2): 24 °C, at 140 rpm, for 20 h (± 20 min). 
Reaction conditions (1): 10 mM 15a, 10 mM LAD, E. coli harboring P411-C10 variants (OD600 = 60 for L1, L5 and 
L10, OD600 = 30 for the rest), D-glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 24 h. 
Reaction conditions (2): 12 mM 15a, 12 mM LAD, E. coli harboring P411-C10 variants (OD600 = 30 for L7, OD600 
= 60 for the rest), D-glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 24 h. 
 
Table B-7. Different substrates tested for lactone-carbene C–H insertion. 
   
    
pMe-DMA 
(15a) 
pOMe-
DMA (15b) 
pCl-DMA 
(15c) 
mMe-
DMA 
(15d) 
DMA 
(15e) 
oMe-
DMA (15f) 
Me,Et-Ani 
(15g) 
 
   
  
 
DEA 
(15h) 
Ph-pyr 
(15i) 
diMePh-
pyr (15j) 
mClPh-
pyr (15k) 
pOMe-
pyr (15l) 
pFmCl-
pyr (15n) 
pMe-DEA 
N
Me
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Ph-aze 
(15m) 
THQ indoline Ph-mor Ph-pip pTol-aze 
 
Table B-8. Substrate screening results for lactone-carbene C–H insertion. 
 
Substrate screening was carried out in two rounds:  
(1) Rapid screening (without accurate quantification): 
The enzyme lineage L1 to L10 was expressed in each line of a 96-well plate (column 2 to column 11 with variants 
L1 to L10, respectively). Enzymatic reactions were set up with substrate concentration of 10 mM for both LAD 
and aniline derivative (one substrate in one line). After the reactions were completed, acetonitrile (600 µL/well) 
was added to reaction plates. The plates were tightly sealed with a reusable silicone mat, vortexed (15 s × 3) and 
centrifuged (4,500 × g, 5 min). The supernatant (200 µL/well) was filtered through an AcroPrep 96-well filter 
plate (0.2 µm) into a shallow-well plate for reversed-phase HPLC analysis (C18 Kromasil column, MeCN:H2O 
gradient from 40:60 to 100:0, 1.2 mL/min flow, 230 or 254 nm). Promising substrates were then identified with 
new compound peaks observed on HPLC followed by further confirmation of products with NMR based on 
reaction scale-up and product isolation. 
Note: Substrates Ph-mor, Ph-pip and pTol-aze were found inactive towards lactone-carbene C–H insertion 
using variants L1 to L10. Substrates THQ and indoline were found to generate mixtures of C–H insertion 
products at multiple sites of the molecules (with poor regio- and stereo-selectivities). 
(2) Plate re-screening (with accurate quantification): 
The re-screening was performed with the substrates identified with promising products, following the 
procedure used for rapid screening but with internal standard for quantification and using specific HPLC 
methods developed for each substrate. 
N
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Notes: (1) The products quantified here correspond to the sum of all the products when different diastereomers 
or regio-isomers were formed. (2) Some diastereomers or regio-isomers could be separated from each other on 
HPLC, while others did not show separation. (3) Expression level of enzyme variants in plate may be different 
from that in flasks for validation. 
 
Table B-9. Substrates tested for carbene N–H insertion. 
 
Notes: 6-membered lactone diazo was inactive towards N–H insertion; Me-EDA and Et-EDA showed promising 
reactivities with late variants in the enzyme lineage from L1 to L10.  
 
Table B-10. Enantioselectivity screening of Rma cyt c variants-catalyzed lactone-carbene B–H insertion. 
 
 
well 
location 
Mutations at specific sites 
site 66 site 67 site 75 site 89 site 99 site 100 site 101 site 103 
B2 - - V75K - - M100D T101Y M103A 
B3 - - - - - M100D - - 
B4 - - V75K - - M100D - - 
B5 - - V75R - - M100D - - 
B6 - - V75P - - M100D - - 
NH2 NH2
Me
NH2
MeO
NH2
Cl
H
N
Me
H
N
Et
H
N
Me
Me
H
N
Me
Me
H
N
Allyl
H
N
H
N
Ph NH2 Ph
NH2
Amine substrates
Diazo substrates
O
O
N2
Me
OEt
O
N2
Et
OEt
O
N2O
O
N2
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B7 - - V75C - - M100D - - 
B8 - - V75G - - M100D - - 
B9 - - V75T - - M100D - - 
B10 - - V75K - - M100D - M103V 
B11 - - V75K - - M100D - M103N 
C2 - - V75K - - M100D - M103Q 
C3 - - V75K - - M100D - M103T 
C4 - - V75K - - M100D - M103A 
C5 - - V75K - - M100D - M103S 
C6 - - V75K - - M100D - M103Y 
C7 - - V75K - - M100D T101C M103A 
C8 - - V75K - - M100D T101M M103A 
C9 - - V75K - - M100D T101F M103A 
C10 - - V75R - - M100D - M103Q 
C11 - - V75R - - M100D - M103K 
D2 - - V75R - - M100D - M103F 
D3 - - V75R - - M100D - M103I 
D4 - - V75R - - M100D - M103V 
D5 - - V75R - - M100D - M103D 
D6 - - V75R - - M100D - M103G 
D7 - - V75R - - M100D T101G M103D 
D8 - - V75R - - M100D T101V M103D 
D9 - - V75R - - M100D T101Q M103D 
D10 - - V75R - M99W M100D - M103D 
D11 - - V75R - M99C M100D - M103D 
E2 - - V75R - M99P M100D - M103D 
E3 - - V75R - M99Y M100D - M103D 
E4 - - V75R - M99V M100D - M103D 
E5 - - V75R M89L - M100D - M103D 
E6 - - V75R M89K - M100D - M103D 
E7 - - V75P - M99C M100D - - 
E8 - - V75P - M99Y M100D - - 
E9 - - V75P - M99P M100D - - 
E10 - - V75P - M99K M100D - - 
E11 - - V75P - M99L M100D - - 
F2 - - V75P - M99Y M100D T101W - 
F3 - - V75P - M99Y M100D T101A - 
F4 - - V75P - M99Y M100D T101Y - 
F5 - - V75P - - M100D - M103N 
F6 - - V75P - - M100D - M103S 
F7 - - V75P - - M100D - M103A 
F8 - - V75P - - M100D - M103L 
F9 - - V75P - - M100D - M103D 
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F10 - - V75P - - M100D - M103E 
F11 - - V75T - - M100D - M103E 
G2 - - V75T - - M100D - M103I 
G3 - - V75T - - M100D - M103L 
G4 - - V75T - - M100D - M103V 
G5 - - V75T - - M100D - M103Q 
G6 R66Y - V75G - - M100D - - 
G7 - R67L V75G - - M100D - - 
G8 - R67P V75G - - M100D - - 
G9 - R67W V75G - - M100D - - 
G10 - - V75G M89F - M100D - - 
G11 - - V75G M89H - M100D - - 
Notes: numbers in the heat-map table are the ee values (in %) of the B–H insertion products produced by the 
corresponding Rma cyt c variants in the 96-well plate. 
 
Table B-11. List of mutations in P411, P450 and Rma cyt c variants involved in Chapter 3. 
P411 variant Mutations relative to wild-type protein (P450BM3 or Rma cyt c) 
P411-G8S 
L75Y V78A F87V P142S T175I L181I A184V S226R H236Q E252G T268A A290V L353V I366V 
C400S L437F T438Q E442K (relative to P450-WT) 
P450-G8S 
L75Y V78A F87V P142S T175I L181I A184V S226R H236Q E252G T268A A290V L353V I366V 
L437F T438Q E442K (relative to P450-WT) 
P411-C10 (L1) 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L 
L437Q E442K ΔFAD (relative to P450-WT) 
L2 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V T327V A328V A330Y L353V I366V C400S I401L T436L 
L437Q E442K ΔFAD (relative to P450-WT) 
L3 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V T327V A328V A330Y L353V I366V C400S I401L T436L 
E442K ΔFAD (relative to P450-WT) 
L4 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V T327V A328V A330Y S332A L353V I366V C400S I401L 
T436L E442K ΔFAD (relative to P450-WT) 
L5 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V T327V A328V A330Y S332A L353V I366V C400S I401L 
T436L E442K ΔFAD (relative to P450-WT) 
L6 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y A264S H266V T268G A290V T327V A328V A330Y S332A L353V I366V 
C400S I401L T436L E442K ΔFAD (relative to P450-WT) 
L7 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y A264S H266V T268G A290V T327P A328V A330Y S332A L353V I366V 
C400S I401L T436L E442K ΔFAD (relative to P450-WT) 
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L8 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y A264S H266V E267D T268G A290V T327P A328V A330Y S332A L353V 
I366V C400S I401L T436L E442K ΔFAD (relative to P450-WT) 
L9 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y A264S H266V E267D T268G A290V T327P A328L A330Y S332A L353V 
I366V C400S I401L T436L E442K ΔFAD (relative to P450-WT) 
L10 
N70E A74G V78L A82L F87P M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y A264S H266V E267D T268G A290V T327P A328R A330Y S332A L353V 
I366V C400S I401L T436L E442K ΔFAD (relative to P450-WT) 
Rma cyt c-D M100D (relative to Rma cyt c-WT) 
Rma cyt c-RD V75R M100D (relative to Rma cyt c-WT) 
Rma cyt c-RDV V75R M100D M103V (relative to Rma cyt c-WT) 
Rma cyt c-BORLac V75R M99Q M100D T101Y M103V (relative to Rma cyt c-WT) 
Note: ΔFAD means FAD domain truncation. See the publications for the nucleotide and amino acid sequences 
of the hemeprotein variants. 
 
B.2 Supporting Figures B-1 to B-2 
 
 
Figure B-1. Comparison of the iron-carbene intermediates with different axial ligands by DFT. Gibbs 
free energy obtained at the B3LYP/def2-TZVP//B3LYP/6-31G(d)-LANL2DZ level. OSS is open-shell singlet; CSS 
is closed-shell singlet. *Note: No major difference in electronic state distribution, energy level or structural 
geometry is observed. 
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Figure B-2. Comparison of the electronic states of iron-porphyrin carbene intermediates. The Gibbs 
free energies were obtained at B3LYP-D3(BJ)/def2-TZVPP//B3LYP/def2-SVP level. 
 
A.3 Preparation of lactone-diazo substrates 
3-Diazodihydrofuran-2(3H)-one (LAD) 
 
The preparation of the title compound 1 followed a modified procedure reported by 
Sattely et al. Sodium azide (4.83 g, 74.3 mmol, 4 equiv.), sodium hydroxide (80 mL of 2 
M in water, 160 mmol), tetrabutylammonium bromide (60.0 mg, 0.190 mmol, 0.01 
equiv.), and hexane (80 mL) were combined in a 500-mL flask with magnetic stir bar open to the air 
and cooled to 0 °C. With vigorous stirring, triflic anhydride (6.20 mL, 37.1 mmol, 2 equiv.) was added 
dropwise. After 15 min, a solution of 2-acetyl-butyrolactone (2.00 mL, 18.6 mmol) in acetonitrile (70 
mL) was poured into the vessel through a funnel, followed by an additional 10 mL of acetonitrile to 
complete the transfer. The initially colorless reaction mixture immediately turned yellow. After 
stirring for 20 min at 0 °C, the mixture was diluted with ice water (50 mL) and chilled EtOAc (50 
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mL) and transferred to a separatory funnel. After phase separation and removal of the organic 
fraction, the aqueous layer was washed with chilled EtOAc (50 mL × 5). The combined organic layer 
was dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting crude 
product was purified through a silica column using hexane: ethyl acetate (3:1 to 2:1) as eluents. The 
yellow-colored fractions were concentrated to afford the product as a bright yellow crystalline solid 
(1.2 ‒ 1.6 g, 60 ‒ 75% yield). 
 
3-Diazotetrahydro-2H-pyran-2-one (LAD-2) and 3-diazooxepan-2-one (LAD-3) 
 
The preparation of the title compounds LAD-2 and LAD-3 followed a 
modified procedure reported by DeAngelis et al. A flame-dried round-
bottomed flask was charged with diisopropylamine (1.88 mL, 13.41 
mmol) under a nitrogen atmosphere. Anhydrous THF (40mL) was added and the flask was cooled 
to 0 °C. A solution of n-butyllithium (5.36 mL, 13.4 mmol) (2.5M solution in hexanes) was added 
dropwise and the mixture was stirred for 30 min and subsequently cooled to −78 °C by a bath of dry 
ice/acetone. A solution of tetrahydro-2H-pyran-2-one or oxepan-2-one (11.2 mmol) in 27 mL of 
anhydrous THF was added dropwise and the reaction was stirred at −78 °C for 15 minutes. 2,2,2-
Trifluoroethyl trifluoroacetate (TFEA) (2.24 mL, 16.8 mmol) was then added dropwise and the 
reaction was stirred at −78 °C for 30 minutes and then allowed to warm to room temperature over 1 
hour. The reaction was quenched with 50 mL of 10% HCl and extracted with Et2O (50 mL × 3). The 
combined organic layer was washed with brine, dried over anhydrous MgSO4, and concentrated 
under reduced pressure. The crude product 3-(2,2,2-trifluoroacetyl)tetrahydro-2H- pyran-2-one or 
3-(2,2,2-trifluoroacetyl)oxepan-2-one was used for the next step without further purification. 
The crude product was dissolved in anhydrous CH2Cl2 (110 mL), and o-nitrobenzenesulfonyl 
azide (o-NBSA) (3.21 g, 14.1 mmol) was added followed by dropwise addition of 1,8-
diazabicyclo(5.4.0)undec-7-ene (DBU, 2.39 mL, 16 mmol) and the reaction was stirred at room 
temperature for 3 hours. The reaction was quenched by water (50 mL) and the product was 
extracted by ether (40 mL × 7). The combined organic layer was washed with brine, dried over 
anhydrous MgSO4, and concentrated under reduced pressure. The resulting crude product was 
purified through a silica column using hexane: ethyl acetate (2:1 to 1:2) as eluents. The yellow-
colored fractions were concentrated to afford product LAD-2 as a bright yellow crystalline solid 
(1.06 g, 75% yield) and product LAD-3 as an orange oil (1.28 g, 82% yield). 
 
B.4 Preparation of racemic standard products 
General procedure for the synthesis of spiro[2.4]-lactone standard products: 
To a 20 mL vial was added olefin (1.0 mmol, 2.0 equiv.), Rh2(OAc)4 (2.2 mg, 1 mol%) and DCM 
(5 mL). The mixture was cooled to –78 °C, and a solution of LAD (0.5 mmol, 1.0 equiv.) in DCM (3 
mL) was added dropwise to the reaction mixture over 2 hours through a syringe pump. The reaction 
was allowed to slowly warm up to room temperature over 8 hours and stirred at room temperature 
for another 8 hours. Evaporation of the organic solvent and purification by silica column 
chromatography using hexane and ethyl acetate as eluents afforded racemic cyclopropane products 
in 20‒60% yields (diastereomers can be separated). 
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(E)-1-Phenyl-5-oxaspiro[2.4]heptan-4-one ((E)-12a) 
 
1H NMR (400 MHz, CDCl3) δ 7.39–7.30 (m, 2H), 7.30–7.23 (m, 1H), 7.18–7.08 
(m, 2H), 4.40 (td, J = 8.9, 5.6 Hz, 1H), 4.27 (td, J = 8.9, 6.7 Hz, 1H), 2.76 (dd, J = 
9.4, 7.1 Hz, 1H), 2.15 (ddd, J = 13.1, 8.9, 6.8 Hz, 1H), 1.90 (ddd, J = 13.0, 8.8, 5.6 
Hz, 1H), 1.80 (dd, J = 9.4, 5.1 Hz, 1H), 1.47 (dd, J = 7.1, 5.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 179.50, 
136.11, 128.74, 128.17, 127.24, 66.01, 31.10, 27.53, 25.51, 18.53.  
(Z)-1-Phenyl-5-oxaspiro[2.4]heptan-4-one ((Z)-12a) 
 
1H NMR (400 MHz, CDCl3) δ 7.34–7.19 (m, 5H), 4.51–4.36 (m, 2H), 2.74–2.54 
(m, 2H), 2.27 (ddd, J = 12.7, 7.2, 2.9 Hz, 1H), 1.93 (dd, J = 7.7, 5.3 Hz, 1H), 1.54 
(dd, J = 8.9, 5.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.97, 135.38, 129.02, 128.24, 
127.19, 65.66, 34.76, 32.10, 27.83, 17.33. 
HRMS (TOF) m/z: 189.0917 (M+H+); calc. for C12H13O2: 189.0916. 
 
(E)-1-(4-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12b) 
 
1H NMR (400 MHz, CDCl3) δ 7.05 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.8 Hz, 
2H), 4.40 (td, J = 9.0, 5.5 Hz, 1H), 4.26 (td, J = 8.9, 6.9 Hz, 1H), 3.80 (s, 
3H), 2.71 (dd, J = 9.4, 7.1 Hz, 1H), 2.12 (ddd, J = 13.0, 8.9, 6.9 Hz, 1H), 1.88 
(ddd, J = 13.0, 8.7, 5.5 Hz, 1H), 1.77 (dd, J = 9.4, 5.1 Hz, 1H), 1.40 (dd, J = 7.1, 5.1 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 179.66, 158.84, 129.31, 127.99, 114.18, 66.02, 55.44, 30.64, 27.29, 25.56, 18.52. 
(Z)-1-(4-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12b) 
 
1H NMR (400 MHz, CDCl3) δ 7.17 (d, J = 8.3 Hz, 2H), 6.82 (d, J = 8.8 Hz, 
2H), 4.46 (td, J = 9.0, 2.9 Hz, 1H), 4.40 (ddd, J = 9.8, 9.0, 7.3 Hz, 1H), 3.77 
(s, 3H), 2.61 (dt, J = 12.1, 9.1 Hz, 2H), 2.25 (ddd, J = 12.7, 7.1, 2.8 Hz, 1H), 
1.87 (dd, J = 7.6, 5.2 Hz, 1H), 1.51 (dd, J = 8.9, 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 176.15, 158.69, 
130.04, 127.42, 113.70, 65.67, 55.34, 34.27, 32.05, 27.66, 17.47. 
HRMS (TOF) m/z: 219.1024 (M+H+); calc. for C13H15O3: 219.1021. 
 
(E)-1-(3-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12c) 
 
1H NMR (400 MHz, CDCl3) δ 7.22–7.15 (m, 1H), 6.74 (ddd, J = 8.3, 2.6, 0.9 
Hz, 1H), 6.64 (dp, J = 7.7, 0.8 Hz, 1H), 6.62 – 6.57 (m, 1H), 4.34 (td, J = 8.9, 
5.7 Hz, 1H), 4.21 (td, J = 8.9, 6.7 Hz, 1H), 3.74 (s, 3H), 2.66 (dd, J = 9.3, 7.1 
Hz, 1H), 2.09 (ddd, J = 13.1, 8.9, 6.8 Hz, 1H), 1.86 (ddd, J = 13.0, 8.8, 5.7 Hz, 1H), 1.71 (dd, J = 9.3, 5.1 
Hz, 1H), 1.38 (dd, J = 7.1, 5.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 179.38, 159.80, 137.67, 129.64, 120.28, 
114.14, 112.24, 65.96, 55.25, 31.01, 27.44, 25.46, 18.47. 
(Z)-1-(3-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12c) 
 
1H NMR (400 MHz, CDCl3) δ 7.13 (t, J = 7.9 Hz, 1H), 6.77 (ddd, J = 6.9, 1.5, 
0.8 Hz, 1H), 6.73 (t, J = 2.1 Hz, 1H), 6.69 (dd, J = 8.2, 2.5 Hz, 1H), 4.43 – 
4.30 (m, 2H), 3.72 (s, 3H), 2.63–2.48 (m, 2H), 2.19 (ddd, J = 12.9, 7.1, 2.9 
O
O
MeO
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Hz, 1H), 1.84 (dd, J = 7.7, 5.3 Hz, 1H), 1.46 (dd, J = 8.8, 5.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
175.79, 159.33, 136.89, 129.08, 121.31, 114.89, 112.34, 65.53, 55.17, 34.63, 32.02, 27.77, 17.33. 
HRMS (TOF) m/z: 219.1021 (M+H+); calc. for C13H15O3: 219.1021. 
 
(E)-1-(4-Tolyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12d) 
 
1H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 7.9 Hz, 2H), 7.01 (d, J = 8.1 Hz, 
2H), 4.40 (td, J = 8.9, 5.6 Hz, 1H), 4.26 (td, J = 8.9, 6.8 Hz, 1H), 2.72 (dd, J 
= 9.4, 7.1 Hz, 1H), 2.34 (s, 3H), 2.14 (ddd, J = 13.0, 8.9, 6.8 Hz, 1H), 1.89 (ddd, 
J = 12.9, 8.7, 5.5 Hz, 1H), 1.78 (dd, J = 9.3, 5.1 Hz, 1H), 1.43 (dd, J = 7.1, 5.1 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 179.63, 136.96, 132.99, 129.44, 128.09, 66.03, 30.94, 27.40, 25.54, 21.19, 18.47. 
(Z)-1-(4-Tolyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12d) 
 
1H NMR (400 MHz, CDCl3) δ 7.12 (q, J = 8.1 Hz, 4H), 4.49–4.37 (m, 2H), 
2.69–2.54 (m, 2H), 2.30 (s, 3H), 2.24 (dd, J = 7.1, 2.9 Hz, 1H), 1.90 (dd, J = 
7.7, 5.2 Hz, 1H), 1.51 (dd, J = 8.9, 5.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
176.09, 136.79, 132.33, 129.01, 128.88, 65.66, 34.57, 32.12, 27.73, 21.27, 17.34. 
HRMS (TOF) m/z: 203.1074 (M+H+); calc. for C13H15O2: 203.1072 
 
(E)-1-(4-Chlorophenyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12e) 
 
1H NMR (400 MHz, CDCl3) δ 7.31 (d, J = 8.5 Hz, 2H), 7.06 (d, J = 8.1 Hz, 
2H), 4.41 (td, J = 9.0, 5.8 Hz, 1H), 4.28 (td, J = 8.9, 6.5 Hz, 1H), 2.72 (dd, J = 
9.3, 7.1 Hz, 1H), 2.14 (ddd, J = 13.1, 8.9, 6.5 Hz, 1H), 1.88 (ddd, J = 13.0, 8.8, 
5.8 Hz, 1H), 1.80 (dd, J = 9.3, 5.2 Hz, 1H), 1.42 (dd, J = 7.1, 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
179.19, 134.71, 133.12, 129.50, 128.96, 65.98, 30.34, 27.61, 25.49, 18.70. 
(Z)-1-(4-Chlorophenyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12e) 
 
1H NMR (400 MHz, CDCl3) δ 7.25 (d, J = 8.5 Hz, 2H), 7.18 (d, J = 8.3 Hz, 
2H), 4.47 (td, J = 9.0, 3.0 Hz, 1H), 4.40 (ddd, J = 9.6, 9.0, 7.4 Hz, 1H), 2.68–
2.54 (m, 2H), 2.28 (ddd, J = 12.7, 7.3, 2.9 Hz, 1H), 1.89 (dd, J = 7.7, 5.3 Hz, 
1H), 1.55 (dd, J = 8.9, 5.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.85, 133.89, 133.00, 130.37, 128.41, 
65.69, 33.93, 31.91, 27.92, 17.61. 
HRMS (TOF) m/z: 223.0542 (M+H+); calc. for C12H12O2Cl: 223.0526. 
 
(E)-1-(4-Bromophenyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12f) 
 
1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 8.5 Hz, 
2H), 4.41 (td, J = 9.0, 5.8 Hz, 1H), 4.28 (td, J = 8.9, 6.6 Hz, 1H), 2.77–2.63 (m, 
1H), 2.14 (ddd, J = 13.1, 8.9, 6.5 Hz, 1H), 1.88 (ddd, J = 13.2, 8.8, 5.8 Hz, 1H), 
1.80 (dd, J = 9.3, 5.2 Hz, 1H), 1.42 (dd, J = 7.1, 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 179.15, 135.25, 
131.90, 129.85, 121.17, 65.98, 30.40, 27.61, 25.48, 18.66. 
(Z)-1-(4-Bromophenyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12f) 
O
O
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O
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1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.1 Hz, 
2H), 4.47 (td, J = 9.0, 3.0 Hz, 1H), 4.40 (ddd, J = 9.6, 9.0, 7.4 Hz, 1H), 2.66 – 
2.54 (m, 2H), 2.28 (ddd, J = 13.0, 7.5, 3.2 Hz, 1H), 1.88 (dd, J = 7.7, 5.4 Hz, 
1H), 1.55 (dd, J = 8.8, 5.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.84, 134.43, 131.33, 130.73, 121.14, 
65.69, 33.97, 31.89, 27.91, 17.56. 
HRMS (TOF) m/z: 267.0044 (M+H+); calc. for C12H12O2Br: 267.0021. 
 
(E)-1-((4-(Trifluoromethyl)phenyl))-5-oxaspiro[2.4]heptan-4-one ((E)-12g) 
 
1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.9 Hz, 2H), 7.24 (d, J = 8.7 Hz, 
2H), 4.43 (td, J = 9.0, 5.9 Hz, 1H), 4.29 (td, J = 9.0, 6.4 Hz, 1H), 2.80 (dd, J 
= 9.3, 7.1 Hz, 1H), 2.17 (ddd, J = 13.1, 8.9, 6.4 Hz, 1H), 1.94–1.82 (m, 2H), 1.51 
(dd, J = 7.1, 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 178.94, 140.47, 129.54 (130.02, 129.70, 129.37, 
129.05, q, J = 32.5 Hz), 128.45, 125.73 (125.79, 125.75, 125.71, 125.67, q, J =3.8 Hz), 124.16 (128.21, 125.51, 
122.81, 120.11, q, J = 271.8 Hz), 65.98, 30.48, 28.00, 25.46, 18.91. 
(Z)-1-((4-(Trifluoromethyl)phenyl))-5-oxaspiro[2.4]heptan-4-one ((Z)-12g) 
 
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.6 Hz, 
2H), 4.49 (td, J = 9.0, 3.1 Hz, 1H), 4.42 (td, J = 9.3, 7.4 Hz, 1H), 2.74 – 2.57 
(m, 2H), 2.32 (ddd, J = 12.8, 7.3, 3.1 Hz, 1H), 1.96 (dd, J = 7.7, 5.4 Hz, 1H), 
1.61 (dd, J = 8.8, 5.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.69, 139.45, 129.39, 129.33 (129.81, 129.49, 
129.16, 128.84, q, J = 32.5 Hz), 125.19 (125.24, 125.21, 125.17, 125.13, q, J = 3.8 Hz), 124.29 (128.34, 125.64, 
122.94, 120.22, q, J = 271.9 Hz), 65.73, 34.06, 31.89, 28.23, 17.69. 
HRMS (TOF) m/z: 257.0796 (M+H+); calc. for C13H12O2F3: 257.0789. 
 
(E)-1-(2-Fluorophenyl)-5-oxaspiro[2.4]heptan-4-one ((E)-12h) 
 
1H NMR (400 MHz, CDCl3) δ 7.31–7.23 (m, 1H), 7.12 (td, J = 7.5, 1.1 Hz, 1H), 7.10–
7.02 (m, 2H), 4.41 (dtd, J = 8.9, 4.9, 0.3 Hz, 1H), 4.34 (td, J = 8.6, 7.5 Hz, 1H), 
2.84–2.70 (m, 1H), 2.15 (ddd, J = 13.0, 9.0, 7.4 Hz, 1H), 1.84–1.74 (m, 2H), 1.45 (dd, 
J = 7.2, 5.0 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 179.32, 162.49 (163.72, 161.27, d, J = 248.2 Hz), 129.39 
(129.41, 129.38, d, J = 3.7 Hz), 129.18 (129.22, 129.14, d, J = 8.2 Hz), 124.39 (124.40, 124.37, d, J = 3.7 Hz), 
123.73 (123.80, 123.66, d, J = 14.7 Hz), 115.62 (115.73, 115.51, d, J = 21.5 Hz), 66.15, 26.49, 25.89, 25.50 
(25.52, 25.48, d, J = 3.7 Hz), 17.43 (17.43, 17.42, d, J = 1.5 Hz). 
(Z)-1-(2-Fluorophenyl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12h) 
 
1H NMR (400 MHz, CDCl3) δ 7.26–7.17 (m, 2H), 7.09 (td, J = 7.5, 1.1 Hz, 1H), 
6.99 (ddd, J = 9.6, 8.3, 1.2 Hz, 1H), 4.52–4.44 (m, 2H), 2.68–2.54 (m, 2H), 2.33 
(ddd, J = 12.7, 6.3, 4.0 Hz, 1H), 1.86 (dd, J = 7.7, 5.3 Hz, 1H), 1.54 (dd, J = 8.7, 5.3 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 176.26, 162.33 (163.54, 161.11, d, J = 245.9 Hz), 130.43 (130.45, 
130.41, d, J = 3.7 Hz), 128.97 (129.01, 128.93, d, J = 8.3 Hz), 123.90 (123.92, 123.88, d, J = 3.5 Hz), 123.15 
(123.22, 123.07, d, J = 14.8 Hz), 114.94 (115.04, 114.83, d, J = 21.4 Hz), 65.92, 31.56, 28.11 (28.13, 28.09, d, 
J = 3.8 Hz), 26.95, 16.51. 
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HRMS (TOF) m/z: 207.0842 (M+H+); calc. for C12H12O2F: 207.0821. 
 
(E)-1-(Naphthalen-2-yl)-5-oxaspiro[2.4]heptan-4-one ((E)-12i) 
 
1H NMR (400 MHz, CDCl3) δ 7.87–7.76 (m, 3H), 7.60–7.55 (m, 1H), 7.53–
7.44 (m, 2H), 7.26 (dd, J = 8.4, 1.8 Hz, 1H), 4.40 (td, J = 9.0, 5.5 Hz, 1H), 
4.26 (td, J = 8.9, 6.8 Hz, 1H), 2.92 (dd, J = 9.2, 7.2 Hz, 1H), 2.18 (ddd, J = 
13.1, 8.9, 6.8 Hz, 1H), 1.95–1.82 (m, 2H), 1.63 (dd, J = 7.2, 5.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
179.48, 133.70, 133.47, 132.64, 128.47, 127.82, 127.70, 126.70, 126.58, 126.50, 126.11, 66.07, 31.36, 27.80, 
25.61, 18.53. 
(Z)-1-(Naphthalen-2-yl)-5-oxaspiro[2.4]heptan-4-one ((Z)-12i) 
 
1H NMR (400 MHz, CDCl3) δ 7.81–7.74 (m, 3H), 7.71 (dd, J = 1.9, 1.0 Hz, 
1H), 7.47–7.39 (m, 2H), 7.37 (dd, J = 8.5, 1.8 Hz, 1H), 4.52–4.42 (m, 2H), 
2.80 (t, J = 8.3 Hz, 1H), 2.67 (dt, J = 12.5, 9.3 Hz, 1H), 2.34 (ddd, J = 12.7, 6.9, 
3.3 Hz, 1H), 2.07 (dd, J = 7.7, 5.3 Hz, 1H), 1.62 (dd, J = 8.8, 5.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 
175.97, 133.31, 132.89, 132.72, 127.91, 127.87, 127.85, 127.75, 127.14, 126.13, 125.81, 65.71, 34.97, 32.15, 17.60. 
HRMS (TOF) m/z: 239.1079 (M+H+); calc. for C16H15O2: 239.1072. 
 
(E)-1-Phenethyl-5-oxaspiro[2.4]heptan-4-one ((E)-12j) 
 
1H NMR (400 MHz, CDCl3) δ 7.31–7.26 (m, 2H), 7.23–7.13 (m, 3H), 4.36 (td, 
J = 9.0, 3.5 Hz, 1H), 4.18 (q, J = 8.6 Hz, 1H), 2.79–2.54 (m, 2H), 2.39 (dt, J = 
12.5, 9.0 Hz, 1H), 2.09–1.83 (m, 3H), 1.30 (p, J = 7.4 Hz, 1H), 1.23–1.10 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ 178.51, 141.60, 128.71, 128.48, 126.02, 65.79, 35.82, 31.87, 30.36, 28.56, 
24.18, 20.22. 
(Z)-1-Phenethyl-5-oxaspiro[2.4]heptan-4-one ((Z)-12j) 
 
1H NMR (400 MHz, CDCl3) δ 7.32–7.26 (m, 2H), 7.24–7.15 (m, 3H), 4.37 
(td, J = 8.6, 6.7 Hz, 1H), 4.20 (td, J = 8.7, 6.4 Hz, 1H), 2.83–2.68 (m, 2H), 
2.17–2.05 (m, 2H), 1.74–1.59 (m, 2H), 1.51 (dq, J = 9.1, 6.8 Hz, 1H), 1.40 (dd, 
J = 9.1, 4.2 Hz, 1H), 0.60 (dd, J = 6.7, 4.2 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 180.22, 141.31, 128.51, 
128.48, 126.13, 65.92, 35.64, 31.89, 25.59, 25.52, 24.17, 21.13. 
HRMS (TOF) m/z: 217.1233 (M+H+); calc. for C14H17O2: 217.1229. 
 
General procedure for the synthesis of α-thio-γ-lactone standard products: 
To a 100 mL round-bottom flask was added (substituted) thiophenol (2.0 mmol, 1.0 equiv.), 
NaOMe (162 mg, 3.0 mmol, 1.5 equiv.) and dry MeOH (30 mL). The mixture was stirred at room 
temperature for 1 hour before 3-bromodihydrofuran-2(3H)-one (214 μL, 1.3 equiv.) was added in one 
portion. The reaction was stirred at room temperature for another 24 hours. Methanol was 
evaporated under reduced pressure. The crude mixture was then dissolved in DCM and washed 
with water. The aqueous phase was extracted by DCM (30 mL × 3). The combined organic layer was 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification by silica column 
chromatography using hexane and ethyl acetate as eluents afforded racemic α-thio-γ-lactones in 
O
O
O
O
154 
 
 
50‒80% yields. 
 
3-(Phenylthio)dihydrofuran-2(3H)-one (14a) 
 
1H NMR (400 MHz, CDCl3) δ 7.61–7.50 (m, 2H), 7.39–7.29 (m, 3H), 4.31–4.17 (m, 
2H), 3.86 (dd, J = 8.6, 6.2 Hz, 1H), 2.67 (dddd, J = 13.4, 8.7, 7.7, 6.6 Hz, 1H), 2.27 
(ddt, J = 13.5, 7.4, 6.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.10, 133.73, 131.81, 
129.40, 128.86, 66.62, 44.54, 30.10. HRMS (TOF) m/z: 195.0468 (M+H+); calc. for C10H11O2S: 195.0480. 
 
3-((3-Methoxyphenyl)thio)dihydrofuran-2(3H)-one (14b) 
 
1H NMR (400 MHz, CDCl3) δ 7.28–7.21 (m, 1H), 7.12 (dt, J = 7.4, 1.6 Hz, 
2H), 6.87 (ddd, J = 8.4, 2.3, 1.3 Hz, 1H), 4.31–4.20 (m, 2H), 3.88 (dd, J = 8.7, 
6.4 Hz, 1H), 3.80 (s, 3H), 2.68 (dddd, J = 13.5, 8.7, 7.5, 6.6 Hz, 1H), 2.28 
(ddt, J = 13.6, 7.4, 6.3 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.12, 160.00, 133.04, 130.17, 125.53, 118.46, 
114.82, 66.65, 55.51, 44.53, 30.17. HRMS (TOF) m/z: 225.0564 (M+H+); calc. for C11H13O3S: 225.0585. 
 
3-((4-Fluorophenyl)thio)dihydrofuran-2(3H)-one (14c) 
 
1H NMR (400 MHz, CDCl3) δ 7.57 (dd, J = 8.9, 5.3 Hz, 2H), 7.05 (dd, J = 8.9, 
8.5 Hz, 2H), 4.31–4.17 (m, 2H), 3.77 (dd, J = 8.7, 6.2 Hz, 1H), 2.66 (dddd, J = 
13.5, 8.7, 7.7, 6.6 Hz, 1H), 2.25 (ddt, J = 13.5, 7.4, 6.1 Hz, 1H). 13C NMR (101 
MHz, CDCl3) δ 174.80, 163.41 (164.66, 162.17, d, J = 150.8 Hz), 136.72 (136.76, 136.67, d, J = 8.5 Hz), 
126.49 (126.51, 126.48, d, J = 3.6 Hz), 116.49 (116.60, 116.39, d, J = 22.1 Hz), 66.43, 44.82 (44.83, 44.81, 
d, J = 1.4 Hz), 29.73. HRMS (FAB) m/z: 213.0386 (M+H+); calc. for C10H10O2SF: 213.0396. 
 
3-((4-Chlorophenyl)thio)dihydrofuran-2(3H)-one (14d) 
 
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.6 Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 
4.27 (t, J = 6.9 Hz, 2H), 3.82 (dd, J = 8.7, 6.3 Hz, 1H), 2.74–2.62 (m, 1H), 2.25 
(td, J = 13.4, 6.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 174.83, 135.31, 135.12, 
130.26, 129.59, 66.59, 44.55, 29.93. HRMS (TOF) m/z: 229.0080 (M+H+); calc. for C10H10O2SCl: 
229.0090. 
 
3-((4-Bromophenyl)thio)dihydrofuran-2(3H)-one (14e) 
 
1H NMR (400 MHz, CDCl3) δ 7.53–7.36 (m, 4H), 4.28 (td, J = 7.0, 1.0 Hz, 2H), 
3.83 (dd, J = 8.7, 6.4 Hz, 1H), 2.68 (ddtd, J = 14.1, 8.7, 7.0, 0.6 Hz, 1H), 2.25 
(dqd, J = 13.4, 6.7, 1.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 174.81, 135.20, 
132.54, 130.98, 123.40, 66.60, 44.43, 29.95. HRMS (TOF) m/z: 271.9518 (M+H+); calc. for C10H9O2SBr: 
271.9507. 
 
3-((4-Tolyl)thio)dihydrofuran-2(3H)-one (14f) 
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1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.1 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 
4.27–4.15 (m, 2H), 3.78 (dd, J = 8.7, 6.0 Hz, 1H), 2.64 (dddd, J = 13.5, 8.7, 7.8, 
6.7 Hz, 1H), 2.35 (s, 3H), 2.31–2.21 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
175.19, 139.44, 134.52, 130.22, 127.85, 66.62, 44.82, 29.99, 21.38. HRMS (TOF) m/z: 209.0631 (M+H+); 
calc. for C11H13O2S: 209.0636. 
 
3-((4-Isopropylphenyl)thio)dihydrofuran-2(3H)-one (14g) 
 
1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.3 Hz, 2H), 7.20 (d, J = 8.1 Hz, 
2H), 4.28–4.14 (m, 2H), 3.80 (dd, J = 8.7, 6.1 Hz, 1H), 2.90 (hept, J = 7.0 Hz, 
1H), 2.65 (dddd, J = 13.5, 8.7, 7.7, 6.6 Hz, 1H), 2.27 (ddt, J = 13.5, 7.4, 6.0 Hz, 
1H), 1.24 (d, J = 7.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 175.25, 150.17, 
134.42, 128.26, 127.60, 66.61, 44.80, 33.97, 30.10, 23.95. HRMS (TOF) m/z: 237.0931 (M+H+); calc. for 
C13H17O2S: 237.0949. 
 
3-((4-(Trifluoromethyl)phenyl)thio)dihydrofuran-2(3H)-one (14h) 
 
1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.3 Hz, 
2H), 4.36 (qdd, J = 9.1, 7.5, 6.2 Hz, 2H), 3.98 (dd, J = 8.7, 6.5 Hz, 1H), 2.75 
(dddd, J = 13.7, 8.7, 7.5, 6.4 Hz, 1H), 2.29 (ddt, J = 13.7, 7.5, 6.3 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 174.48, 137.51, 131.68, 130.02 (130.51, 130.18, 129.86, 129.53, q, J = 32.3 Hz), 
126.04 (126.09, 126.06, 126.02, 125.98, q, J = 3.8 Hz), 123.85 (127.90, 125.20, 122.49, 119.79, q, J = 273.1 
Hz), 66.53, 43.48, 29.98. HRMS (FAB) m/z: 263.0347 (M+H+); calc. for C11H10O2SF3: 263.0354. 
 
3-((3,4-Dimethoxyphenyl)thio)dihydrofuran-2(3H)-one (14i) 
 
1H NMR (400 MHz, CDCl3) δ 7.19 (dd, J = 8.3, 2.1 Hz, 1H), 7.15 (d, J = 2.1 
Hz, 1H), 6.85 (d, J = 8.3 Hz, 1H), 4.24 (ddd, J = 8.9, 7.8, 5.8 Hz, 1H), 4.15 
(ddd, J = 8.9, 7.6, 6.5 Hz, 1H), 3.90 (s, 6H), 3.75 (dd, J = 8.8, 6.2 Hz, 1H), 
2.66 (dddd, J = 13.4, 8.7, 7.8, 6.5 Hz, 1H), 2.28 (ddt, J = 13.5, 7.6, 6.0 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 175.41, 150.38, 149.20, 128.46, 121.81, 117.98, 111.50, 66.57, 56.16, 56.03, 45.26, 29.73. HRMS 
(TOF) m/z: 255.0707 (M+H+); calc. for C12H15O4S: 255.0691. 
 
3-(Naphthalen-2-ylthio)dihydrofuran-2(3H)-one (14j) 
 
1H NMR (400 MHz, Chloroform-d) δ 8.06 (d, J = 1.7 Hz, 1H), 7.85–7.78 (m, 
3H), 7.60 (dd, J = 8.6, 1.9 Hz, 1H), 7.55–7.47 (m, 2H), 4.30–4.21 (m, 2H), 
3.96 (dd, J = 8.7, 6.3 Hz, 1H), 2.74–2.64 (m, 1H), 2.36–2.27 (m, 1H). 13C NMR 
(101 MHz, CDCl3) δ 175.10, 133.67, 133.16, 133.07, 130.24, 129.13, 129.08, 127.86, 127.02, 126.89, 66.67, 
44.58, 30.11. HRMS (TOF) m/z: 245.0619 (M+H+); calc. for C14H13O2S: 245.0636. 
 
General procedure for the synthesis of organoborane standard products: 
The preparation of racemic organoborane standard products follows the reported protocol 
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using rhodium acetate277 or iodine283 as catalyst for carbene B–H insertion. Iodine (10 mol%) or 
Rh2(OAc)4 (2 mol%) was added to the solution of NHC-BH3 (1.0 equiv) in dichloromethane. The 
mixture was allowed to stir for 5 min. A solution of diazo compound (1.2 equiv) in dichloromethane 
was then added through a syringe pump. The reaction mixture was allowed to stir for 10 h. Quick 
filtration and further purification through a silica column using hexane:ethyl acetate (2:1 to 0:1) or 
hexane:(ethyl acetate:acetone 5:5) (2:1 to 0:1) elution system afforded the organoborane standard 
products. 
Note: The 1H NMR resonances of the B–H protons are broad (due to geminal coupling with boron) 
and generally in the range of 0.4–1.6 ppm. The 13C NMR resonances of the boron-binding NHC 
quaternary carbons usually appear at around 170 ppm and are typically broad (due to germinal 
coupling with boron) and weak; these signals are sometimes not visible in the 13C NMR spectra. 
 
(1,3-Dimethyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20a) 
 
1H NMR (400 MHz, CDCl3) δ 6.83 (s, 2H), 4.45 (dddd, J = 10.7, 8.1, 6.8, 1.0 Hz, 
1H), 4.27 (tq, J = 9.0, 1.1 Hz, 1H), 3.83–3.69 (m, 6H), 2.53–2.25 (m, 1H), 2.01–1.93 
(m, 1H), 1.88–1.80 (m, 1H), 1.79–1.16 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 187.91, 
120.62, 67.86, 36.15, 30.86; 11B NMR (128 MHz, CDCl3) δ -27.08 (t, J = 89.6Hz). HRMS (FAB+) m/z: 
193.1144 ((M+H+)–H2); calc. for C9H14O2N2B: 193.1148. 
 
(2-Oxotetrahydrofuran-3-yl)(1,3,5-trimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (20b) 
 
1H NMR (400 MHz, CDCl3) δ 6.57 (q, J = 1.1 Hz, 1H), 4.47 (ddd, J = 10.8, 8.2, 6.8 
Hz, 1H), 4.28 (ddd, J = 9.0, 8.2, 1.8 Hz, 1H), 3.70 (s, 3H), 3.64 (s, 3H), 2.45–2.33 
(m, 1H), 2.18 (d, J = 1.2 Hz, 3H), 2.00–1.92 (m, 1H), 1.89–1.59 (m, 2H), 1.49 – 1.11 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 165.20, 128.29, 117.79, 67.89, 35.77, 32.59, 
30.95, 9.67; 11B NMR (128 MHz, CDCl3) δ -26.77 (t, J = 89.4 Hz). HRMS (FAB+) m/z: 207.1317 
((M+H+)–H2); calc. for C10H16O2N2B: 207.1305. 
 
(1,3-Dimethyl-5-(trifluoromethyl)-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-
yl)dihydroborate (20c) 
 
1H NMR (400 MHz, CDCl3) δ 7.28 (q, J = 1.3 Hz, 1H), 4.45 (ddd, J = 10.4, 8.3, 7.0 
Hz, 1H), 4.29 (ddd, J = 8.9, 8.3, 2.2 Hz, 1H), 3.87 (d, J = 0.8 Hz, 3H), 3.81 (s, 3H), 
2.51–2.32 (m, 1H), 2.07–1.65 (m, 3H), 1.59–1.10 (m, 1H); 13C NMR (101 MHz, CDCl3) 
δ 187.70, 122.82 (q, J = 4.2 Hz), 122.52 (q, J = 41.1 Hz), 119.39 (q, J = 268.7 Hz), 
68.00, 36.81, 34.25, 34.23, 34.21, 34.19, 30.65; 11B NMR (128 MHz, CDCl3) δ -27.15 (t, J = 90.7 Hz). 
HRMS (FAB+) m/z: 261.1030 ((M+H+)–H2); calc. for C10H13O2N2F3B: 261.1022. 
 
(1-Ethyl-3-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20d) 
 
1H NMR (400 MHz, CDCl3) δ 6.88 (d, J = 2.0 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 
4.45 (ddd, J = 10.8, 8.2, 6.8 Hz, 1H), 4.27 (ddd, J = 8.9, 8.2, 1.8 Hz, 1H), 4.24–4.09 
(m, 2H), 3.76 (s, 3H), 2.50–2.29 (m, 1H), 2.02–1.66 (m, 3H), 1.61–1.13 (m, 1H), 1.40 
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(t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 187.77, 121.00, 118.45, 67.82, 43.72, 36.07, 30.93, 15.90; 
11B NMR (128 MHz, CDCl3) δ -27.10 (t, J = 89.6 Hz). HRMS (FAB+) m/z: 207.1296 ((M+H+)–H2); calc. 
for C10H16O2N2B: 207.1305. 
 
(3-Hexyl-1-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20e) 
 
1H NMR (400 MHz, CDCl3) δ 6.86 (d, J = 1.9 Hz, 1H), 6.83 (d, J = 1.9 Hz, 1H), 4.45 
(ddd, J = 10.8, 8.2, 6.8 Hz, 1H), 4.27 (ddd, J = 8.9, 8.2, 1.8 Hz, 1H), 4.17–4.01 (m, 
2H), 3.76 (s, 3H), 2.48–2.31 (m, 1H), 2.13–1.64 (m, 5H), 1.58–1.14 (m, 7H), 0.88 (t, 
J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 187.77, 120.82, 119.03, 67.82, 48.85, 36.12, 31.46, 30.95, 
30.65, 26.36, 22.61, 14.12; 11B NMR (128 MHz, CDCl3) δ -27.09 (t, J = 90.3 Hz). HRMS (FAB+) m/z: 
263.1927 ((M+H+)–H2); calc. for C14H24O2N2B: 263.1931. 
 
(1,3-Dimethyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-yl)dihydroborate (20f) 
 
1H NMR (400 MHz, CDCl3) δ 6.80 (s, 2H), 4.46 (dddd, J = 11.0, 7.4, 3.7, 1.0 Hz, 
1H), 4.26–4.19 (m, 1H), 3.74 (s, 6H), 2.14–1.95 (m, 3H), 1.89–1.75 (m, 1H), 1.71–1.55 
(m, 2H), 1.51–1.15 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 181.58, 120.48, 69.44, 
36.10, 27.17, 22.39; 11B NMR (128 MHz, CDCl3) δ -24.71 (t, J = 90.4 Hz). HRMS (FAB+) m/z: 207.1330 
((M+H+)–H2); calc. for C10H16O2N2B: 207.1305. 
 
(1-Ethyl-3-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-yl)dihydroborate 
(20g) 
 
1H NMR (400 MHz, CDCl3) δ 6.86 (d, J = 2.0 Hz, 1H), 6.82 (d, J = 1.9 Hz, 1H), 
4.46 (dddd, J = 10.8, 7.4, 3.7, 1.0 Hz, 1H), 4.26–4.10 (m, 3H), 3.75 (s, 3H), 2.14–
1.94 (m, 3H), 1.86–1.74 (m, 1H), 1.70–1.10 (m, 3H), 1.43–1.38 (m, 3H);  13C NMR 
(101 MHz, CDCl3) δ 181.45, 120.88, 118.29, 69.42, 43.64, 36.02, 27.22, 22.40, 15.88; 
11B NMR (128 MHz, CDCl3) δ -24.73 (t, J = 90.4 Hz). HRMS (FAB+) m/z: 221.1452 ((M+H+)–H2); calc. 
for C11H18O2N2B: 221.1461. 
 
(1,3-Dimethyl-5-(trifluoromethyl)-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-
yl)dihydroborate (20h) 
 
1H NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 4.43 (dddd, J = 10.7, 7.1, 3.7, 1.1 Hz, 
1H), 4.30–4.19 (m, 1H), 3.90–3.82 (m, 3H), 3.79 (s, 3H), 2.13–1.96 (m, 3H), 1.90–
1.59 (m, 3H), 1.54–1.11 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 181.22, 122.70 (q, J 
= 4.1 Hz), 122.32 (q, J = 40.8 Hz), 119.44 (q, J = 267.6 Hz), 69.76, 36.71, 34.14, 
34.12, 27.29, 22.32; 11B NMR (128 MHz, CDCl3) δ -24.93 (t, J = 91.3 Hz). HRMS (FAB+) m/z: 275.1170 
((M+H+)–H2); calc. for C11H15O2N2F3B: 275.1179. 
 
B.5 Enzymatic preparation of lactone-carbene C–H insertion products 
General procedure for enzymatic synthesis of β-amino lactone products: 
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To 50-mL falcon tubes were added a suspension of E. coli expressing P411-C10 variant (OD600 = 
60, 30 mL), LAD (0.1‒0.5 mmol), aniline derivative (1.2 equiv.), D-glucose (~20 mM), M9-N 
buffer/EtOH (~20:1 v/v) under anaerobic conditions. The tubes were capped and shaken (600 rpm) 
inside an anaerobic chamber at room temperature for 20‒24 h. After the reaction was completed, 
the reaction mixture was transferred to 500 mL centrifuge bottle, and ~100 mL of hexane/ethyl 
acetate (1:1) mixed solvent was added. After the bottle was capped, it was shaken vigorously and 
centrifuged (6,000 × g, 6 min). The organic layer was separated, and the aqueous layer was subjected 
to three more rounds of extraction. The organic layers were combined, dried over Na2SO4 and 
concentrated under reduced pressure. Purification by silica column chromatography with 
hexane/ethyl acetate afforded the desired β-amino lactone products. 
Notes: 1. C10 variants (usually the most active and/or selective ones) were chosen for each substrate 
according to the plate screening result, and substrate loading in each reaction was based on rough 
estimation of the enzymes’ activity in plate screening. 2. Total turnovers or yields were not 
accurately quantified (yields are in the range of 30‒80%). The products isolated from these 
preparative-scale enzymatic reactions were further used for HPLC calibration curves and 
quantification of analytical-scale reactions. 3. The absolute configuration of the β-amino lactone 
products was not determined. 
 
3-((Methyl(p-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16a) 
 
Product 16a was synthesized using variant L4. 1H NMR (400 MHz, CDCl3) δ 7.07 
(d, J = 8.2 Hz, 2H), 6.68 (d, J = 8.7 Hz, 2H), 4.35 (td, J = 8.8, 2.6 Hz, 1H), 4.15 (ddd, 
J = 10.0, 9.1, 6.6 Hz, 1H), 3.94 (dd, J = 15.1, 4.5 Hz, 1H), 3.43 (dd, J = 15.1, 8.0 Hz, 1H), 
2.96 (s, 3H), 2.91 (dddd, J = 10.6, 8.6, 8.0, 4.5 Hz, 1H), 2.34 (dddd, J = 12.7, 9.0, 6.6, 
2.6 Hz, 1H), 2.26 (s, 3H), 2.12 (dtd, J = 12.7, 10.2, 8.6 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 178.48, 146.77, 130.03, 126.65, 113.06, 66.74, 53.31, 39.56, 38.67, 28.10, 20.36. HRMS (TOF) 
m/z: 220.1311 (M+H+); calc. for [C13H17NO2+H+]: 220.1332. 
 
3-(((4-Methoxyphenyl)(methyl)amino)methyl)dihydrofuran-2(3H)-one (16b) 
 
Product 16b was synthesized using variant L6. 1H NMR (400 MHz, CDCl3) δ 6.85 
(d, J = 9.1 Hz, 2H), 6.75 (d, J = 7.9 Hz, 2H), 4.34 (td, J = 8.8, 2.6 Hz, 1H), 4.15 (ddd, 
J = 9.8, 9.1, 6.7 Hz, 1H), 3.86 (dd, J = 14.8, 4.3 Hz, 1H), 3.76 (s, 3H), 3.37 (dd, J = 14.8, 
8.3 Hz, 1H), 2.92 (s, 3H), 2.90–2.82 (m, 1H), 2.34 (dddd, J = 11.3, 8.9, 6.7, 2.6 Hz, 1H), 
2.18–2.04 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 178.48, 118.03, 115.22, 115.00, 114.74, 
66.74, 55.86, 54.34, 40.16, 38.56, 28.23. HRMS (TOF) m/z: 236.1288 (M+H+); calc. for [C13H17NO3+H+]: 
236.1281. 
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3-(((4-Chlorophenyl)(methyl)amino)methyl)dihydrofuran-2(3H)-one (16c) 
 
Product 16c was synthesized using variant L7. 1H NMR (400 MHz, CDCl3) δ 7.18 
(d, J = 9.1 Hz, 2H), 6.65 (d, J = 9.1 Hz, 2H), 4.35 (td, J = 8.8, 2.4 Hz, 1H), 4.16 (ddd, 
J = 10.1, 9.1, 6.6 Hz, 1H), 3.93 (dd, J = 15.3, 4.7 Hz, 1H), 3.46 (dd, J = 15.2, 7.7 Hz, 1H), 
2.97 (s, 3H), 2.89 (dddd, J = 10.8, 8.8, 7.7, 4.8 Hz, 1H), 2.35 (dddd, J = 12.6, 8.8, 6.5, 
2.4 Hz, 1H), 2.09 (dddd, J = 12.6, 10.8, 10.1, 8.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) 
δ 178.13, 147.35, 129.25, 122.10, 113.70, 66.67, 53.01, 39.51, 38.65, 27.96. HRMS (TOF) m/z: 240.0785 
(M+H+); calc. for [C12H14ClNO2+H+]: 240.0786. 
 
3-((Methyl(m-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16d) 
 
Product 16d was synthesized using variant L9. 1H NMR (400 MHz, CDCl3) δ 7.14 
(dd, J = 9.1, 7.4 Hz, 1H), 6.67–6.52 (m, 3H), 4.36 (td, J = 8.8, 2.5 Hz, 1H), 4.16 (ddd, 
J = 10.0, 9.1, 6.6 Hz, 1H), 3.98 (dd, J = 15.2, 4.6 Hz, 1H), 3.46 (dd, J = 15.2, 7.9 Hz, 
1H), 2.99 (s, 3H), 2.94 (dddd, J = 10.7, 8.8, 8.0, 4.6 Hz, 1H), 2.41–2.33 (m, 1H), 2.32 
(s, 3H), 2.13 (dddd, J = 12.7, 10.7, 10.0, 8.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 178.40, 148.86, 139.25, 
129.35, 118.19, 113.36, 109.84, 66.72, 52.94, 39.42, 38.77, 28.02, 22.07. HRMS (TOF) m/z: 220.1341 
(M+H+); calc. for [C13H17NO2+H+]: 220.1332. 
 
3-((Methyl(phenyl)amino)methyl)dihydrofuran-2(3H)-one (16e) 
 
Product 16e was synthesized using variant L6. 1H NMR (400 MHz, CDCl3) δ 7.29–
7.22 (m, 3H), 6.75 (dtt, J = 7.3, 1.9, 1.0 Hz, 3H), 4.36 (td, J = 8.8, 2.6 Hz, 1H), 4.16 
(ddd, J = 9.9, 9.1, 6.6 Hz, 1H), 3.98 (dd, J = 15.2, 4.5 Hz, 1H), 3.48 (dd, J = 15.2, 7.8 
Hz, 1H), 3.00 (s, 3H), 2.93 (dddd, J = 10.8, 8.8, 7.9, 4.6 Hz, 1H), 2.36 (dddd, J = 12.6, 
8.9, 6.6, 2.5 Hz, 1H), 2.13 (dddd, J = 12.7, 10.7, 10.0, 8.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 178.37, 
148.79, 129.52, 117.24, 112.61, 66.73, 52.96, 39.38, 38.78, 28.03. HRMS (TOF) m/z: 206.1167 (M+H+); 
calc. for [C12H15NO2+H+]: 206.1176. 
 
3-((Methyl(o-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16f) 
 
Product 16f was synthesized using variant L9. 1H NMR (400 MHz, CDCl3) δ 
7.24–7.17 (m, 2H), 7.14 (d, J = 7.8 Hz, 1H), 7.04 (td, J = 7.3, 1.5 Hz, 1H), 4.35 (td, 
J = 8.8, 3.0 Hz, 1H), 4.17 (ddd, J = 9.6, 9.1, 6.9 Hz, 1H), 3.62 (dd, J = 12.9, 4.2 Hz, 
1H), 3.00 (dd, J = 12.9, 10.3 Hz, 1H), 2.78 (tdd, J = 10.1, 8.8, 4.3 Hz, 1H), 2.69 (s, 
3H), 2.33 (s, 3H), 2.32 – 2.24 (m, 1H), 2.12 (dtd, J = 12.9, 9.8, 8.6 Hz, 1H). 13C NMR (101 MHz, CDCl3) 
δ 178.66, 150.84, 133.89, 131.35, 126.82, 124.10, 120.95, 66.97, 55.95, 43.43, 38.63, 28.13, 18.12. HRMS 
(TOF) m/z: 220.1332 (M+H+); calc. for [C13H17NO2+H+]: 220.1332. 
 
3-((Ethyl(pheny)amino)methyl)dihydrofuran-2(3H)-one (16g) 
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Product 16g was synthesized using variants L9 and L10. 1H NMR (400 MHz, CDCl3) 
δ 7.29 – 7.20 (m, 3H), 6.82–6.64 (m, 3H), 4.36 (td, J = 8.8, 2.5 Hz, 1H), 4.16 (ddd, J 
= 9.9, 9.1, 6.6 Hz, 1H), 3.91 (dd, J = 15.1, 4.6 Hz, 1H), 3.55–3.30 (m, 3H), 2.93 (tdd, J 
= 10.8, 8.3, 4.6 Hz, 1H), 2.38 (dddd, J = 12.5, 8.9, 6.6, 2.5 Hz, 1H), 2.13 (dtd, J = 12.6, 
10.3, 8.7 Hz, 1H), 1.15 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.47, 147.63, 129.56, 117.01, 
112.97, 66.77, 50.65, 46.17, 39.10, 28.00, 12.21. HRMS (TOF) m/z: 220.1311 (M+H+); calc. for 
[C13H17NO2+H+]: 220.1332. 
 
3-(1-(Methyl(phenyl)amino)ethyl)dihydrofuran-2(3H)-one (16g’) 
 
Product 16g’ was observed in the enzymatic reaction using variant L10 and was 
obtained in a mixture form with a side product 16g’’ (via N–H insertion after 
demethylation, see Fig. 3.11.b). 1H NMR (400 MHz, CDCl3) δ 7.31–7.21 (m, 2H), 
6.91–6.70 (m, 3H), 4.57 (dd, J = 8.8, 11.1 Hz, 2H), 4.35 (td, J = 8.7, 3.1 Hz, 1H), 4.14 
(td, J = 9.2, 7.1 Hz, 1H), 2.91 (td, J = 9.8, 3.9 Hz, 1H), 2.80 (s, 3H), 2.37–2.18 (m, 2H), 1.31 (d, J = 6.9 
Hz, 3H). HRMS (TOF) m/z: 220.1342 (M+H+); calc. for [C13H17NO2+H+]: 220.1332. 
 
3-(1-(Ethyl(phenyl)amino)ethyl)dihydrofuran-2(3H)-one (16h) 
 
Product 16h was synthesized with a diastereomeric ratio of 16:1 using variant L9. 
Further silica column purification using dichloromethane/acetone/hexane as 
eluent was able to afford the pure major diastereomer. 1H NMR (400 MHz, CDCl3) 
δ 7.30–7.21 (m, 3H), 6.85 (dd, J = 9.0, 1.1 Hz, 2H), 6.76 (tt, J = 7.3, 1.0 Hz, 1H), 4.51 
(qd, J = 6.9, 3.7 Hz, 1H), 4.35 (td, J = 8.8, 2.6 Hz, 1H), 4.13 (ddd, J = 9.8, 8.9, 6.9 Hz, 1H), 3.37 – 3.18 
(m, 2H), 2.93 (ddd, J = 10.8, 9.1, 3.7 Hz, 1H), 2.37–2.25 (m, 1H), 2.25–2.15 (m, 1H), 1.31 (d, J = 6.9 Hz, 
3H), 1.15 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.12, 147.76, 129.57, 117.65, 114.35, 66.51, 
52.38, 42.43, 39.62, 24.27, 14.65, 14.55. HRMS (TOF) m/z: 234.1483 (M+H+); calc. for [C14H19NO2+H+]: 
234.1489. 
 
3-(1-Phenylpyrrolidin-2-yl)dihydrofuran-2(3H)-one (16i) 
 
Product 16i was synthesized with a diastereomeric ratio of 9:1 using variant L9. 
The major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.33–7.22 (m, 2H), 6.81–6.62 
(m, 3H), 4.47 (dt, J = 7.9, 3.7 Hz, 1H), 4.38 (ddd, J = 9.0, 6.5, 4.6 Hz, 1H), 4.17–4.08 
(m, 1H), 3.57 (ddd, J = 9.2, 6.9, 5.6 Hz, 1H), 3.41 (td, J = 9.9, 3.9 Hz, 1H), 3.34–3.25 
(m, 1H), 2.36–2.19 (m, 1H), 2.18–1.99 (m, 4H), 1.81 (dtd, J = 12.7, 6.2, 3.5 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 178.13, 146.67, 129.55, 116.89, 112.90, 66.73, 56.78, 49.63, 41.16, 27.89, 24.36, 23.91. HRMS 
(TOF) m/z: 232.1321 (M+H+); calc. for [C14H17NO2+H+]: 232.1332. 
 
3-(1-(3-Chlorophenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16j) 
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Product 16j was synthesized with a diastereomeric ratio of 9:1 using variant L9. 
The major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.14 (t, J = 8.1 Hz, 1H), 6.69 
(ddd, J = 7.8, 1.9, 0.8 Hz, 1H), 6.62 (t, J = 2.2 Hz, 1H), 6.54 (ddd, J = 8.4, 2.5, 0.8 Hz, 
1H), 4.44–4.38 (m, 1H), 4.38–4.25 (m, 1H), 4.13 (td, J = 9.0, 8.0 Hz, 1H), 3.50 (ddd, J 
= 9.3, 7.0, 5.7 Hz, 1H), 3.34 (td, J = 10.0, 4.0 Hz, 1H), 3.26 (dt, J = 9.3, 7.4 Hz, 1H), 
2.36–2.18 (m, 1H), 2.16–1.95 (m, 4H), 1.83–1.74 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 177.81, 147.66, 
135.38, 130.42, 116.75, 112.78, 111.00, 66.67, 56.85, 49.65, 41.04, 27.90, 24.25, 23.86. HRMS (TOF) m/z: 
266.0937 (M+H+); calc. for [C14H16ClNO2+H+]: 266.0942. 
 
3-(1-(2,3-Dimethylphenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16k) 
 
Product 16k was synthesized with a diastereomeric ratio of 1:1.6 using variant 
L9. The diastereomers can be easily separated by silica chromatography. 
Major diastereomer (16k2): 1H NMR (400 MHz, CDCl3) δ 7.04 (d, J = 4.6 Hz, 
2H), 6.88 (t, J = 4.3 Hz, 1H), 4.14–4.02 (m, 3H), 3.51–3.42 (m, 1H), 2.77–2.68 
(m, 1H), 2.62 (td, J = 9.0, 5.3 Hz, 1H), 2.39–2.27 (m, 1H), 2.26 (s, 3H), 2.23 (s, 
3H), 2.19–2.04 (m, 2H), 2.00–1.82 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 178.08, 149.05, 138.00, 132.78, 
125.94, 125.31, 118.85, 66.71, 60.32, 56.02, 44.40, 31.13, 25.56, 24.45, 20.83, 14.59. HRMS (TOF) m/z: 
260.1631 (M+H+); calc. for [C16H21NO2+H+]: 260.1645. 
Minor diastereomer (16k1): 1H NMR (400 MHz, CDCl3) δ 7.12–7.02 (m, 2H), 6.91 (dd, J = 6.7, 1.7 Hz, 
1H), 4.29 (td, J = 9.1, 3.0 Hz, 1H), 4.14 (ddd, J = 8.0, 7.3, 4.7 Hz, 1H), 4.08 (td, J = 9.3, 7.4 Hz, 1H), 3.45 
(ddd, J = 9.1, 7.3, 5.5 Hz, 1H), 2.91 (td, J = 9.7, 4.6 Hz, 1H), 2.65 (ddd, J = 9.1, 7.9, 6.6 Hz, 1H), 2.27 (s, 
3H), 2.23–2.05 (m, 5H), 1.99–1.82 (m, 3H), 1.71–1.61 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 178.88, 
146.87, 138.26, 132.69, 126.03, 125.29, 117.37, 67.16, 58.57, 54.78, 40.52, 26.16, 23.61, 23.02, 20.80, 14.36. 
HRMS (TOF) m/z: 260.1628 (M+H+); calc. for [C16H21NO2+H+]: 260.1645. 
 
3-(1-(4-Methoxyphenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16l) 
 
Product 16l was synthesized using variant L7 (with a diastereomeric ratio of 1.4:1) 
and L9 (with a diastereomeric ratio of 4:1). The major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 6.86 (d, J = 9.1 Hz, 2H), 6.65 (d, J = 9.1 Hz, 2H), 4.35 (ddd, J = 8.7, 
7.1, 4.4 Hz, 2H), 4.17–4.07 (m, 1H), 3.76 (s, 3H), 3.53 (ddd, J = 8.9, 6.7, 5.6 Hz, 1H), 
3.32 (td, J = 9.9, 4.0 Hz, 1H), 3.19 (dt, J = 8.8, 7.4 Hz, 1H), 2.33–1.91 (m, 5H), 1.81–
1.70 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 178.33, 151.78, 141.48, 115.21, 114.20, 66.79, 
57.28, 55.99, 50.53, 41.28, 27.85, 24.44, 23.82. HRMS (TOF) m/z: 262.1421 (M+H+); calc. for 
[C15H19NO3+H+]: 262.1438. 
 
3-(1-Phenylazetidin-2-yl)dihydrofuran-2(3H)-one (16m) 
 
Product 16m was synthesized with a diastereomeric ratio of >20:1 using variant L10. 
1H NMR (400 MHz, CDCl3) δ 7.25–7.19 (m, 2H), 6.78 (tt, J = 7.4, 1.1 Hz, 1H), 6.57–
6.42 (m, 2H), 4.63 (ddd, J = 8.3, 7.0, 5.0 Hz, 1H), 4.45 (td, J = 9.0, 3.0 Hz, 1H), 4.29 
(td, J = 9.3, 7.2 Hz, 1H), 3.95 (ddd, J = 8.9, 7.1, 4.1 Hz, 1H), 3.67 (dt, J = 8.8, 7.3 Hz, 
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1H), 3.30 (td, J = 9.7, 5.1 Hz, 1H), 2.63–2.51 (m, 1H), 2.43–2.31 (m, 2H), 2.21 (ddt, J = 11.4, 8.8, 7.2 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 176.93, 151.30, 129.28, 118.40, 111.82, 67.28, 62.19, 50.18, 43.12, 23.63, 
18.92. HRMS (TOF) m/z: 218.1183 (M+H+); calc. for [C13H15NO2+H+]: 218.1176. 
 
3-(1-(3-Chloro-4-fluorophenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16n) 
 
Product 16n was synthesized with a diastereomeric ratio of 13:1 using variant L9. 
The major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.01 (t, J = 8.9 Hz, 1H), 6.63 
(dd, J = 6.1, 3.0 Hz, 1H), 6.48 (dt, J = 9.1, 3.4 Hz, 1H), 4.40–4.31 (m, 2H), 4.14 (td, J 
= 8.9, 7.9 Hz, 1H), 3.49 (ddd, J = 9.1, 7.1, 5.5 Hz, 1H), 3.28 (td, J = 9.9, 4.0 Hz, 1H), 
3.21 (dt, J = 9.1, 7.4 Hz, 1H), 2.30–2.18 (m, 1H), 2.13–1.97 (m, 4H), 1.83–1.73 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 177.80, 150.72 (d, J = 239.4 Hz), 143.81 (d, J = 2.0 Hz), 
121.48 (d, J = 18.4 Hz), 117.05 (d, J = 21.8 Hz), 114.02, 111.82 (d, J = 6.1 Hz), 66.69, 57.22, 50.19, 41.06, 
27.98, 24.36, 23.81. HRMS (TOF) m/z: 284.0839 (M+H+); calc. for [C14H15FClNO2+H+]: 284.0848. 
 
B.5 Analysis of biotransformations for strained carbocycle construction 
B.5.1 Enzymatic synthesis of spiro[2.4]lactones 
All enzymatic reactions for spiro[2.4]-lactone formation in analytical scale were conducted 
following the general procedure described below and analyzed with gas chromatography (GC). All 
TTNs for the different products were determined using the GC standard curve of the corresponding 
racemic standard product made with Rh2(OAc)4. 
All enzymatic reactions for spiro[2.4]-lactone formation in preparative scale were conducted 
following the general procedure described below and the corresponding spiro[2.4]-lactone products 
were isolated. Detailed conditions for preparative-scale reactions of different substrates are 
indicated separately. 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing P411-G8S 
variant (OD600 = 20‒30), olefin (0.25‒2.0 mmol), LAD (1.0 equiv.), D-glucose (10–15 mM, 250 mM 
stock in M9-N), 1–5 vol% EtOH, M9-N buffer (pH 7.4) under anaerobic conditions. The vial or flask 
was capped and shaken (420 rpm for vials and 250 rpm for flasks) at room temperature for 12 h. 
After the reaction was completed, 35 mL portions of preparative-scale reaction mixture were 
transferred to 50 mL centrifuge tubes. The reaction container was washed with water (2 mL × 2) 
followed by mixed organic solvent (hexane/ethyl acetate = 1:1, 2 mL × 3). The washing solution was 
combined with the reaction mixture in the centrifuge tubes. An additional 12 mL of hexane / ethyl 
acetate solvent was added to every tube. After the tube (with ~48 mL mixture in total) was capped, 
it was vortexed (1 min × 3) and shaken vigorously, and centrifuged (12,000 × g, 5 min). The organic 
layer was separated and the aqueous layer was subjected to three more rounds of extraction. The 
organic layers were combined, dried over Na2SO4 and concentrated under reduced pressure. 
Purification by silica column chromatography with hexane/ethyl acetate as eluent afforded the 
desired spiro[2.4]-lactones. TTNs were calculated based on measured protein concentration and 
isolated product yield. 
 
(1S, 2S)-1-Phenyl-5-oxaspiro[2.4]heptan-4-one (12a) 
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Analysis Data (10 mM 11a): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12a-(1) 6096.9 679.8 8.969 4.54 1.32 3445  
12a-(2) 5411.4 645.4 8.384 4.25 1.32 3230  
12a-(3) 5192.7 627.3 8.278 4.20 1.32 3191  
12a-(4) 5137.1 619.8 8.288 4.21 1.32 3194 3265 
12a-(5) 31945 3196 9.995 5.03 1.62 3103  
12a-(6) 29685 3210 9.248 4.67 1.62 2882  
12a-(7) 28300 3177 8.908 4.51 1.62 2781  
12a-(8) 28124 3037 9.260 4.68 1.62 2886 2913 
 
Chiralpak OJ-H, 20% i-PrOH in hexane, 1.0 mL/min, 24 °C, 235 nm 
 
 
rac-Z- and E-12a (1S, 2S)-12a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
15.315 (E) 33379.8 41.30 15.431 1901.6 98.60 
16.539 (E) 34416.7 42.58 16.713 16.7 0.86 
22.940 (Z) 6497.4 8.04 23.159 4.6 0.24 
24.044 (Z) 6536.8 8.08 24.299 5.8 0.30 
Total 80830.7 100.00 Total 1928.7 100.00 
 
(1S, 2S)-1-(4-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one (12b) 
Analysis Data (10 mM 11b): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12b-(1) 46399 2981 15.565 8.53 0.81 10524  
12b-(2) 48120 2993 16.078 8.78 0.81 10838  
12b-(3) 46572 3013 15.457 8.47 0.81 10457  
12b-(4) 46397 3128 14.833 8.16 0.81 10072 10473 
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Preparative-scale reaction: 
E. coli suspension expressing P411-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
28 32.0 2.618 0.0877 2.0 ~15 
olefin (11b) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
2.0 400 0.80 1.0 800 0.80 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
124.3 0.600 71% 6500 
Note: [PC] = protein concentration in original cell suspension, n_pro = amount of protein in the 
reaction, [Glu] = D-glucose concentration in reaction mixture, n_1 = amount of olefin in the reaction, 
n_2 = amount of LAD in the reaction, m[Pdt] = mass of product isolated, n[Pdt] = amount of 
product. The same for the following tables. 
 
Optical rotation: [α]23D = ‒ 159.9 ± 0.3° (c 0.6, ethyl acetate). 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-Z- and E-12b (1S, 2S)-12b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.219 (E) 1862.5 32.97 13.262 43.5 0.20 
14.333 (E) 1819.7 32.22 14.116 20914.3 99.80 
22.285 (Z) 836.6 14.81 - - - 
23.845 (Z) 1129.5 20.00 - - - 
Total 5648.3 100.00 Total 20957.8 100.00 
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Crystal structure information of 12b: 
 
Identification code       v18081 
Empirical formula       C13H14O3 
Formula weight        218.24 
Temperature         175 K 
Wavelength         1.54178 Å 
Crystal system        Orthorhombic 
Space group         P212121 
Unit cell dimensions      a = 6.2610(7) Å α = 90° 
          b = 7.4076(8) Å β = 90° 
          c = 24.242(2) Å γ = 90° 
Volume         1124.3(2) Å3 
Z          4 
Density (calculated)      1.289 g/cm3 
Absorption coefficient      0.744 mm-1 
F(000)         464 
Crystal size        0.26 x 0.21 x 0.15 mm3 
Theta range for data collection    3.646 to 80.268°. 
Index ranges        -7<=h<=7, -9<= k<= 9, -30<= l<= 30 
Reflections collected      28343 
Independent reflections 2423     [R(int) = 0.0298] 
Completeness to theta = 67.679°    100.0 %  
Absorption correction      Semi-empirical from equivalents 
Max. and min. transmission     1.0000 and 0.9262 
Refinement method      Full-matrix least-squares on F2 
Data / restraints / parameters    2423 / 0 / 147 
Goodness-of-fit on F2      1.092 
Final R indices [I>2sigma(I)]     R1 = 0.0261, wR2 = 0.0678 
R indices (all data)       R1 = 0.0261, wR2 = 0.0679 
Absolute structure parameter [Flack]   0.03(3) 
Absolute structure parameter [Hooft]   0.05(3) 
Extinction coefficient      0.0083(9) 
Largest diff. peak and hole     0.179 and -0.132 e.Å-3 
 
(1S, 2S)-1-(3-Methoxyphenyl)-5-oxaspiro[2.4]heptan-4-one (12c) 
Analysis Data (10 mM 11c): 
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Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12c-(1) 50973 3011 16.929 9.60 0.81 11854  
12c-(2) 50742 2986 16.993 9.64 0.81 11895  
12c-(3) 48424 3070 15.773 9.00 0.81 11112  
12c-(4) 41983 3068 13.684 7.90 0.81 9746 11152 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
27 85.0 3.218 0.2734 5 ~13 
olefin (11c) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
2.0 1000 2.0 1.0 2000 2.0 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
415.8 1.91 95% 6970 
 
Optical rotation: [α]23D = ‒ 138.0 ± 0.3° (c 0.8, ethyl acetate). 
Chiralpak OD-H, 12% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-Z- and E-12c (1S, 2S)-12c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.561 (E) 3572.1 26.00 14.370 18512.0 99.89 
15.510 (E) 3653.2 26.59 15.508 20.0 0.11 
32.441 (Z) 3295.4 23.99 - - - 
43.220 (Z) 3217.4 23.42 - - - 
Total 13738.1 100.00 Total 18532.0 100.00 
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(1S, 2S)-1-(4-Tolyl)-5-oxaspiro[2.4]heptan-4-one (12d) 
Analysis Data (10 mM 11d): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12d-(1) 37022 3016 12.275 6.83 1.62 4216  
12d-(2) 31892 3006 10.609 5.98 1.62 3693  
12d-(3) 39781 3192 12.463 6.93 1.62 4274  
12d-(4) 33482 3047 10.989 6.18 1.62 3814 3999 
 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-Z- and E-12d (1S, 2S)-12d 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
8.345 (E) 3711.6 33.33 8.380 17.6 0.20 
9.018 (E) 3734.9 33.54 8.994 8588.6 99.80 
11.533 (Z) 1812.1 16.27 - - - 
13.369 (Z) 1878.4 16.87 - - - 
Total 11137.0 100.00 Total 8606.2 100.00 
 
(1S, 2S)-1-(4-Chlorophenyl)-5-oxaspiro[2.4]heptan-4-one (12e) 
Analysis Data (10 mM 11e): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12e-(1) 36851 3058 12.051 6.73 1.62 4153  
12e-(2) 32339 3091 10.462 5.87 1.62 3623  
12e-(3) 29981 3095 9.687 5.45 1.62 3362  
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12e-(4) 30644 3032 10.107 5.68 1.62 3504 3660 
 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-Z- and E-12e (1S, 2S)-12e 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
11.666 (E) 13836.6 30.27 11.776 19.1 0.14 
12.234 (E) 15269.7 33.40 12.157 13271.6 99.86 
15.066 (Z) 7751.6 16.96 - - - 
15.918 (Z) 8858.9 19.38 - - - 
Total 45716.8 100.00 Total 13290.7 100.00 
 
(1S, 2S)-1-(4-Bromophenyl)-5-oxaspiro[2.4]heptan-4-one (12f) 
Analysis Data (10 mM 11f): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12f-(1) 27512 3015 9.125 5.20 1.62 3207  
12f-(2) 28599 3090 9.255 5.27 1.62 3251  
12f-(3) 28701 2984 9.618 5.47 1.62 3374  
12f-(4) 24259 2994 8.103 4.63 1.62 2860 3173 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
28 32.0 2.618 0.0877 2 ~15 
olefin (11f) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 250 0.25 1.0 250 0.25 
purification eluent Product 
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Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
42.4 0.159 64% 1810 
Optical rotation: [α]23D = ‒ 139.7 ± 0.5° (c 0.3, ethyl acetate). 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
 
rac-Z- and E-12f (1S, 2S)-12f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.069 (E) 5457.4 46.93 13.003 10229.1 100.00 
16.245 (Z) 3026.5 26.02 - - - 
17.461 (Z) 3145.8 27.05 - - - 
Total 11629.4 100.00 Total 10229.1 100.00 
Chiralpak OD-H, 10% i-PrOH in hexane, 1.2 mL/min, 40 °C, 235 nm 
 
rac-Z- and E-12f (1S, 2S)-12f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
12.126 (E) 4399.4 20.03 12.474 43.6 0.28 
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12.764 (E) 3765.8 17.14 12.822 15758.5 99.72 
13.229 (Z) 13800.5 62.83 - - - 
Total 21965.7 100.00 Total 15802.1 100.00 
 
Crystal structure information of 12f: 
 
Identification code       v18091 
Empirical formula       C12H11BrO2 
Formula weight        267.12 
Temperature         100 K 
Wavelength         0.71073 Å 
Crystal system        Orthorhombic 
Space group         P212121 
Unit cell dimensions      a = 6.3854(18) Å α = 90° 
          b = 6.702(2) Å β = 90° 
          c = 25.222(5) Å γ = 90° 
Volume         1079.4(5) Å3 
Z          4 
Density (calculated)      1.644 g/cm3 
Absorption coefficient      3.783 mm-1 
F(000)         536 
Crystal size        0.30 x 0.26 x 0.14 mm3 
Theta range for data collection    3.145 to 45.297°. 
Index ranges        -12<= h<= 10, -13<= k<= 13, -50<= l<= 50 
Reflections collected      65957 
Independent reflections 8908     [R(int) = 0.0351] 
Completeness to theta = 25.242°    99.9 %  
Absorption correction      Semi-empirical from equivalents 
Max. and min. transmission     1.0000 and 0.8289 
Refinement method      Full-matrix least-squares on F2 
Data / restraints / parameters    8908 / 0 / 137 
Goodness-of-fit on F2      1.025 
Final R indices [I>2sigma(I)]     R1 = 0.0210, wR2 = 0.0533 
R indices (all data)       R1 = 0.0262, wR2 = 0.0542 
Absolute structure parameter [Flack]   0.028(4) 
Absolute structure parameter [Hooft]   0.046(3) 
Extinction coefficient      n/a 
Largest diff. peak and hole     0.633 and -0.799 e.Å-3 
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(1S, 2S)-1-((4-(Trifluoromethyl)phenyl))-5-oxaspiro[2.4]heptan-4-one (12g) 
Analysis Data (10 mM 11g): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12g-(1) 12126 3113 3.895 2.60 1.62 1605  
12g-(2) 12245 2903 4.218 2.81 1.62 1734  
12g-(3) 10252 2928 3.501 2.35 1.62 1448  
12g-(4) 11080 2887 3.838 2.56 1.62 1583 1592 
 
Chiral HPLC trace: 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-Z- and E-12g (1S, 2S)-12g 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.229 (E) 9090.3 32.72 10.366 12.6 0.12 
10.716 (E) 10145.7 36.51 10.835 10408.0 99.53 
11.768 (Z) 4309.0 15.51 12.085 36.8 0.35 
12.954 (Z) 4240.2 15.26 - - - 
Total 27785.2 100.00 Total 10457.4 100.00 
 
(1S, 2S)-1-(2-Fluorophenyl)-5-oxaspiro[2.4]heptan-4-one (12h) 
Analysis Data (5 mM 11h): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12h-(1) 9723 3063 3.174 1.92 1.16 1651  
12h-(2) 9766 3134 3.116 1.89 1.16 1621  
12h-(3) 9697 3044 3.186 1.93 1.16 1657  
12h-(4) 9879 3059 3.229 1.96 1.16 1679 1652 
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Chiralpak OD-H, 10% i-PrOH in hexane, 1.2 mL/min, 40 °C, 235 nm 
 
rac-Z- and E-12h (1S, 2S)-12h 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.479 (E) 2041.9 29.79 9.410 2641.7 98.50 
10.035 (E) 2113.2 30.83 9.984 21.6 0.81 
11.311 (Z) 1328.8 19.38 11.324 18.6 0.69 
12.029 (Z) 1370.7 20.00 - - - 
Total 6854.6 100.00 Total 2681.9 100.00 
 
(1S, 2S)-1-(Naphthalen-2-yl)-5-oxaspiro[2.4]heptan-4-one (12i) 
Analysis Data (10 mM 11i): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12i-(1) 27834 3149 8.839 4.73 1.62 2916  
12i-(2) 28556 3193 8.943 4.78 1.62 2949  
12i-(3) 23350 3223 7.245 3.90 1.62 2410  
12i-(4) 25288 3386 7.468 4.02 1.62 2481 2613 
 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
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rac-Z and E-12i (1S, 2S)-12i 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.968 (E) 22742.3 41.91 11.072 114.4 0.44 
12.455 (E) 22947.4 42.28 12.503 25881.0 99.56 
19.082 (Z) 3991.7 7.36 - - - 
20.099 (Z) 4583.7 8.45 - - - 
Total 54265.1 100.00 Total 25995.4 100.00 
 
(‒)-(Z)-1-Phenethyl-5-oxaspiro[2.4]heptan-4-one (12j) 
Analysis Data (5 mM 11j): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
12j-(1) 11942 2840 4.205 2.14 1.16 1835  
12j-(2) 12393 3173 3.906 1.99 1.16 1707  
12j-(3) 12453 3189 3.905 1.99 1.16 1706  
12j-(4) 11944 3062 3.901 1.99 1.16 1704  
12j-(5) 12213 3030 4.031 2.05 1.16 1760 1743 
 
Preparative-scale reaction: 
E. coli suspension expressing P411-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
24 98 1.37 0.1343 5 ~12 
olefin (11j) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 250 0.25 1.0 250 0.25 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
35.8 0.166 66% 1230 
 
Optical rotation: [α]23D = ‒ 55.0 ± 0.6° (c 0.2, ethyl acetate). 
Chiralpak OD-H, 10% i-PrOH in hexane, 1.2 mL/min, 40 °C, 220 nm 
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rac-Z- and E-12j (‒)-Z-12j 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.125 (E) 1904.2 36.06 9.135 56.8 1.94 
10.072 (E) 1977.2 37.44 - - - 
12.654 (Z) 689.4 13.06 - - - 
13.362 (Z) 709.8 13.44 13.270 2868.3 98.06 
Total 5280.6 100.00 Total 2925.1 100.00 
 
B.5.2 Enzymatic synthesis of α-thio-γ-lactones 
All enzymatic reactions for α-thio-γ-lactone synthesis in analytical scale were conducted 
following the general procedure described below and analyzed with gas chromatography (GC). All 
TTNs for the different products were determined using the GC standard curve of the corresponding 
racemic standard products. 
All enzymatic reactions for α-thio-γ-lactone synthesis in preparative scale were conducted 
following the general procedure described below and the corresponding α-thio-γ-lactone products 
were isolated. Detailed conditions for preparative-scale reactions of different substrates are 
indicated separately. 
General procedure for preparative-scale reactions:  
To a 40 mL vial or 250 mL flask were added degassed suspension of E. coli expressing P450-
G8S variant (OD600 = 15‒20), thiol (1.5 equiv.), LAD (1.5 or 2.4 mmol.), D-glucose (10–15 mM, 250 
mM stock in M9-N), 1–5 vol% EtOH, M9-N buffer (pH 7.4) under anaerobic conditions. The flask 
was capped and shaken (250 rpm) at room temperature for 2 h. 
After the reaction was completed, 35 mL portions of preparative-scale reaction mixture were 
transferred to 50 mL centrifuge tubes. The reaction container was washed with water (2 mL × 2) 
followed by mixed organic solvent (hexane/ethyl acetate = 1:1, 2 mL × 3). The washing solution was 
combined with the reaction mixture in the centrifuge tubes. An additional 12 mL of hexane / ethyl 
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acetate solvent was added to every tube. After the tube (with ~48 mL mixture in total) was capped, 
it was vortexed (1 min × 3) and shaken vigorously, and centrifuged (12,000 × g, 5 min). The organic 
layer was separated and the aqueous layer was subjected to three more rounds of extraction. The 
organic layers were combined, dried over Na2SO4 and concentrated under reduced pressure. 
Purification by silica column chromatography with hexane/ethyl acetate as eluent afforded the 
desired α-thio-γ-lactones. Enantioselectivity was measured by chiral HPLC. TTNs were calculated 
based on measured protein concentration and isolated product yield. 
 
(R)-3-(Phenylthio)dihydrofuran-2(3H)-one (14a) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14a-(1) 25062 3496 7.169 6.54 4.21 1552  
14a-(2) 27038 3413 7.922 7.22 4.21 1715  
14a-(3) 28412 3453 8.228 7.50 4.21 1782  
14a-(4) 26034 3429 7.592 6.92 4.21 1644 1673 
14a-(5) 24779 3388 7.314 6.67 4.28 1558  
14a-(6) 23497 3388 6.935 6.32 4.28 1478  
14a-(7) 24733 3275 7.552 6.89 4.28 1609  
14a-(8) 24427 3373 7.242 6.60 4.28 1543 1547 
 
Chiralpak OJ-H, 24% i-PrOH in hexane, 1.2 mL/min, 24 °C, 235 nm 
 
rac-14a R-14a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.778 3476.6 49.99 17.759 546.8 8.08 
21.927 3477.0 50.01 21.779 6223.7 91.92 
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Total 6953.6 100.00 Total 6770.5 100.00 
 
(R)-3-((3-Methoxyphenyl)thio)dihydrofuran-2(3H)-one (14b) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14b-(1) 33529 3364 9.967 7.91 4.28 1849  
14b-(2) 33478 3418 9.795 7.78 4.28 1818  
14b-(3) 32920 3379 9.743 7.74 4.28 1809  
14b-(4) 33936 3458 9.814 7.79 4.28 1822 1824 
 
Chiralpak OD-H, 12% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-14b R-14b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
20.566 7657.0 47.61 20.687 22518.9 94.44 
21.435 8426.2 52.39 21.669 1325.7 5.56 
Total 16083.2 100.00 Total 23844.6 100.00 
 
(R)-3-((4-Fluorophenyl)thio)dihydrofuran-2(3H)-one (14c) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14c-(1) 44068 5404 8.155 8.09 4.43 1826  
14c-(2) 42946 5518 7.782 7.73 4.43 1745  
14c-(3) 42540 5443 7.816 7.76 4.43 1752  
14c-(4) 42676 5503 7.755 7.70 4.43 1739 1765 
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Chiralpak OD-H, 10% i-PrOH in hexane, 1.2 mL/min, 40 °C, 235 nm 
 
rac-14c R-14c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.082 4962.6 50.35 14.008 3532.1 93.21 
15.822 4892.7 49.65 15.769 257.2 6.79 
Total 9855.3 100.00 Total 3789.3 100.00 
 
(R)-3-((4-Chlorophenyl)thio)dihydrofuran-2(3H)-one (14d) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14d-(1) 35908 3306 10.861 8.18 4.28 1913  
14d-(2) 37309 3237 11.526 8.65 4.28 2023  
14d-(3) 37284 3289 11.336 8.52 4.28 1991  
14d-(4) 36890 3390 10.882 8.20 4.28 1916 1961 
 
Preparative-scale reaction: 
E. coli suspension expressing P450-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
20 150 4.506 0.8757 10 ~15 
thiol (13d) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
2.0 1800 3.60 1.0 2400 2.40 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
438.3 1.92 80% 2190 
 
Optical rotation: [α]23D = ‒ 45.6 ± 0.2° (c 0.8, ethyl acetate). 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
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rac-14d R-14d 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
16.171 1834.6 49.77 16.222 338.2 6.98 
17.370 1850.1 50.23 17.320 4510.2 93.02 
Total 3684.7 100.00 Total 4848.4 100.00 
R-14d_scale-up 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.149 496.7 6.11 
18.332 7628.2 93.89 
Total 8124.9 100.00 
 
(R)-3-((4-Bromophenyl)thio)dihydrofuran-2(3H)-one (14e) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14e-(1) 36496 3382 10.791 7.98 4.28 1866  
14e-(2) 34803 3354 10.377 7.70 4.28 1799  
14e-(3) 34274 3318 10.330 7.67 4.28 1792  
14e-(4) 35519 3357 10.581 7.84 4.28 1832 1822 
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Preparative-scale reaction: 
E. coli suspension expressing P450-G8S in M9-N D-glucose in M9-N 
OD600 volume/mL [PC]/μM n_pro/μmol volume/mL [Glu]/mM 
15 160 3.320 0.7149 10 ~15 
thiol (13e) stock in EtOH LAD stock in EtOH 
stock/M volume/μL n_1/mmol stock/M volume/μL n_2/mmol 
1.0 2250 2.25 1.0 1500 1.50 
purification eluent Product 
Ethyl acetate in hexanes 
(0% to 25% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
386.5 1.42 94% 1980 
 
Optical rotation: [α]23D = ‒ 41.7 ± 0.2° (c 0.8, ethyl acetate). 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
 
rac-14e R-14e 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.405 2136.7 50.02 17.530 560.1 8.24 
19.056 2133.6 49.98 19.039 6235.9 91.76 
Total 4270.3 100.00 Total 6796.6 100.00 
R-14e_scale-up 
Retention Time 
(min) 
Area (mAU*s) Area % 
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16.934 661.0 6.86 
18.412 8979.1 93.14 
Total 9640.1 100.00 
 
Crystal structure information of 14e: 
 
Identification code       V18160 
Empirical formula       C10H9BrO2S 
Formula weight        273.14 
Temperature         100(2) K 
Wavelength         0.71073 Å 
Crystal system        Monoclinic 
Space group         P21 
Unit cell dimensions      a = 5.7304(6) Å α = 90°. 
          b = 8.3275(7) Å β = 92.034(3)°. 
          c = 10.4712(8) Å γ = 90°. 
Volume         499.37(8) Å3 
Z          2 
Density (calculated)      1.817 Mg/m3 
Absorption coefficient      4.292 mm-1 
F(000)         272 
Crystal size        0.250 x 0.150 x 0.150 mm3 
Theta range for data collection    3.126 to 36.330°. 
Index ranges        -9<=h<=9, -13<=k<=13, -17<=l<=17 
Reflections collected      13036 
Independent reflections 4669     [R(int) = 0.0244] 
Completeness to theta = 25.242°    99.6 %  
Absorption correction      Semi-empirical from equivalents 
Max. and min. transmission     0.7471 and 0.6420 
Refinement method      Full-matrix least-squares on F2 
Data / restraints / parameters    4669 / 1 / 127 
Goodness-of-fit on F2      0.859 
Final R indices [I>2sigma(I)]     R1 = 0.0163, wR2 = 0.0408 
R indices (all data)       R1 = 0.0175, wR2 = 0.0412 
Absolute structure parameter    0.030(4) 
Extinction coefficient      n/a 
Largest diff. peak and hole     0.388 and -0.336 e.Å-3 
 
(R)-3-((4-Tolyl)thio)dihydrofuran-2(3H)-one (14f) 
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Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14f-(1) 23458 3376 6.948 4.61 4.28 1077  
14f-(2) 22953 3235 7.095 4.70 4.28 1099  
14f-(3) 23421 3341 7.010 4.65 4.28 1086  
14f-(4) 23731 3351 7.082 4.69 4.28 1097 1089 
 
Chiralpak OJ-H, 24% i-PrOH in hexane, 1.2 mL/min, 28 °C, 220 nm 
 
rac-14f R-14f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
16.373 1840.0 49.97 16.306 2647.7 12.44 
17.622 1842.5 50.03 17.412 18639.0 87.56 
Total 3682.5 100.00 Total 21286.7 100.00 
 
(R)-3-((4-Isopropylphenyl)thio)dihydrofuran-2(3H)-one (14g) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14g-(1) 9404 3133 3.002 1.80 4.28 422  
14g-(2) 9015 2968 3.037 1.83 4.28 427  
14g-(3) 9040 3255 2.777 1.67 4.28 391  
14g-(4) 9319 2983 3.124 1.88 4.28 439 420 
 
Chiralpak OD-H, 10% i-PrOH in hexane, 1.2 mL/min, 40 °C, 235 nm 
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rac-14g R-14g 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.760 7857.7 50.00 10.072 1790.6 27.36 
10.398 7857.3 50.00 10.687 4754.7 72.64 
Total 15715.0 100.00 Total 6545.3 100.00 
 
(R)-3-((4-Trifluoromethylphenyl)thio)dihydrofuran-2(3H)-one (14h) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14h-(1) 1062 678.8 1.565 1.32 4.81 275  
14h-(2) 1124.1 681.5 1.649 1.39 4.81 290  
14h-(3) 1211.8 678.9 1.785 1.51 4.81 314  
14h-(4) 1236.2 674.1 1.834 1.55 4.81 322 300 
 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-14h R-14h 
Retention Time Area (mAU*s) Area % Retention Time Area (mAU*s) Area % 
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(min) (min) 
15.352 11827.4 50.11 15.469 436.1 20.03 
18.400 11774.0 49.89 18.514 1741.5 79.97 
Total 23601.4 100.00 Total 2177.6 100.00 
 
(R)-3-((3,4-Dimethoxyphenyl)thio)dihydrofuran-2(3H)-one (14i) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14i-(1) 9814 3203 3.064 2.64 4.28 617  
14i-(2) 9941 4040 2.461 2.13 4.28 499  
14i-(3) 10085 4349 2.319 2.01 4.28 471  
14i-(4) 10000 3671 2.724 2.36 4.28 551 534 
 
Chiralpak OD-H, 12% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
Area% report for rac- and R-14i:  
rac-14i R-14i 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
28.834 15965.9 50.10 29.384 4271.0 92.17 
36.512 15901.9 49.90 37.577 362.7 7.82 
Total 31867.8 100.00 Total 4633.7 100.00 
 
(R)-3-(Naphthalen-2-ylthio)dihydrofuran-2 (3H)-one (14j) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
14j-(1) 6820 3552 1.920 1.17 4.28 273  
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14j-(2) 6843 3267 2.095 1.27 4.28 298  
14j-(3) 8152 3195 2.551 1.55 4.28 361  
14j-(4) 7779 3394 2.292 1.39 4.28 325 328 
 
Chiralpak IA, 8% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
rac-14j R-14j 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
20.286 7644.6 49.75 20.338 1139.1 14.33 
21.838 7721.4 50.25 21.847 6810.3 85.67 
Total 15366.0 100.00 Total 7949.4 100.00 
 
B.5.3 Enzymatic synthesis of α-alkyl-γ-lactones 
All enzymatic reactions for lactone-carbene C–H insertion in analytical scale were conducted 
following the general procedure described below and analyzed with HPLC. All TTNs for different 
products were determined using the HPLC standard curves of the corresponding products obtained 
from the preparative-scale enzymatic reactions. 
 
3-((Methyl(p-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16a) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16a-L6_a 6946.0 1177.9 5.8969 9.6049 3.57 2694  
16a-L6_b 7124.5 1181.0 6.0326 9.8259 3.57 2756  
16a-L6_c 7387.5 1191.3 6.2012 10.1005 3.57 2833 2761 
 
L7 
OD600 = 30 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16a-L7_a 8503.9 1178.9 7.2134 11.7492 4.10 2865  
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16a-L7_b 8814.0 1180.6 7.4657 12.1601 4.10 2965  
16a-L7_c 8693.1 1201.0 7.2382 11.7896 4.10 2875  
16a-L7_d 8801.1 1170.2 7.5210 12.2502 4.10 2987 2923 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16a-L9_a 5770.5 1207.4 4.7793 7.7845 5.18 1502  
16a-L9_b 5860.1 1146.8 5.1100 8.3231 5.18 1606  
16a-L9_c 5807.0 1173.3 4.9493 8.0614 5.18 1556 1555 
 
L10 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16a-L10_a 757.5 1282.2 0.5908 0.9623 2.71 355  
16a-L10_b 781.0 1303.6 0.5991 0.9758 2.71 360  
16a-L10_c 767.1 1260.3 0.6087 0.9914 2.71 366 361 
 
Chiralpak OD-H, 6% IPA in hexane, 1.0 ml/min, 32 °C, 254nm 
 
 
 
L4: 41% ee 
L6: 63% ee 
L7: 74.5% ee 
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16a by variant L4 16a by variant L6 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
18.05 8004.1 70.69 17.77 54379 81.57 
18.95 3319.3 29.31 18.79 12286.3 18.43 
Total 11323.4 100.00 Total 66665.3 100.00 
16a by variant L7 16a by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
17.77 62599.4 87.23 17.95 26916.5 95.29 
18.86 9165.0 12.77 19.00 1329.6 4.71 
Total 71764.4 100.00 Total 28246.1 100.00 
16a by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
18.13 884.7 15.92 
18.93 4672.1 84.08 
Total 5556.8 100.00 
 
3-(((4-Methoxyphenyl)(methyl)amino)methyl)dihydrofuran-2(3H)-one (16b) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16b-L6_a 7269.6 1175.4 6.1848 7.2473 3.57 2032  
16b-L6_b 7306.7 1168.5 6.2531 7.3273 3.57 2055  
16b-L6_c 7300.7 1173.5 6.2213 7.2901 3.57 2044 2044 
 
L9: 90.5% ee 
L10: ‒68% ee 
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L7 
OD600 = 30 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16b-L7_a 8352.8 1184.0 7.0547 8.2667 4.40 1878  
16b-L7_b 8083.9 1180.5 6.8479 8.0243 4.40 1823  
16b-L7_c 8109.2 1200.5 6.7549 7.9153 4.40 1798 1833 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16b-L9_a 5711.2 1165.9 4.8985 5.7401 5.18 1108  
16b-L9_b 6011.9 1184.9 5.0738 5.9454 5.18 1147  
16b-L9_c 6498.1 1203.1 5.4011 6.3290 5.18 1221 1159 
 
Chiralpak OD-H, 6% IPA in hexane, 1.0 ml/min, 32 °C, 254nm 
 
 
 
L6: 61% ee 
L7: 70% ee 
L9: 90% ee 
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16b by variant L6 16b by variant L7 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
38.58 7786.8 19.37 38.44 8465.6 15.10 
40.60 32411.2 80.63 40.31 47615.7 84.90 
Total 40198.0 100.00 Total 56081.3 100.00 
16b by variant L9 16b by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
38.95 1328.3 5.02 37.73 2168.9 91.48 
40.76 25138.5 94.98 40.47 202.0 8.52 
Total 26466.8 100.00 Total 2370.9 100.00 
 
3-(((4-Chlorophenyl)(methyl)amino)methyl)dihydrofuran-2(3H)-one (16c) 
Analysis Data: 
L7 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16c-L7_a 2074.3 1354.6 1.5313 3.6794 8.80 418  
16c-L7_b 2092.0 1363.4 1.5344 3.6869 8.80 419  
16c-L7_c 2131.2 1366.2 1.5599 3.7482 8.80 426 421 
 
Chiralpak IA, 3% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
L10: ‒83% ee 
L7: 76.5% ee 
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16c by variant L7 16c by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
19.10 43991.8 88.25 19.76 91.1 18.68 
20.47 5858.8 11.75 21.04 396.5 81.32 
Total 49850.6 100.00 Total 487.6 100.00 
 
3-((Methyl(m-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16d) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16d-L6_a 2184.8 1198.0 1.8237 4.5611 3.57 1279  
16d-L6_b 2292.9 1197.8 1.9143 4.7876 3.57 1343  
16d-L6_c 2234.6 1204.8 1.8547 4.6387 3.57 1301 1308 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16d-L9_a 3309.9 1166.7 2.8370 7.0953 5.18 1369  
16d-L9_b 3557.4 1191.0 2.9869 7.4702 5.18 1442  
16d-L9_c 3516.9 1195.6 2.9415 7.3568 5.18 1420 1410 
 
L10 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16d-L10_a 975.1 1273.6 0.7656 1.9148 2.71 707  
16d-L10_b 992.8 1264.3 0.7853 1.9639 2.71 725  
16d-L10_c 979.1 1252.8 0.7815 1.9546 2.71 722 718 
 
Chiralpak OD-H, 6% IPA in hexane, 1.0 ml/min, 32 °C, 254nm 
 
L10: ‒62.5% ee 
L6: ‒12% ee 
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16d by variant L6 16d by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
22.20 3686.3 43.97 22.12 7172.2 92.11 
23.15 4697.4 56.03 23.20 614.7 7.89 
Total 8383.7 100.00 Total 7786.9 100.00 
16d by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
21.86 1559.3 22.75 
22.71 5296.2 77.25 
Total 6855.5 100.00 
 
3-((Methyl(phenyl)amino)methyl)dihydrofuran-2(3H)-one (16e) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16e-L6_a 2614.2 2092.9 1.2491 2.2205 3.57 623  
16e-L6_b 2254.9 2094.7 1.0765 1.9137 3.57 537  
16e-L6_c 2440.0 2083.2 1.1713 2.0822 3.57 584 581 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16e-L9_a 2284.6 2141.1 1.0670 1.8968 5.18 366  
16e-L9_b 2652.9 2066.7 1.2836 2.2819 5.18 440  
16e-L9_c 2555.8 2037.2 1.2546 2.2302 5.18 430 412 
 
L9: 84% ee 
L10: ‒54.5% ee 
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L10 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16e-L10_a 5067.8 2157.2 2.3492 4.1763 2.71 1542  
16e-L10_b 5809.1 2190.8 2.6516 4.7137 2.71 1741  
16e-L10_c 5639.4 2190.4 2.5746 4.5769 2.71 1690 1658 
 
Chiralpak OD-H, 6% IPA in hexane, 1.0 ml/min, 32 °C, 254nm 
 
 
  
16e by variant L6 16e by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
31.66 1550.3 59.10 31.63 662.6 12.68 
35.61 1072.7 40.90 35.32 4562.6 87.32 
Total 2623.0 100.00 Total 5225.2 100.00 
16e by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
31.27 13177.7 93.25 
35.57 953.5 6.75 
Total 14131.2 100.00 
 
L6: 18% ee 
L9: 75% ee 
L10: ‒86.5% ee 
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3-((Methyl(o-tolyl)amino)methyl)dihydrofuran-2(3H)-one (16f) 
Analysis Data: 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16f-L7_a 4037.9 1292.2 3.1248 7.4890 5.18 1445  
16f-L7_b 4090.4 1278.3 3.1999 7.6688 5.18 1480  
16f-L7_c 4210.4 1286.0 3.2740 7.8465 5.18 1514 1480 
 
Chiralpak IC, 6% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
  
16f by variant L9 16f by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
23.41 8512.3 87.21 23.61 82.1 61.64 
24.38 1248.3 12.79 24.49 51.1 38.36 
Total 9760.6 100.00 Total 133.2 100.00 
Note: Variant L10 is not able to give good activity or reverse the enantioselectivity (compared to that 
with L9) when using substrates bearing an ortho-substituent on the phenyl ring (e.g., substrates 15f 
and 15k). 
 
3-((Ethyl(pheny)amino)methyl)dihydrofuran-2(3H)-one (16g) 
3-(1-(Methyl(phenyl)amino)ethyl)dihydrofuran-2(3H)-one (16g’) 
Analysis Data: 
L6 
OD600 = 60 
Pdt-16g Pdt-16g’ Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16g/g’-L6_a 2871.8 77.7 1247.7 2.3639 4.2603 3.57 1195  
16g/g’-L6_b 2911.5 79.1 1241.2 2.4094 4.3423 3.57 1218  
16g/g’-L6_c 2889.4 80.9 1253.4 2.3698 4.2708 3.57 1198 1203 
L7: 74.5% ee 
L10: 23% ee 
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L9 
OD600 = 60 
Pdt-16g Pdt-16g’ Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16g/g’-L9_a 6070.1 84.9 1250.8 4.9209 8.8684 5.18 1711  
16g/g’-L9_b 6498.3 84.5 1292.6 5.0927 9.1780 5.18 1771  
16g/g’-L9_c 6185.2 85.3 1323.9 4.7364 8.5359 5.18 1647 1710 
 
L10 
OD600 = 60 
Pdt-16g Pdt-16g’ Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
16g/g’-L10_a 1606.2 672.3 1414.3 1.6110 2.9034 2.71 1072  
16g/g’-L10_b 1701.5 712.6 1404.6 1.7187 3.0975 2.71 1144  
16g/g’-L10_c 1698.3 712.0 1395.3 1.7274 3.1132 2.71 1150 1122 
 
Chiralpak IC, 8% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
 
 
 
L9: purified pdt 
16g/16g’ > 98:2 
16g, 95% ee 
L10: purified pdt 
(16g and 16g’ together) 
L10: purified pdt  
16g only, ‒62% ee 
L6: 2g/2g’ > 98:2 
16g, 53% ee 
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16g by variant L6 16g by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
18.99 8049.1 76.35 19.08 42425.3 97.52 
20.19 2492.9 23.65 20.32 1077.1 2.48 
Total 10542.0 100.00 Total 43502.4 100.00 
16g by variant L10 16g’ by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
18.82 8522.1 18.98 21.13 3816.1 98.76 
19.94 36384.8 81.02 24.36 47.9 1.24 
Total 44906.9 100.00 Total 3864 100.00 
Note: The ee of 16g’ with variants L6 and L9 here cannot be accurately determined due to the peak 
overlap between one enantiomer of 2g and one enantiomer of 16g’ (which is also very obvious in 
the situation of L10). Silica chromatography partially separated 16g and 16g’, which allowed the ee 
determination of 2g and 2g’ with L10. Additionally, the confirmed side product 16g’’ had no effect 
on the ee determination of 16g and 16g’ due to a very different retention time on chiral HPLC. 
 
3-(1-(Ethyl(phenyl)amino)ethyl)dihydrofuran-2(3H)-one (16h) 
Analysis Data: 
L6 
OD600 = 60 
Pdt-
16h1 
Pdt-16h2 Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16h-L6_a 3483.2 984.7 2133.1 2.0946 2.0740 3.57 582  
16h-L6_b 3664.9 1031.0 2107.2 2.2285 2.2067 3.57 619  
16h-L6_c 3645.1 1021.7 2127.3 2.1938 2.1723 3.57 609 603 
 
L9 
OD600 = 60 
Pdt-
16h1 
Pdt-16h2 Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16h-L9_a 8696.2 583.0 2114.0 4.3894 4.3464 5.18 839  
16h-L9_b 8734.5 572.4 2112.3 4.4061 4.3629 5.18 842  
16h-L9_c 9017.8 591.4 2112.6 4.5485 4.5039 5.18 869 850 
 
L10 
OD600 = 60 
Pdt-16h1 
Pdt-
16h2 
Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
16h-L10_a 4435.5 56.4 2218.1 2.0251 2.0053 2.71 740  
16h-L10_b 4492.9 59.2 2209.8 2.0600 2.0398 2.71 753  
L10: purified pdt 
16g’ only, 97.5% ee 
single diastereomer 
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16h-L10_c 4288.2 56.5 2211.3 1.9648 1.9455 2.71 718 737 
 
Chiralpak IC, 4.5% IPA in hexane, 1.1 ml/min, 28 °C, 254nm 
 
 
 
 
  
16h1 by variant L6 16h2 by variant L6 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
26.68 1489.5 29.50 25.68 492.8 35.27 
32.24 3560.2 70.50 27.78 904.3 64.73 
Total 5049.7 100.00 Total 1397.1 100.00 
Purified diastereomer 16h1 
L6: 78:22 d.r. 
41% ee and ‒30% ee 
L9: 94:6 d.r. 
81% ee and ‒15% ee 
Two sets of 
diastereomers 
L10: 99:1 d.r. 
‒94.5% ee and ‒19% ee 
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16h1 by variant L9 16h2 by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
26.71 1132.8 9.58 25.71 321.9 43.27 
32.20 10688.7 90.42 27.83 423.1 56.73 
Total 11821.5 100.00 Total 744.0 100.00 
16h1 by variant L10 16h2 by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
26.55 21781.6 97.20 25.68 112.2 40.62 
32.27 626.5 2.80 27.77 164.0 59.38 
Total 22408.1 100.00 Total 276.2 100.00 
 
3-(1-Phenylpyrrolidin-2-yl)dihydrofuran-2(3H)-one (16i) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16i-L6_a 5487.8 1314.6 4.1745 9.1104 3.57 2555  
16i-L6_b 5440.1 1301.8 4.1789 9.1200 3.57 2558  
16i-L6_c 5450.8 1308.0 4.1673 9.0947 3.57 2550 2554 
 
L7 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16i-L7_a 6040.7 1293.6 4.6697 10.1911 8.80 1157  
16i-L7_b 6051.7 1295.3 4.6720 10.1963 8.80 1158  
16i-L7_c 6017.4 1281.8 4.6945 10.2453 8.80 1164 1160 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16i-L9_a 4648.3 1371.8 3.3885 7.3950 5.27 1404  
16i-L9_b 4805.3 1370.5 3.5062 7.6520 5.27 1453  
16i-L9_c 4844.6 1402.7 3.4538 7.5375 5.27 1431 1429 
 
L10 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16i-L10_a 2388.6 1356.8 1.7605 3.8420 2.71 1419  
16i-L10_b 2507.7 1307.3 1.9182 4.1863 2.71 1546  
16i-L10_c 2576.4 1373.3 1.8761 4.0943 2.71 1512 1492 
 
Chiralpak IC, 6% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
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16i1 by variant L6 16i2 by variant L6 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
25.68 923.2 2.68 32.59 11960.9 38.18 
29.20 33575.7 97.32 33.44 19366.3 61.82 
Total 34498.9 100.00 Total 31327.2 100.00 
16i1 by variant L7 16i2 by variant L7 
Retention Time Area (mAU*s) Area % Retention Time Area (mAU*s) Area % 
L7: 58:42 d.r. 
94.5% ee and ‒49.5% ee 
L9: 88:12 d.r. 
86.5% ee and ‒72.5% ee 
L10: 96:4 d.r. 
‒72% ee and ‒30% ee 
L6: 52:48 d.r. 
94.5% ee and ‒24% ee 
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(min) (min) 
25.64 1909.7 2.82 32.54 12292.9 25.19 
29.07 65791.6 97.18 33.31 36513.8 74.81 
Total 67701.3 100.00 Total 48806.7 100.00 
16i1 by variant L9 16i2 by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
25.71 2948.2 6.80 33.01 827.6 13.79 
29.22 40408.6 93.20 33.59 5175.1 86.21 
Total 43356.8 100.00 Total 6002.7 100.00 
16i1 by variant L10 16i2 by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
25.59 30279.5 85.99 32.72 483.0 34.87 
29.30 4934.2 14.01 33.60 902.0 65.13 
Total 35213.7 100.00 Total 1385.0 100.00 
 
3-(1-(3-Chlorophenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16j) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16j-L6_a 3072.0 1337.8 2.2963 3.4116 3.45 990  
16j-L6_b 2853.6 1324.3 2.1548 3.2014 3.45 929  
16i-L6_c 2911.2 1312.4 2.2182 3.2956 3.45 957 959 
 
L7 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16j-L7_a 4395.6 1188.0 3.7000 5.4971 8.80 624  
16j-L7_b 3527.1 1067.0 3.3056 4.9112 8.80 558  
16j-L7_c 5181.6 1248.0 4.1519 6.1685 8.80 701 628 
 
L8 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16j-L8_a 4296.0 1189.8 3.6107 5.3644 6.43 834  
16j-L8_b 4214.8 1189.6 3.5430 5.2639 6.43 819  
16j-L8_c 4289.5 1180.8 3.6327 5.3971 6.43 839  
16j-L8_d 4790.6 1193.6 4.0136 5.9630 6.43 927 855 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16j-L9_a 5079.1 1171.5 4.3356 6.4413 5.19 1241  
16j-L9_b 6388.1 1177.2 5.4265 8.0622 5.19 1554  
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16j-L9_c 5941.2 1160.0 5.1217 7.6093 5.19 1466  
16j-L9_d 6305.6 1154.1 5.4637 8.1173 5.19 1564 1456 
 
Chiralpak IA, 3% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
 
 
 
L8: 41:59 d.r. 
96% ee and 7% ee 
L9: 88:12 d.r. 
91% ee and 14% ee 
L6: 34:66 d.r. 
95% ee and ‒27% ee 
L7: 44:56 d.r. 
96% ee and ‒11% ee 
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16j1 by variant L6 16j2 by variant L6 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.47 6729.2 97.62 15.17 4921.9 36.32 
14.48 164.1 2.38 16.46 8630.9 63.68 
Total 6893.3 100.00 Total 13552.8 100.00 
16j1 by variant L7 16j2 by variant L7 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.37 12711.4 97.88 15.10 7466.2 44.66 
14.44 275.8 2.12 16.39 9253.5 55.34 
Total 12987.2 100.00 Total 16719.7 100.00 
16j1 by variant L8 16j2 by variant L8 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.36 11618.9 98.11 15.06 8995.1 53.37 
14.41 224.4 1.89 16.38 7857.6 46.63 
Total 11843.3 100.00 Total 16852.7 100.00 
16j1 by variant L9 16j2 by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.32 26734.2 95.44 15.21 2229.5 57.13 
14.44 1277.3 4.56 16.49 1673.2 42.87 
Total 28011.5 100.00 Total 3902.7 100.00 
16j1 by variant L10 16j2 by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
13.74 1563.6 41.66 15.52 168.3 23.88 
14.65 2189.9 58.34 16.77 536.6 76.12 
Total 3753.5 100.00 Total 704.9 100.00 
 
3-(1-(2,3-Dimethylphenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16k) 
Analysis Data: 
L7 
OD600 = 30 
Pdt-
16k1 
Pdt-16k2 Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16k-L7_a 6348.1 1742.6 1185.9 6.8224 10.3360 4.40 2348  
L10: 84:16 d.r. 
‒17% ee and ‒52% ee 
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16k-L7_b 6633.2 1820.7 1210.0 6.9867 10.5848 4.40 2404  
16k-L7_c 6673.6 1839.2 1197.0 7.1118 10.7743 4.40 2447 2400 
 
L8 
OD600 = 30 
Pdt-
16k1 
Pdt-16k2 Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16k-L8_a 5871.2 1294.8 1138.0 6.2970 9.5400 3.51 2716  
16k-L8_b 5708.7 1247.3 1152.8 6.0340 9.1415 3.51 2602  
16k-L8_c 5912.4 1280.9 1132.5 6.3517 9.6228 3.51 2739  
16k-L8_d 6284.3 1359.8 1149.4 6.6505 10.0755 3.51 2868 2731 
 
L9 
OD600 = 30 
Pdt-
16k1 
Pdt-16k2 Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16k-L9_a 5705.5 3229.5 1257.1 7.1076 10.7681 2.63 4089  
16k-L9_b 5650.4 3192.2 1286.2 6.8750 10.4156 2.63 3955  
16k-L9_c 5418.3 3073.9 1233.8 6.8830 10.4277 2.63 3959 4001 
 
Chiralpak OD-H, 4% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
 
 
Purified diastereomer 16k2 
(with small amount of 16k1) 
L7: 22:78 d.r. 
96.5% ee and 86% ee 
Purified diastereomer 16k1 
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16k1 by variant L7 16k2 by variant L7 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
27.33 204.2 1.77 35.08 37486.7 93.03 
30.45 11312.8 98.23 37.14 2808.9 6.97 
Total 11517.0 100.00 Total 40295.6 100.00 
16k1 by variant L8 16k2 by variant L8 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
27.39 94.3 1.74 35.36 23095.7 95.40 
30.59 5327.5 98.26 37.25 1114.4 4.60 
Total 5421.8 100.00 Total 24210.1 100.00 
16k1 by variant L9 16k2 by variant L9 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
27.27 95.7 0.62 35.31 23381.7 92.52 
30.39 15259.3 99.38 37.21 1889.3 7.48 
Total 15355.0 100.00 Total 25271.0 100.00 
16k1 by variant L10 16k2 by variant L10 
L8: 18:82 d.r. 
96.5% ee and 91% ee 
L9: 38:62 d.r. 
99% ee and  
85% ee 
L10: 48:52 d.r. 
56% ee and  
56% ee 
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Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
27.39 32.2 22.04 36.27 124.1 78.00 
31.23 113.9 77.96 37.84 35.0 22.00 
Total 146.1 100.00 Total 159.1 100.00 
 
3-(1-(4-Methoxyphenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16l) 
Analysis Data: 
L6 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16l-L6_a 2160.9 1152.1 1.8756 3.1685 3.35 947  
16l-L6_b 2200.0 1141.9 1.9266 3.2546 3.35 973  
16l-L6_c 2174.0 1179.3 1.8435 3.1142 3.35 931  
16l-L6_d 2197.9 1142.6 1.9236 3.2495 3.35 971 955 
 
L7 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16l-L7_a 6904.9 1125.9 6.1328 10.3601 8.20 1263  
16l-L7_b 7614.6 1117.4 6.8146 11.5119 8.20 1403  
16l-L7_c 6405.5 1118.7 5.7258 9.6727 8.20 1179  
16l-L7_d 6480.6 1116.2 5.8059 9.8080 8.20 1196 1260 
 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16l-L9_a 657.9 1213.1 0.5423 0.9162 4.55 201  
16l-L9_b 658 1179.6 0.5578 0.9423 4.55 207  
16l-L9_c 667.2 1189.6 0.5609 0.9475 4.55 208  
16l-L9_d 679.7 1170.3 0.5808 0.9811 4.55 216 208 
 
Chiral HPLC trace: 
Chiralpak IC, 25% IPA in hexane, 1.2 ml/min, 28 °C, 254nm 
Chiralpak IB, 12% IPA in hexane, 1.2 ml/min, 28 °C, 254nm 
(Note: The four stereo-isomers of product 16l could not be fully separated by chiral HPLC columns. 
We thus used two different columns to have three sets of peaks each, as labelled in the HPLC traces, 
and then calculated the enantiomeric excess according to the peak ratios). 
 
L6 (IC column) 
16l1-1 + 16l2-1 
16l1-2 
16l2-2 
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16l peak-1 peak-2 peak-3 sum 
L6-IC 1574.8 3964.1 2434.1 7973 
 19.75% 49.72% 30.53% 100.00% 
L6-IB 6120.8 2575.1 150.3 8846.2 
 69.19% 29.11% 1.70% 100.00% 
 16l1-1 16l1-2 16l2-1 16l2-2 
 1.70% 50.43% 18.05% 29.82% 
52:48 d.r. 
16l1  16l2  
93% ee  ‒26% ee  
 
 
 
16l peak-1 peak-2 peak-3 sum 
L7-IC 4822.1 25378.6 14162 44362.7 
 10.87% 57.21% 31.92% 100.00% 
L7-IB 32610.9 15769.6 317.4 48697.9 
 66.97% 32.38% 0.65% 100.00% 
 16l1-1 16l1-2 16l2-1 16l2-2 
 0.65% 56.98% 10.22% 32.15% 
58:42 d.r. 
16l1  16l2  
98% ee  ‒51.5% ee  
 
L7 (IC column) 
L7 (IB column) 
L6 (IB column) 
16l1-2 + 16l2-1 
16l2-2 
16l1-1 
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16l peak-1 peak-2 peak-3 sum 
L9-IC 492.4 13834.2 3068.4 17395 
 2.83% 79.53% 17.64% 100.00% 
L9-IB 14006.6 3056.2 121.3 17184.1 
 81.51% 17.79% 0.71% 100.00% 
 16l1-1 16l1-2 16l2-1 16l2-2 
 0.71% 79.46% 2.12% 17.71% 
80:20 d.r. 
16l1  16l2  
98% ee  ‒78.5% ee  
 
 
 
16l peak-1 peak-2 peak-3 sum 
L10-IC 2554.8 1123.7 179.8 3858.3 
 66.22% 29.12% 4.66% 100.00% 
L10-IB 1921.9 188.5 2686.8 4797.2 
L9 (IC column) 
L9 (IB column) 
L10 (IC column) 
L10 (IB column) 
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 40.06% 3.93% 56.01% 100.00% 
 16l1-1 16l1-2 16l2-1 16l2-2 
 56.01% 29.49% 10.21% 4.29% 
80:20 d.r. 
16l1  16l2  
‒31% ee  37% ee  
 
3-(1-Phenylazetidin-2-yl)dihydrofuran-2(3H)-one (16m) 
Analysis Data: 
L10 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16m-L10_a 374.2 760.4 0.4921 0.3916 2.71 145  
16m-L10_b 374.3 755.3 0.4956 0.3944 2.71 146  
16m-L10_c 360.4 760.7 0.4738 0.3770 2.71 139 143 
 
Chiralpak IC, 8% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
  
16m by variant L10 
Retention Time 
(min) 
Area (mAU*s) Area % 
23.02 5582.2 56.31 
25.95 4330.3 43.69 
Total 9912.5 100.00 
 
3-(1-(3-Chloro-4-fluorophenyl)pyrrolidin-2-yl)dihydrofuran-2(3H)-one (16n) 
Analysis Data: 
L9 
OD600 = 60 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. TTN 
16n-L9_a 2025.3 1375.6 1.4723 2.4395 5.27 463  
16n-L9_b 1834.4 1379.1 1.3301 2.2039 5.27 418  
16n-L9_c 1841.7 1367.4 1.3469 2.2316 5.27 424 435 
 
 
 
 
 
 
L10: 14% ee 
single 
diastereomer 
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Chiralpak IA, 3% IPA in hexane, 1.2 ml/min, 32 °C, 254nm 
 
Note: Only three peaks were observed and confirmed to belong to the stereo-isomers of product 
16n. No conclusion on ee should be made unless further analysis is carried out. 
 
B.5.4 Enzymatic synthesis of α-boryl-γ-lactones 
All enzymatic reactions for lactone-based organoborane formation in analytical scale were 
conducted following the general procedure described below and analyzed with gas 
chromatography-mass spectrometry (GC-MS). All TTNs for the different products were determined 
using the GC standard curve of the corresponding racemic standard product made with Rh2(OAc)4 
or I2. 
All enzymatic reactions for lactone-based organoborane formation in preparative scale were 
conducted following the general procedure described below, and the corresponding lactone-based 
organoborane products were isolated. Detailed conditions for preparative-scale reactions of 
different substrates are indicated separately. 
General procedure for preparative-scale reactions:  
To a 20 mL vial were added degassed suspension of E. coli expressing Rma cytochrome c (5 mL, 
OD600 = 15), borane (150 μL of 400 mM stock solution in MeCN, 0.24 mmol), lactone diazo (150 μL 
of 400 mM stock solution in MeCN, 0.24 mmol), D-glucose (50 mM), in M9-N buffer (pH 7.4) under 
anaerobic conditions. The vial was capped and shaken (480 rpm) at room temperature for 18 h. 
Reactions for each substrate were set up in quadruplicate. 
After the reaction was completed, reactions in replicate were combined and transferred to 50 
mL centrifuge tubes. The reaction vials were washed with water (2 mL × 2) followed by mixed 
organic solvent (hexane/ethyl acetate = 1:1, 2 mL × 3). The washing solution was combined with the 
reaction mixture in the centrifuge tubes. An additional 15 mL of hexane/ethyl acetate solvent was 
added to every tube. The tube was then vortexed (1 min × 3) and shaken vigorously, and centrifuged 
(5,000 × g, 5 min). The organic layer was separated and the aqueous layer was subjected to three 
more rounds of extraction. The organic layers were combined, dried over Na2SO4 and concentrated 
under reduced pressure. Purification by silica column chromatography with hexane/(ethyl 
acetate:acetone 7:3) as eluent afforded the desired lactone-based organoboranes. Enantioselectivity 
was measured by chiral HPLC. TTNs were calculated based on measured protein concentration and 
isolated product yield. 
 
(1,3-Dimethyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20a) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN Avg. Avg. 
L9 
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TTN yield 
20a-(1) 38262 5643 6.780 7.45 8.30 898   
20a-(2) 40969 5630 7.277 7.94 8.30 957   
20a-(3) 43223 5984 7.223 7.89 8.30 950   
20a-(4) 49313 5559 8.871 9.46 8.30 1140 986 81.8% 
 
Chiralpak IC, 40% i-PrOH in hexane, 1.5 mL/min, 32 °C, 235 nm 
 
  
rac-20a Enzymatically produced 20a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
10.867 23203.7 49.92 10.991 341.95 3.71 
12.315 23282 50.08 12.857 8868.83 96.29 
Total 46485.7 100.00 Total 9210.78 100.00 
 
Preparative-scale reaction: 
E. coli suspension expressing BORLAC in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol weight/mg [Glu]/mM 
15 20 8.30 0.166 180 50 
borane (19a) stock in MeCN diazo (1) stock in MeCN 
stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 600 0.24 400 600 0.24 
purification eluent Product 
(ethyl acetate: acetone 7:3) in 
hexanes 
(30% to 100% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
41.4 0.213 89% 1290 
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(2-Oxotetrahydrofuran-3-yl)(1,3,5-trimethyl-1H-imidazol-3-ium-2-yl)dihydroborate (20b) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20b-(1) 53629 5587 9.599 9.50 8.20 1159   
20b-(2) 47943 4968 9.650 9.54 8.20 1164   
20b-(3) 50689 5641 8.986 9.03 8.20 1102   
20b-(4) 51778 5029 10.296 10.01 8.20 1221 1161 95.2% 
 
Chiralpak IC, 40% i-PrOH in hexane, 1.5 mL/min, 32 °C, 235 nm 
 
  
rac-20b Enzymatically produced 20b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
15.490 21393.4 49.79 15.708 1217.7 4.21 
16.725 21570.9 50.21 16.711 27716.5 95.79 
Total 42964.3 100.00 Total 28934.2 100.00 
 
(1,3-Dimethyl-5-(trifluoromethyl)-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-
yl)dihydroborate (20c) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20c-(1) 47111 4874 9.666 6.53 8.20 796   
20c-(2) 43029 5227 8.232 5.63 8.20 687   
20c-(3) 48256 5249 9.193 6.24 8.20 761   
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20c-(4) 49190 5251 9.368 6.35 8.20 774 754 61.9% 
Chiralpak IC, 12% i-PrOH in hexane, 1 mL/min, 32 °C, 235 nm 
 
  
rac-20c Enzymatically produced 20c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
22.535 5887.98 49.99 22.175 20384.4 89.75 
24.001 5889.43 50.01 23.993 2327.8 10.25 
Total 11777.41 100.00 Total 22712.2 100.00 
 
(1-Ethyl-3-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20d) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20d-(1) 68768 6671 10.308 7.90 8.20 964   
20d-(2) 63101 6924 9.113 7.11 8.20 868   
20d-(3) 68256 6203 11.004 8.35 8.20 1018   
20d-(4) 68771 6607 10.409 7.97 8.20 972 955 78.3% 
 
Chiralpak OD-H, 15% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
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rac-20d Enzymatically produced 20d 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.436 6629.85 49.96 14.592 315.7 2.92 
25.874 6641.54 50.04 25.523 10512.1 97.08 
Total 13271.39 100.00 Total 10827.8 100.00 
 
(3-Hexyl-1-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydrofuran-3-yl)dihydroborate (20e) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20e-(1) 69850 6510 10.730 6.59 8.20 803   
20e-(2) 70694 6131 11.531 7.01 8.20 855   
20e-(3) 73353 5669 12.939 7.75 8.20 945   
20e-(4) 70012 5728 12.223 7.38 8.20 900 876 71.8% 
 
Chiralpak IC, 20% i-PrOH in hexane, 1.3 mL/min, 32 °C, 235 nm 
 
 
rac-20e Enzymatically produced 20e 
Retention Time Area (mAU*s) Area % Retention Time Area (mAU*s) Area % 
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(min) (min) 
25.014 6255.77 50.06 25.012 1415.05 16.10 
30.231 6241.89 49.94 30.026 7373.32 83.90 
Total 12497.66 100.00 Total 8788.37 100.00 
 
(1,3-Dimethyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-yl)dihydroborate (20f) 
Analysis Data: 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20f-(1) 41922 4513 9.289 9.34 8.30 1125   
20f-(2) 39155 4803 8.152 8.39 8.30 1011   
20f-(3) 46105 4530 10.178 10.04 8.30 1209   
20f-(4) 42958 4690 9.159 9.23 8.30 1112 1114 92.5% 
 
Chiralpak IC, 30% i-PrOH in hexane, 1.3 mL/min, 32 °C, 235 nm 
 
  
rac-20f Enzymatically produced 20f 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
19.294 7664.61 49.93 19.758 1044.9 7.17 
21.186 7685.51 50.07 21.398 13525.3 92.83 
Total 15350.12 100.00 Total 14570.2 100.00 
 
Preparative-scale reaction: 
E. coli suspension expressing BORLAC in M9-N D-glucose 
OD600 volume/mL [PC]/μM n_pro/μmol weight/mg [Glu]/mM 
15 20 8.30 0.166 180 50 
borane (19a) stock in MeCN diazo (1) stock in MeCN 
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stock/mM volume/μL n_1/mmol stock/mM volume/μL n_2/mmol 
400 600 0.24 400 600 0.24 
purification eluent Product 
(ethyl acetate: acetone 7:3) in 
hexanes 
(30% to 100% gradient) 
m[Pdt]/mg n[Pdt]/mmol yield TTN 
41.3 0.198 83% 1200 
 
(1-Ethyl-3-methyl-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-yl)dihydroborate 
(20g) 
Analysis Data: 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20g-(1) 45859 4230 10.841 9.05 8.30 1090   
20g-(2) 48114 4168 11.544 9.57 8.30 1153   
20g-(3) 49338 3648 13.525 11.02 8.30 1327   
20g-(4) 43728 3735 11.708 9.69 8.30 1168 1185 98.3% 
 
Chiralpak IC, 18% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
  
rac-20g Enzymatically produced 20g 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
44.709 10687.5 49.94 44.807 2011.8 3.94 
52.633 10715 50.06 51.617 48996.4 96.06 
Total 21402.5 100.00 Total 51008.2 100.00 
 
(1,3-Dimethyl-5-(trifluoromethyl)-1H-imidazol-3-ium-2-yl)(2-oxotetrahydro-2H-pyran-3-
yl)dihydroborate (20h) 
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Analysis Data: 
Pdt- 
Entries 
Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
20h-(1) 59591 4739 12.575 9.10 8.30 1096   
20h-(2) 60894 4605 13.223 9.50 8.30 1145   
20h-(3) 60528 4424 13.682 9.78 8.30 1178   
20h-(4) 63271 4501 14.057 10.01 8.30 1206 1156 96.0% 
 
Chiralpak IC, 18% i-PrOH in hexane, 1.2 mL/min, 32 °C, 235 nm 
 
  
rac-20h Enzymatically produced 20h 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
9.726 3220.99 49.95 9.708 7427.81 94.78 
10.691 3227.01 50.05 10.714 408.77 5.22 
Total 6448 100.00 Total 7836.58 100.00 
 
 
GC-MS traces for the reactions between borane 19a and lactone-diazos LAD, LAD-2 and LAD-3: 
internal standard 
substrate 
Product 
m/z 194 
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Chapter 4 
 
ENZYMATIC ASSEMBLY OF DIVERSE LACTONE STRUCTURES: 
AN INTRAMOLECULAR C–H FUNCTIONALIZATION STRATEGY 
 
4.1 Abstract 
To further exploit the catalytic ability of hemeprotein carbene transferases, especially in 
assembling lactones with a higher order of structural diversity, we have developed a new strategy 
for lactone synthesis through an intramolecular carbene C–H insertion process. Directed evolution 
of a P411 enzyme (P411-C10) led to the discovery of a potent variant, which allowed for the formation 
of a γ-lactone product in high efficiency and perfect stereoselectivity (5800 TTN and >99.9% ee). 
Interestingly, the enzyme lineage obtained from the evolution process could also function 
efficiently to produce δ-lactones, by specifically targeting the benzylic sites for C–H insertion. 
Besides, another enzyme variant was identified from the C10 family, capable of functionalizing a 
remote C–H bond, affording a 7-membered ε-lactone product. Of these examples, C–H bond 
strength is seemingly the key factor in selecting C–H bonds to be functionalized, regardless of the 
geometric distance to the carbene center, which is typically the opposite to the established systems 
with rhodium catalysts. By realizing this, we further tested substrates bearing available benzylic or 
allylic C–H bonds for this cyclization chemistry and found that the enzyme lineage was able to 
synthesize a broad range of lactone and lactam products, even with sophisticated three-
dimensional structures based on fused, spiro and bridged rings. 
 
4.2 Introduction 
 In Chapter 3, we described an enzymatic approach to build lactone derivatives based on a 
lactone-carbene strategy, which allowed for rapid access to a broad range of α-substituted lactones. 
However, the use of lactone-based carbenes still limits the structural diversity of lactone products 
in some aspects, especially when lactones with substitutions at β-, γ-, or multiple positions, or the 
ones with more complicated ring scaffolds (i.e., fused/spiro/bridged rings), are the targets. To 
address this, we have been seeking to establish a different enzymatic platform for lactone assembly. 
As discussed in Chapter 3, nature typically employs a mode of C‒O disconnection for the 
construction of lactones. In principle, lactone structures could also be forged via disconnection at 
any C–C bond in the ring, if a corresponding method is available. We therefore reasoned that C–C 
bond disconnection between the carbons at α- and β-positions can possibly provide an efficient 
route to diverse lactone products with substitutions at different positions (or even with complicated 
ring systems). As a continuing story of our enzymatic system based on hemeprotein carbene 
transferases, we would like to develop an intramolecular C–H functionalization strategy for the 
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synthesis of lactone products (Fig. 4.1). 
 
Figure 4.1. Different disconnection modes for lactone assembly. Non-native strategies: intermolecular 
lactone-carbene C/X‒H insertion, and intramolecular carbene C–H insertion. 
 Such a strategy for lactone assembly can potentially be achieved using α-diazo esters as 
substrates, if a catalyst is identified to perform the desired intramolecular carbene C–H insertion 
reactions. In fact, a variety of synthetic catalysts based on rhodium, iridium, copper, ruthenium, 
cobalt and other transition metals, have been intensively explored for intramolecular carbene C–H 
insertion reactions214,215,286,287 (Fig. 4.2.a). For instance, Doyle has made significant contribution to 
the development of chiral dirhodium carboxamidate catalysts for enantioselective intramolecular 
C–H insertion reactions, yielding a variety of γ-lactones218,219,249,288-290. Catalytic systems based on 
different dirhodium complexes 291 - 293  or iridium/ruthenium-porphyrins 294 , 295  have also been 
employed for the synthesis of β- or γ-lactones as well as lactams when using α-diazo amides as 
substrates. Copper catalysts enabled by bis(oxazoline) (Box) ligands could also take acceptor-
acceptor-type carbenes (with two electron-withdrawing groups appended to the carbene center, 
which are usually more reactive towards C–H insertion compared to the acceptor-only ones) and 
perform intramolecular C–H insertion reactions to afford 5- or 6-membered ring products296-299. In 
contrast, iron catalysts have shown very restricted capability for carbene C–H insertion reactions, 
intermolecularly or intramolecularly. However, examples do exist 300 : White reported an 
intramolecular C–H insertion reaction using acceptor-acceptor carbenes with an iron-
phtalocyanine catalyst230, and Costas also described a system based on a highly electrophilic iron 
catalyst combined with a lithium aluminum alkyoxide salt for carbene insertion into unactivated C–
H bonds251. These examples, nonetheless, are not enantioselective, and only synthesized a limited 
set of ring structures. 
Though difficult, our previous success with intermolecular carbene C–H insertion has 
demonstrated that engineering of iron-based hemeproteins would help to reconfigure the catalyst 
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framework and accelerate the desired C–H insertion reaction by lowering the energy barrier, while 
exerting exquisite stereo-control77. Therefore, we anticipate that an intramolecular version of C–H 
insertion could also be possible if the enzyme is evolved to accommodate the carbene intermediate 
in a favorable orientation and then facilitate the C–H insertion process in a stereoselective manner. 
We also hypothesize that engineering of the enzyme scaffolds may confer different regio-
selectivities of the C–H insertion process169, leading to lactone products of different sizes, whereas 
synthetic catalysts only produce 4- or 5-membered lactones. In addition, once established, the 
enzymatic platform could also be possibly extended to the synthesis of other cyclic structures, such 
as lactams and cyclic ketones, which may allow for synthesis of diverse drug targets or 
pharmaceutical intermediates (Fig. 4.2.b). 
 
Figure 4.2. Intramolecular carbene C–H insertion. a, Representative catalytic systems previously 
developed for intramolecular carbene C–H insertion. b, Possible extension of the proposed enzymatic carbene 
C–H insertion strategy to the synthesis of other cyclic structures, including lactams and cyclic ketones, and 
potential pharmaceutical targets. 
 
4.3 Directed evolution of P411-C10 for intramolecular carbene C–H insertion 
To establish such an enzymatic platform for intramolecular C–H insertion, we first screened a 
broad library of P411 variants collected from previous projects, in the form of E. coli whole-cell 
catalysts, against a diazo substrate (21a), to search for an enzyme variant with promising activity. 
Interestingly, a P411 variant, C10, previously found with promiscuous activities for internal alkyne 
cyclopropenation301  and lactone-carbene C–H insertion, was also active for the C–H insertion 
219 
 
 
reaction here, producing a γ-lactone product (22a) in 3–5% yield. But we observed full conversion 
of the substrate in this enzymatic reaction with P411-C10; a set of side reactions were identified, 
including carbene O‒H insertion by H2O and co-solvent EtOH, carbene Wolff rearrangement, 
carbene dimerizations and [3+2] cycloadditions between carbene dimers and diazo substrate. Thus 
evolution will need to engineer the enzyme to be not only more efficient but also more specific 
towards the desired C–H insertion reaction, while circumventing the undesired pathways. 
 
Figure 4.3. Directed evolution of P411-C10 for intramolecular carbene C–H insertion. Reactions were 
performed in quadruplicate under the following conditions: 10 mM 21a, E. coli harboring P411-C10 variants 
(OD600 = 10), D-glucose (25 mM), M9-N buffer/EtOH (19:1), anaerobic, 18 h. Optimized conditions used whole 
E. coli cell catalysts at OD600 = 2.5 and 2.5 mM substrate loading. Product formation was quantified by HPLC, 
TTNs were determined based on protein concentration, and enantioselectivity was measured using chiral 
HPLC. The heme-domain structure of P411-E10 variant (pdb: 5UCW) was used to guide site-saturation 
mutagenesis. Active-site mutations are highlighted in blue and non-active-site mutations are in orange. 
 We performed directed evolution of P411-C10 to enhance the catalytic efficiency and chemo-
selectivity for the intramolecular C–H insertion reaction (Fig. 4.3). We first targeted active-site 
residues for site-saturation mutagenesis (SSM) and upon screening obtained several beneficial 
mutations, Q437I, V328I, L78M and L436R, all together boosting the activity by 4 folds. Interestingly, 
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a mutation, L401V, in the cysteine loop (the region containing the heme-ligating residue), was found 
to improve TTN to 2460, presumably by reorienting the heme cofactor for the desired 
transformation. However, subsequent screening of SSM libraries targeting more than 30 residues in 
the active-site regions (72-88, 180-188, 260-272, 326-333 and 435-439) was not fruitful, with no 
further enhancement in enzyme activity. We hypothesized that the overall protein dynamics may 
be important for substrate binding with a proper orientation for C–H insertion. Then we targeted a 
few non-active-site residues, which are known to contribute to the overall dynamics of P450BM3 
when binding native substrates302,303, for further engineering. Three more beneficial mutations were 
discovered, leading to a final variant, LoS (short for lactone synthase), with 3520 total turnovers 
and 51% yield to product 22a. The evolved enzyme also delivered perfect stereo-control, affording 
the desired product with >99.9% enantiopurity. After evolution, the side reactions, typically 
carbene O‒H insertions and Wolff rearrangement, were greatly suppressed, to <5%; however, 
carbene dimer formation and subsequent [3+2] cycloadditions together still took up almost half 
conversion of the substrate. Nevertheless, thinking that lowering substrate concentration may help 
to attenuate these bimolecular pathways, final optimization of reaction condtions led to the use of 
lower substrate and enzyme loadings, which improved the overall activity to 5640 TTN and 81% 
yield. 
 
4.4 Intramolecular carbene C–H insertion for δ- and ε-lactone synthesis 
 Having achieved γ-lactone formation through intramolecular C–H insertion, we were curious 
whether our enzymatic platform could access lactones of different sizes (Fig. 4.4). With a diazo 
substrate (21b) bearing one more carbon compared to 21a, the established system based on 
dirhodium catalysts could only produce a γ-lactone product through C–H insertion at the homo-
benzylic position304-306. Surprisingly, reacting substrate 21b with our evolved enzyme, LoS, afforded 
a δ-lactone product (with ~30% yield) by targeting benzylic C–H bonds only. Apparently, our 
enzymatic system features a distinct site-preference from the rhodium system – with enzymes, C–
H bond strength is typically a crucial factor in selecting C–H bonds for insertion, while the 
geometric distance of the C–H bonds to the carbene center plays a more important role in selectivity 
with rhodium catalysts. Therefore, we asked if the 7-membered ε-lactone can be accessed. Generally, 
7-membered rings are more challenging to construct compared to 5- or 6-membered ones, due to 
the disfavored enthalpy and entropy costs during the cyclization process307,308. Despite the difficulty, 
we challenged our enzyme, LoS, with a substrate (21c) bearing remote benzylic C–H bonds; we were 
delighted to observe an ε-lactone product (22c), albeit with only 0.2% yield. 
 To further improve enzyme activity for δ- and ε-lactone formation, we first screened the whole 
enzyme family of the C10 variant using substrates 21b and 21c. Interestingly, a middle variant in the 
enzyme lineage of LoS, C10-IIMRV, was identified as the most active towards δ-lactone formation. 
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As δ-lactones could undergo slow hydrolysis to yield hydroxyl carboxylic acids in the neutral 
medium, slightly diminished TTN and yield of ~4400 and ~60% were obtained for product 22b, 
however, still with good enantioselectivity (90% ee). For ε-lactone formation, it was surprising to us 
that a variant previously evolved for internal alkyne cyclopropenation, C10-WIRF_GA, exhibited 
significantly improved activity (9% yield, 600 TTN) compared to LoS, again highlighting the 
promiscuous feature of P411 enzymes for different carbene transfer chemistries. Directed evolution 
of C10-WIRF_GA introduced 9 mutations and yielded an efficient variant for the sysnthesis of ε-
lactone 22c in 3100 TTN and 65% yield under optimized conditions. However, the enantioselectivity 
of ε-lactone is still not satisfying, giving only 32% ee. Further engineering will still be required to 
solve the enantioselectivity problem. 
 
Figure 4.4. Intramolecular carbene C–H insertion for γ-, δ- and ε-lactone formation. 
 
4.5 Mechanistic investigation and scope evaluation of intramolecular carbene C–H 
insertion 
 As our enzymatic system has displayed a unique site-preference for C–H insertion, typically 
dependent on C–H bond strength, we would like to interrogate the origin of this selectivity. We 
therefore first employed DFT calculation to study the reaction mechanism using a truncated heme 
complex as the simplified catalyst. The most favorable pathway for this intramolecular C–H 
insertion reaction is shown in Fig. 4.5. The C–H insertion takes place in a stepwise manner, 
involving one hydrogen-atom-transfer (HAT) step and subsequent radical rebound to form a C–C 
bond230, which is different from the concerted C–H insertion mechanism by rhodium catalysts for 
the same type of transformation. The free energy barriers of the two steps are 16.0 kcal/mol and 13.0 
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kcal/mol, respectively, suggesting that hydrogen atom abstraction may be the rate-limiting step in 
the catalytic cycle (carbene formation is usually with a relatively low energy barrier). So it would be 
reasonable to argue that C–H bond strength reflected by bond dissociation energy (BDE, benzylic 
C–H bonds with BDE of 85 kcal/mol vs aliphatic C–H bonds with BDE of 98 kcal/mol) may be 
crucial to the HAT step, while the effect from geometric distance can be undermined through proper 
positioning of the carbene intermediate in the enzyme’s active site. 
 
Figure 4.5. Mechanism of intramolecular carbene C–H insertion suggested by DFT calculation. A step-
wise radical mechanism of γ-lactone formation is presented here, involving hydrogen atom abstraction and 
subsequent radical rebound. The detailed steps in carbene formation are omitted. Gibbs free energy obtained 
at the B3LYP/def2-TZVP//B3LYP/6-31G(d)-LANL2DZ level. 
 Having obtained mechanistic insights into this intramolecular C–H insertion chemisty, we 
assayed a range of diazo substrates with benzylic or allylic C–H bonds available for carbene insertion 
(Fig. 4.6). Diazo esters are easy to prepare in one step from corresponding alcohols in gram quantity 
and with high yields (80–96%), rendering our enzymatic approach to lactones typically simple and 
straightforward. Intramolecular carbene C–H insertion proceeded smoothly with variant LoS, 
furnishing γ-lactones with various aryl or alkenyl substitutions at β-position (22a, 22d to 22i). C10-
IIMRV also served as a potent biocatalyst and established a highly efficient and versatile platform 
for δ-lactone synthesis (22b, 22j to 22q). While γ-lactone formation was sensitive to the electronic 
effect of the substitutions on the aromatic ring (with lower activity observed for the electronically 
deficient substrates), the δ-lactone-forming system accepted a broad panel of substrates featuring 
different electronic or steric properties. However, the enantioselectivity of the δ-lactone products 
varied a lot from 12% ee to 98% ee, suggesting that there may be more complicated mechanistic 
profiles for different substrates (e.g., change in rate-limiting step, different radical coupling 
mechanisms, Fig. C-2 in Appendix C). 
 Besides simple lactones, we were also curious whether this enzymatic platform can be used for 
the construction of other cyclic structures or even more complicated ring systems. Indeed, lactams 
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could also be prepared using corresponding diazo amide substrates, and no protection groups were 
required for the nitrogen atoms (22r and 22s). Additionally, complicated lactone structures based 
on fused (24a to 24d), spiro (24e), or even bridged rings could also be accessible using our 
biocatalysts. Interestingly, when racemic substrates (23f to 23h) bearing two different sets of 
benzylic C–H bonds were subjected to our enzymatic system, different lactones products, either 
spiro/bridged lactones (24f-1 and 24f-2) or fused/bridged lactones (24g-1 and 24g-2, 24h-1 and 24h-
2) were obtained. We suspected that the product pairs may result from a parallel kinetic resolution 
process of the corresponding substrate racemates by the enzymes. Further validation is still ongoing. 
 
Figure 4.6. Scope of lactones and lactams via enzymatic intramolecular carbene C–H insertion. 
 
4.6 Conclusion 
Enzyme engineering has enabled cytochrome P450 hemeproteins to adopt a new strategy for 
the assembly of lactone or even lactam structures via an intramolecular carbene C–H insertion 
process. Directed evolution of a P411 enzyme (P411-C10) led to the discovery of a lineage of powerful 
biocatalysts, capable of producing a broad range of lactone products in different sizes (5- to 7-
membered rings) and doing so with high efficiency and tunable stereoselectivity. Our enzymatic 
platform targeted C–H bonds with weaker bond strength for carbene insertion, regardless of the 
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geometric distance to the carbene center, which is typically the opposite to the synthetic systems 
based on rhodium catalysts capable of γ-lactone formation only. Computational study revealed a 
step-wise C–H insertion mechanism of the enzymatic transformation, involving a hydrogen-atom-
transfer step and a subsequent radical rebound process, which provides a possible explanation for 
the selectivity towards weaker C–H bonds. 
Evaluation of diverse substrates established that the engineered enzymatic platform was able 
to assemble a broad range of lactone or lactam products, not limited to those simple ones, but also 
the ones with more sophisticated three-dimensional structures based on fused, spiro and bridged 
rings. These results, once again, highlight the capability of P450 enzymes in achieving molecular 
complexity even through non-natural carbene-transfer chemistries. Nature has created a 
superfamily of cytochrome P450 enzymes with adaptive active sites to accept and functionalize 
highly diversified natural molecules by performing their native oxygenation chemistry. We envision 
that the immense potential of P450 enzymes and other hemeproteins as carbene transferases will 
be further unveiled to provide rapid access to even broader classes of molecular structures by 
directed evolution! 
 
4.7 Experimental methods 
4.7.1 General information 
Unless otherwise noted, all chemicals and reagents were obtained from commercial suppliers 
(Sigma-Aldrich, VWR, Alfa Aesar, Acros, Combi-Blocks, TCI and Ark Pharm) and used without 
further purification. Silica gel chromatography was carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were taken using a Bruker Prodigy 400 MHz instrument and are 
internally referenced to the residual solvent peak (chloroform). Data for 1H NMR are reported as 
follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = 
pentet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, ddd = doublet of doublet 
of doublets), coupling constant (Hz), integration. Sonication was performed using a Qsonica Q500 
sonicator. High-resolution mass spectra were obtained at the California Institute of Technology 
Mass Spectral Facility. Synthetic reactions were monitored using thin layer chromatography (Merck 
60 gel plates) using a UV-lamp for visualization. 
 
4.7.2 Chromatography 
Analytical reversed-phase high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and a Kromasil 100 C18 column (4.6 × 50 mm, 5 µm) with 
water and acetonitrile as the mobile phase and visualization at 210 nm for library screening. 
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Analytical normal-phase HPLC was carried out using an Agilent 1200 series instrument and chiral 
columns Chiralpak IC (4.6 mm × 25 cm), IA (4.6 mm × 25 cm), AS-H (4.6 mm × 25 cm) and OJ-H 
(4.6 mm × 25 cm) with n-hexane and isopropanol as the mobile phase and visualization at 210 nm 
for chiral separation. Gas chromatography (GC) analyses were carried out using an Agilent 7820A 
or Shimadzu GC-17A gas chromatograph, FID detector, a J&W HP-5 column (30 m × 0.32 mm, 0.25 
μm film) and CycloSil-B column (30 m × 0.25 mm, 0.25 μm film). Gas chromatography-mass 
spectrometry (GC-MS) analyses were carried out using a Shimadzu GCMS-QP2010SE system and 
J&W HP-5m column. 
 
4.7.3 Cloning and site-saturation mutagenesis 
pET22b(+) containing a C-terminal 6x-His tag was used as a cloning and expression vector for 
all enzymes described in this study. Site-saturation mutagenesis was performed using a modified 
QuikChangeTM mutagenesis protocol170. Primer sequences are available upon request. The PCR 
products were digested with DpnI, gel purified, and fragments were assembled using Gibson Mix171. 
The ligation mixture was used to directly transform E. coli strain BL21 E. cloni® (Lucigen). Cells were 
grown using Luria-Bertani medium (LB) or Hyperbroth (AthenaES) (HB) with 0.1 mg/mL ampicillin 
(LBamp or HBamp). Electrocompetent E. coli cells were prepared following the protocol of Sambrook 
et al172. T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New England 
Biolabs (NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N buffer; pH 7.4) was 
used as a buffering system for whole cells, lysates, and purified proteins, unless otherwise specified. 
M9-N buffer was used without a carbon source; it contains 47.7 mM Na2HPO4, 22.0 mM KH2PO4, 
8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2. 
 
4.7.4 Determination of hemeprotein concentration 
 1. Preparation of cell lysate: Aliquots of ~3 mL OD600 = 60 cells were prepared in 15 mL 
conical tubes, which were then placed on wet ice. Cells were lysed by sonication following the 
program below: sonication for 4 min, 1 second on - 1 second off, 35% amplitude. The sonicated 
samples were then transferred to two Eppendorf tubes, and then centrifuged down (14,000 rpm, 15 
min, 4 °C). The supernatants (~2.5 mL) were then collected to a 5-mL glass vial for analysis. 
2. Hemechrome assay for protein concentration measurement: A solution of 
NaOH/pyridine was prepared by mixing 1 mL of NaOH aqueous solution (1 M), 2 mL of water and 
2 mL of pyridine. To 4.5 mL of NaOH/pyridine solution, 22.5 μL of K3Fe(CN)6 aqueous solution (0.1 
M) was added to make solution 1. A background solution was prepared by mixing 500 μL M9-N 
and 500 μL of the NaOH/pyridine solution, which was used for UV background subtraction. When 
measuring samples with a UV spectrometer, a spectrum of a mixed solution (oxidized spectrum) 
226 
 
 
with 500 μL cell lysate + 500 μL solution 1 was taken at the wavelength range 380 nm to 650 nm. 
Subsequently, 5 μL of dithionite solution (0.5 M in 0.1 M NaOH solution) was added to the same 
sample and mixed by pipetting; a spectrum of this solution (reduced spectrum) was taken at 380 
nm to 650 nm. The protein concentration was calculated using the extinction coefficient and 
dilution factor (2× dilution in volume): ε_[557reduced ‒ 540oxidized] = 23.98 mM‒1cm‒1 (ref 173). 
 
4.7.5 Expression of P411 proteins 
E. coli BL21 E. cloni® cells carrying a plasmid encoding a P450 or P411 variant were grown 
overnight in 5 mL LBamp (37 °C, 250 rpm). The pre-culture was used to inoculate 45 mL of HBamp in 
a 125 mL Erlenmeyer flask; this culture was incubated at 37 °C, 220 rpm for 2 h and 15 min. Cultures 
were then cooled on ice (20‒40 min), and expression was induced with IPTG and ALA with final 
concentrations of 0.5 mM and 1.0 mM, respectively. Expression was conducted at 24 °C, at 140 rpm, 
for 20 h (± 20 min). Cultures were then centrifuged (4,500 × g, 5 min, 4 °C), and the pellets were 
resuspended to an OD600 of 60 in M9-N minimal medium (no nitrogen). Aliquots of the cell 
suspension (3–4 mL) were used to determine the P450 and P411 expression level after lysis by 
sonication. The expression level in OD600 = 60 lysates is typically in the range of 6‒16 μM for P411-
C10 variants. 
 
4.7.6 Biotransformations 
Resuspended cells in M9-N (340 or 355 µL, at a certain OD600) were added to 2 mL vials, 
followed by D-glucose (40 µL, 250 mM in M9-N). Then the vial were transferred into an anaerobic 
chamber (oxygen level: < 40 ppm). Diazo substrate (5 or 20 µL of an EtOH stock, 200 mM) was 
added to the vials inside the anaerobic chamber. Final concentrations were typically 2.5 or 10.0 mM 
diazo substrate and 25 mM glucose; final reaction volume was 400 µL. The vials were sealed and 
shaken inside the anaerobic chamber at room temperature and 560 rpm for 18 to 24 h. 
After the reaction was completed and the vials removed from the anaerobic chamber, internal 
standard (20 μL of 20 mM stock solution in acetonitrile) was added followed by acetonitrile (0.6 
mL). The mixture was transferred to a 1.7-mL Eppendorf tube, and then subjected to vortexing (15 s 
× 3) and centrifugation (14,000 rpm, 5 min, 4 °C). A sample of the supernatant (0.8 mL) was 
transferred to a vial for reverse-phase HPLC analysis. 
 
4.7.7 Reaction screening in 96-well plate format 
Enzyme libraries (site-saturation libraries generated employing the “22c-trick” method or 
collections of heme protein variants) were screened in 96-well plates. 
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E. coli libraries for P411 variants were cultured in LBamp (300 µL/well) at 37 °C, 250 rpm and 80% 
relative humidity overnight. HBamp (950 µL/well) was inoculated with the pre-culture (50 µL/well) 
and incubated at 37 °C, 230 rpm, 80% humidity for 2 h and 45 min. The plates were cooled on ice 
for 30 minutes, and expression was induced with 0.5 mM IPTG and 1.0 mM ALA (final 
concentrations). Expression was conducted at 22 °C and 220 rpm for 20 h. 
The cells were pelleted (4,500 × g, 5 min, 4 °C) and resuspended with M9-N buffer (350 µL/well) 
and D-glucose solution (40 µL/well, in M9-N). The 96-well plate was then transferred to an 
anaerobic chamber. In the anaerobic chamber, substrate (10 µL/well, 100 mM in EtOH) was added 
to the plate. The plate was sealed with an aluminum foil and shaken inside the anaerobic chamber 
at 560 rpm. 
After 18 h, the plate was moved out from the anaerobic chamber. The seal was removed and 
acetonitrile (600 µL/well) was added. The plate was tightly sealed with a reusable silicone mat, 
vortexed (15 s × 3) and centrifuged (4,500 × g, 5 min). The supernatant (200 µL/well) was filtered 
through an AcroPrep 96-well filter plate (0.2 µm) into a shallow-well plate for reversed-phase HPLC 
analysis (C18 poroshell column, MeCN:H2O 40:60 for 3.5 min -> gradient to 100:0 -> 100:0 for 3.5 
min, 1.2 mL/min flow, 7.5 min, 210 nm). 
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Appendix C 
 
SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
 
B.1 Supporting Tables C-1 to C-6 
Table C-1. Directed evolution of P411-C10 for γ-lactone formation. 
 
P411-C10 variant TTN yield 
C10 360 ± 20 5.2 ± 0.3% 
C10-Q437I 710 ± 20 12.4 ± 0.3% 
C10-Q437I V328I 1150 ± 210 14.8 ± 2.9% 
C10-Q437I V328I L78M 1320 ± 70 20.2 ± 0.9% 
C10-Q437I V328I L78M L436R 1460 ± 30 21.2 ± 1.6% 
C10-Q437I V328I L78M L436R L401V 2460 ± 200 30.3 ± 1.4% 
C10-Q437I V328I L78M L436R L401V L162I 3070 ± 30 41.9 ± 0.3% 
C10-Q437I V328I L78M L436R L401V L162I R190L 3150 ± 220 42.1 ± 4.5% 
C10-Q437I V328I L78M L436R L401V L162I R190L E70S 3520 ± 80 50.7 ± 1.3% 
Note: Analytical reactions were set up in quadruplicate using whole E. coli cells harboring P411-C10 variants 
(OD600 = 10 for all). Product formation was quantified by HPLC and TTNs were determined based on protein 
concentration. 
 
Table C-2. Condition optimization of γ-lactone formation with P411-C10 variants. 
 
P411-C10 variant condition 1 condition 2 
C10-Q437I V328I L78M L436R 1430 TTN, 22.7% yield 2840 TTN, 45% yield 
C10-Q437I V328I L78M L436R L401V 2660 TTN, 31.6% yield 4930 TTN, 53.7% yield 
C10-Q437I V328I L78M L436R L401V L162I 3090 TTN, 41.6% yield 5060 TTN, 68.0% yield 
C10-Q437I V328I L78M L436R L401V L162I R190L 3370 TTN, 46.6% yield 5270 TTN, 72.9% yield 
C10-Q437I V328I L78M L436R L401V L162I R190L E70S 3440 TTN, 52.0% yield 5640 TTN, 81.2% yield 
Note: Analytical reactions were set up in quadruplicate using whole E. coli cells harboring P411-C10 variants 
under certain conditions. Product formation was quantified by HPLC and TTNs were determined based on 
protein concentration. 
 
O
N2
O
Ph
H
E. coli (OD600 = 10) harboring
P411-C10 variant
M9-N buffer (pH 7.4)
room temp., 18 h
O
O
Ph
21a, 10 mM 22a
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Table C-3. Screening of LoS lineage for δ-lactone formation. 
 
P411-C10 variant relative activity 
C10-Q437I V328I 1.00 ± 0.05 
C10-Q437I V328I L78M 2.45 ± 0.03 
C10-Q437I V328I L78M L436R 2.63 ± 0.04 
C10-Q437I V328I L78M L436R L401V 2.80 ± 0.07 
C10-Q437I V328I L78M L436R L401V L162I 2.37 ± 0.03 
C10-Q437I V328I L78M L436R L401V L162I R190L 1.68 ± 0.07 
C10-Q437I V328I L78M L436R L401V L162I R190L E70S 1.70 ± 0.05 
Note: Analytical reactions were set up in duplicate using whole E. coli cells harboring P411-C10 variants (OD600 
= 10 for all). The reactions were run for a relatively shorter time (8 h) due to the hydrolysis problem. Relative 
activity is simply based on product formation, quantified by HPLC. 
 
 condition 1 condition 2 
results ~3500 TTN, ~48% yield ~4400 TTN, ~61% yield 
Note: Analytical reactions were set up in quadruplicate using whole E. coli cells harboring P411-C10-IIMRV 
under certain conditions. Total turnovers and yields could not be accurately determined due to the hydrolysis 
problem. Even with shorter reaction time (6–9 h), >10% lactone product was hydrolyzed. 
 
Table C-4. Results for ε-lactone formation with P411-C10 variants. 
 
P411-C10 variant condition 1 condition 2 
C10-WIRF_GA 600 TTN, 9% yield - 
P411-7LoS 2300 TTN, 47% yield 3100 TTN, 65% yield 
Note: Analytical reactions were set up in quadruplicate using whole E. coli cells harboring P411-C10 variants 
under certain conditions. Product formation was quantified by HPLC and TTNs were determined based on 
protein concentration. 
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Table C-5. List of mutations in P411 variants involved in Chapter 4. 
P411 variant Mutations relative to wild-type protein (relative to P450BM3) 
P411-C10 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L 
L437Q E442K ΔFAD 
C10-Q437I 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328V A330Y L353V I366V C400S I401L T436L L437I 
E442K ΔFAD 
C10-II 
N70E A74G V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401L T436L L437I 
E442K ΔFAD 
C10-IIM 
N70E A74G V78M A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401L T436L L437I 
E442K ΔFAD 
C10-IIMR 
N70E A74G V78M A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401L T436R L437I 
E442K ΔFAD 
C10-IIMRV 
N70E A74G V78M A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401V T436R L437I 
E442K ΔFAD 
C10-IIMRVI 
N70E A74G V78M A82L F87A M118S P142S F162I T175I M177L A184V S226R H236Q 
E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401V T436R L437I 
E442K ΔFAD 
C10-IIMRVIL 
N70E A74G V78M A82L F87A M118S P142S F162I T175I M177L A184V R190L S226R 
H236Q E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401V 
T436R L437I E442K ΔFAD 
C10-IIMRVILS 
(LoS) 
N70S A74G V78M A82L F87A M118S P142S F162I T175I M177L A184V R190L S226R 
H236Q E252G I263Y H266V T268G A290V A328I A330Y L353V I366V C400S I401V 
T436R L437I E442K ΔFAD 
C10-WIRF_GA 
N70E S72F V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V A328V A330Y S332G L353V I366V C400S I401L T436R L437I 
E442K ΔFAD 
C10-WIRF_GAP 
N70E S72F V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V T327P A328V A330Y S332G L353V I366V C400S I401L 
T436R L437I E442K ΔFAD 
C10-WIRV_GAP 
N70E S72V V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V T327P A328V A330Y S332G L353V I366V C400S I401L 
T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P) 
N70E S72V V78L A82L F87A M118S P142S F162L T175I M177L A184V S226R H236Q E252G 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V I366V C400S 
I401L T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S 
N70E S72V V78L A82L F87A M118S P142S F162L T175I M177L A184V H236Q E252G 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V I366V C400S 
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I401L T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
F 
N70E S72V V78L A82L F87A H92F M118S P142S F162L T175I M177L A184V H236Q E252G 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V I366V C400S 
I401L T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
FF 
N70E S72V V78L A82L F87A H92F M118S P142S T175I M177L A184V H236Q E252G 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V I366V C400S 
I401L T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
FFR 
N70E S72V V78L A82L F87A H92F M118S P142S T175I M177L A184V H236Q E252R 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V I366V C400S 
I401L T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
FFRI 
N70E S72V V78L A82L F87A H92F M118S P142S T175I M177L A184V H236Q E252R 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V C400S I401L 
T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
FFRIG 
N70E S72V V78L A82L F87A H92F M118S P142G T175I M177L A184V H236Q E252R 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V C400S I401L 
T436R L437I E442K ΔFAD 
C10-
WIRV_GAP(P)S_
FFRIGT 
N70E S72V V78L A82T F87A H92F M118S P142G T175I M177L A184V H236Q E252R 
I263W H266V T268G A290V T327P A328V (P329P) A330Y S332G L353V C400S I401L 
T436R L437I E442K ΔFAD 
Note: ΔFAD means FAD domain truncation. 
 
Table C-6. Substrates prepared and tested for intramolecular carbene C–H insertion. 
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C.2 Supporting Figures C-1 to C-2 
 
Figure C-1. The overall conversion of substrate 21a with variant P411-C10. The desired intramolecular C–
H insertion product 22a was formed in 3–5% dependent on different reaction conditions. 
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Figure C-2. Different mechanisms of intramolecular C–H insertion suggested by DFT calculation. The 
detailed mechanism of the intramolecular C–H insertion reaction may differ (e.g., changes in the energy 
barriers of the HAT and radical rebound steps), when different substrates or different enzyme scaffolds are 
used. Besides, another pathway involving a Fe–C bond dissociation step followed by direct radical coupling 
may also be applied to the C–H insertion reaction. 
 
C.3 Preparation of diazo substrates 
2-(2-Tosylhydrazineylidene)acetyl chloride 
 
4-Methylbenzenesulfonohydrazide (55.9 g, 
0.3 mol, 1.0 equiv.) was dissolved in aqueous 
hydrochloric acid (2 M, 180 mL) and warmed to 50 °C (solution 
1). 2-Oxoacetic acid (44.4 g of 50% in water, 0.3 mol, 1.0 equiv.) 
was dissolved in water (300 mL) and heated to 50 °C (solution 2). 
Pre-warmed solution 1 was slowly transferred to solution 2. The 
reaction mixture was then stirred at 60 °C for 4 h until all the 
hydrozone product crashed out. The mixture was cooled to 0 °C 
and kept for 2 h. The product 2-(2-tosylhydrazineylidene) acetic 
acid (~70 g, 97% yield) was collected by filtration, washed with hexane: ether (10:1, 20 mL × 3) and 
dried under vaccum. 
2-(2-Tosylhydrazineylidene)acetic acid (70 g, 0.29 mmol, 1.0 equiv.) was dissolved in dry 
dichloromethane (300 mL). Thionyl chloride (50 mL) and N,N-dimethyl formaldehyde (4 drops, 
cat.) were added to the solution. The reaction mixture was stirred at room temperature for 1 h and 
then heated to reflux (~ 50 °C) for 5 h until the starting material was completely dissolved and the 
reaction turned clear and light yellow. After the reaction was cooled to room temperature, organic 
solvent and the excess thionyl chloride were removed under reduced pressure. The resulting 
mixture was treated with ether (20 mL) and sonicated for 5 min. Hexane (150 mL) was then slowly 
added to the mixture to completely crash out the acyl chloride product. The mixture was cooled to 
0 °C and kept for 2 h. The product 2-(2-tosylhydrazineylidene)acetyl chloride (~74 g, 98% yield, pale 
yellow) was collected by filtration, washed with hexane (20 mL × 2) and dried under vaccum. 
N N
N N
Fe
OMe
O
O
H
R
H
N N
N N
Fe
OMe
N N
N N
Fe
OMe
O
O R
H
H
H
O
RN2
O
H
N2
hydrogen atom abstraction
radical
rebound
O
O
R
n
nn
n
O
O
R
n
Fe C bond 
dissociation
radical 
coupling
racemization of
radical carbon 
chiral center? step-wise
radical mechanism
234 
 
 
General procedure for the preparation of diazo esters 
 
An alcohol substrate (1.0 equiv.) was dissolved in dry dichloromethane (conc. ~ 0.2‒0.5 M) and kept 
at 0 °C. 2-(2-Tosylhydrazineylidene)acetyl chloride (1.05 equiv.) was then added to the solution. The 
mixture was stirred at 0 °C for 10 min before the addition of N,N-dimethyl aniline (1.3 equiv.). The 
resulting mixture was then stirred for another 10 min. Triethylamine (2.0 equiv.) was added to the 
reaction, which was then allowed to slowly warm up to room temperature over 20 min. The reaction 
was concentrated under reduced pressure and quenched by citric acid (saturated aqueous solution). 
The resulting mixture was transferred to a separatory funnel. Dichloromethane and water were used 
in minimum amount to wash the reaction container and transfer everything to the separatory 
funnel. Hexane/ethyl acetate (13:1) was used for extraction for three times. The combined organic 
layer was then washed with saturated citric acid solution and brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. The resulting crude product was purified through a silica 
column using pentane/ether (1:0 to 10:1) as eluents. The yellow-colored fractions were concentrated 
to afford the diazo product as a yellow liquid (80‒96% yield). 
 
C.4 Analysis of lactone products by enzymatic reactions 
4-Phenyldihydrofuran-2(3H)-one (22a) 
Calibration curve: 
 
Analysis Data (LoS, OD600=10, 10 mM substrate): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22a-(1) 7088.5 6194.8 1.144 5.18 1.51 3420   
22a-(2) 7045.3 6165.9 1.143 5.17 1.51 3416   
22a-(3) 7102.7 6180 1.149 5.20 1.51 3435   
22a-(4) 7075.7 6089.2 1.162 5.26 1.51 3473 3436 52.0% 
 
Analysis Data (LoS, OD600=2.5, 2.5 mM substrate): 
R
OH
COClTsHNN
R
O
O
N2
1.0 equiv.
1.
DCM, 0 C, 10 min
(1.05 equiv.)
2. PhNMe2 (1.3 equiv.)
0 C, 10 min
3. Et3N (2.0 equiv.)
0 C r.t., 20 min
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Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22a-(1) 2887.1 6110.7 0.472 2.14 0.38 5649   
22a-(2) 2794.5 6185.1 0.452 2.04 0.38 5402   
22a-(3) 2812.4 6110.2 0.460 2.08 0.38 5503   
22a-(4) 2753.6 6122.4 0.450 2.03 0.38 5378 5483 83.0% 
 
Chiralpak IA, 2.5% isopropanol in hexane, 1.2 ml/min, 32 °C, 210nm 
 
 
rac-22a Enzymatically produced 22a 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
14.531 32456.5 49.33 - - - 
15.647 33342.0 50.67 15.812 20071.7 100.00 
Total 65798.5 100.00 Total 20071.7 100.00 
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4-Phenyltetrahydro-2H-pyran-2-one (22b) 
Analysis Data (C10-IIMRV, OD600=10, 10 mM substrate, 6 h): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22b-(1) 6869.1 6524.8 1.053 4.76 1.38 3460   
22b-(2) 6893.1 6458.7 1.067 4.83 1.38 3508   
22b-(3) 6888.4 6446.8 1.068 4.83 1.38 3512   
22b-(4) 7018.9 6526.4 1.075 4.87 1.38 3535 3504 48.2% 
 
Analysis Data (C10-IIMRV, OD600=2.5, 2.5 mM substrate, 9 h): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22b-(1) 2146.3 6570.5 0.327 1.48 0.34 4295   
22b-(2) 2223.5 6506.1 0.342 1.55 0.34 4493   
22b-(3) 2239.8 6587.8 0.340 1.54 0.34 4470   
22b-(4) 2213.9 6590.5 0.336 1.52 0.34 4416 4419 60.8% 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
 
rac-22b Enzymatically produced 22b 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
27.322 2108.20 49.96 26.870 2602.32 94.75 
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29.040 2111.33 50.04 28.542 144.11 5.25 
Total 4219.53 100.00 Total 2746.43 100.00 
 
 
1H NMR (400 MHz, CDCl3) δ 7.42–7.32 (m, 2H), 7.32–7.26 (m, 1H), 7.25–7.17 (m, 
2H), 4.51 (ddd, J = 11.5, 4.9, 3.9 Hz, 1H), 4.40 (ddd, J = 11.5, 10.4, 3.8 Hz, 1H), 3.24 
(tdd, J = 10.6, 5.9, 4.5 Hz, 1H), 2.93 (ddd, J = 17.6, 5.9, 1.6 Hz, 1H), 2.64 (dd, J = 17.6, 
10.7 Hz, 1H), 2.18 (ddtd, J = 14.0, 4.5, 3.9, 1.7 Hz, 1H), 2.04 (dtd, J = 14.1, 10.5, 4.9 Hz, 
1H). 13C NMR (101 MHz, CDCl3) δ 170.81, 142.88, 129.13, 127.38, 126.59, 68.80, 37.65, 37.60, 30.45. 
 
 
O
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4-(4-Methoxyphenyl)oxepan-2-one (22c) 
Analysis Data (7LoS, OD600=10, 10 mM substrate, 6 h): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22c-(1) 4916.5 6757.0 0.728 4.82 2.27 2118   
22c-(2) 4630.9 6808.2 0.680 4.50 2.27 1980   
22c-(3) 5148.7 6858.3 0.751 4.97 2.27 2186   
22c-(4) 5101.2 6840.4 0.746 4.94 2.27 2171 2114 48.1% 
 
Analysis Data (7LoS, OD600=2.5, 2.5 mM substrate, 9 h): 
Entries Pdt Std Pdt/Std [Pdt]/mM [PC]/μM TTN 
Avg. 
TTN 
Avg. 
yield 
22c-(1) 1856.2 6758.7 0.275 1.82 0.57 3198   
22c-(2) 1950.3 6776.2 0.288 1.90 0.57 3352   
22c-(3) 1578.5 6772.3 0.233 1.54 0.57 2714   
22c-(4) 1738.2 6777.8 0.256 1.70 0.57 2986 3063 69.6% 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 235nm 
 
 
rac-22c Enzymatically produced 22c 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
28.354 5588.97 50.81 28.710 18161.1 33.96 
37.242 5411.71 49.19 36.575 35319.5 66.04 
Total 11000.68 100.00 Total 53480.6 100.00 
 
239 
 
 
4-(4-Methoxyphenyl)oxepan-2-one (22c) 
 
1H NMR (400 MHz, CDCl3) δ 7.17–7.04 (m, 2H), 6.85 (d, J = 8.7 Hz, 2H), 
4.37 (dddd, J = 12.8, 5.5, 2.2, 1.4 Hz, 1H), 4.33–4.24 (m, 1H), 3.79 (s, 3H), 3.01 
(dd, J = 12.9, 11.7 Hz, 1H), 2.90 (td, J = 12.0, 2.8 Hz, 1H), 2.79 (dt, J = 13.1, 1.4 
Hz, 1H), 2.15–2.01 (m, 2H), 1.99–1.85 (m, 1H), 1.85–1.70 (m, 1H). 13C NMR (101 
MHz, CDCl3) δ 174.74, 158.47, 137.83, 127.34, 114.23, 69.22, 55.42, 41.95, 40.00, 38.07, 29.16. 
 
 
 
O
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(E)-4-(Prop-1-en-1-yl)tetrahydro-2H-pyran-2-one 
 
1H NMR (400 MHz, CDCl3) δ 5.52 (dqd, J = 15.4, 6.4, 1.1 Hz, 1H), 5.37 (ddq, J = 15.4, 
6.5, 1.6 Hz, 1H), 4.42 (dt, J = 11.4, 4.7 Hz, 1H), 4.28 (ddd, J = 11.4, 9.9, 3.9 Hz, 1H), 
2.75–2.54 (m, 2H), 2.32 (dd, J = 16.8, 9.3 Hz, 1H), 1.95 (dqd, J = 14.1, 4.4, 1.8 Hz, 1H), 
1.72–1.62 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 171.02, 132.58, 126.02, 68.51, 36.33, 34.51, 29.25, 18.03. 
 
 
 
 
241 
 
 
2',3'-Dihydro-2H-spiro[furan-3,1'-inden]-5(4H)-one 
 
1H NMR (400 MHz, CDCl3) δ 7.29–7.21 (m, 4H), 4.32 (s, 2H), 2.98 (t, J = 7.2 Hz, 2H), 
2.84 (d, J = 17.3 Hz, 1H), 2.66 (d, J = 17.3 Hz, 1H), 2.31 (dt, J = 12.8, 6.7 Hz, 1H), 2.18 
(dt, J = 12.9, 7.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 176.44, 144.21, 143.48, 128.26, 
127.40, 125.20, 122.09, 78.22, 52.13, 41.65, 38.37, 30.22. 
 
 
 
 
242 
 
 
(3aR,8aS)-3,3a,8,8a-Tetrahydro-2H-indeno[2,1-b]furan-2-one 
 
1H NMR (400 MHz, CDCl3) δ 7.30–7.19 (m, 4H), 5.30 (ddd, J = 5.8, 3.7, 2.7 Hz, 
1H), 4.02 (ddt, J = 9.3, 5.7, 1.3 Hz, 1H), 3.33 (s, 1H), 3.32 (d, J = 1.1 Hz, 1H), 3.05 
(dd, J = 17.8, 9.3 Hz, 1H), 2.75 (dd, J = 17.8, 1.5 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 176.46, 142.15, 140.13, 128.45, 127.85, 125.42, 124.79, 84.43, 45.58, 39.07, 35.48. 
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(4aR,9aR)-4,4a,9,9a-Tetrahydroindeno[2,1-c]pyran-3(1H)-one 
 
1H NMR (400 MHz, CDCl3) δ 7.26–7.13 (m, 4H), 4.39 (dd, J = 11.4, 5.0 Hz, 1H), 
4.09 (dd, J = 11.4, 8.8 Hz, 1H), 3.81 (dt, J = 9.9, 7.9 Hz, 1H), 3.30 (dd, J = 16.8, 9.7 
Hz, 1H), 3.10–2.96 (m, 2H), 2.81 (dd, J = 16.8, 3.9 Hz, 1H), 2.57 (dd, J = 15.3, 7.8 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 172.79, 143.96, 141.31, 127.91, 127.56, 125.06, 124.27, 70.26, 41.04, 
35.81, 34.93, 34.90. 
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2,3,5',6'-Tetrahydrospiro[indene-1,4'-pyran]-2'(3'H)-one 
 
1H NMR (400 MHz, CDCl3) δ 7.29–7.11 (m, 4H), 4.54–4.43 (AB, ddd, J = 4.6, 8.1, 11.7 
Hz, 1H; ddd, J = 5.3, 5.9, 11.7 Hz, 1h), 2.96 (t, J = 7.1 Hz, 2H), 2.68 (dd, J = 17.2, 1.1 Hz, 
1H), 2.63 (d, J = 17.2 Hz, 1H), 2.17 (ddd, J = 14.3, 8.1, 5.4 Hz, 1H), 2.08 (t, J = 7.1 Hz, 
2H), 1.91 (dddd, J = 14.1, 5.8, 4.6, 1.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 170.99, 
147.79, 142.87, 127.77, 127.18, 125.16, 122.42, 67.13, 45.72, 41.80, 38.95, 33.89, 29.75. 
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1,5,6,7-Tetrahydro-1,7-methanobenzo[e]oxonin-3(2H)-one 
 
1H NMR (400 MHz, CDCl3) δ 7.30–7.14 (m, 4H), 4.10 (ddd, J = 11.9, 5.1, 3.0 Hz, 
1H), 4.02 (td, J = 11.6, 3.1 Hz, 1H), 3.68 (dt, J = 9.4, 4.9 Hz, 1H), 3.52–3.44 (m, 1H), 
2.90 (dd, J = 12.5, 4.9 Hz, 1H), 2.66–2.55 (m, 2H), 2.39 (dddd, J = 14.8, 11.4, 5.0, 
3.5 Hz, 1H), 2.22 (dt, J = 13.7, 1.0 Hz, 1H), 2.00 (ddt, J = 14.8, 4.5, 3.1 Hz, 1H). 13C 
NMR (101 MHz, CDCl3) δ 175.67, 145.81, 144.21, 127.93, 127.70, 125.02, 124.72, 66.57, 42.81, 42.69, 41.28, 
37.01, 36.46. 
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4-(4-Methoxyphenyl)tetrahydro-2H-pyran-2-one 
 
 
Note: The turnover numbers and yields were estimated according to HPLC signals. Accurate 
analysis will require the corresponding calibration curve of the standard product. It is the same for 
the following analysis. 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
 
rac pdt Enzymatically produced pdt 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
40.889 1539.36 49.99 40.127 2099.63 59.41 
49.768 1539.95 50.01 48.804 1434.70 40.59 
Total 3079.31 100.00 Total 3534.33 100.00 
 
 condition 1 condition 2 
C10-IIMRV 
~5000 TTN, 70% yield 
(10 mM, 5 h) 
~4500 TTN, 65% yield 
(2.5 mM, 7 h) 
247 
 
 
4-(4-Fluorophenyl)tetrahydro-2H-pyran-2-one 
 
 
 
 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
 
rac pdt Enzymatically produced pdt 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
26.117 10917.9 49.98 26.240 2258.89 76.85 
30.767 10928.2 50.02 30.903 680.37 23.15 
Total 21846.1 100.00 Total 2939.26 100.00 
 
 condition 1 condition 2 
C10-IIMRV 
~3000 TTN, 40% yield 
(10 mM, 13 h) 
~3500 TTN, 45% yield 
(2.5 mM, 15 h) 
O
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4-(4-Bromophenyl)tetrahydro-2H-pyran-2-one 
 
 
 
 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
 
rac pdt Enzymatically produced pdt 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
29.738 2943.32 49.61 29.902 1616.40 56.16 
38.107 2989.08 50.39 38.240 1261.56 43.84 
Total 5932.40 100.00 Total 2877.96 100.00 
 
  
 condition 1 condition 2 
C10-IIMRV 
~3500 TTN, 45% yield 
(10 mM, 20 h) 
~3000 TTN, 35% yield 
(2.5 mM, 24 h) 
O
O
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4-(p-Tol)tetrahydro-2H-pyran-2-one 
 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
rac pdt Enzymatically produced pdt 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
- - - 26.215 2744.48 73.10 
- - - 27.144 1010.19 26.90 
Total - - Total 3754.67 100.00 
 
4-(Thiophen-2-yl)tetrahydro-2H-pyran-2-one 
 
 
 
 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
rac pdt Enzymatically produced pdt 
 condition 1 condition 2 
C10-IIMRV 
~4500 TTN, 65% yield 
(10 mM, 8 h) 
~4500 TTN, 65% yield 
(2.5 mM, 10 h) 
 condition 1 condition 2 
C10-IIMRV 
~5000 TTN, 70% yield 
(10 mM, 4 h) 
~5500 TTN, 75% yield 
(2.5 mM, 6 h) 
O
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Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
- - - 27.895 525.88 15.72 
- - - 29.739 2818.43 84.38 
Total - - Total 3344.31 100.00 
 
4-(Furan-2-yl)tetrahydro-2H-pyran-2-one 
 
 
 
 
 
Chiralpak IC, 25% isopropanol in hexane, 1.2 ml/min, 28 °C, 210nm 
 
rac pdt Enzymatically produced pdt 
Retention Time 
(min) 
Area (mAU*s) Area % 
Retention Time 
(min) 
Area (mAU*s) Area % 
- - - 22.104 30.31 1.23 
- - - 23.347 2440.35 98.77 
Total - - Total 2470.66 100.00 
 
 
 
 condition 1 condition 2 
C10-IIMRV 
~4000 TTN, 50% yield 
(10 mM, 5 h) 
~5500 TTN, 75% yield 
(2.5 mM, 5 h) 
O
O
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